Sentence,class,file
J Steroid Biochem Mol Biol 2010; 118:51-8; PMID:19815066; http://dx.doi.org/10.1016/j.jsbmb.2009.09.017 23.,OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
J Steroid Biochem Mol Biol 2004; 88:27-36; PMID:15026081; http://dx.doi.org/10.1016/j.jsbmb.2003.10.005 24.,OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
Biochem Biophys Res Commun 1999; 256:462-8; PMID:10080920; http://dx.doi.org/10.1006/bbrc.1999.0367 25.,OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
Biochem Biophys Res Commun 2008; 370:541-6; PMID:18358233; http://dx.doi.org/10.1016/j.bbrc.2008.03.054References 1.,OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
Epigenomics 2012; 4:355-7; PMID:22920174; http://dx.doi.org/10.2217/epi.12.35 2.,Non-OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
J  Mol Endocrinol 2011; 46:R11-32; PMID:21322125; http://dx.doi.org/10.1677/JME-10-0053 3.,Non-OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
J Mol Endocrinol 2012; 49:R61-7; PMID:22798698; http://dx.doi.org/10.1530/JME-12-0066 4.,Non-OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
Biochem Pharmacol 2006; 72:1589-96; PMID:16844098; http://dx.doi.org/10.1016/j.bcp.2006.05.024 5.,Non-OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
Epigenetics 2010; 5:100-4; PMID:20160483; http://dx.doi.org/10.4161/epi.5.2.10778 6.,Non-OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
Epigenetics 2009; 4:47-53; PMID:19029819; http://dx.doi.org/10.4161/epi.4.1.7288 7.,Non-OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
Cell 2006; 125:483-95; PMID:16603237; http://dx.doi.org/10.1016/j.cell.2006.03.027 9.,OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
Nat Cell Biol 2007; 9:347-53; PMID:17277772; http://dx.doi.org/10.1038/ncb1546 10.,OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
Oncogene 2012; 31:3444-56; PMID:22120715; http://dx.doi.org/10.1038/onc.2011.512 11.,Non-OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
Environ Toxicol 2012; PMID:22987612; http://dx.doi.org/10.1002/tox.21812 13.,Non-OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
Toxicol Sci 2011; 121:123-31; PMID:21292640; http://dx.doi.org/10.1093/toxsci/kfr032 14.,OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
Reprod Toxicol 2013; 35:144-9; PMID:23117151; http://dx.doi.org/10.1016/j.repro-tox.2012.10.010 15.,OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
Toxicol Appl Pharmacol 2009; 239:46-54; PMID:19464308; http://dx.doi.org/10.1016/j.taap.2009.04.023 ©2013 Landes Bioscience.,Non-OADS,/arxiv_data1/oa_pdf/2e/e6/epi-8-1061.PMC3891687.pdf
"Epigenetics 8:10, 1080–1088; October 2013; © 2013 Landes Bioscience REsEaR ch papER 1080 Epigenetics Volume 8 Issue 10*Correspondence to: Bernard W Futscher; Email: BFutscher@uacc.arizona.edu Submitted: 06/27/13; Revised: 07/24/13; Accepted: 07/27/13http://dx.doi.org/10.4161/epi.25926Introduction One important function of epigenetics is to provide a mechanism  of genomic plasticity so that cells may respond to a changing and potentially harmful environment.",Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
19-27 Perhaps the most  compelling evidence that silencing of ZNFs in the arsenite-transformed pros - tate epithelial model is a relevant event in human carcinomas are the publicly available TCGA gene expression and DNA methylation data sets from nor - mal prostate and prostate adenocarci - noma tissues (http://cancergenome.nih.gov/).,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Curr Biol 2003; 13:1192-200; PMID:12867029;  http://dx.doi.org/10.1016/S0960-9822(03)00432-9 3.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Nature 2006; 439:871-4; PMID:16357870; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Nat Genet  2007; 39:232-6; PMID:17200670; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Nature  2007; 448:714-7; PMID:17687327; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Development 2013; 140:519-29; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Cell Rep 2012; 2:766- 73; http://dx.doi.org/10.1016/j.celrep.2012.08.043; PMID:23041315 8.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
PLoS Genet  2010; 6:e1000869; http://dx.doi.org/10.1371/journal.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Biochem Biophys Res Commun 2006; 346:621-8;  PMID:16793018; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Nature 2010;  463:237-40; http://dx.doi.org/10.1038/nature08674;  PMID:20075919 11.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Carcinogenesis  2008; 29:1500-8; PMID:18448484; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Toxicol  Appl Pharmacol 2009; 241:221-9; PMID:19716837;  http://dx.doi.org/10.1016/j.taap.2009.08.019 13.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Toxicol Sci 2010; 116:44-57; PMID:20375083; http://dx.doi.org/10.1093/toxsci/ kfq106 14.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Epigenetics 2012; 7:1238-48; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
PLoS One 2011; 6:e17121; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Nat Genet 2007; 39:157-8;  PMID:17200673; http://dx.doi.org/10.1038/ng1941 17.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
PLoS  Genet 2007; 3:e89; PMID:17542650; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Genome Res 2006; 16:1493-504; PMID:17038565;  http://dx.doi.org/10.1101/gr.5391806 19.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Cancer Res 2010; 70:6516-26; http://dx.doi.org/10.1158/0008-5472.CAN-09-4566;  PMID:2068279420.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Cancer Biol Ther  2008; 7:1146-56; PMID:18535405; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Cancer Sci 2006; 97:64-71; PMID:16367923; http://dx.doi.org/10.1111/j.1349- 7006.2006.00136.x 22.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Endocr Relat Cancer 2011; 18:465-78;  PMID:21636702; http://dx.doi.org/10.1530/ERC-11-0083 23.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Epigenetics 2012; 7:1249- 57; PMID:22983262; http://dx.doi.org/10.4161/ epi.22191 25.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Oncogene  2011; 30:1390-401; PMID:21132003; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Cancer  2009; 115:3412-26; PMID:19472401; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Am J Pathol  2006; 169:1643-51; PMID:17071588; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
J  Natl Cancer Inst 2002; 94:1888-91; PMID:12488483;  http://dx.doi.org/10.1093/jnci/94.24.1888 48.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Toxicol Appl Pharmacol 2005; 206:288- 98; PMID:16039940; http://dx.doi.org/10.1016/j.taap.2004.11.017 49.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Genome Res 2011; 21:2026-37; PMID:21873453; http://dx.doi.org/10.1101/ gr.123935.111 52.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Bioinformatics 2007; 23:257-8; PMID:17098774; http://dx.doi.org/10.1093/bioin- formatics/btl567 53.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Nucleic Acids Res 2003; 31:e15;  PMID:12582260; http://dx.doi.org/10.1093/nar/ gng015 54.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Nucleic Acids Res 2012; 40:8993-9007; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Virology  2011; 411:273-87; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Genome Res  2011; 21:1800-12; http://dx.doi.org/10.1101/ gr.121749.111; PMID:21784874 41.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Semin Cancer Biol 2010;  20:246-53; http://dx.doi.org/10.1016/j.semcan- cer.2010.05.005; PMID:20685251 42.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Biochem J 2012;  441:645-52; http://dx.doi.org/10.1042/BJ20111417; PMID:21985173 43.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Mol Cell 2009; 34:271-84; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Free Radic Biol Med 2013;  61C:249-56; http://dx.doi.org/10.1016/j.freerad- biomed.2013.04.019; PMID:23602911 45.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Biochem J 2013;  449:623-30; http://dx.doi.org/10.1042/BJ20121429;  PMID:23116180 46.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Carcinogenesis 1997; 18:1215- 23; PMID:9214605; http://dx.doi.org/10.1093/car-cin/18.6.121529.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Int J Cancer  2002; 98:713-7; PMID:11920640; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Biochem Biophys Res Commun 2006; 347:288-96; PMID:16815308;  http://dx.doi.org/10.1016/j.bbrc.2006.06.076 32.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Biochem Biophys  Res Commun 2005; 333:1050-9; PMID:15964543;  http://dx.doi.org/10.1016/j.bbrc.2005.05.193 33.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Biochem Biophys  Res Commun 2004; 325:1383-92; PMID:15555580;  http://dx.doi.org/10.1016/j.bbrc.2004.10.183 34.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Biochem Biophys Res Commun 2005; 333:5- 13; PMID:15936718; http://dx.doi.org/10.1016/j.bbrc.2005.05.069 36.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Biochem Biophys Res Commun 2004; 320:45-53;  PMID:15207700; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
Biochem Biophys Res Commun 2005; 333:206- 15; PMID:15950191; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b1/a1/epi-8-1080.PMC3891689.pdf
"Dr Bock highlighted the 450k array’s accuracy and similarity to genotyping applications in addition to having a quick and easy analysis workflow compared with sequencing based methods and to this end briefly presented a 450k analy - sis tool developed in his group, RnBeads (http://rnbeads.bioinf.mpi-inf.mpg.de).",OADS,/arxiv_data1/oa_pdf/00/cf/epi-8-1123.PMC3891693.pdf
This consortium has been organized to bring together researchers studying the genetic  Correspondence to: Robert Lowe and Tiffany Morris;   Email: r.lowe@qmul.ac.uk and tiffany.morris@ucl.ac.ukSubmitted: 08/01/13; Accepted: 08/07/13http://dx.doi.org/10.4161/epi.26073the i llumina i nfinium HumanMethylation450 BeadChip— the successor to their hugely popular HumanMethylation27  BeadChip—is arguably the most prevalent platform for large- scale studies of D nA methylome analysis.,Non-OADS,/arxiv_data1/oa_pdf/00/cf/epi-8-1123.PMC3891693.pdf
"Tiffany Morris (Cancer Institute, University College London,  UK) presented the recently released ChAMP package, an R-package available for download at http://www2.cancer.ucl.ac.uk/medicalgenomics/champ/.",Non-OADS,/arxiv_data1/oa_pdf/00/cf/epi-8-1123.PMC3891693.pdf
"Readers wishing to keep informed of issues related to the  Illumina 450k platform are encouraged to visit the actively-used web forum set up last year, http://groups.google.com/group/epigenomicsforum Disclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed.",Non-OADS,/arxiv_data1/oa_pdf/00/cf/epi-8-1123.PMC3891693.pdf
"Robert Lowe (Queen Mary University of London, UK) pre - sented his recent work on a new public database for Illumina 450k data known as Marmal-Aid (http://marmal-aid.org/).",Non-OADS,/arxiv_data1/oa_pdf/00/cf/epi-8-1123.PMC3891693.pdf
Epigenetics 2012; 7:961- 2; PMID:22722984; http://dx.doi.org/10.4161/ epi.209412.,Non-OADS,/arxiv_data1/oa_pdf/00/cf/epi-8-1123.PMC3891693.pdf
Epigenetics 2013; 8:333-46; PMID:23422812;  http://dx.doi.org/10.4161/epi.24008,Non-OADS,/arxiv_data1/oa_pdf/00/cf/epi-8-1123.PMC3891693.pdf
"Letter from the Editor ronald Ellis1,* and Eva M. r iedmann2 1senior Vice President r &d and c hief t echnology o fficer; n asVax, Ltd.; n ess Ziona, Israel; 2acquisitions Editor; Landes Bioscience; Vienna, a ustria *Correspondence to: Ronald Ellis; Email: rellis@landesbioscience.com Submitted: 1/22/12; Accepted: 1/22/12http://dx.doi.org/10.4161/hv.24171",Non-OADS,/arxiv_data1/oa_pdf/c7/1c/hvi-9-447.PMC3891697.pdf
"www.landesbioscience.com Human Vaccines & Immunotherapeutics 449Human Vaccines & Immunotherapeutics 9:3, 449–449; March 2013; © 2013 Landes Bioscience EdItor’s caornEr PrEfacE Eighth World Congress   on Vaccines, Immunisation and Immunotherapy Edouard Kurstak Infections c ontrol World o rganization; f aculty of Medicine; University of Montreal; Montreal, Q c, canada *Correspondence to: Edouard Kurstak; Email: icwo@sympatico.ca Submitted: 11/30/12; Accepted: 11/30/12http://dx.doi.org/10.4161/hv.23219This special issue of Human  Vaccines  & Immunotherapeutics is  based on the Eighth World Congress on Vaccines, Immunisation and  Immunotherapy  (WCVII), which was organized from 5–7 of June,  2012 by the Infections Control World Organization (ICWO) in Barcelona, Spain.",Non-OADS,/arxiv_data1/oa_pdf/38/50/hvi-9-449.PMC3891698.pdf
"www.landesbioscience.com Human Vaccines & Immunotherapeutics 471Human Vaccines & Immunotherapeutics 9:3, 471–479; March 2013; © 2013 Landes Bioscience ReseaR cH papeR ReseaR cH papeR *Correspondence to: Annaliesa S. Anderson; Email: annaliesa.anderson@pfizer.com Submitted: 10/17/2012; Accepted: 10/29/2012http://dx.doi.org/10.4161/hv.23222Introduction Neisseria meningitidis  is a Gram-negative bacterium commonly  found in the throat and nasal passages of healthy individuals.",Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Vaccine 2009; 27(Suppl 2):B71- 7; PMID:19477055; http://dx.doi.org/10.1016/j.vac- cine.2009.04.070.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
J Clin  Microbiol 2011; 49:506-12; PMID:21123536; http://dx.doi.org/10.1128/JCM.01322-10.3.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
J Clin Microbiol 2012; 50:264-73; PMID:22135261;  http://dx.doi.org/10.1128/JCM.05385-11.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Vaccine 2006; 24:4692-700;  PMID:16621189; http://dx.doi.org/10.1016/j.vac- cine.2006.03.034.5.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Available via the Internet: http://www.cdc.gov/ abcs/reports-findings/survreports/mening09.pdf.,OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
J Exp Med 1969; 129:1307- 26; PMID:4977280; http://dx.doi.org/10.1084/ jem.129.6.1307.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Vaccine 2006; 24:5093-107; PMID:16838413; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Vaccine 2010; 28:7667-75; PMID:20875489;  http://dx.doi.org/10.1016/j.vaccine.2010.09.038.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Lancet Infect Dis 2012; 12:597-607;  PMID:22569484; http://dx.doi.org/10.1016/S1473- 3099(12)70087-7.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
J Exp Med 2003; 197:789- 99; PMID:12642606; http://dx.doi.org/10.1084/ jem.20021911.20.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Vaccine  2011; 29:6049-58; PMID:21704667; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
PLoS  One 2012; 7:e44102; PMID:22952888; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Vaccine 2004; 22:1087-96; PMID:15003635; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Expert Rev Vaccines  2011; 10:617-34; PMID:21604983; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
J Infect Dis 2009; 200:379-89; PMID:19534597;  http://dx.doi.org/10.1086/600141.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Vaccine  2010; 28:2122-9; PMID:20044056; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Infect Immun 2004;  72:2088-100; PMID:15039331; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
http://ecdc.europa.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Vaccine 2009;  27(Suppl 2):B51-63; PMID:19477562; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Hum Vaccin 2010; 6:1025-7; PMID:21150271;  http://dx.doi.org/10.4161/hv.6.12.13145.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
J Clin Microbiol  2004; 42:5146-53; PMID:15528708; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Lancet Infect Dis 2010; 10:853-61;  PMID:21075057; http://dx.doi.org/10.1016/S1473- 3099(10)70251-6.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
FEMS Microbiol  Rev 2007; 31:101-7; PMID:17168998; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Lancet 2002; 359:1829-31; PMID:12044380; http://dx.doi.org/10.1016/S0140-6736(02)08679-8.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Clin Vaccine Immunol 2010; 17:840- 7; PMID:20219881; http://dx.doi.org/10.1128/ CVI.00529-09.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
Expert Rev Anti  Infect Ther 2011; 9:761-74; PMID:21905785; http://dx.doi.org/10.1586/eri.11.89.,Non-OADS,/arxiv_data1/oa_pdf/53/5e/hvi-9-471.PMC3891702.pdf
"Human Vaccines & Immunotherapeutics 9:3, 480–487; March 2013; © 2013 Landes Bioscience ReseaR cH papeR 480 Human Vaccines & Immunotherapeutics Volume 9 Issue 3ReseaR cH papeR *Correspondence to: Annaliesa Anderson; Email: Annaliesa.anderson@pfizer.com Submitted: 10/17/12; Accepted: 10/26/12http://dx.doi.org/10.4161/hv.23223Introduction Staphylococcus aureus  are Gram-positive commensal bacteria that  asymptomatically colonize ~30% of humans.1 A breach in the  skin or other mucosal barriers allows S. aureus  to invade the host  and cause diseases ranging from mild skin infection to more  devastating conditions such as bacteremia, osteomyelitis and endocarditis.",Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
J Infect Dis 2008; 197:1226-34; PMID:18422434;  http://dx.doi.org/10.1086/533494.2.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Clin Infect Dis 2012; 54:1126- 33; PMID:22438343; http://dx.doi.org/10.1093/cid/ cis022.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Clin Microbiol Infect  2012; 18:725-34; PMID:22448902; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Semin Immunopathol 2012; 34:185-200;  PMID:22160374; http://dx.doi.org/10.1007/s00281- 011-0300-x.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
J Clin Invest  1970; 49:1528-38; PMID:4194088; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
J Infect Dis 2012; 206:1041-9; PMID:22829645;  http://dx.doi.org/10.1093/infdis/jis463.,OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Clin Infect Dis  2012; 54:560-7; PMID:22186773; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
J Clin Invest 1967; 46:668- 79; PMID:6021213; http://dx.doi.org/10.1172/ JCI105568.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
J Lab Clin Med  2004; 143:358-65; PMID:15192652; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Infect Immun 2001; 69:6796- 803; PMID:11598052; http://dx.doi.org/10.1128/IAI.69.11.6796-6803.2001.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Infect Immun  2003; 71:656-62; PMID:12540542; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Hum Vaccin 2011; 7(Suppl):51- 9; PMID:21245656; http://dx.doi.org/10.4161/ hv.7.0.14562.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Clin Vaccine Immunol 2006; 13:165-9; PMID:16467321; http://dx.doi.org/10.1128/ CVI.13.2.165-169.2006.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Vaccine 2009; 27:3276-80; PMID:19200819;  http://dx.doi.org/10.1016/j.vaccine.2009.01.062.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
J Gen Microbiol 1991;  137:1155-62; PMID:1865184; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Crit Care Med  2002; 30:315-22; PMID:11889301; http://dx.doi.org/10.1097/00003246-200202000-00009.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Methods Mol Biol 2007; 412:489-504;  PMID:18453130; http://dx.doi.org/10.1007/978-1-59745-467-4_30.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Curr Opin Immunol 2003; 15:578- 84; PMID:14499268; http://dx.doi.org/10.1016/S0952-7915(03)00109-2.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
J Clin Invest 1975; 55:1357- 72; PMID:166094; http://dx.doi.org/10.1172/ JCI108055.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Clin Vaccine Immunol  2012; 19:1641-50; PMID:22896688; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Curr Opin Microbiol  2012; 15:92-9; PMID:22088393; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
Clin Infect Dis 2012; 55:1188- 97; PMID:22806596; http://dx.doi.org/10.1093/cid/ cis624.,Non-OADS,/arxiv_data1/oa_pdf/76/3c/hvi-9-480.PMC3891703.pdf
"www.landesbioscience.com Human Vaccines & Immunotherapeutics 561Human Vaccines & Immunotherapeutics 9:3, 561–567; March 2013; © 2013 Landes Bioscience ReseaR cH papeR ReseaR cH papeR *Correspondence to: Roberto Gasparini; Email: gasparini@unige.it Submitted: 11/07/12; Accepted: 11/19/12http://dx.doi.org/10.4161/hv.23235Introduction Influenza continues to be one of the most common respiratory  diseases in the world1 and, at the same time, poses a potential  pandemic threat.2 Apart from the serious harm to health and since 2000, a sentinel surveillance of influenza, INFLUN eT, exists in Italy.",Non-OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
Eur J Clin Microbiol Infect  Dis 2007; 26:619-28; PMID:17610094; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
Science 2012; 336:1529-31; PMID:22723411;  http://dx.doi.org/10.1126/science.1223204.,Non-OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
PLoS Comput Biol 2009; 5:e1000564;  PMID:19911053; http://dx.doi.org/10.1371/journal.,OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
"Influenza Available at  http://www.who.int/influenza/surveillance_monitor- ing/en/ Accessed on July 23, 2012.",OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
"Avaliable at http://www.salute.gov.it/influenza/influ- enza.jsp/ Accessed on July 23, 2012.",Non-OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
"Avaliable at http://www.iss.it Accessed on July 23, 2012.",Non-OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
"Available at http://www.cirinet.it/dati_prec/epi/risul- tati_2009_2010/nazionale/nazionale.htm Accessed on  June 23, 2012.",Non-OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
Lancet Infect Dis 2012; 12:687-95; PMID:22738893;  http://dx.doi.org/10.1016/S1473-3099(12)70121-4.,Non-OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
Ital J Pediatr 2011; 37:54; PMID:22074674; http://dx.doi.org/10.1186/1824- 7288-37-54.,OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
Pediatr Crit Care Med 2012; 13:e11-7; PMID:21263368; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
PLoS  One 2012; 7:e45051; PMID:23028756; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
Pediatr Infect Dis J 2012; 31:745- 51; PMID:22466322; http://dx.doi.org/10.1097/ INF .0b013e31825687b0.,OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
"http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm294057.htm Accessed on September 19, 2012.",Non-OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
J Med  Virol 2003; 70:463-9; PMID:12767012; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
Value Health 2007; 10:98-116; PMID:17391419; http://dx.doi.org/10.1111/j.1524- 4733.2006.00157.x.,Non-OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
http://www.cdc.gov/flu/international/activity.htm.,Non-OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
Arch Pediatr Adolesc Med  2004; 158:391-4; PMID:15066881; http://dx.doi.org/10.1001/archpedi.158.4.391.,OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
"Available at at: http://www.iss.it/flue/  Accessed on October 1, 2012.",Non-OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
"Inter-University Centre of Research on Influenza and other T ransmissible Infections (CIRI-IT) – Available  at: http://www.cirinet.it Accessed on October 1, 2012.",Non-OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
Available at http://www.salute.gov.it/influenza/ influenza.jsp,Non-OADS,/arxiv_data1/oa_pdf/13/3c/hvi-9-561.PMC3891712.pdf
"Human Vaccines & Immunotherapeutics 9:3, 692–698; March 2013; © 2013 Landes Bioscience ReseaR cH papeR 692 Human Vaccines & Immunotherapeutics Volume 9 Issue 3ReseaR cH papeR *Correspondence to: Rosa López-Gigosos; Email: roslopgig@uma.es Submitted: 10/19/12; Accepted: 10/29/12http://dx.doi.org/10.4161/hv.23267Introduction Traveler’s diarrhea (TD) is the most common disease in people  from industrialized countries who travel to less developed ones, especially to countries of sub-Saharan Africa, Southern Asia and South America.",Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
"The Oxford Center for Evidence-Based Medicine (http://www.cebm.net/) classifies cohort studies as having a level of evidence of 2b, which is the category immediately below randomized clini - cal trials.",Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
J T ravel Med 2006; 13:203-11;  PMID:16884402; http://dx.doi.org/10.1111/j.1708-8305.2006.00046.x.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
Emerg Infect Dis 2009; 15:1783-90; PMID:19891866; http://dx.doi.org/10.3201/ eid1511.091147.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
J T ravel Med 2008; 15:110-8;  PMID:18346244; http://dx.doi.org/10.1111/j.1708- 8305.2008.00189.x.5.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
Clin Infect Dis 2006; 43:898-901;  PMID:16941373; http://dx.doi.org/10.1086/507540.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
J T ravel Med 2009; 16:28-34;  PMID:19192125; http://dx.doi.org/10.1111/j.1708- 8305.2008.00270.x.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
JAMA 1983;  249:1176-80; PMID:6823079; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
Adv Ther 2006; 23:519-27; PMID:17050494;  http://dx.doi.org/10.1007/BF02850040.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
Infect Dis  Clin North Am 1998; 12:325-54; PMID:9658248; http://dx.doi.org/10.1016/S0891-5520(05)70008-8.11.,OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
J Infect Dis 1992; 165:385-8; PMID:1730905; http://dx.doi.org/10.1093/infdis/165.2.385.,OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
Med Mal Infect 2007; 37:722-7;  PMID:17942257; http://dx.doi.org/10.1016/j.med - mal.2007.09.004.,OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
Clin Infect Dis 2001; 32:1706-9; PMID:11360211;  http://dx.doi.org/10.1086/320756.,OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
T ravel  Med Infect Dis 2007; 5:380-4; PMID:17983977;  http://dx.doi.org/10.1016/j.tmaid.2007.06.001.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
BMC Infect Dis 2009; 9:65;  PMID:19445712; http://dx.doi.org/10.1186/1471-2334-9-65.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
J T ravel Med 2007; 14:297-305;  PMID:17883460; http://dx.doi.org/10.1111/j.1708- 8305.2007.00142.x.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
Lancet Infect Dis 2005; 5:349-60; PMID:15919621; http://dx.doi.org/10.1016/S1473-3099(05)70139-0.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
Aliment Pharmacol Ther 2008; 27:741-51;  PMID:18284650; http://dx.doi.org/10.1111/j.1365-2036.2008.03647.x.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
Clin Infect Dis 2005; 41(Suppl 8):S536-40;  PMID:16267715; http://dx.doi.org/10.1086/432948.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
Lancet  1991; 338:1285-9; PMID:1682684; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
J T ravel  Med 1995; 2:22-7; PMID:9815355; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
J Infect Dis 2002; 185:497-502;  PMID:11865402; http://dx.doi.org/10.1086/338834.,OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
Digestion 2006;  73(Suppl 1):102-8; PMID:16498258; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
J Infect 2004; 48:161-7; PMID:14720492; http://dx.doi.org/10.1016/S0163-4453(03)00138-5.,OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
http://www.who.int/vaccine_research/diseas- es/diarrhoeal/en/index4.html 20.,Non-OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
Lancet 1986; 2:124-7;  PMID:2873397; http://dx.doi.org/10.1016/S0140- 6736(86)91944-6.,OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
N Engl J Med 1993; 328:1821- 7; PMID:8502272; http://dx.doi.org/10.1056/ NEJM199306243282507.,OADS,/arxiv_data1/oa_pdf/7c/d2/hvi-9-692.PMC3891730.pdf
"J Mol Biol 2013; 425:3046-59; PMID:23770111; http://dx.doi.org/10.1016/j.jmb.2013.06.006Keywords:  yeast, prion, [ PIN+], [PSI+] Submitted: 06/17/13 Accepted: 07/09/13 Citation: Sharma J, Liebman SW. Variant-specific  prion interactions: Complicating factors.",OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
"Cell Logist 2013; 3:25698; http://dx.doi.org/10.4161/cl.25698*Correspondence to: Susan W. Liebman;   Email: sliebman@unr.eduPrions are protein conformations  that “self-seed” the misfolding of  their non-prion iso-forms into prion, often amyloid, conformations.",OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Curr Biol 2001; 11:366-9;  PMID:11267875; http://dx.doi.org/10.1016/S0960- 9822(01)00099-9 17.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
EMBO J 2000; 19:1942- 52; PMID:10790361; http://dx.doi.org/10.1093/ emboj/19.9.1942 18.,Non-OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Cell 2001; 106:171-82; PMID:11511345; http://dx.doi.org/10.1016/S0092-8674(01)00427-5 22.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Proc Natl Acad Sci U S A 2004; 101:12934-9; PMID:15326312; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
EMBO J 1999; 18:1182- 91; PMID:10064585; http://dx.doi.org/10.1093/ emboj/18.5.1182 9.,Non-OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
EMBO J 2001; 20:6236-45; PMID:11707395;  http://dx.doi.org/10.1093/emboj/20.22.6236 10.,Non-OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
PLoS Genet 2013;  9:e1003257; PMID:23382698; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
J Biol Chem 2003; 278:49636-43;  PMID:14507919; http://dx.doi.org/10.1074/jbc.M307996200 12.,Non-OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
J Biol Chem 2004; 279:51042-8; PMID:15465809; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Science  2010; 330:680-3; PMID:21030659; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Nature  2007; 449:233-7; PMID:17767153; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
PLoS Biol 2004;  2:e321; PMID:15383837; http://dx.doi.org/10.1371/ journal.pbio.0020321Acknowledgments This work was supported by the National  Institutes of Health (NIH) Grant R01GM056350 to SWL.,Non-OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Nat  Rev Mol Cell Biol 2007; 8:552-61; PMID:17585315;  http://dx.doi.org/10.1038/nrm2204 2.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Cell  2011; 147:498-508; PMID:22036560; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Cell 2012; 149:968-77; PMID:22632966;  http://dx.doi.org/10.1016/j.cell.2012.05.007 4.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
J Mol Biol  2012; 421:491-8; PMID:22245492; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
J Mol Biol  2013; 425:3046-59; PMID:23770111; http://dx.doi.org/10.1016/j.jmb.2013.06.006 6.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Science 1994; 264:566-9; PMID:7909170;  http://dx.doi.org/10.1126/science.7909170 7.,Non-OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Proc Natl Acad Sci U S A 2005;  102:6098-102; PMID:15829582; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Proc Natl Acad Sci U S A 2008; 105:2403-8; PMID:18268327; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Science 1995; 268:880-4;  PMID:7754373; http://dx.doi.org/10.1126/sci - ence.7754373 40.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Mol Microbiol  2001; 39:37-46; PMID:11123686; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Cell 2013;  154:134-45; PMID:23791384; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Genetics 2012; 191:1041-72; PMID:22879407; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Nature 2004; 428:323-8; PMID:15029196; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
J Neurosci  2010; 30:4528-35; PMID:20357103; http://dx.doi.org/10.1523/JNEUROSCI.5924-09.201024.,Non-OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Methods 2006; 39:23- 34; PMID:16793281; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Cell 2001; 106:183-94;  PMID:11511346; http://dx.doi.org/10.1016/S0092- 8674(01)00440-8 27.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
J Biol Chem 2007; 282:1779- 87; PMID:17121829; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Eukaryot Cell  2009; 8:968-76; PMID:19411620; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
Mol Biol Cell 2008; 19:2433-43; PMID:18353968;  http://dx.doi.org/10.1091/mbc.E08-01-0078 30.,Non-OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
PLoS Genet 2013; 9:e1003236; PMID:23358669; http://dx.doi.org/10.1371/jour - nal.pgen.1003236,OADS,/arxiv_data1/oa_pdf/9b/5e/cl-3-e25698.PMC3891757.pdf
"OncoImmunology 2013; 2:e27157;  http://dx.doi.org/10.4161/onci.27157Immune effectors required   for the therapeutic activity of vorinostat Oliver Kepp1,2,3,4, Lorenzo Galluzzi3,4,5, and Guido Kroemer1,2,3,4,6 1INserM, U848; Villejuif, France; 2Metabolomics and Cell Biology Platforms, Gustave r oussy; Villejuif, France; 3equipe 11 labellisée par la Ligue Nationale contre le Cancer,   Centre de r echerche des Cordeliers; Paris, France; 4Université Paris d escartes/Paris V; s orbonne Paris Cité; Paris, France; 5Gustave r oussy; Villejuif, France;   6Pôle de Biologie, Hôpital e uropéen Georges Pompidou, a P-HP; Paris, France Keywords:  B lymphocytes, histone deacetylase inhibitors, immunogenic cell death, interferon γ , natural killer cells, SAHA",Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Oncologist 2007; 12:1247-52;  PMID:17962618 ;  http://dx.doi.org/10.1634/theoncologist.12-10-1247 2.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Blood 2007; 109:31- 9; PMID:16960145 ; http://dx.doi.org/10.1182/ blood-2006-06-025999 3.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
J Clin Oncol 2007; 25:3109-15; PMID:17577020 ;  http://dx.doi.org/10.1200/JCO.2006.10.2434 4.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Blood 2010; 116:3013-22; PMID:20647567 ; http://dx.doi.org/10.1182/ blood-2010-05-284968 6.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Immunity 2013; 39:74-88; PMID:23890065 ;  http://dx.doi.org/10.1016/j.immuni.2013.06.014 7.,OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798 ; http://dx.doi.org/10.1038/ nrd36268.,OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Proc Natl Acad Sci U S A 2011; 108:4141-6;  PMID:21368108 ; http://dx.doi.org/10.1073/ pnas.1011037108 9.,OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Oncoimmunology 2012; 1:377- 9; PMID:22737621 ; http://dx.doi.org/10.4161/ onci.18804 10.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Oncoimmunology 2012; 1:1629-31; PMID:23264917 ; http://dx.doi.org/10.4161/ onci.21652 11.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Cancer Res 2013;  Forthcoming; PMID :24158093 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Nat Rev Clin Oncol 2011; 8:151-60;  PMID:21364688 ; http://dx.doi.org/10.1038/ nrclinonc.2010.223 13.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Oncoimmunology 2012; 1:271-8;  PMID:22737602 ;  http://dx.doi.org/10.4161/onci.18684 14.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Oncoimmunology  2012; 1:1610-1;  PMID:23264910 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Annu Rev Immunol 2013; 31:51-72;  PMID :23157435 ; http://dx.doi.org/10.1146/ annurev-immunol-032712-10000816.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Oncoimmunology  2012; 1:1640-2;  PMID:23264921 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Sci Transl Med 2012; 4:143ra99; PMID:22814852 ;  http://dx.doi.org/10.1126/scitranslmed.3003807 19.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Cell Death Differ 2013; Forthcoming;  PMID:23744294 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Oncoimmunology 2012; 1:393-5; PMID:22737627 ; http://dx.doi.org/10.4161/ onci.19070 21.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Oncoimmunology 2012; 1:179- 88; PMID:22720239 ; http://dx.doi.org/10.4161/ onci.1.2.19026 22.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Cancer Lett  2008; 272:110-21;  PMID:18718708 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Blood  2013; 122:684-93;  PMID:23801635 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Cell Immunol 2009; 257:97-104; PMID:19358983 ; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Clin Immunol 2010; 136:348- 63; PMID:20478744 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Gastroenterology 2010; 138:583-94; PMID:19879272 ; http://dx.doi.org/10.1053/j.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Oncoimmunology 2012; 1:948- 50; PMID:23162767 ; http://dx.doi.org/10.4161/ onci.20306 28.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
FEBS Lett 2007; 581:1317-22;  PMID:17349632 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Cancer Lett 2010; 295:173-81; PMID:20346580 ;  http://dx.doi.org/10.1016/j.canlet.2010.02.024 30.,OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Proc Natl Acad Sci U S A  2004; 101:3921-6;  PMID :15001702 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Mol Ther 2013; 21:887- 94; PMID:23295947 ; http://dx.doi.org/10.1038/ mt.2012.265 33.,OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Br J Pharmacol 2011; 162:1590-602 ;  PMID:21198545 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
J Exp Med 2005; 202:1691-701; PMID:16365148 ;  http://dx.doi.org/10.1084/jem.20050915 36.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Oncoimmunology  2012; 1:1313-22;  PMID:23243595 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Cancer Res 2011; 71:5601-5; PMID:21846822 ;  http://dx.doi.org/10.1158/0008-5472.CAN-11-131638.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Oncoimmunology 2012; 1:1156- 8; PMID:23170262 ; http://dx.doi.org/10.4161/ onci.21653 39.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Oncoimmunology 2012; 1:432- 40; PMID:22754761 ; http://dx.doi.org/10.4161/ onci.19545 40.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Oncoimmunology 2012; 1:1623- 5; PMID :23264915 ; http://dx.doi.org/10.4161/ onci.21650 41.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Oncoimmunology 2012; 1:1323-43; PMID:23243596 ; http://dx.doi.org/10.4161/ onci.22009 42.,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
Nat Med 2011; 17:700-7; PMID :21552268 ;  http://dx.doi.org/10.1038/nm.2366,Non-OADS,/arxiv_data1/oa_pdf/d4/ff/onci-2-e27157.PMC3891759.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/6e/89/jpr-7-037.PMC3891762.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Pain Research 2014:7 37–46Journal of Pain Research Dove press submit your manuscript | www.dovepress.co m Dove press  37ORiginal ReseaRchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JPR.S51636Real-world comparison of health care utilization  between duloxetine and pregabalin initiators   with fibromyalgia X Peng1 P sun2 D novick1 J andrews1 s sun2 1Eli Lilly and Company, Indianapolis,   IN, USA; 2Kailo Research Group,   Indianapolis, IN, USA correspondence: Peter sun   Kailo Research Group, 8247 Jo Ellen  Drive, Fishers, IN 46038, USA   Tel +317 841 9141   Fax +317 841 9150   email psun001@yahoo.co mObjectives:  To compare health care utilization of duloxetine initiators and pregabalin initiators  among fibromyalgia patients in a real-world setting.",Non-OADS,/arxiv_data1/oa_pdf/6e/89/jpr-7-037.PMC3891762.pdf
"Available from:  http://www.localhealth.com/article/fibromyalgi a. Accessed May 5, 2009.",Non-OADS,/arxiv_data1/oa_pdf/6e/89/jpr-7-037.PMC3891762.pdf
Available from: http://fmaware.org/PageServera6cc.html?,Non-OADS,/arxiv_data1/oa_pdf/6e/89/jpr-7-037.PMC3891762.pdf
"Journal of Pain Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-pain-research-journa lThe Journal of Pain Research is an international, peer-reviewed, open  access, online journal that welcomes laboratory and clinical findings  in the fields of pain research and the prevention and management  of pain.",Non-OADS,/arxiv_data1/oa_pdf/6e/89/jpr-7-037.PMC3891762.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/6e/89/jpr-7-037.PMC3891762.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/7c/97/tcrm-10-037.PMC3891763.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpTherapeutics and Clinical Risk Management 2014:10 37–43Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  37ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S5421 3subfoveal choroidal thickness after photodynamic  therapy in patients with acute idiopathic   central serous chorioretinopathy Yalong Dang1–3,# Xinfeng sun2,# Y ongsheng Xu3,# Yalin Mu2 Manli Zhao2 Jing Zhao2  Yu Zhu1 Chun Zhang3 1Department of Ophthalmology,   First affiliated hospital of  Zhengzhou University, Zhengzhou,   henan Province, 2Department of  Ophthalmology, Yellow River hospital,   henan University of science and  T echnology, sanmenxia, henan  Province, 3Clinical stem Cell Research  Center, Peking University Third  hospital, Beijing, People’s Republic   of China #These authors contributed equally to  this work Correspondence: Yu Zhu   First Affiliated Hospital of  Zhengzhou University,   Jianshe east Road, Zhengzhou, henan  Province, People’s Republic of China   Tel +86 39 8228 9268   Fax +86 39 8282 3634   email dr.dang@aol.co m    Chun Zhang   Clinical stem Cell Research Center,  Peking University Third hospital, Beijing,  People’s Republic of China   email zhang.chun@aol.co mBackground:  The purpose of this study was to evaluate changes in subfoveal choroidal thickness  after photodynamic therapy in patients with acute idiopathic central serous chorioretinopathy  (ICSCR).",Non-OADS,/arxiv_data1/oa_pdf/7c/97/tcrm-10-037.PMC3891763.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/7c/97/tcrm-10-037.PMC3891763.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/7c/97/tcrm-10-037.PMC3891763.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ce/c2/tcrm-10-027.PMC3891764.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpTherapeutics and Clinical Risk Management 2014:10 27–35Therapeutics and Clinical Risk Management Video abstract Point your Smar tPhone at the code abo ve.,Non-OADS,/arxiv_data1/oa_pdf/ce/c2/tcrm-10-027.PMC3891764.pdf
"Or use: http://dvpr.es/1hyS1E lDove press submit your manuscript | www.dovepress.co m Dove press  27Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S5481 0Transient ischemic attacks: predictability   of future ischemic stroke or transient   ischemic attack events Harsh v Gupta1 Ann M Farrell2 Manoj K Mittal3 1Department of Neurology,   The University of Arkansas  Medical Sciences, Little Rock, AR,   2Department of Knowledge and  evaluation Research, Mayo Clinic,  Rochester, MN, 3Department of  Neurology, The University of Kansas  Medical Center, Kansas City, KS, USA Correspondence: Manoj K Mittal   Department of Neurology,   The University of Kansas Medical Center,   3599 Rainbow Blvd, Mailstop 2012,   Kansas City, KS 66160, USA   email mmittal2@kumc.ed uAbstract:  The short-term risk of an ischemic stroke after a transient ischemic attack (TIA)  is estimated to be approximately 3%–10% at 2 days, 5% at 7 days, and 9%–17% at 90 days,  depending on active or passive ascertainment of ischemic stroke.",Non-OADS,/arxiv_data1/oa_pdf/ce/c2/tcrm-10-027.PMC3891764.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/ce/c2/tcrm-10-027.PMC3891764.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/ce/c2/tcrm-10-027.PMC3891764.pdf
"www.jpis.orgpISSN 2093-2278 eISSN 2093-2286Editorial Copyright © 2013 Korean Academy of Periodontology This is an Open Access article distributed under the terms of the Creative Commons Attribution   Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).New Year’s resolution in JPISJ Periodontal Implant Sci 2013;43:249-250 • http://dx.doi.org/10.5051/jpis.2013.43.6.249 Two years ago, the journal Nature  expressed a deep concern about   a surge in retracted scientific papers going out of control  (doi:10.1038/478026a).",Non-OADS,/arxiv_data1/oa_pdf/95/15/jpis-43-249.PMC3891855.pdf
"www.jpis.orgJournal of Periodontal & Implant Science JPIS pISSN 2093-2278 eISSN 2093-2286Copyright © 2013 Korean Academy of Periodontology This is an Open Access article distributed under the terms of the Creative Commons Attribution   Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Advances in the design of macroporous polymer  scaffolds for potential applications in dentistry Sidi A. Bencherif1,2,*, Thomas M. Braschler1,3, Philippe Renaud3 1School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, USA  2Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA  3Laboratory of Microsystems, STI-LMIS4, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland A paradigm shift is taking place in medicine and dentistry from using synthetic implants and tissue grafts to a tissue engi - neering approach that uses degradable porous three-dimensional (3D) material hydrogels integrated with cells and bioactive  factors to regenerate tissues such as dental bone and other oral tissues.",Non-OADS,/arxiv_data1/oa_pdf/32/38/jpis-43-251.PMC3891856.pdf
"Keywords:  Hydrogels, Polymers, Tissue engineering.J Periodontal Implant Sci 2013;43:251-261 • http://dx.doi.org/10.5051/jpis.2013.43.6.251Review Article INTRODUCTION Pore size and porosity are of paramount importance in the  design of biomaterial scaffolds for tissue engineering appli - cations.",Non-OADS,/arxiv_data1/oa_pdf/32/38/jpis-43-251.PMC3891856.pdf
http://dx.doi.org/ 10.1089/ten.,Non-OADS,/arxiv_data1/oa_pdf/32/38/jpis-43-251.PMC3891856.pdf
"www.jpis.orgJournal of Periodontal & Implant Science JPIS pISSN 2093-2278 eISSN 2093-2286Copyright © 2013 Korean Academy of Periodontology This is an Open Access article distributed under the terms of the Creative Commons Attribution   Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Photobiomodulation and implants:   implications for dentistry  Elieza Tang, Praveen Arany* Cell Regulation and Control Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA The use of dental implants has become a mainstay of rehabilitative and restorative dentistry.",Non-OADS,/arxiv_data1/oa_pdf/e7/4d/jpis-43-262.PMC3891857.pdf
"Keywords:  Dental implants, Low-level laser therapy, Peri-implantitis, Phototherapy.J Periodontal Implant Sci 2013;43:262-268 • http://dx.doi.org/10.5051/jpis.2013.43.6.262Review Article INTRODUCTION  Low-level light therapy (LLLT) or photobiomodulation (PBM)  has become a routine treatment modality in many dental  clinical settings and has been demonstrated to be efficacious  in wound healing and tissue regeneration [1].",Non-OADS,/arxiv_data1/oa_pdf/e7/4d/jpis-43-262.PMC3891857.pdf
"www.jpis.orgJournal of Periodontal & Implant Science JPIS pISSN 2093-2278 eISSN 2093-2286Copyright © 2013 Korean Academy of Periodontology This is an Open Access article distributed under the terms of the Creative Commons Attribution   Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Comparative evaluation of NovaMin desensitizer  and Gluma desensitizer on dentinal tubule  occlusion: a scanning electron microscopic study Surabhi Joshi1, Ashwini Shivananje Gowda2, Chintan Joshi3,* 1Department of Periodontics, Karnavati School of Dentistry, Gandhinagar, India 2Department of Periodontics, M.S.",Non-OADS,/arxiv_data1/oa_pdf/89/6e/jpis-43-269.PMC3891858.pdf
"Keywords:  Dentin sensitivity, Gluma desensitizer, NovaMin, Scanning electron microscopy.J Periodontal Implant Sci 2013;43:269-275 • http://dx.doi.org/10.5051/jpis.2013.43.6.269Research Article INTRODUCTION Following the decline of dental caries, the management of  periodontal diseases gained priority, and other, painful den - tal problems, such as dentin hypersensitivity drew attention  [1].",Non-OADS,/arxiv_data1/oa_pdf/89/6e/jpis-43-269.PMC3891858.pdf
"www.jpis.orgJournal of Periodontal & Implant Science JPIS pISSN 2093-2278 eISSN 2093-2286Copyright © 2013 Korean Academy of Periodontology This is an Open Access article distributed under the terms of the Creative Commons Attribution   Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Analysis of periodontal attachment loss in  relation to root form abnormalities Young-Mi Chung, Seong-Nyum Jeong*  Department of Periodontology, Daejeon Dental Hospital, Wonkwang University School of Dentistry, Daejeon, Korea  Purpose:  The aim of this study was to explore root shape abnormalities, to investigate the influence of root form abnormali - ties on periodontal attachment loss, and to gather basic data to assist in the diagnosis and treatment of aggressive periodonti - tis.",Non-OADS,/arxiv_data1/oa_pdf/c9/16/jpis-43-276.PMC3891859.pdf
"Keywords:  Aggressive periodontitis, Periodontal attachment loss, Tooth loss, Tooth root.J Periodontal Implant Sci 2013;43:276-282 • http://dx.doi.org/10.5051/jpis.2013.43.6.276Research Article INTRODUCTION Aggressive periodontitis is characterized by a rapid loss of  periodontal attachment and alveolar bone.",Non-OADS,/arxiv_data1/oa_pdf/c9/16/jpis-43-276.PMC3891859.pdf
www.jpis.orgJournal of Periodontal & Implant Science JPIS pISSN 2093-2278 eISSN 2093-2286Copyright © 2013 Korean Academy of Periodontology This is an Open Access article distributed under the terms of the Creative Commons Attribution   Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/0b/a1/jpis-43-283.PMC3891860.pdf
"J Periodontal Implant Sci 2013;43:283-290 • http://dx.doi.org/10.5051/jpis.2013.43.6.283Research Article INTRODUCTION In recent years, it has become clear that each person has a  different gingival character.",Non-OADS,/arxiv_data1/oa_pdf/0b/a1/jpis-43-283.PMC3891860.pdf
"www.jpis.orgJournal of Periodontal & Implant Science JPIS pISSN 2093-2278 eISSN 2093-2286Copyright © 2013 Korean Academy of Periodontology This is an Open Access article distributed under the terms of the Creative Commons Attribution   Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Dissolution behavior and early bone apposition of  calcium phosphate-coated machined implants Ji-Wan Hwang1,†, Eun-Ung Lee1,†, Jung-Seok Lee1, Ui-Won Jung1, In-Seop Lee2, Seong-Ho Choi1,* 1Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul, Korea 2Institute of Physics & Applied Physics, Atomic-Scale Surface Science Research Center, Yonsei University, Seoul, Korea Purpose:  Calcium phosphate (CaP)-coated implants promote osseointegration and survival rate.",Non-OADS,/arxiv_data1/oa_pdf/9c/aa/jpis-43-291.PMC3891861.pdf
"Keywords:  Calcium phosphate, Dental implantation, Osseointegration.J Periodontal Implant Sci 2013;43:291-300 • http://dx.doi.org/10.5051/jpis.2013.43.6.291Research Article INTRODUCTION The implant surface plays an important role in enhancing  osseointegration and achieving rapid secondary stability [1].",Non-OADS,/arxiv_data1/oa_pdf/9c/aa/jpis-43-291.PMC3891861.pdf
"www.jpis.orgJournal of Periodontal & Implant Science JPIS pISSN 2093-2278 eISSN 2093-2286Copyright © 2013 Korean Academy of Periodontology This is an Open Access article distributed under the terms of the Creative Commons Attribution   Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).The effect of pretreating resorbable blast media  titanium discs with an ultrasonic scaler or  toothbrush on the bacterial removal efficiency of  brushing Minchul Koh1,†, Jun-Beom Park2,†, Yun-Ji Jang3, Youngkyung Ko2,* 1Graduate School of Clinical Dental Science, The Catholic University of Korea, Seoul, Korea  2Department of Periodontics, Seoul St Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea  3Department of Oral Microbiology and Immunology, Seoul National University School of Dentistry, Seoul, Korea Purpose:  This in vitro  study was performed to assess the adherence of Porphyromonas gingivalis  to a resorbable blast media  (RBM) titanium surface pretreated with an ultrasonic scaler or toothbrush and to evaluate the effects of the treatment of the  RBM titanium discs on the bacterial removal efficiency of brushing by crystal violet assay and scanning electron microscopy.",Non-OADS,/arxiv_data1/oa_pdf/3e/4e/jpis-43-301.PMC3891862.pdf
"Keywords:  Bacteria, Dental scaling, Scanning electron microscopy, Surface properties, Titanium, Toothbrushing.J Periodontal Implant Sci 2013;43:301-307 • http://dx.doi.org/10.5051/jpis.2013.43.6.301Research Article INTRODUCTION Titanium is recognized for its excellent biocompatibility in  many applications, including dental and hip implants [1], and  osseointegrated titanium dental implants have played an im - portant role in restoring the missing dentition [2].",Non-OADS,/arxiv_data1/oa_pdf/3e/4e/jpis-43-301.PMC3891862.pdf
"www.jpis.orgJournal of Periodontal & Implant Science JPIS pISSN 2093-2278 eISSN 2093-2286Copyright © 2013 Korean Academy of Periodontology This is an Open Access article distributed under the terms of the Creative Commons Attribution   Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Assessment of dentists’ subjective satisfaction  with a newly developed device for maxillary sinus  membrane elevation by the crestal approach Young-Kyun Kim1,*, Yong-Seok Cho2, Pil-Young Yun1 1Department of Oral and Maxillofacial Surgery, Section of Dentistry, Seoul National University Bundang Hospital, Seongnam, Korea 2Apsun Dental Hospital, Seoul, Korea Purpose:  The purposes of this study were to assess the dentists’ subjective satisfaction with the crestal approach sinus (CAS)  kit, a device for maxillary sinus membrane elevation by the crestal approach using a special drilling system and hydraulic pres - sure, and to summarize the subjective satisfaction of dental implants placed after a sinus lift procedure with the CAS kit.",Non-OADS,/arxiv_data1/oa_pdf/1b/0e/jpis-43-308.PMC3891863.pdf
J Periodontal Implant Sci 2013;43:308-314 • http://dx.doi.org/10.5051/jpis.2013.43.6.308Research Article INTRODUCTION Implant placement has become a widespread dental proce - dure to restore the edentulous jaw with functional defects.,Non-OADS,/arxiv_data1/oa_pdf/1b/0e/jpis-43-308.PMC3891863.pdf
SUPPLEMENTARY MATERIAL The questionnaire can be found via http://www.jpis.org/src/ sm/jpis-43-308-s001.pdf.,Non-OADS,/arxiv_data1/oa_pdf/1b/0e/jpis-43-308.PMC3891863.pdf
"www.jpis.orgJournal of Periodontal & Implant Science JPIS pISSN 2093-2278 eISSN 2093-2286Copyright © 2013 Korean Academy of Periodontology This is an Open Access article distributed under the terms of the Creative Commons Attribution   Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).Periodontal regeneration with   nano-hyroxyapatite-coated silk scaffolds in dogs Cheryl Yang1, Jung-Seok Lee1, Ui-Won Jung1, Young-Kwon Seo2, Jung-Keug Park2, Seong-Ho Choi1,* 1Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul, Korea 2Department of Medical Biotechnology, Dongguk University, Seoul, Korea Purpose:  In this study, we investigated the effect of silk scaffolds on one-wall periodontal intrabony defects.",Non-OADS,/arxiv_data1/oa_pdf/42/41/jpis-43-315.PMC3891864.pdf
"Keywords:  Dental pulp, Periodontal ligament, Silk, Tissue engineering, Tissue scaffolds.J Periodontal Implant Sci 2013;43:315-322 • http://dx.doi.org/10.5051/jpis.2013.43.6.315Research Article INTRODUCTION  Periodontal regeneration requires the attachment of a new  connective tissue to the root surface, a process that involves  the regeneration of periodontal fibers and the insertion of  these fibers into a newly formed cementum.",Non-OADS,/arxiv_data1/oa_pdf/42/41/jpis-43-315.PMC3891864.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided theoriginal work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d5/6b/trt066.PMC3892027.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3705 | DOI: 10.1038/srep03705 6",Non-OADS,/arxiv_data1/oa_pdf/b2/56/srep03705.PMC3892178.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3700 | DOI: 10.1038/srep03700 6",Non-OADS,/arxiv_data1/oa_pdf/91/46/srep03700.PMC3892179.pdf
"The confidence interval of GRACE estimates given for this location is represented by the grey area (1 uresolution, downloaded from http://grace.jpl.nasa.gov/data/gracemonthlymassgridsland/).www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3697 | DOI: 10.1038/srep03697 3",Non-OADS,/arxiv_data1/oa_pdf/63/f5/srep03697.PMC3892180.pdf
Documentation concerning the ANR SHIVA project methodology is available at http://www.shiva-anr.org/publishedpapers.html.,Non-OADS,/arxiv_data1/oa_pdf/63/f5/srep03697.PMC3892180.pdf
"GRACE land data were processed by Sean Swenson, supported by the NASA MEaSUREs Program, and are available at http://grace.jpl.nasa.gov.",OADS,/arxiv_data1/oa_pdf/63/f5/srep03697.PMC3892180.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3697 | DOI: 10.1038/srep03697 10",Non-OADS,/arxiv_data1/oa_pdf/63/f5/srep03697.PMC3892180.pdf
"While there is little seasonal variation in temperature in the tropics, temperatures typically vary by approxi- mately 8 uC on a regular daily basis (NOAA National Climate Data Center web site, http://www.ncdc.noaa.gov/).",Non-OADS,/arxiv_data1/oa_pdf/e0/15/srep03706.PMC3892181.pdf
"With diurnal temperatures in the tropics typically varying by approximately 8 uC (NOAA Na- tional Climate Data Center web site, http://www.ncdc.noaa.gov/),studies based on constant temperature regimes are likely to signifi-cantly underestimate the negative effects of climate warming on themany tropical terrestrial ectotherms that experience daily fluctua- tions in temperature.",Non-OADS,/arxiv_data1/oa_pdf/e0/15/srep03706.PMC3892181.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3706 | DOI: 10.1038/srep03706 9",Non-OADS,/arxiv_data1/oa_pdf/e0/15/srep03706.PMC3892181.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/56/50/srep03702.PMC3892183.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3702 | DOI: 10.1038/srep03702 7",Non-OADS,/arxiv_data1/oa_pdf/56/50/srep03702.PMC3892183.pdf
Acknowledgments This research was supported in part by the European Union Marie Curie Initial Training Network Cornucopia (http://www.yeast-cornucopia.se/).,Non-OADS,/arxiv_data1/oa_pdf/8e/21/srep03707.PMC3892184.pdf
"Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.How to cite this article: Ravasio, D., Walther, A., Trost, K., Vrhovsek, U.",Non-OADS,/arxiv_data1/oa_pdf/8e/21/srep03707.PMC3892184.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3707 | DOI: 10.1038/srep03707 4",Non-OADS,/arxiv_data1/oa_pdf/8e/21/srep03707.PMC3892184.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/39/c1/srep03696.PMC3892185.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3696 | DOI: 10.1038/srep03696 8",Non-OADS,/arxiv_data1/oa_pdf/39/c1/srep03696.PMC3892185.pdf
dhttp://molprobity.biochem.duke.edu (using electron-cloud x-H bond-lengths and no N/Q/H ﬂips).,OADS,/arxiv_data1/oa_pdf/71/d3/pro0023-0034.PMC3892297.pdf
"Parental written informed consent was obtainedfor patients and data were handled in a coded and completely anonymous fashion,according to Dutch national ethical guidelines (Code for Proper Secondary Use ofHuman Data, Dutch Federation of Medical Scientific Societies; http://www.federa.org/codes-conduct).",Non-OADS,/arxiv_data1/oa_pdf/c5/4a/srep03703.PMC3892436.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3703 | DOI: 10.1038/srep03703 6",Non-OADS,/arxiv_data1/oa_pdf/c5/4a/srep03703.PMC3892436.pdf
URL http://www.ciao.ncr.gov.,OADS,/arxiv_data1/oa_pdf/b6/f3/srep03694.PMC3892437.pdf
URL http://www.nerc.com/.,Non-OADS,/arxiv_data1/oa_pdf/b6/f3/srep03694.PMC3892437.pdf
URL https://www.entsoe.eu/.,Non-OADS,/arxiv_data1/oa_pdf/b6/f3/srep03694.PMC3892437.pdf
URL http://www.epri.com/search/Pages/results.aspx?k 5Mitigating% 20Cascading%20Outages%20on%20Power%20Systems:%20Recent% 20Research%20Approaches%20and%20Emerging%20Methods.,Non-OADS,/arxiv_data1/oa_pdf/b6/f3/srep03694.PMC3892437.pdf
URL https://reports.energy.gov/.,OADS,/arxiv_data1/oa_pdf/b6/f3/srep03694.PMC3892437.pdf
URL http://www.ee.washington.edu/research/ pstca/.,OADS,/arxiv_data1/oa_pdf/b6/f3/srep03694.PMC3892437.pdf
URL http://www.nrel.gov/docs/fy08osti/42292.pdf.,Non-OADS,/arxiv_data1/oa_pdf/b6/f3/srep03694.PMC3892437.pdf
URL {http://www.trec-uk.org.uk/resources/ airtricity\textunderscoresupergrid\textunderscoreV1.4.pdf}.,OADS,/arxiv_data1/oa_pdf/b6/f3/srep03694.PMC3892437.pdf
URL http://www.desertec.org/en/global-mission/milestones/.,Non-OADS,/arxiv_data1/oa_pdf/b6/f3/srep03694.PMC3892437.pdf
URL http://www.win.tue.nl/rhofstad/NotesRGCN.pdf.,Non-OADS,/arxiv_data1/oa_pdf/b6/f3/srep03694.PMC3892437.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3694 | DOI: 10.1038/srep03694 9",Non-OADS,/arxiv_data1/oa_pdf/b6/f3/srep03694.PMC3892437.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/8e/c1/srep03693.PMC3892440.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3693 | DOI: 10.1038/srep03693 7",Non-OADS,/arxiv_data1/oa_pdf/8e/c1/srep03693.PMC3892440.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3699 | DOI: 10.1038/srep03699 5",Non-OADS,/arxiv_data1/oa_pdf/65/df/srep03699.PMC3892442.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/e0/bc/srep03708.PMC3892443.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3708 | DOI: 10.1038/srep03708 11",Non-OADS,/arxiv_data1/oa_pdf/e0/bc/srep03708.PMC3892443.pdf
"2013;18(3):218-221 http://dx.doi.org/10.3746/pnf.2013.18.3.218 pISSN 2287-1098 ㆍeISSN 2287-8602Research Note Received May 20, 2013; Accepted July 1, 2013 Correspondence to Gun-Hee Kim, Tel: +82-2-901-8496, E-mail: ghkim@duksung.ac.kr  Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/b8/15/pnf018-03-11.PMC3892485.pdf
"2013;18(3):214-217 http://dx.doi.org/10.3746/pnf.2013.18.3.214 pISSN 2287-1098 ㆍeISSN 2287-8602Research Note Received June 20, 2013; Accepted August 23, 2013 Correspondence to Induck Choi, Tel: +82-63-840-2258, E-mail: ichoi829@korea.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/0f/3a/pnf018-03-10.PMC3892486.pdf
"2013;18(3):157-162 http://dx.doi.org/10.3746/pnf.2013.18.3.157 pISSN 2287-1098 ㆍeISSN 2287-8602 Received February 18, 2013; Accepted August 16, 2013 Correspondence to Chang-Ho Lee, Tel: +82-31-780-9226, E-mail: chang@kfri.re.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/82/a7/pnf018-03-01.PMC3892487.pdf
"2013;18(3):181-187 http://dx.doi.org/10.3746/pnf.2013.18.3.181 pISSN 2287-1098 ㆍeISSN 2287-8602 Received June 5, 2013; Accepted August 23, 2013 Correspondence to Myung-Sook Choi, Tel: +82-53-950-6232, E-mail: mschoi@knu.ac.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/c3/55/pnf018-03-05.PMC3892488.pdf
"2013;18(3):222-225 http://dx.doi.org/10.3746/pnf.2013.18.3.222 pISSN 2287-1098 ㆍeISSN 2287-8602Research Note Received June 12, 2013; Accepted July 6, 2013 Correspondence to Seung-Cheol Lee, Tel: +82-55-249-2684, E-mail: sclee@kyungnam.ac.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/4d/3f/pnf018-03-12.PMC3892489.pdf
"2013;18(3):163-168 http://dx.doi.org/10.3746/pnf.2013.18.3.163 pISSN 2287-1098 ㆍeISSN 2287-8602 Received May 24, 2013; Accepted August 28, 2013 Correspondence to Ji-Sook Han, Tel: +82-51-510-2836, E-mail: hanjs@pusan.ac.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/9f/0d/pnf018-03-02.PMC3892490.pdf
"2013;18(3):169-174 http://dx.doi.org/10.3746/pnf.2013.18.3.169 pISSN 2287-1098 ㆍeISSN 2287-8602 Received July 4, 2013; Accepted August 5, 2013 Correspondence to Ja-Young Moon, Tel: +82-55-213-3552, E-mail: jymoon@changwon.ac.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/71/63/pnf018-03-03.PMC3892491.pdf
"2013;18(3):203-209 http://dx.doi.org/10.3746/pnf.2013.18.3.203 pISSN 2287-1098 ㆍeISSN 2287-8602 Received July 1, 2013; Accepted July 31, 2013 Correspondence to Yoonhwa Jeong, Tel: +82-31-8005-3176, E-mail: yjeong@dankook.ac.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/db/b0/pnf018-03-08.PMC3892492.pdf
"2013;18(3):210-213 http://dx.doi.org/10.3746/pnf.2013.18.3.210 pISSN 2287-1098 ㆍeISSN 2287-8602Research Note Received May 23, 2013; Accepted July 8, 2013 Correspondence to Tae Youl Ha, Tel: +82-31-780-9054, E-mail: tyhap@kfri.re.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/9a/ab/pnf018-03-09.PMC3892493.pdf
"2013;18(3):196-202 http://dx.doi.org/10.3746/pnf.2013.18.3.196 pISSN 2287-1098 ㆍeISSN 2287-8602 Received May 7, 2013; Accepted June 20, 2013 Correspondence to Kwang-Soon Shin, Tel: +82-31-249-9655, E-mail: ksshin@kyonggi.ac.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/07/07/pnf018-03-07.PMC3892494.pdf
"2013;18(3):175-180 http://dx.doi.org/10.3746/pnf.2013.18.3.175 pISSN 2287-1098 ㆍeISSN 2287-8602 Received March 5, 2013; Accepted August 23, 2013 Correspondence to Hyun-Lyung Jung, Tel: +82-53-950-5944~5, E-mail: woman-jhl@hanmail.net Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/2d/85/pnf018-03-04.PMC3892495.pdf
"2013;18(2):111-116 http://dx.doi.org/10.3746/pnf.2013.18.2.111 pISSN 2287-1098 ㆍeISSN 2287-8602 Received February 19, 2013; Accepted May 21, 2013 Correspondence to Gun-Hee Kim, Tel: +82-2-901-8496, E-mail: ghkim@duksung.ac.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/29/ad/pnf018-02-05.PMC3892496.pdf
"2013;18(2):98-103 http://dx.doi.org/10.3746/pnf.2013.18.2.098 pISSN 2287-1098 ㆍeISSN 2287-8602 Received March 11, 2013; Accepted June 3, 2013 Correspondence to Hye Jeong Kim, Tel: +82-54-479-1283, E-mail: hjkim11@ikw.ac.kr  Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/e1/1b/pnf018-02-03.PMC3892497.pdf
"2013;18(2):117-123 http://dx.doi.org/10.3746/pnf.2013.18.2.117 pISSN 2287-1098 ㆍeISSN 2287-8602 Received April 3, 2013; Accepted May 27, 2013 Correspondence to Eun-Soon Lyu, Tel: +82-51-629-5848, E-mail: eslyu@pknu.ac.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/d4/1d/pnf018-02-06.PMC3892498.pdf
"2013;18(2):85-91 http://dx.doi.org/10.3746/pnf.2013.18.2.085 pISSN 2287-1098 ㆍeISSN 2287-8602 Received April 22, 2013; Accepted May 21, 2013 Correspondence to Akifumi Nagatomo, Tel: +81-72-800-1044, E-mail: a-nagatomo@jintan.co.jp Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/b0/c2/pnf018-02-01.PMC3892499.pdf
"2013;18(2):104-110 http://dx.doi.org/10.3746/pnf.2013.18.2.104 pISSN 2287-1098 ㆍeISSN 2287-8602 Received April 1, 2013; Accepted April 15, 2013 Correspondence to Woon Kyu Lee, Tel: +82-32-890-1182, E-mail: wklee@inha.ac.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/6a/10/pnf018-02-04.PMC3892500.pdf
"2013;18(2):92-97 http://dx.doi.org/10.3746/pnf.2013.18.2.092 pISSN 2287-1098 ㆍeISSN 2287-8602 Received June 13, 2013; Accepted June 19, 2013 Correspondence to In-Sook Kwun, Tel: +82-54-820-5917, E-mail: iskwun@andong.ac.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/62/6f/pnf018-02-02.PMC3892502.pdf
"2013;18(2):139-144 http://dx.doi.org/10.3746/pnf.2013.18.2.139 pISSN 2287-1098 ㆍeISSN 2287-8602 Received March 28, 2013; Accepted May 9, 2013 Correspondence to Eun-Sun Hwang, Tel: +82-31-670-5182, E-mail: ehwang@hknu.ac.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/43/48/pnf018-02-09.PMC3892503.pdf
http://www.ryandrum.com/seaxpan1.html (accessed Feb 2013).,Non-OADS,/arxiv_data1/oa_pdf/43/48/pnf018-02-09.PMC3892503.pdf
"2013;18(2):150-156 http://dx.doi.org/10.3746/pnf.2013.18.2.150 pISSN 2287-1098 ㆍeISSN 2287-8602Research Note Received April 8, 2013; Accepted May 13, 2013 Correspondence to Mira Jun, Tel: +82-51-200-7323, E-mail: mjun@dau.ac.kr Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/a7/d3/pnf018-02-11.PMC3892504.pdf
"2013;18(2):124-132 http://dx.doi.org/10.3746/pnf.2013.18.2.124 pISSN 2287-1098 ㆍeISSN 2287-8602 Received May 7, 2013; Accepted May 27, 2013 Correspondence to Se-Kwon Kim, Tel: +82-51-629-7094, E-mail: sknkim@pknu.ac.kr  Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/88/6d/pnf018-02-07.PMC3892505.pdf
"2013;18(2):133-138 http://dx.doi.org/10.3746/pnf.2013.18.2.133 pISSN 2287-1098 ㆍeISSN 2287-8602 Received January 21, 2013; Accepted May 27, 2013 Correspondence to Sung Gyu Lee, Tel: +82-53-665-5062, E-mail: ks20823@nate.com Copyright © 2013 by The Korean Society of Food Science and Nutrition.",Non-OADS,/arxiv_data1/oa_pdf/45/5e/pnf018-02-08.PMC3892506.pdf
Start a QR-code reading  software (see list of free applications from http://tinyurl.com/yzlh2tc) and point the camera to the QR-code printed in the  journal.,Non-OADS,/arxiv_data1/oa_pdf/c2/64/SAJC-2-126.PMC3892512.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free applications.Announcement,Non-OADS,/arxiv_data1/oa_pdf/c2/64/SAJC-2-126.PMC3892512.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/28/c0/SAJC-2-145.PMC3892524.pdf
Available from: http://cpancf.com/articles_files/ PsychologicalCopingCancer.asp [Last accessed on 2012 Mar 5].,Non-OADS,/arxiv_data1/oa_pdf/a0/0b/SAJC-2-113.PMC3892531.pdf
Available from: http://www.mcrh.org/Cancer- Child/16654.,Non-OADS,/arxiv_data1/oa_pdf/a0/0b/SAJC-2-113.PMC3892531.pdf
Available from: http://www.cancersa.org.,Non-OADS,/arxiv_data1/oa_pdf/a0/0b/SAJC-2-113.PMC3892531.pdf
Available  from: http://www.thaindian.com/newsportal/health/.,Non-OADS,/arxiv_data1/oa_pdf/e9/72/SAJC-2-121.PMC3892536.pdf
"WHO 19- 20 September 2011,  Available from: http://www.who.int/nmh/events/un_ncd_ summit2011/en/[Last accessed on 30 Apr 2013].",Non-OADS,/arxiv_data1/oa_pdf/1d/cd/SAJC-2-109.PMC3892537.pdf
"Available from:  http://seer.cancer.gov/csr/1975_2010/, based on November  2012 SEER data submission, [Last sited on 2013].",OADS,/arxiv_data1/oa_pdf/82/e0/SAJC-2-119.PMC3892538.pdf
The  application can be downloaded from https://market.android.com/details?id=comm.app.medknow.,Non-OADS,/arxiv_data1/oa_pdf/20/57/SAJC-2-158.PMC3892539.pdf
[http://www.cdc.gov/nci - dod/dhqp/pdf/guidelines/Disinfection_Nov  _2008.pdf]  16.,Non-OADS,/arxiv_data1/oa_pdf/33/20/idr-2010-2-e17.PMC3892586.pdf
[http://www.doh.state.fl.us/  disease_ctrl/epi/topics/64D-3_11-08.pdf] Article,Non-OADS,/arxiv_data1/oa_pdf/33/20/idr-2010-2-e17.PMC3892586.pdf
Available from: http://www.who.int/csr/resources/publica- tions/bse/whoemczdi989.pdf.,OADS,/arxiv_data1/oa_pdf/b3/82/idr-2013-2-e10.PMC3892608.pdf
The sequences obtained were compared with those deposited in the GenBank database by using BLAST (http://www.ncbi.nlm.nih.gov/BLAST).,OADS,/arxiv_data1/oa_pdf/db/95/idr-2013-2-e12.PMC3892610.pdf
"Brasília, DF: MS, 2008 Available from: http://portal.saude.gov.br/portal/ arquivos/pdf/manual_laboratorio_tb_3_9_ 10.pdf.",Non-OADS,/arxiv_data1/oa_pdf/db/95/idr-2013-2-e12.PMC3892610.pdf
"The taxonomy of all available isolates was determined by amplification and sequencing of the 16S rRNA encoding gene, followed by BLAST (Basic Local Alignment Search Tool) querying the National Center for Biotechnology Information (NCBI) nucleotide database (http://blast.ncbi.nlm.nih.gov/ Blast.cgi).",OADS,/arxiv_data1/oa_pdf/06/aa/idr-2013-1-e5.PMC3892616.pdf
Allelic variants of the blaKPC gene were identified using methods published by Bradford et al.15Multilocus sequence typing (MLST) was performed to characterize K. pneumoniae genotypes as described on the K. pneumoniae MLST website (http://www.pas- teur.fr/recherche/genopole/PF8/mlst/Kpneumo niae.html).,Non-OADS,/arxiv_data1/oa_pdf/06/aa/idr-2013-1-e5.PMC3892616.pdf
Available from: http://www.ncbi.nlm.nih.gov/books/ NBK1295/.,Non-OADS,/arxiv_data1/oa_pdf/e3/6e/idr-2013-1-e6.PMC3892618.pdf
Available from: http://www.unaids.org/ en/media/unaids/contentassets/docu- ments/epidemiology/2012/jc2296_unaids_ togetherreport_2012_en.pdf.,Non-OADS,/arxiv_data1/oa_pdf/f2/13/idr-2013-s1-e5.PMC3892620.pdf
Available from: http://apps.who.int/iris/bit- stream/10665/75183/1/9789241503938_en g.pdf.,OADS,/arxiv_data1/oa_pdf/f2/13/idr-2013-s1-e5.PMC3892620.pdf
Available from: http://www.who.int/hiv/mediacentre/uni- versal_access_progress_report_en.pdf.6.,Non-OADS,/arxiv_data1/oa_pdf/f2/13/idr-2013-s1-e5.PMC3892620.pdf
Available from: http://www.unaids.org/en/media/unaids/co ntentassets/documents/document/2011/0 6/20110610_un_a-res-65-277_en.pdf Ac - cessed: November 2012.,Non-OADS,/arxiv_data1/oa_pdf/af/df/idr-2013-s1-e2.PMC3892621.pdf
Available from: http://www.unaids.org/en/media/unaids/co ntentassets/documents/epidemiolo- gy/2012/gr2012/20121120_UNAIDS_Global _Report_2012_en.pdf Accessed: November 2012.,Non-OADS,/arxiv_data1/oa_pdf/af/df/idr-2013-s1-e2.PMC3892621.pdf
Available from: http://i-base.info/wp-con- tent/uploads/2012/07/2012-pipeline- web.pdf Accessed: November 2012.,Non-OADS,/arxiv_data1/oa_pdf/af/df/idr-2013-s1-e2.PMC3892621.pdf
Available from: http://www.southafrica.info/about/health/h iv-291112.htm.,Non-OADS,/arxiv_data1/oa_pdf/af/df/idr-2013-s1-e2.PMC3892621.pdf
Available from: http://www.change.org/petitions/plhiv-call- on-sa-governmentand-wits-reproductive- health-and-hiv-institute-to-phase-out-d4t- and-stop-the-planned-lowdose-d4t-study- in-south-africa Accessed: November 2012.,Non-OADS,/arxiv_data1/oa_pdf/af/df/idr-2013-s1-e2.PMC3892621.pdf
Available from: http://apps.who.int/iris/bit- stream/10665/75183/1/9789241503938_en g.pdf Accessed: November 2012.,Non-OADS,/arxiv_data1/oa_pdf/af/df/idr-2013-s1-e2.PMC3892621.pdf
Available from: http://www.unaids.org/en/media/unaids/co ntentassets/documents/unaidspublica- tion/2012/JC2286_Sourcing-African- Solutions_en.pdf Accessed: November 2012.,Non-OADS,/arxiv_data1/oa_pdf/af/df/idr-2013-s1-e2.PMC3892621.pdf
Available from: http://pag.aids2012.org/ses- sion.aspx?s=240 Accessed: November 2012.Review,Non-OADS,/arxiv_data1/oa_pdf/af/df/idr-2013-s1-e2.PMC3892621.pdf
"Prior to 2005, HIV-1 subtype C or recombinant forms containing at least the env gene of subtype C were responsible for 50% or more of all HIV-1 infections worldwide.10,11This was partly a result of the pandemics in Southern Africa, South America and Asia.10,12-14However, in recent years, HIV-1 subtype B has become the most predominant strain worldwide, with 60.1% infections (based on the subtype distri- bution available from the Los Alamos HIV Database; http://www.hiv.lanl.gov/).",Non-OADS,/arxiv_data1/oa_pdf/61/5b/idr-2013-s1-e4.PMC3892622.pdf
Availablefrom: http://www.hiv.lanl.gov/content/ sequence/HIV/COMPENDIUM/2008/front-matter.pdf 5.,Non-OADS,/arxiv_data1/oa_pdf/3a/93/idr-2013-s1-e8.PMC3892625.pdf
"Retinal degenerations associated with mutations in the  ABCA4  gene are consequently proposed to be caused by the  accumulation of a lipofuscin fluorophore, N-retinylidene-N- retinylethanolamine (A2E), that is formed when the ABCA4  rim protein is missing or dysfunctional and therefore cannot Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> Received 25 March 2013 | Accepted 3 January 2014 | Published 7 January 2014© 2014 Molecular Vision 89Association between genotype and phenotype in families with  mutations in the ABCA4  gene Ulrika Kjellström Department of Ophthalmology, University of Lund, Lund, Sweden Purpose:  To investigate the genotype and phenotype in families with adenosine triphosphate–binding cassette, sub- family A, member 4 ( ABCA4 )–associated retinal degeneration.",Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  90clear the photoreceptor outer segment from NRPE.,Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  91Table  1.,Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  92 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
"Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  93Multifocal electroretinography:  MERGs were recorded with  a Visual Evoked Response Imaging System (VERIS 4; EDI,  San Mateo, CA) according to the ISCEV guidelines [ 35,36].",Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  94Table  3. f f-erg resul Ts for The righ T eye of The PaTienTs.,Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  95showed attenuation (Figure 2).,Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
"Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  96the same mutations as patient 2IIb (Table 2) has no symptoms  yet, but the mERG was reduced (Figure 6), and OCT demon - strated attenuated retina in the innermost five segments of  the macular map as well as intraretinal fluid in the center.",Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  97grown slightly deeper and wider over the years (Figure 7).,Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
"Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  98DISCUSSION The fact that ABCA4  mutations are associated with a wide  spectrum of retinal degenerations regarding age of onset,  visual problems, and course of disease leads to great chal - lenges concerning prognostic counseling.",Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  99correlate well with the observations in our patients (onset at  the age of 48 and 23).,Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  100described mother/daughter pairs with the same mutations as  patients 2Ib and 2IIa.,Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
"Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  101cone responses on the lower margin, and more widely spread  retinal attenuation on OCT (Figure 8F compared to Figure  8B).",Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
"Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  102demonstrated a similar clinical picture with deteriorating  VA and large scotomas that do not match the small scotomas  of his mother, patient 3Ia.",Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  103Graefes Arch Clin Exp Ophthalmol  2002; 240:628-38.,Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
Molecular Vision  2014; 20:89-104 <http://www.molvis.org/molvis/v 20/89> © 2014 Molecular Vision  104ISCEV standard for clinical multifocal electroretinography  (mfERG) (2011 edition).,Non-OADS,/arxiv_data1/oa_pdf/15/b8/mv-v20-89.PMC3892680.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/licenses/by-nc/3.0/), which permits non- commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9d/03/btt634.PMC3892686.pdf
"Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.How to cite this article: Izumikawa, T., Sato, B.",Non-OADS,/arxiv_data1/oa_pdf/b3/03/srep03701.PMC3892716.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3701 | DOI: 10.1038/srep03701 12",Non-OADS,/arxiv_data1/oa_pdf/b3/03/srep03701.PMC3892716.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: This work has been included in a patent application by the Tianjin Institute of Industrial Biotechnology.,Non-OADS,/arxiv_data1/oa_pdf/4c/9a/srep03698.PMC3892717.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3698 | DOI: 10.1038/srep03698 6",Non-OADS,/arxiv_data1/oa_pdf/4c/9a/srep03698.PMC3892717.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3709 | DOI: 10.1038/srep03709 8",Non-OADS,/arxiv_data1/oa_pdf/7c/98/srep03709.PMC3892718.pdf
Methods Data .The weekly data for epidemic cholera outbreaks in African countries during 1990–2006 has been assembled from the records of the World Health Organisation (http://apps.who.int/globalatlas/).,OADS,/arxiv_data1/oa_pdf/b0/46/srep03710.PMC3892719.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/b0/46/srep03710.PMC3892719.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3710 | DOI: 10.1038/srep03710 7",Non-OADS,/arxiv_data1/oa_pdf/b0/46/srep03710.PMC3892719.pdf
The V35 region of the 16S rRNA gene from each sample was ampliﬁed and sequenced using the 454Titanium sequencing platform at the Baylor College of Medicine HumanGenome Sequencing Center as described elsewhere ( http://www.mothur .org/wiki/454_SOP ).,OADS,/arxiv_data1/oa_pdf/e8/b3/mBio.00692-13.PMC3892781.pdf
rithm random forest as implemented in the software environment R (http://CRAN.R-project.org ) (47).,OADS,/arxiv_data1/oa_pdf/e8/b3/mBio.00692-13.PMC3892781.pdf
All sff ﬁles and the MIMARKS spreadsheet areavailable at http://www.mothur.org/aomdss_dynamics/ .,OADS,/arxiv_data1/oa_pdf/e8/b3/mBio.00692-13.PMC3892781.pdf
Numbering indicates nucleotide positions in the PAVE-HPV18 genome( http://pave.niaid.nih.gov ) (52).,OADS,/arxiv_data1/oa_pdf/5f/80/mBio.00845-13.PMC3892783.pdf
The pSheLL18 L1/L2 packaging plasmids were pro-vided by Chris Buck (National Cancer Institute; http://home.ccr.cancer .gov/Lco ).,Non-OADS,/arxiv_data1/oa_pdf/5f/80/mBio.00845-13.PMC3892783.pdf
All raw data have beendeposited in the datadryad website ( http://datadryad.org ).,OADS,/arxiv_data1/oa_pdf/e6/55/mBio.00869-13.PMC3892789.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/36/76/cia-9-129.PMC3892958.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treat - ments intended to prevent or delay the onset of maladaptive correlates  of aging in human beings.",Non-OADS,/arxiv_data1/oa_pdf/36/76/cia-9-129.PMC3892958.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/36/76/cia-9-129.PMC3892958.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/87/68/cia-9-105.PMC3892960.pdf
Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 105–110Clinical Interventions in Aging Video abstract Point your Smar tPhone at the code abo ve.,Non-OADS,/arxiv_data1/oa_pdf/87/68/cia-9-105.PMC3892960.pdf
"Or use: http://dvpr.es/1lA66SvDove press submit your manuscript | www.dovepress.co m Dove press  105OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S5461 1relationship between cognitive impairment   and nutritional assessment on functional   status in Calabrian long-term-care Alba Malara giovanni sgrò Chiara Caruso Francesco Ceravolo giuseppe Curinga grazia Francesca renda  Fausto spadea Michele garo Vincenzo rispoli scientific Committee of the national  Association of Third Age structures  (AnAsTe) Calabria, ItalyObjective:  The interaction between dementia and nutritional state is very complex and not yet  fully understood.",Non-OADS,/arxiv_data1/oa_pdf/87/68/cia-9-105.PMC3892960.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treat - ments intended to prevent or delay the onset of maladaptive correlates  of aging in human beings.",Non-OADS,/arxiv_data1/oa_pdf/87/68/cia-9-105.PMC3892960.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/87/68/cia-9-105.PMC3892960.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
"Information on how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of General Medicine 2014:7 59–70International Journal of General Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  59HypotHesIsopen access to scientific and medical research open Access Full text Article http: //dx.doi.org/10.2147/IJGM.S5484 6Mitochondrial disorder caused Charles Darwin’s  cyclic vomiting syndrome Josef Finsterer1 John Hayman2 1Krankenanstalt Rudolfstiftng, Vienna,  Austria; 2Department of pathology,  University of Melbourne, Victoria,  Australia Correspondence: Josef Finsterer   KAR, po Box 20, 1180 Vienna, Austria   tel +43 1 7116 592 085   Fax +43 1 4781 711   email fifigs1@yahoo.d eBackground:  Charles Darwin (CD), “father of modern biology,” suffered from multisystem  illness from early adulthood.",Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.cvsaonline.org /.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-119 /.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available  from: http://www.darwinproject.ac.uk/entry-73 /.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-41 1.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
A vailable  from: http://www.darwinproject.ac.uk/entry-57 2.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-55 5.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-70 4.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-76 3.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-84 7.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available  from: http://www.darwinproject.ac.uk/entry-123 6.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-123 4.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-124 1.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-124 9.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-362 0.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://darwin-online.org.u k. Accessed  Aug 2013.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-4717 f.  Accessed Aug 2013.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-483 4.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://darwin-online.org.uk.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-364 1.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-37 8.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-382.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-60 0.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://darwin-online.org.uk/ EmmaDiaries.htm l. Accessed Aug 2013.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-49 3.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available  from: http://www.archive.org/details/emmadarwincentur02lit c.  Accessed Aug 2013.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-240 0.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Available from: http://www.darwinproject.ac.uk/entry-4397.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
"International Journal of General Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-general-medicine-journa lThe International Journal of General Medicine is an international,  peer-reviewed open-access journal that focuses on general and internal  medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat - ment protocols.",Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/20/1b/ijgm-7-059.PMC3892961.pdf
This article is distributed under the terms of an Attribution–   Noncommercial–Share Alike–No Mirror Sites license for the first six months  after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"After six months  it is available under a Creative Commons License (Attribution–Noncommercial– Share Alike 3.0 Unported license, as described at http://creativecommons.org/   licenses/by-nc-sa/3.0/).The Journal of Experimental Medicine",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/   10.1038/sj.emboj.760115 9 Cheng, T., H. Shen, N. Rodrigues, S. Stier, and D.T.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1182/blood.V98.13.364 3 Chi, S.W., J.B. Zang, A. Mele, and R.B.",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1182/blood-2010-12-32208 1 de Sousa Abreu, R., P.C.",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1074/jbc.M80960520 0 Dykstra, B., D. Kent, M. Bowie, L. McCaffrey, M. Hamilton, K. Lyons,  S.-J.",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1016/j.stem.2007.05.01 5 Hope, K.J., S. Cellot, S.B.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1016/j.stem.2010.06.00 7 Imai, T., A. Tokunaga, T. Yoshida, M. Hashimoto, K. Mikoshiba, G.  Weinmaster, M. Nakafuku, and H. Okano.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"21:3888– 3900. http://dx.doi.org/10.1128/MCB.21.12.3888-3900.200 1 Ito, T., H.Y.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"466:765– 768. http://dx.doi.org/10.1038/nature0917 1 Kale, V.P.",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10   .1084/jem.2006046 5 Karsunky, H., M.A.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1182/blood-2007-11-12621 9 Kawahara, H., T. Imai, H. Imataka, M. Tsujimoto, K. Matsumoto, and  H. Okano.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1083/jcb.20070800 4 Kharas, M.G., C.J.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1038/nm.218 7 Langmead, B., and S.L.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1038/nmeth.192 3 Larsson, J., U. Blank, H. Helgadottir, J.M.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1182/blood-2003-04-   1300 Larsson, J., U. Blank, J. Klintman, M. Magnusson, and S. Karlsson.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1016/j.cell.2005.02.01 3 Anders, S., A. Reyes, and W .",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10   .1101/gr.133744.11 1 Arumugam, K., Y. Wang, L.L.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi   .org/10.1038/emboj.2009.33 7 Arumugam, K., M.C.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10   .1074/jbc.M111.30068 1 Beckmann, J., S. Scheitza, P .",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1182/blood-   2006-11-05592 1 Beerman, I., D. Bhattacharya, S. Zandi, M. Sigvardsson, I.L.",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1084/jem   .2012161 0 Brümmendorf, T.H., W. Dragowska, and P.M. Lansdorp.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
872:265– 273. http://dx.doi.org/10.1111/j.1749-6632.1999.tb08471.,Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1016/j   .stem.2010.02.00 2 Chambers, S.M., D.C. Weksberg, and M.A.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10   .1182/blood-2008-01-13252 2 Charlesworth, A., A. Wilczynska, P .",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1016/j.exphem.2005.02.00 3 Loeb, G.B., A.A. Khan, D. Canner, J.B. Hiatt, J. Shendure, R.B.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1016/j.molcel.2012.10.00 2 Martin, C.H., I. Aifantis, M.L.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1038/ni96 5 Matsumoto, A., S. Takeishi, T. Kanie, E. Susaki, I. Onoyama, Y. Tateishi,  K. Nakayama, and K.I.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1016/j.stem.2011.06.01 4 McCarthy, D.J., Y. Chen, and G.K. Smyth.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi   .org/10.1093/nar/gks04 2 Nakamura, M., H. Okano, J.A.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1016/   0896-6273(94)90460- X Okano, H., H. Kawahara, M. Toriya, K. Nakao, S. Shibata, and T. Imai.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1016/j.yexcr.2005.02.02 1 Pang, W .W ., E.A.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1073/   pnas.111611010 8 Passegué, E., A.J.",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1084/jem.2005096 7 Pereira, J.K.N., F .",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1016/   j.leukres.2012.06.01 0 Robinson, M.D., and A. Oshlack.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1186/gb-2010-11-3-r2 5 Scandura, J.M., P. Boccuni, J. Massagué, and S.D.",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1182/blood-2011-10-38873 6 Sitnicka, E., F.W.",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1073/   pnas.050658010 2 Trapnell, C., B.A.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"28:511– 515. http://dx.doi.org/10.1038/nbt.162 1 Uchida, N., B. Dykstra, K.J.",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1016/j.exphem   .2003.09.00 1 Wang, X., C. T erfve, J.C. Rose, and F .",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi.org/10.1093/   bioinformatics/btr02 8 Wu, M., H.Y.",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
"http://dx.doi   .org/10.1016/j.cell.2011.09.05 3 Zou, P ., H. Y oshihara, K. Hosokawa, I. Tai, K. Shinmyozu, F .",OADS,/arxiv_data1/oa_pdf/9d/dd/JEM_20130736.PMC3892968.pdf
This article is distributed under the terms of an Attribution–   Noncommercial–Share Alike–No Mirror Sites license for the first six months  after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"After six months  it is available under a Creative Commons License (Attribution–Noncommercial–   Share Alike 3.0 Unported license, as described at http://creativecommons.org/   licenses/by-nc-sa/3.0/).The Journal of Experimental Medicine",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
Online supplemental material is available at http://www.jem.org/cgi/   content/full/jem.20130720/DC1.,Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1002/glia.2026 3 Bardin, A.J., and A. Amon.",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
http://dx.doi.org/10.1038/3509902 0uridine (Sigma-Aldrich) to eliminate all nonneuronal cells.,Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1677/   ERC-07-007 7 Jessen, K.R., and R. Mirsky.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10   .1038/nrn174 6 Larrea, M.D., S.A.",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/   10.1097/01.sap.0000112281.97409.a 6 Li, H., H. Yang, Y .",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"45:277–   283. http://dx.doi.org/10.1007/s12031-011-9518- 2 Martin, J.R., and H.D.",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1016/0012-1606(73)90251- 0 Mercuri, E., J. Pennock, F .",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1016/S0014-5793(97)01007- 7 Nakagawa, M., Y .",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1002/glia.107 5 Nave, K.A., and J.L.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1016/   j.conb.2006.08.00 8 Nodari, A., D. Zambroni, A. Quattrini, F .A.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10   .1083/jcb.20061001 4 Panattoni, M., F .",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1084/jem.2007072 5 Pereira, J.A., Y .",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1083/jcb.20080900 8 Previtali, S.C., A. Nodari, C. Taveggia, C. Pardini, G. Dina, A. Villa, L. Wrabetz, A.  Quattrini, and M.L.",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1002/glia.2117 5 Shackleford, T .J., and F .X.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"5:26. http://dx.doi.org/10.1186/1747-1028-5-2 6 Sherman, D.L., and P .J.",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10   .1038/nrn174 3 Sherman, D.L., C. Fabrizi, C.S.",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10   .1016/S0896-6273(01)00327- 0 Shorer, Z., J. Philpot, F .",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"177:1051– 1061. http://dx.doi.org/10.1083/jcb.20061010 8 Berti, C., L. Bartesaghi, M. Ghidinelli, D. Zambroni, G. Figlia, Z.L.",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1242/dev.06549 0 Birchmeier, C., and K.A.",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1002/glia.2075 3 Bolino, A., A. Bolis, S.C. Previtali, G. Dina, S. Bussini, G. Dati, S. Amadio, U. Del  Carro, D.D.",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1083/jcb.20040701 0 Bradley, W .G., and M. Jenkison.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi   .org/10.1016/0022-510X(73)90009- 9 Bray, G.M., S. David, T. Carlstedt, and A.J.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1002/   mus.88006070 5 Casaccia-Bonnefil, P ., R.J. Hardy, K.K.",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://www.nature.com/ embor/journal/v2/n2/full/embor480.htm l Chen, Z.L., and S. Strickland.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1083/jcb.20030706 8 Cheng, X., Z. Zhou, G. Xu, J. Zhao, H. Wu, L. Long, H. Wen, X. Gu, and   Y .",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/   10.1007/s12031-013-9969- 8 Chow, C.Y ., Y .",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1038/nature0587 6 Delague, V ., A. Jacquier, T. Hamadouche, Y .",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1086/51842 8 Feltri, M.L., and L. Wrabetz.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
http://dx.doi.org/10.1111/j.1085-9489.2005.0010204.,Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
http://dx.doi.org/10.1046/j.1460-9568.1999.00568.,Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10   .1083/jcb.20010902 1 Grove, M., N.H. Komiyama, K.A.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1083/jcb.20060902 1 Guo, L.T., X.U.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10   .1177/08830738950100061 0 Stendel, C., A. Roos, T. Deconinck, J. Pereira, F .",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1086/51877 0 Stevens, B., and R.D.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1177/   10738584020080020 5 Stirling, C.A.",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"47:681– 694. http://dx.doi.org/10.1016/j.neuron.2005.08.01 7 T omoda, K., Y .",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1242/jcs.0316 8 Wang, D., F .",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi   .org/10.1016/0012-1606(73)90250- 9 Wei, Q., W .K.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1128/MCB.23.12.4035-4045.200 3 Wolpowitz, D., T.B.",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1016/S0896-6273(00)80873- 9 Wrabetz, L., M.L.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1083/jcb.148.5.102 1 Wrabetz, L., M. D’Antonio, M. Pennuto, G. Dati, E. Tinelli, P .",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10   .1523/JNEUROSCI.3819-05.200 6 Xu, H., X.-R. Wu, U.M.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10.1038/ng1194-29 7 Yang, D., J. Bierman, Y .S.",OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
"http://dx.doi.org/10   .1083/jcb.20041115 8 Y u, W .M., M.L.",Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
http://dx.doi.org/10   .1523/JNEUROSCI.5032-04.200 5,Non-OADS,/arxiv_data1/oa_pdf/a7/30/JEM_20130720.PMC3892969.pdf
This article is distributed under the terms of an Attribution–   Noncommercial–Share Alike–No Mirror Sites license for the first six months  after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"After six months  it is available under a Creative Commons License (Attribution–Noncommercial–   Share Alike 3.0 Unported license, as described at http://creativecommons.org/   licenses/by-nc-sa/3.0/).The Journal of Experimental Medicine",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1038/384364a 0 Han, S., K. Hathcock, B. Zheng, T.B.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1016/j.immuni.2008.07.01 6 Hase, H., Y. Kanno, M. Kojima, K. Hasegawa, D. Sakurai, H. Kojima, N.  Tsuchiya, K. Tokunaga, N. Masawa, M. Azuma, et al.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1182/blood-2003-08-269 4 Hershberg, U., M. Uduman, M.J. Shlomchik, and S.H.",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1093/   intimm/dxn02 6 Hsu, B.L., S.M.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1038/ni129 2 Johnston, R.J., A.C. Poholek, D. DiToro, I. Yusuf, D. Eto, B. Barnett, A.L.",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1126/science.117587 0 Kapasi, Z.F., D. Qin, W.G.",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1016/j.immuni.2011.03.02 4 Khalil, A.M., J.C. Cambier, and M.J. Shlomchik.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1126/science.121336 8 Krautler, N.J., V .",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1016/j.cell.2012.05.03 2 Lefranc, M.P., V. Giudicelli, Q. Kaas, E. Duprat, J. Jabado-Michaloud, D.  Scaviner, C. Ginestoux, O. Clément, D. Chaume, and G. Lefranc.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1093/nar/   gki06 5 Lesley, R., Y. Xu, S.L.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10   .1038/ni144 5 Linterman, M.A., L. Beaton, D. Y u, R.R.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10   .1084/jem.2009173 8 Linterman, M.A., W .",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1038/nm.242 5 Lu, Y .F ., M. Singh, and J. Cerny.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
http://dx.doi.org/10.1093/intimm/13.5.64 3mutations could arise in those positions.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1016/j.smim.2007.12.00 1 Bauquet, A.T., H. Jin, A.M. Paterson, M. Mitsdoerffer, I.C.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1038/ni.169 0 Bossen, C., T.G.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"111:1004– 1012. http://dx.doi.org/10.1182/blood-2007-09-11087 4 Cancro, M.P.",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
http://dx.doi.org/10   .1111/j.0105-2896.2004.0099.,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1038/nm.242 6 Foy, T.M., D.M.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1084/jem.178.5.156 7 Gavin, A.L., B. Duong, P .",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.4049/jimmunol.110085 3 Good-Jacobson, K.L., C.G.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1038/ni.187 7 Gorelik, L., K. Gilbride, M. Dobles, S.L.",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1177/096120331036765 7 Mackay, F., and P. Schneider.",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1038/nri257 2 Mantchev, G.T., C.S.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi   .org/10.1016/j.coi.2009.05.01 0 Moore, P .A., O. Belvedere, A. Orr, K. Pieri, D.W .",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1126/science.285.5425.26 0 O’Connor, B.P., V.S.",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1084/jem.2003133 0 Ozaki, K., R. Spolski, C.G.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"298:1630– 1634. http://dx.doi.org/10.1126/science.107700 2 Rahman, Z.S., S.P .",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10   .1016/j.jim.2008.09.01 7 Sage, P.T., L.M.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1038/ni.249 6 Schiemann, B., J.L.",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10   .1126/science.106196 4 Schneider, P ., F .",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1084/jem.189.11.174 7 Scholz, J.L., J.E.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1038/nature0557 3 Schwickert, T.A., G.D. Victora, D.R.",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"18:279– 288. http://dx.doi.org/10.1016/S1074-7613(03)00025- 6 Shaffer, A.L., K.I.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10   .1016/S1074-7613(02)00335- 7 Stadanlick, J.E., M. Kaileh, F .G.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10   .1038/ni.166 6 Thompson, J.S., S.A. Bixler, F. Qian, K. Vora, M.L.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1126/science.106196 5 Tsuji, S., C. Cortesão, R.J. Bram, J.L.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1182/blood-2011-05-35396 1 Uduman, M., G. Yaari, U. Hershberg, J.A.",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1093/   nar/gkr41 3 Victora, G.D., and M.C.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1146/annurev- immunol-   020711-07503 2 Victora, G.D., T.A.",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi   .org/10.1016/j.cell.2010.10.03 2 von Bülow, G.U., and R.J. Bram.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1126/science.278.5335.13 8 von Bülow, G.U., J.M.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1016/S1074-7613(01)00130- 3 Wang, Y ., and R.H. Carter.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1016/   j.immuni.2005.04.01 2 Yaari, G., M. Uduman, and S.H.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1093/nar/gks45 7 Yan, M., J.R. Brady, B. Chan, W .P .",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi.org/10.1016/   S0960-9822(01)00481- X Yan, M., H. Wang, B. Chan, M. Roose-Girma, S. Erickson, T. Baker, D. Tumas,  I.S.",OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
"http://dx.doi   .org/10.1038/8979 0 Zotos, D., J.M.",Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
http://dx.doi.org/10   .1084/jem.2009177 7,Non-OADS,/arxiv_data1/oa_pdf/f9/0a/JEM_20130505.PMC3892970.pdf
This article is distributed under the terms of an Attribution– Noncommercial–Share Alike–No Mirror Sites license for the first six months  after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"After six months  it is available under a Creative Commons License (Attribution–Noncommercial–   Share Alike 3.0 Unported license, as described at http://creativecommons.org/   licenses/by-nc-sa/3.0/).The Journal of Experimental Medicine",Non-OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.1136/jmg.37.1.5 5 Auricchio, N., I. Malinowska, R. Shaw, B.D.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi   .org/10.1371/journal.pone.003190 0 Brand, T.M., M. Iida, N. Luthar, M.M.",Non-OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.4065/   75.6.59 1 Crino, P.B., K.L.",Non-OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10   .1056/NEJMra05532 3 Dabora, S.L., S. Jozwiak, D.N.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.1086/   31695 1 Dalle Pezze P., A.G. Sonntag, A. Thien, M.T.",Non-OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.1016/j.molcel.2010.06.02 2 Egan, K.M., J.A.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/   10.1126/science.110333 3 Evans, A.M., C.D.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/   10.1056/NEJM20010809345060 7 Galamb, O., S. Spisák, F. Sipos, K. Tóth, N. Solymosi, B. Wichmann,  T. Krenács, G. Valcz, Z. Tulassay, and B. Molnár.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi   .org/10.1172/JCI5870 9 Howe, S.R., M.M.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.1210/en.136.11.499 6 Jaeschke, A., J. Hartkamp, M. Saitoh, W. Roworth, T. Nobukuni, A.  Hodges, J. Sampson, G. Thomas, and R. Lamb.",Non-OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.1083/jcb.jcb.20020610 8 Karbowniczek, M., A. Astrinidis, B.R.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi   .org/10.1164/rccm.200208-969O C Krymskaya, V.P.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.1165/rcmb.2011-0381E D Lee, P.S., S.W.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.1165/rcmb.2009-0050O C Liu, F., E.P.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.1371/journal.pone.003858 9 Mann, J.R., M.G.",Non-OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"Pages 87-115. http://dx.doi.org/10.1002/9783527630073.ch 6 McCormack, F.X., R.J. Panos, and B.C.",Non-OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.1007/978-1-59745-384- 4 McCormack, F.X., Y. Inoue, J. Moss, L.G.",Non-OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/ 10  .1056/NEJMoa110039 1McCormack, F.X., W.D.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.1164/rccm.201205-0848O E Müller, R. 2004.",Non-OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"3:189– 200. http://dx.doi.org/10.1002/emmm.20110013 1 Onda, H., A. Lueck, P.W.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"104:687– 695. http://dx.doi.org/10.1172/JCI731 9 Parkhitko, A., F. Myachina, T.A.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.1378/chest.11-066 9 Sevigny, M.B., C.F.",Non-OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.1016/j.febslet.2006.10.07 3 Sreekumar, A., L.M.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.1164/ajrccm.163.1.200500 4 Subbaramaiah, K., P.G.",Non-OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"2:356– 365. http://dx.doi.org/10.1158/2159-8290.CD-11-024 1 Takada, Y., A. Bhardwaj, P. Potdar, and B.B.",Non-OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi   .org/10.1089/lrb.2009.002 4 Wang, D., and R.N.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10.1038/nrc280 9 Wang, M.T., K.V.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"303-327. http://dx.doi.org/10.1016/S1874-6047   (10)27016- 6 Yu, J., A. Astrinidis, S. Howard, and E.P.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
"http://dx.doi.org/10   .1152/ajplung.00204.200 3 Yu, J.J., V.A.",OADS,/arxiv_data1/oa_pdf/08/09/JEM_20131080.PMC3892971.pdf
This article is distributed under the terms of an Attribution–   Noncommercial–Share Alike–No Mirror Sites license for the first six months  after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"After six months  it is available under a Creative Commons License (Attribution–Noncommercial–   Share Alike 3.0 Unported license, as described at http://creativecommons.org/   licenses/by-nc-sa/3.0/).The Journal of Experimental Medicine",Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.4049/jimmunol.090394 0 Bayer, A.L., A. Yu, and T.R.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10   .1016/j.immuni.2012.03.02 0 Boursalian, T.E., J. Golob, D.M.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1038/ni104 9 Boyman, O., M. Kovar, M.P.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1126/science.112292 7 Burchill, M.A., J. Yang, C. Vogtenhuber, B.R.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1038/nri291 6 Chaudhry, A., R.M.",Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1016/j.immuni.2011.03.01 8 Cheng, G., A. Yu, and T.R.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
http://dx.doi.org/10.1111/j.1600-065X.2011.01004.,Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.4049/   jimmunol.120121 8 Cinamon, G., M.A.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1038/ni154 2 Cretney, E., A. Xin, W. Shi, M. Minnich, F. Masson, M. Miasari, G.T.",Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10   .1016/j.immuni.2004.07.00 9 Huehn, J., K. Siegmund, and A. Hamann.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1016/j.immuni.2008.03.01 8 Jenabian, M.A., P. Ancuta, N. Gilmore, and J.P. Routy.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1016/   S1074-7613(04)00103- 7 Koch, M.A., K.R.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1016/j.immuni.2012.05.03 1 Long, S.A., J.H.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1016/j.clim.2013.02.00 5 Luther, S.A., H.L.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"26:453– 479. http://dx.doi.org/10.1146/annurev.immunol.26.021607.09035 7 Malek, T.R., and J.D.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi   .org/10.1084/jem.161.6.157 5 Malhotra, D., A.L.",Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1111/imr.1202 3 Moran, A.E., K.L.",Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10   .1084/jem.2011030 8 Ouyang, W., and M.O.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10   .1016/j.it.2010.10.00 5 Pandiyan, P., L. Zheng, S. Ishihara, J. Reed, and M.J. Lenardo.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"8:1353– 1362. http://dx.doi.org/10.1038/ni153 6 Pierson, W., B. Cauwe, A. Policheni, S.M.",Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1038/ni.264 9 Raychaudhuri, S., E.F. Remmers, A.T. Lee, R. Hackett, C. Guiducci, N.P.",Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1038/ng.23 3 Rech, A.J., R. Mick, S. Martin, A. Recio, N.A.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1016/j.immuni.2009.04.00 6 Rosenblum, M.D., I.K.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
http://dx.doi.org/10.1016/0092-8674(93)80067- Otranscription factors Blimp-1 and IRF4 jointly control the differentiation   and function of effector regulatory T cells.,OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1038/ni.200 6 Cretney, E., A. Kallies, and S.L.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1016/j.immuni.2012.04.00 7 Darrasse-Jèze, G., S. Deroubaix, H. Mouquet, G.D. Victora, T. Eisenreich,  K.H.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi   .org/10.1084/jem.2009074 6 Dong, C., and R.I. Nurieva.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10   .1016/S0896-8411(03)00119- 7 Fisson, S., G. Darrasse-Jèze, E. Litvinova, F. Septier, D. Klatzmann, R.  Liblau, and B.L.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1084/jem.2003068 6 Fontenot, J.D., J.P. Rasmussen, M.A.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1038/ni126 3 Fontenot, J.D., J.P. Rasmussen, L.M.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1016/S0092-8674(00)80059- 8 Förster, R., A.C. Davalos-Misslitz, and A. Rot.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1002/art.3023 5 Gasteiger, G., S. Hemmers, M.A.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1084/jem.2012246 2 Gigoux, M., J. Shang, Y. Pak, M. Xu, J. Choe, T.W.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.4049/jimmunol.130021 2 Hall, A.O., D.P.",Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1016/j.immuni.2012.06.01 4 Herman, A.E., G.J.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi   .org/10.1084/jem.2004017 9 Hippen, K.L., J.L.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1016/j.smim.2011.07.00 8 Hsieh, C.S., Y. Liang, A.J.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1016/j.coi.2004.09.01 2 Sallusto, F., D. Lenig, R. Förster, M. Lipp, and A. Lanzavecchia.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10   .1038/4438 5 Sather, B.D., P. Treuting, N. Perdue, M. Miazgowicz, J.D.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1084/jem.2007008 1 Schneider, M.A., J.G.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10   .1084/jem.2006140 5 Setoguchi, R., S. Hori, T. Takahashi, and S. Sakaguchi.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1084/jem.2004198 2 Simpson, T.R., S.A. Quezada, and J.P. Allison.",Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1016/   j.coi.2010.01.00 1 Sitrin, J., A.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1084/jem.2012224 8 Soper, D.M., D.J.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1002/eji.20073710 1 Tadokoro, C.E., G. Shakhar, S. Shen, Y. Ding, A.C. Lino, A. Maraver,  J.J. Lafaille, and M.L.",Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1084/jem.2005078 3 Takahashi, N., K. Matsumoto, H. Saito, T. Nanki, N. Miyasaka, T. Kobata,  M. Azuma, S.K.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10   .4049/jimmunol.080325 6 Tan, A.H., S.C. Wong, and K.P.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1074/ jbc.M60408120 0 Tang, Q., K.J.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1016/   j.immuni.2008.03.01 6 Tang, Q., J.A.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"184:3433– 3441. http://dx.doi.org/10.4049/jimmunol.090402 8 Vignali, D.A., L.W.",Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1038/   nri234 3 Walker, L.S., A. Chodos, M. Eggena, H. Dooms, and A.K.",Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10   .1084/jem.2003031 5 Wang, J., L.S.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1016/j.smim.2009   .04.00 4 Willerford, D.M., J. Chen, J.A.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1084/jem   .2006170 6 Yadav, M., C. Louvet, D. Davini, J.M.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
"http://dx.doi.org/10.1084/jem.2012082 2 Zheng, L., R. Sharma, F. Gaskin, S.M.",OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
http://dx.doi.org/10   .4049/jimmunol.120050 7,Non-OADS,/arxiv_data1/oa_pdf/93/96/JEM_20131142.PMC3892972.pdf
© 2014 Starbeck-Miller  This article is distributed under the terms of an Attribution–   Noncommercial–Share Alike–No Mirror Sites license for the first six months  after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"After six months  it is available under a Creative Commons License (Attribution–Noncommercial–   Share Alike 3.0 Unported license, as described at http://creativecommons.org/   licenses/by-nc-sa/3.0/).The Journal of Experimental Medicine",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1038/ni.207 9 Gately, M.K., A.G. Wolitzky, P .M.",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1016/0008-8749(92)90011- D Gesbert, F ., W .R.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1074/jbc   .M00729120 0 Gil, M.P ., M.J. Ploquin, W .T.",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1182/   blood-2012-05-42867 2 Harty, J.T., and V .P .",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1038/nri225 1 Haring, J.S., V .P .",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1016/j.immuni.2006   .07.001 Hikono, H., J.E.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
http://dx.doi   .org/10.1111/j.0105-2896.2006.00385.,Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1016/j.coi.2007.05.00 5 Hogquist, K.A., S.C. Jameson, W .R.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1016/0092-8674(94)90169- 4 Hou, S., L. Hyland, K.W.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1038/369652a 0 Huang, W., B.T.",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1038/nprot.2008.21 1 Intlekofer, A.M., N. Takemoto, E.J.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi   .org/10.1038/ni126 8 Joshi, N.S., W. Cui, A. Chandele, H.K.",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi   .org/10.1016/j.immuni.2007.07.01 0 Kalia, V., S. Sarkar, S. Subramaniam, W.N.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1016/j.immuni.2009.11.01 0 Kallies, A., E.D.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1038/ni132 1 Kallies, A., A. Xin, G.T.",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1016/   j.immuni.2009.06.02 1 Keppler, S.J., K. Theil, S. Vucikuja, and P .",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"39:1774– 1783. http://dx.doi.org/10.1002/eji.20083909 3 Keppler, S.J., K. Rosenits, T. Koegl, S. Vucikuja, and P .",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
http://dx.doi   .org/10.1111/j.0105-2896.2006.00384.,Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi   .org/10.1038/nm125 7 Badovinac, V.P., J.S.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1016/   j.immuni.2007.04.01 3 Bensinger, S.J., P.T.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1126/science.112292 7 Busch, D.H., I.M.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1016/S1074-7613(00)80540- 3 Cannarile, M.A., N.A.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"7:1317– 1325. http://dx.doi.org/10.1038/ni140 3 Chua, A.O., V .L.",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"15:42–   48. http://dx.doi.org/10.1016/j.gde.2004.12.00 7 Cronin, S.J., and J.M.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"197:1141– 1151. http://dx.doi.org/10.1084/jem.2002191 0 Curtsinger, J.M., J.O.",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
http://dx.doi.org/10.1101/gad.12.22.349 9,Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1016/0092-8674(93)90152- G Trinchieri, G. 1998.",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi   .org/10.1016/0092-8674(93)80065- M Vignali, D.A., and V.K.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10   .1038/ni.236 6 Waldmann, T.A.",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1038/nri190 1 Wang, I.C., Y .J.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi   .org/10.1074/jbc.M70989220 0 Wang, Z., A. Ahmad, Y .",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1016/j.ctrv.2009   .11.00 6 Williams, M.A., A.J.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1038/nature0479 0 Wirth, T.C., H.H.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1016/   j.immuni.2010.06.01 4 Xiao, Z., K.A.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.4049/   jimmunol.080348 4 Xue, H.H., P.E.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10   .1038/ni.215 8 Zhou, B.P ., Y .",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
3:245–   252. http://dx.doi.org/10.1038/3506003 2the interplay of type I IFN and IL-12 in CD8 T cell responses.,OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1371/journal.pone.004086 5 Kolumam, G.A., S. Thomas, L.J.",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1084/jem.2005082 1 Lali, F.V., J. Crawley, D.A.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1038/ncb121 7 Lefrançois, L. 2006.",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
http://dx.doi.org/10.1111/ j.0105-2896.2006.00393.,Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1128/MCB.24.7.2649-2661.200 4 Malek, T.R.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"26:453– 479. http://dx.doi.org/10.1146/annurev.immunol.26.021607.09035 7 Malek, T.R., A. Y u, L. Zhu, T. Matsutani, D. Adeegbe, and A.L.",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1007/s10875-   008-9235- y Masson, F ., F .",Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.4049/jimmunol   .100191 8 Mescher, M.F., J.M.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
http://dx.doi.org/10.1111/j.0105-2896.2006.00382.,Non-OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"http://dx.doi.org/10.1016/j.immuni.2009.11.01 2 Pope, C., S.K.",OADS,/arxiv_data1/oa_pdf/78/d9/JEM_20130901.PMC3892973.pdf
"After six months it is available under a Crea - tive Commons License (Attribution–Noncommercial–Share Alike 3.0   Unported license, as described at http://creativecommons.org/   licenses/by-nc-sa/3.0/).The Journal of Experimental Medicine",Non-OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi.org/10.1146/annurev-biochem-   051710-13410 0 Slomiany, B.A., K.L.",OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi.org/10.1128/   MCB.20.16.5986-5997.200 0 Somervaille, T.C., and M.L.",Non-OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi   .org/10.1016/j.ccr.2009.12.04 0 Zaret, K.S., and J.S.",OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi.org/10.1101/gad.176826.11 1 Zhang, P ., J. Iwasaki-Arai, H. Iwasaki, M.L.",OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi   .org/10.1016/j.immuni.2004.11.00 6 Zuber, J., I. Radtke, T .S.",OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi.org/10.1101/gad.177140 9 Zuber, J., A.R.",OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
http://dx.doi.org/10.1038/nature1033 4J.,Non-OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi.org/10.1016/   j.molcel.2010.01.02 6 Mohan, M., C. Lin, E. Guest, and A. Shilatifard.",OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi   .org/10.1038/nrc291 5 Nerlov, C. 2004.",OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"4:394– 400. http://dx.doi.org/10.1038/nrc136 3 Ohlsson, E., M.S.",OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi.org/10.1038/8651 5 Pabst, T., B.U.",OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi.org/10.1038/8582 0 Porse, B.T., T.A.",OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi   .org/10.1016/S0092-8674(01)00516- 5 Rosenbauer, F ., and D.G.",OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi.org/10   .1038/nri202 4 Shih, A.H., O. Abdel-Wahab, J.P. Patel, and  R.L.",Non-OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi.org/10.1038/ng76 5 Calkhoven, C.F., C. Müller, and A. Leutz.",Non-OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi.org/10.1182/   blood-2011-03-34108 1 Jin, S., H. Zhao, Y. Yi, Y. Nakata, A. Kalota,  and A.M. Gewirtz.",Non-OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi.org/10.1172/JCI3803 0 Kirstetter, P ., M.B.",OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi.org/10.1016/j.ccr.2008.02.00 8 Krivtsov, A.V., and S.A. Armstrong.",OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
"http://dx.doi.org/10.1038/   nrc225 3 Krivtsov, A.V., D. Twomey, Z. Feng, M.C.",OADS,/arxiv_data1/oa_pdf/a0/15/JEM_20132530.PMC3892974.pdf
This article is distributed under the terms of an Attribution– Noncommercial–Share Alike–No Mirror Sites license for the first six months  after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"After six months  it is available under a Creative Commons License (Attribution–Noncommercial–   Share Alike 3.0 Unported license, as described at http://creativecommons.org/   licenses/by-nc-sa/3.0/ ).The Journal of Experimental Medicine",Non-OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1002/ar.109224022 0 Carlson, J., W .G.",Non-OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.2353/ajpath.2009   .09003 5 Caunt, C.J., C.A.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10   .1074/jbc.M70662420 0 Chen, J.R., L.I.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10   .1074/jbc.M41153020 0 Cui, Y., G. Riedlinger, K. Miyoshi, W. Tang, C. Li, C.X.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"24:8037– 8047. http://dx.doi.org/10.1128/MCB.24.18.8037-8047.200 4 Gupta, N., A.P.",Non-OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.4049/jimmunol.100001 5 He, Y.Z., K. Staser, S.D.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1371/journal.pone.002478 0 Hennighausen, L., and G.W.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1101/gad.164390 8 Hoelbl, A., B. Kovacic, M.A.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1182/blood-2005-09-359 6 Ilaria, R.L.",Non-OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1074/jbc.271.49.3170 4 Karsenty, G., and E.F .",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi   .org/10.1016/S1534-5807(02)00157- 0 Khapli, S.M., L.S.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10   .1016/S0925-5710(98)00025- 5 Lacey, D.L., E. Timms, H.L.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1016/S0092-8674(00)81569- X Miyazaki, T., H. Katagiri, Y. Kanegae, H. Takayanagi, Y. Sawada, A.  Yamamoto, M.P.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1083/   jcb.148.2.33 3 Nakamura, H., A. Hirata, T. Tsuji, and T. Yamamoto.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1016/j.cell.2007.07.02 5Dusp3  forward, 5 -TTGAAAGGGCCACAGATTTC-3 ; Dusp3  reverse,  5-AGTTTCACCTTGCCCTCCTT -3 ; Dusp4  forward, 5 -CTGTACCTC - CCAGCACCAAT -3 ; Dusp4  reverse, 5 -GACGGGGATGCACTTGT ACT -3;  Dusp5  forward, 5 -TGCACCACCCACCTACACTA-3 ; Dusp5  reverse,  5-AGGACCTTGCCTCCTTCTTC-3 ; Dusp6  forward, 5 -TTGAAT - GTCACCCCCAATTT -3 ; Dusp6  reverse, 5 -CATCGTTCATGGACAG - GTTG-3; Dusp7  forward, 5 -TGCCAAGGACTCTACCAACC-3 ; Dusp7   reverse, 5-GAGAGGTTCTGGCTCCAGTG-3 ; Dusp8  forward, 5 -GTC - CATGAGCCTCTCTCAGC-3 ; Dusp8  reverse, 5 -TGAAACGGCTCT - CACAGATG-3 ; Dusp9  forward, 5 -ACCTTGAGCTGTGGCCTAGA-3 ;  Dusp9  reverse, 5 -GGGGATCTGCTTGTAGTGGA-3 ; Dusp10  forward,  5-GCGGCAGTACTTTGAAGAGG-3 ; Dusp10  reverse, 5 -AGGTTC - GGGGAAATAATTGG-3 ; Dusp16  forward, 5 -CAGCGAGATGTCCT - CAACAA-3 ; Dusp16  reverse, 5 -TAAGCACACAGCCATTGGAG-3 ;  IL-3 forward, 5 -CTGCCTACATCTGCGAATGA-3 ; IL-3 reverse, and  5-TTAGGAGAGACGGAGCCAGA-3 .",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1172/JCI1053 0 Akira, S. 1999.",Non-OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
http://dx.doi.org/10.1002/stem.17013 8,Non-OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1007/s00198-002-1340- 9 Sommer, B., R. Felix, C. Sprecher, M. Leunig, R. Ganz, and W .",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi   .org/10.1002/jbm.a.3020 2 Suda, T., N. Takahashi, N. Udagawa, E. Jimi, M.T.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1210/er.20.3.34 5 Takahashi, N., T. Akatsu, N. Udagawa, T. Sasaki, A. Yamaguchi, J.M.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1210/   endo-123-5-260 0 Takayanagi, H., H. Iizuka, T. Juji, T. Nakagawa, A. Yamamoto, T. Miyazaki, Y .",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1002/1529- 0131(200002)43:2<259::AID-ANR4>3.0.CO;2- W Takayanagi, H., S. Kim, K. Matsuo, H. Suzuki, T. Suzuki, K. Sato, T. Y okochi,  H. Oda, K. Nakamura, N. Ida, et al.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1038/416744 aTanaka, S. 2007.",Non-OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1159/00010648 4 Tanaka, S., T. Takahashi, H. Takayanagi, T. Miyazaki, H. Oda, K. Nakamura, H.  Hirai, and T. Kurokawa.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1359/jbmr.1998.13.11.171 4 T eglund, S., C. McKay, E. Schuetz, J.M.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1016/   S0092-8674(00)81444- 0 Van Etten, R.A. 2007.",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1038/sj.onc.121075 8 Villa, A., M.M.",Non-OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
"http://dx.doi.org/10.1007/s00223-008-9196- 4 Wakao, H., F .",OADS,/arxiv_data1/oa_pdf/91/1d/JEM_20130538.PMC3892975.pdf
This article is distributed under the terms of an   Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first   six months after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1172/JCI11447 7 Bourque, S.L., S.T.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi   .org/10.1152/ajpregu.00397.201 0 Bourque, S.L., H.A.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi.org/10.1111/j.1476-5381.2011.01696.,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1002/jmor.105083020 4 Burton, G.J., and E. Jauniaux.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1016/j.bpobgyn   .2010.10.01 6 Burton, G.J., A.W .",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1016/j.placenta.2009.02.00 9 Byun, Y .J., H.S.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"50:39– 44. http://dx.doi.org/10.3349/ymj.2009.50.1.3 9 Carter, J.D., A. Ladhani, L.R.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.3899/jrheum.08054 5 Chahoud, I., and F.J. Paumgartten.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10   .1016/j.envres.2009.07.01 5 Chaparro, A., A. Sanz, A. Quintero, C. Inostroza, V .",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1111/jre.1200 8 Collins, S.L., J.S.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1002/uog.1014 9 Conde-Agudelo, A., J. Villar, and M. Lindheimer.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1016/j.ajog.200 7.07.04 0 Conrad, K.P ., T.M.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi.org/10.1111/j.1600-0897.1998.tb00398.,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1160/   TH11-10-073 0 de Pace, V ., G. Chiossi, and F .",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1080/1476705070141945 8 Dechend, R., P .",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1161/01   .HYP .0000154785.50570.6 3 Faas, M.M., G.A.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1093/rheumatology/keq18 5 Boersma, B., and J.M.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1210/er.18.5.64 6 Borzychowski, A.M., I.L.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi   .org/10.1016/j.siny.2006.04.00 1,OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"46:1022– 1025. http://dx.doi.org/10.1161/01.HYP.0000175476.26719.3 6 LaMarca, B.D., M.J. Ryan, J.S.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10   .1007/s11906-007-0088- 1 Lau, S.Y., C.J.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1016/j.jri.2012.12.00 5 Li, Z., Y. Zhang, J. Ying Ma, A.M. Kapoun, Q. Shao, I. Kerr, A. Lam, G.  O’Young, F. Sannajust, P. Stathis, et al.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"50:686– 692. http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.09209 8 Lin, F ., P .",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1016/j.reprotox.2012.09.00 9 Liu, M., and G. Bing.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1006/niox.2000   .0296 Lyall, F., and M. Belfort.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi   .org/10.1111/j.1600-0897.2010.00836.,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1152/ajpheart.00031.200 6 Naicker, T ., S.M.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi.org/10.1034/j.1600-0412.2003.00220.,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1016/   j.jri.2010.10.00 3 Page, E. 1939.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1016/   S0143-4004(83)80043- 5 Pijnenborg, R., L. Vercruysse, and M. Hanssens.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1016/j.placenta.2005.12.00 6 Redman, C.W .G.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1016/0143-4004(91)90339- H Redman, C.W .G., and M. Jefferies.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi.org/10.1016/S0140-6736(88)91667- 4An immunohistological study in experimental pre-eclampsia.,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/   10.1016/j.ajog.2004.03.04 1 Falcón, B.J., T. Cotechini, S.K.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1160/   TH11-09-062 6 Gao, X., H. Zhang, S. Belmadani, J. Wu, X. Xu, H. Elford, B.J.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1152/ajpheart   .00587.200 8 Gardosi, J., A. Chang, B. Kalyan, D. Sahota, and E.M. Symonds.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi   .org/10.1016/0140-6736(92)91342- 6 Germain, S.J., G.P.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi.org/   10.1111/j.1600-0897.1997.tb00281.,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1016/S0002-   9440(10)63192- 6 Hunt, J.S.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi.org/10.1111/j.1600-   0897.1989.tb01015.,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"24:540– 548. http://dx.doi.org/10.1053/plac.2002.094 6 Kam, E.P., L. Gardner, Y.W.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1093/humrep/14.8.213 1 Kaufmann, P ., S. Black, and B. Huppertz.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1095/   biolreprod.102.01497 7 Knight, M., C.W.G.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi.org/10.1111/j.1471-0528.1998.tb10178.,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/   10.1093/humrep/13.8.230 8 Koga, K., Y. Osuga, T. Tajima, Y. Hirota, T. Igarashi, T. Fujii, T. Yano,  and Y. Taketani.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"94:305– 308. http://dx.doi.org/10.1016/j.fertnstert.2009.02.01 5 Kourembanas, S., L.P. McQuillan, G.K. Leung, and D.V.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1172/JCI11660 4 LaMarca, B.B., W.A.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi.org/10.1111/j.1471-   0528.1999.tb08376.,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1016/j.placenta.2011.11.02 6 Strevens, H., D. Wide-Swensson, A. Grubb, A. Hansen, T. Horn, I.  Ingemarsson, S. Larsen, J.R. Nyengaard, O. Torffvit, J. Willner, and S.  Olsen.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi.org/10.1111/j.1471-0528.2003.02051.,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"11:59. http://dx.doi.org/10.1186/1471-2172-11-5 9 Todt, J.C., Y. Yang, J. Lei, M.R.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi.org/10.1111/j.1600-0897.1996.tb00141.,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.3109/1476705100377494 2 Valensise, H., B. Vasapollo, G. Gagliardi, and G.P.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi   .org/10.1161/HYPERTENSIONAHA.108.11735 8 van Asselt, K., S. Gudmundsson, P .",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi.org/10.1034/j.1600-0412.1998.770607.,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1111/j.1471-0528   .2004.00071. x Venegas-Pont, M., M.B.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10   .1161/HYPERTENSIONAHA.110.15768 5 Vercruysse, L., S. Caluwaerts, C. Luyten, and R. Pijnenborg.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.3109/03009742.2011.62644 2 Yung, H.W., S. Calabrese, D. Hynx, B.A.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.2353/ajpath.2008.07119 3 Zhang, H., Y.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1042/CS2008019 6 Zhou, P., X. Luo, H.B.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1007/s00011-012-0507- xRedman, C.W., G.P.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1016/S0002-9378(99)70239- 5 Reister, F ., H.G.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1053/plac.1998.037 3 Reister, F., H.G.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1038/labinvest.378032 6 Renaud, S.J., L.M.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1095/biolreprod.104.03800 0 Renaud, S.J., S.K.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1095/   biolreprod.106.05537 6 Renaud, S.J., R. Sullivan, and C.H.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1016/j.placenta.2009.01.00 1 Renaud, S.J., T. Cotechini, J.S.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/   10.4049/jimmunol.100267 9 Rittirsch, D., M.A.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi.org/10.1161/01.HYP .0000188408.,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1161/01.HYP .33.1.8 3 Rubin, L.H., K. Witkiewitz, J.S.",Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10   .1007/s10995-007-0224- 1 Salminen, A., R. Paananen, R. Vuolteenaho, J. Metsola, M. Ojaniemi, H.  Autio-Harmainen, and M. Hallman.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
"http://dx.doi.org/10.1203/PDR   .0b013e318163a8b 2 Shynlova, O., T. Nedd-Roderique, Y. Li, A. Dorogin, and S.J.",OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
http://dx.doi.org/10.1111/j.1582-4934.2012.01650.,Non-OADS,/arxiv_data1/oa_pdf/77/7e/JEM_20130295.PMC3892976.pdf
This article is distributed under the terms of an Attribution– Noncommercial–Share Alike–No Mirror Sites license for the first six months  after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
Online supplemental material is  available at http://www.jem.org/cgi/content/full/jem.20130301/DC 1.,Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1016/0092-8674(91)90141- K Chen, Z., A. Laurence, Y. Kanno, M. Pacher-Zavisin, B.M.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi   .org/10.1038/ni.202 7 Cohen, C.J., S.Q.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.4049/jimmunol.110105 8 Cosmi, L., R. De Palma, V. Santarlasci, L. Maggi, M. Capone, F. Frosali, G.  Rodolico, V. Querci, G. Abbate, R. Angeli, et al.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1084/jem.2008039 7 Cosmi, L., L. Maggi, V. Santarlasci, M. Capone, E. Cardilicchia, F. Frosali, V.  Querci, R. Angeli, A. Matucci, M. Fambrini, et al.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1016/j.jaci.2009.10.01 2 Cosmi, L., L. Maggi, V. Santarlasci, F. Liotta, and F. Annunziato.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10   .1002/cyto.a.2234 8 Crowe, A., and A.M. Tan.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1016/j.taap.2012.03.00 8 Croxford, A.L., F. Mair, and B. Becher.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi   .org/10.1002/eji.20124259 8 Duhen, T., R. Geiger, D. Jarrossay, A. Lanzavecchia, and F. Sallusto.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi   .org/10.1038/ni.176 7 Esplugues, E., S. Huber, N. Gagliani, A.E.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1038/nature1022 8 Eyerich, S., K. Eyerich, D. Pennino, T. Carbone, F. Nasorri, S. Pallotta, F.  Cianfarani, T. Odorisio, C. Traidl-Hoffmann, H. Behrendt, et al.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1210/me.2011-006 8 Ghoreschi, K., A. Laurence, X.P.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1038/nature0944 7 Gottesman, M.M., T. Fojo, and S.E.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1038/nrc70 6 Hirota, K., J.H.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1038/ni.199 3 Hueber, W., B.E.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1136/gutjnl-2011-30166 8 Hyafil, F., C. Vergely, P. Du Vignaud, and T. Grand-Perret.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10   .1038/ni146 7 Afzali, B., P .J.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"43:2043– 2054. http://dx.doi.org/10.1002/eji.20124329 6 Ahern, P.P., C. Schiering, S. Buonocore, M.J. McGeachy, D.J.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1146/   annurev-physiol-021909-13592 6 Aller, S.G., J. Yu, A.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1126/science.116875 0 Ano, S., Y. Morishima, Y. Ishii, K. Yoh, Y. Yageta, S. Ohtsuka, M. Matsuyama,  M. Kawaguchi, S. Takahashi, and N. Hizawa.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.4049/jimmunol.120238 6 Araki, K., A.H. Ellebedy, and R. Ahmed.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1016/j.ceb.2011.08.00 6 Barnes, P.J., and I.M.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1016/   S0140-6736(09)60326- 3 Barrat, F .J., D.J.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
http://dx.doi.org/10.1084/jem.2001162 9,Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"30:531– 564. http://dx.doi.org/10.1146/annurev.immunol.25.022106.14162 3 Kebir, H., I. Ifergan, J.I.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"66:390– 402. http://dx.doi.org/10.1002/ana.2174 8 Kleinschek, M.A., K. Boniface, S. Sadekova, J. Grein, E.E.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1038/ni.241 6 Ludescher, C., J. Thaler, D. Drach, J. Drach, M. Spitaler, C. Gattringer, H.  Huber, and J. Hofmann.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
82:161– 168. http://dx.doi.org/10.1111/j.1365-2141.1992.tb04608.,Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1002/eji.20124264 8 Manel, N., D. Unutmaz, and D.R.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1038/ni.161 0 McGeachy, M.J., K.S.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1038/ni153 9 McGeachy, M.J., Y. Chen, C.M.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1038/ni.169 8 McKinley, L., J.F.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10   .1056/NEJMra070744 9 Muranski, P., Z.A.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1016/j.immuni.2011.09.01 9 Mutalithas, K., C. Guillen, C. Day, C.E.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi   .org/10.1073/pnas.100385210 7 Rivino, L., M. Messi, D. Jarrossay, A. Lanzavecchia, F. Sallusto, and   J. Geginat.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi   .org/10.1084/jem.2004077 4 Roberts, M.M., B.W.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
http://dx.doi.org/10.1046/ j.1365-2141.1999.01231.,Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1038/4438 5 Sallusto, F., C.E.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1002/eji.20124274 1 Schinkel, A.H. 1997.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1006/   scbi.1997.006 8 Simmons, P.J., D.I.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1038/sj.leu.240082 3 So, T., S.W.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1016/j.cytogfr.2008.04.00 3 Strouse, J.J., I. Ivnitski-Steele, A. Waller, S.M.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1016/j.ab.2013.02.01 8 Sundrud, M.S., S.M.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi   .org/10.1126/science.117263 8 Trifari, S., C.D.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1038/ni.177 0 Turtle, C.J., H.M. Swanson, N. Fujii, E.H. Estey, and S.R.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10   .1016/j.immuni.2009.09.01 5 Wan, Q., L. Kozhaya, A. ElHed, R. Ramesh, T.J. Carlson, I.M.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10   .1084/jem.2010251 6 Weiss, J., and W.E.",OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
"http://dx.doi.org/10.1016/S1937-6448(10)80005- X Zorzi, F., I. Monteleone, M. Sarra, E. Calabrese, I. Marafini, M. Cretella,  S. Sedda, L. Biancone, F. Pallone, and G. Monteleone.",Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
http://dx.doi.org/10.1371/journal.pone   .005456 2,Non-OADS,/arxiv_data1/oa_pdf/e7/ef/JEM_20130301.PMC3892977.pdf
This article is distributed under the terms of an Attribution–   Noncommercial–Share Alike–No Mirror Sites license for the first six months  after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"After six months   it is available under a Creative Commons License (Attribution–Noncommercial– Share Alike 3.0 Unported license, as described at http://creativecommons.org/   licenses/by-nc-sa/3.0/).The Journal of Experimental Medicine",Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
Online supplemental material is avail - able at http://www.jem.org/cgi/content/full/jem.20131019/DC1.,Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
http://dx.doi.org/10.1111/j.1600-   065X.1987.tb00506.,Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.1002/ijc.291041080 2 Bauquet, A.T., H. Jin, A.M. Paterson, M. Mitsdoerffer, I.C.",Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10   .1038/ni.169 0 Busse, M., M. Krech, A. Meyer-Bahlburg, C. Hennig, and G. Hansen.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"189:1975– 1982. http://dx.doi.org/10.4049/jimmunol.110358 1 Campbell, D.J., and M.A.",Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.1038/nri291 6 Chang, J.H., Y. Xiao, H. Hu, J. Jin, J. Yu, X. Zhou, X. Wu, H.M. Johnson,  S. Akira, M. Pasparakis, et al.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.1038/ni.226 7 Chang, M., W. Jin, J.H.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
http://dx.doi.org/10.1038/ni.209 0Histology and GC analysis.,Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.1016/   S0092-8674(00)00078- 7 Ramiscal, R.R., and C.G.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.1111/imr.1203 1 Redpath, S.A., N. van der Werf, A.M. Cervera, A.S. MacDonald, D. Gray,  R.M.",Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/   10.1002/eji.20124279 4 Reiley, W.W., M. Zhang, W. Jin, M. Losiewicz, K.B.",Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.1084/jem.2006269 4 Rousset, F., E. Garcia, T. Defrance, C. Péronne, N. Vezzio, D.H. Hsu, R.  Kastelein, K.W.",Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10   .1073/pnas.89.5.189 0 Sage, P .T., L.M.",Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.1038/   ni.249 6 Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/   10.1016/j.cell.2008.05.00 9 Sasaki, Y., D.P.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
246:125– 140. http://dx.doi.org/10.1111/j.1600-065X.2011.01088.,Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi   .org/10.1002/eji.20114189 7 Weiss, U., R. Zoebelein, and K. Rajewsky.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi   .org/10.1002/eji.183022023 3 Wollenberg, I., A. Agua-Doce, A. Hernández, C. Almeida, V.G.",Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.4049/jimmunol.110132 8 Xie, P., L.L.",Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"27:253– 267. http://dx.doi.org/10.1016/j.immuni.2007.07.01 2 Xie, P., Z.J.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/   10.4049/jimmunol.100029 0 Zhou, X., L.T.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.1084/jem.2008070 7Chung, Y., S. Tanaka, F. Chu, R.I. Nurieva, G.J.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.1038/nm.242 6 Elsner, R.A., D.N.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.1128/JVI.06904-1 1 Ganchi, P.A., S.-C. Sun, W.C. Greene, and D.W. Ballard.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.1091/mbc.3.12.133 9 Gardam, S., F. Sierro, A. Basten, F. Mackay, and R. Brink.",Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.1016/j.immuni.2008.01.00 9 Ha, H., D. Han, and Y. Choi.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi   .org/10.1084/jem.2006116 6 Hildebrand, J.M., Z. Yi, C.M.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
http://dx.doi.org/10.1111/j.1600-065X.2011.01055.,Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"199:303– 313. http://dx.doi.org/10.1084/jem.2003156 2 Ito, T., S. Hanabuchi, Y.H.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"28:870– 880. http://dx.doi.org/10.1016/j.immuni.2008.03.01 8 Josefowicz, S.Z., L.F. Lu, and A.Y.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"30:531– 564. http://dx.doi.org/10.1146/annurev.immunol.25.022106.14162 3 King, C., S.G. Tangye, and C.R.",Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"26:741– 766. http://dx.doi.org/10.1146/annurev.immunol.26.021607.09034 4 Liao, G., M. Zhang, E.W.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.1038/nm.242 5 Linterman, M.A., A. Liston, and C.G.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
http://dx.doi.org/10.1111/j.1600- 065X.2012.01121.,Non-OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
"http://dx.doi.org/10.1053/j.gastro.2011   .02.04 7 Mitsdoerffer, M., Y. Lee, A. Jäger, H.J.",OADS,/arxiv_data1/oa_pdf/df/a2/JEM_20131019.PMC3892978.pdf
This article is distributed under the terms of an Attribution– Noncommercial–Share Alike–No Mirror Sites license for the first six months  after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"After six months  it is available under a Creative Commons License (Attribution–Noncommercial– Share Alike 3.0 Unported license, as described at http://creativecommons.org/   licenses/by-nc-sa/3.0/ ).The Journal of Experimental Medicine",Non-OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10.1186/gb-2009-10-3-r2 5 Lee, Y.H., B. Sauer, P.F.",OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10.1146/   annurev-pathol-011811-13243 4 Nerlov, C. 2004.",Non-OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10.1038/nrc136 3 Nguyen, A.T., and Y .",OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10.1101/gad   .205781 1 Reckzeh, K., and J. Cammenga.",OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10.1007/s12185-010-0573- 1 Slany, R.K. 2009.",Non-OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10.3324/haematol.2008.00243 6 Smyth, G.K. 2004.",Non-OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10.1016/j.ccr.2006   .08.02 0 Subramanian, A., P .",OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10.1038/nature0554 1 W agner, K., P .",OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"22:1381– 1396. http://dx.doi.org/10.1101/gad.46880 8 Wilhelm, B.T., M. Briau, P .",Non-OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10.1182/blood-2010-07-29333 2 Wouters, B.J., B. Löwenberg, C.A.",Non-OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10.1182/   blood-2008-09-17989 5 Zeisig, B.B., T. Milne, M.P .",Non-OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10.1128/   MCB.24.2.617-628.200 4 Zhang, P ., J. Iwasaki-Arai, H. Iwasaki, M.L.",OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10.1016/j.immuni.2004.11.00 6were performed as biological replicates, and the correlation coefficients,   r2, were calculated to the following: Cebpafl/fl H3K27me3, 0.938; Cebpa/  H3K27me3, 0.901; Cebpafl/fl H3K4me3, 0.896; Cebpa/ H3K4me3, 0.922;  and Cebpa+/+ C/EBP, 0.805.",OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
Online supplemental material is available at http://www.jem.org/   cgi/content/full/jem.20130932/DC 1.,Non-OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"24:10470– 10478. http://dx.doi.org/10.1128/MCB.24.23.10470-10478.200 4 Estey, E., and H. Döhner.",OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"368:1894– 1907. http://dx.doi.org/10.1016/S0140-6736(06)69780- 8 Gentles, A.J., S.K.",Non-OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10   .1001/jama.2010.186 2 Haferlach, T., A. Kohlmann, L. Wieczorek, G. Basso, G.T.",Non-OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10.1200/JCO.2009.23.473 2 Hasemann, M.S., M.B.",OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"http://dx.doi.org/10.1371/journal.pone.003884 1 Irizarry, R.A., C. Wang, Y. Zhou, and T.P.",Non-OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"7:823– 833. http://dx.doi.org/10.1038/nrc225 3 Kroon, E., J. Krosl, U. Thorsteinsdottir, S. Baban, A.M. Buchberg, and G.  Sauvageau.",OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
"17:3714– 3725. http://dx.doi.org/10.1093/emboj/17.13.371 4 Kühn, R., F .",Non-OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
http://dx.doi.org/10.1126/   science.766012 5,Non-OADS,/arxiv_data1/oa_pdf/8f/ba/JEM_20130932.PMC3892979.pdf
This article is distributed under the terms of an Attribution–   Noncommercial–Share Alike–No Mirror Sites license for the first six months  after the publication date (see http://www.rupress.org/terms).,Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"After six months  it is available under a Creative Commons License (Attribution–Noncommercial– Share Alike 3.0 Unported license, as described at http://creativecommons.org/   licenses/by-nc-sa/3.0/).The Journal of Experimental Medicine",Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
Mammalian EndoU may thus be  functionally distinct from its Xenopus  ortholog because human  EndoU is excluded from the nucleolus of multiple cell lines  (http://www.proteinatlas.org/ENSG00000111405/subcellular).,Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"The region of mouse Chr 15 containing the entire EndoU  locus was analyzed against the human genome using   the VISTA Browser whole genome comparative analysis tool (http://genome.lbl.gov/vista/index.shtml), with a calculation window and minimum conservation  width of 100 bp.",OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi   .org/10.1128/JVI.78.22.12218-12224.200 4 Browne, C.D., C.J.",Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1038/sj   .cr.729004 7 Doody, G.M., L.B.",Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi   .org/10.1016/S1074-7613(00)80094- 1 Gay, D., T. Saunders, S. Camper, and M. Weigert.",OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1084/jem.177.4.99 9 Gijsbers, R., H. Ceulemans, and M. Bollen.",OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi   .org/10.1042/BJ2002194 3 Gioia, U., P .",Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1074/jbc.M50116020 0 Goodnow, C.C., J. Crosbie, S. Adelstein, T.B.",Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1038/334676a 0 Goodnow, C.C., J. Crosbie, H. Jorgensen, R.A.",Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1038/342385a 0 Goodnow, C.C., J.G.",Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/   10.1084/jem.191.5.88 3 Inaoki, M., S. Sato, B.C.",OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1084/jem.186.11.192 3 Ivanov, K.A., T. Hertzig, M. Rozanov, S. Bayer, V .",OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi   .org/10.1074/jbc.M21193720 0 Laneve, P ., U. Gioia, R. Ragno, F .",Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1074/jbc.M80575920 0 Lei, Y ., C.B.",Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi   .org/10.1371/journal.pone.000546 6 Manly, K.F ., R.H. Cudmore Jr., and J.M.",Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"12:930– 932. http://dx.doi.org/10.1007/s00335-001-1016- 3 Nemazee, D.A., and K. Bürki.",OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1038/337562a 0 Nitschke, L., R. Carsetti, B. Ocker, G. Köhler, and M.C.",Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1016/S0960-9822(06)00057- 1Noorchashm, H., A. Bui, H.L.",OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1093/   intimm/11.5.76 5 O’Keefe, T.L., G.T.",OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1126/science.274.5288.79 8 O’Keefe, T.L., G.T.",OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1084/jem.189.8.130 7 Otipoby, K.L., K.B.",Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1038/384634a 0 Poe, J.C., M. Fujimoto, P.J.",OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.4049/jimmunol.120100 0 Renzi, F., E. Caffarelli, P. Laneve, I. Bozzoni, M. Brunori, and B. Vallone.",Non-OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi   .org/10.1016/S1074-7613(00)80270- 8 Shlomchik, M.J. 2008.",OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1016/j.immuni.2007.12   .004 Sonenshein, G.E.",OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1016/   S1096-4959(02)00158- 6 T edder, T.F ., J. Tuscano, S. Sato, and J.H.",OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"http://dx.doi.org/10.1146/annurev   .immunol.15.1.48 1 Tiegs, S.L., D.M.",OADS,/arxiv_data1/oa_pdf/22/18/JEM_20130648.PMC3892980.pdf
"Journal of Visualized Experiments www.jove.com Copyright © 2013  Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported LicenseSeptember 2013 |  79  | e50955 | Page 1 of 6Video Article Assessing Forelimb Function after Unilateral Cervical SCI using Novel Tasks: Limb Step-alternation, Postural Instability and Pasta Handling Zin Z. Khaing*1, Sydney A. Geissler*1, Timothy Schallert2, Christine E. Schmidt1,3 1Department of Biomedical Engineering, The University of Texas at Austin 2Department of Psychology, The University of Texas at Austin 3The J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida *These authors contributed equally Correspondence to: Christine E. Schmidt at schmidt@bme.ufl.edu URL: http://www.jove.com/video/50955 DOI: doi:10.3791/50955 Keywords: Behavior, Issue 79, Behavior, Animal, Motor Activity, Nervous System Diseases, Wounds and Injuries, cervical spinal cord injury, lateral hemisection model, limb alternation, pasta handling, postural instability Date Published: 9/16/2013 Citation: Khaing, Z.Z., Geissler, S.A., Schallert, T., Schmidt, C.E.",Non-OADS,/arxiv_data1/oa_pdf/74/c3/jove-79-50955.PMC3892984.pdf
"Video Link The video component of this article can be found at http://www.jove.com/video/50955/ Introduction Cervical spinal cord injury (cSCI) is the most prevalent form of SCI in patients, representing about 62% of all SCIs ( http:// www.spinalcord.uab.edu).",Non-OADS,/arxiv_data1/oa_pdf/74/c3/jove-79-50955.PMC3892984.pdf
"Woodhead Publishing Series in Biomedicine, 2012.Keywords:  antibody engineering,  therapeutic antibodies, effector function,  antibody fragments, antibody-drug conjugates, antibody manufacturing Submitted: 01/10/13Accepted: 01/10/13http://dx.doi.org/10.4161/mabs.23654 Correspondence to: Paul W.H.I.",Non-OADS,/arxiv_data1/oa_pdf/9b/88/mabs-5-175.PMC3893228.pdf
"*Correspondence to: Janice M. Reichert; Email: janice.reichert@ landesbioscience.comSubmitted: 01/17/13; Accepted: 01/17/13http://dx.doi.org/10.4161/mabs.23655The 23rd Annual Antibody e ngineering, 10th Annual Antibody  Therapeutics international conferences, and the 2012 Annual  Meeting of The Antibody Society, organized by i BC Life  Sciences with contributions from The Antibody Society and two Scientific Advisory Boards, were held December 3–6, 2012 in San Diego, CA.",Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
J  Biol Chem 2004; 279:30375-84; PMID:15075331; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Protein Eng Des Sel 2012; 25:47- 57; PMID:22160867; http://dx.doi.org/10.1093/protein/gzr056 3.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Nat Biotechnol 2010; 28:1203-7; PMID:20953198; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Nat Biotechnol 2012; 30:447-52; PMID:22446692; http://dx.doi.org/10.1038/ nbt.21672.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Nat Biotechnol  2012; 30:1039-43; PMID:23138294; http://dx.doi.org/10.1038/nbt.2406 3.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Nature 2012; 487:500-4; PMID:22763439; http://dx.doi.org/10.1038/nature11183 5.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
J Immunol 2011; 187:1754-63; PMID:21742972; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Sci T ransl Med 2011; 3:99ra85;  PMID:21900592; http://dx.doi.org/10.1126/scitranslmed.3002296 7.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Cancer Res 2012; 72:3715-9; PMID:22815525; http://dx.doi.org/10.1158/0008-5472.CAN-12-0063 8.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
"Cancer Res 2006; 66:4426- 33; PMID:16618769; http://dx.doi.org/10.1158/0008-5472.CAN-05-4489 December 4, 2012: Antibody Engineering   Antibody Targeted CNS Therapy Beyond   the Blood Brain Barrier Nora Zizlsperger James S. Huston (The Antibody Society; Boston Biomedical  Research Institute; Huston BioConsulting, LLC) chaired this session and introduced the speakers.",Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
J Cereb Blood Flow Metab  2012; 32:1959-72; PMID:22929442; http://dx.doi.org/10.1038/jcbfm.2012.126 2.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Methods Enzymol 2012; 503:269-92; PMID:22230573;  http://dx.doi.org/10.1016/B978-0-12-396962-0.00011-2 3.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
J Cereb Blood Flow Metab 2012;  32:1933-8; PMID:22714051; http://dx.doi.org/10.1038/jcbfm.2012.97 4.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Mol Pharm 2011;  8:280-5; PMID:21141969; http://dx.doi.org/10.1021/mp1003515 5.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Mol Pharm 2011; 8:1342-50; PMID:21667973; http://dx.doi.org/10.1021/ mp200136x 6.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
J Neurochem 2005; 95:1201-14;  PMID:16271053; http://dx.doi.org/10.1111/j.1471-4159.2005.03463.x 7.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Nat Rev Nephrol 2010; 6:108-19; http://dx.doi.org/10.1038/nrneurol.2009.219 11.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Alzheimers Res Ther 2011; 3:1; PMID:21211070; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Neurodegener Dis 2012; 10:265-70; PMID:22343072;  http://dx.doi.org/10.1159/000335913 13.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Expert Opin Biol Ther 2009; 9:1189-97;  PMID:19653865; http://dx.doi.org/10.1517/14712590903176387 14.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
J Mol Biol 2008; 377:136-47;  PMID:18237741; http://dx.doi.org/10.1016/j.jmb.2007.11.096,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
PLoS One 2011; 6:e29199; PMID:22216210; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
"MAbs 2012; 4:686-93; PMID:22929188; http://dx.doi.org/10.4161/ mabs.21696 December 4, 2012: Antibody Engineering   Deep Sequencing in B Cell Biology   and Antibody Libraries Yu Zhou Andrew Bradbury  (Los Alamos National Laboratories) chaired  the afternoon session, which was organized by Dr. Bradbury and  Jamie K. Scott  (Simon Fraser University).",Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
"J Mol Biol 2011; 412:55-71; PMID:21787786; http://dx.doi.org/10.1016/j.jmb.2011.07.018 December 4, 2012: Antibody Therapeutics   Clinical and Preclinical Updates   of Antibody-Drug Conjugates Daniel Tavares The session on antibody-drug conjugates (ADCs), was chaired  by Benjamin P. Chen (Ignatius Transaction Partners, LLC), and  the keynote presentation was provided by Peter Senter  (Seattle",OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Leukemia  2011; 25:181-4; PMID:20944674; http://dx.doi.org/10.1038/leu.2010.239 2.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Clin Cancer Res 2007; 13:5586s-91s; PMID:17875793;  http://dx.doi.org/10.1158/1078-0432.CCR-07-1217 3.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Blood 2012; 119:3767-78;  PMID:22271448; http://dx.doi.org/10.1182/blood-2011-09-381988 4.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Bioconjug Chem 2011; 22:709-16; PMID:21395337; http://dx.doi.org/10.1021/ bc100464e 5.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Cancer Res 2004; 64:8443-50; PMID:15548716; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Biotechnol  Bioeng 2010; 106:741-50; PMID:20564612; http://dx.doi.org/10.1002/bit.22763.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Biotechnol Bioeng 2011; 108:2171- 81; PMID:21495017; http://dx.doi.org/10.1002/bit.23166 8.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Blood 2012; 120:3670-6;  PMID:22915649; http://dx.doi.org/10.1182/blood-2012-06-438804 9.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
"Cancer Res 2010; 70:588-97; PMID:20068188; http://dx.doi.org/10.1158/0008-5472.CAN-09-1417 December 5, 2012: Antibody Engineering   Systems Medicine in the Development of Antibody  Therapies/Systematic Validation   of Novel Antibody Targets Yu Zhou Session chair James D. Marks (University of California, San  Francisco) gave the keynote presentation on a systematic approach to generate tumor targeting and internalizing mAbs.",Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Cancer Res 2006;  66:6732-40; PMID:16818648; http://dx.doi.org/10.1158/0008-5472.CAN-05-4199 2.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Cancer Res 2011; 71:2250-9; PMID:21406401; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Nat Biotechnol 2004; 22:568-74; PMID:15097996; http://dx.doi.org/10.1038/nbt961 5.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Chemistry 2012; 18:7729-37; PMID:22588840; http://dx.doi.org/10.1002/chem.201200952 6.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
"Bioconjug  Chem 2010; 21:1836-41; PMID:20806901; http://dx.doi.org/10.1021/bc100198x December 5, 2012: Antibody Engineering   Antibody Activity and Animal Models Kirstin A. Zettlitz The afternoon’s session on antibody activity and animal models  was chaired by Professor Dennis Burton  (The Scripps Research  Institute).",Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
J Virol 2002; 76:8769-75; PMID:12163597; http://dx.doi.org/10.1128/ JVI.76.17.8769-8775.2002 2.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Nat Med 2009; 15:901-6; PMID:19448633; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Nature 2011; 477:466-70; PMID:21849977; http://dx.doi.org/10.1038/ nature103734.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
PLoS One 2012; 7:e42209;  PMID:22848744; http://dx.doi.org/10.1371/journal.pone.0042209 7.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Immunity 1999; 10:431-8; PMID:10229186; http://dx.doi.org/10.1016/S1074- 7613(00)80043-6 8.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Nat Med 2005; 11:615-22; PMID:15880120; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Nature 2012; 492:118-22; PMID:23103874; http://dx.doi.org/10.1038/nature11604 10.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
J Biol Chem 2007; 282:13917-27; PMID:17353196;  http://dx.doi.org/10.1074/jbc.M700661200 13.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
J Biol Chem 2012;  287:35409-17; PMID:22930758; http://dx.doi.org/10.1074/jbc.M112.404483 14.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
"J Biol Chem 2009; 284:25077-86; PMID:19617628; http://dx.doi.org/10.1074/ jbc.M109.022061 December 5, 2012: Antibody Therapeutics   Development Status of Immunomodulatory  Therapeutic Antibodies Peter-Christian Klöhn The morning session of the Antibody Therapeutics track was  chaired by Philip Thorpe  (University of Texas Southwestern).",Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Cancer Res 2007; 67:10948-57;  PMID:18006840; http://dx.doi.org/10.1158/0008-5472.CAN-07-1436 2.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Arthritis Res Ther 2009; 11:R142;  PMID:19781067; http://dx.doi.org/10.1186/ar2814 3.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Atherosclerosis 2011; 214:325-30; PMID:21167484; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Arthritis Res Ther 2007; 9:R9; PMID:17261171; http://dx.doi.org/10.1186/ar2115 5.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
J Exp Med 2005; 202:473-7;  PMID:16087714; http://dx.doi.org/10.1084/jem.200503046.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Neurology 2005; 64:1270-2;  PMID:15824362; http://dx.doi.org/10.1212/01.WNL.0000159399.81861.D5 7.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
N Engl J Med 2005; 352:2499-507; PMID:15958805; http://dx.doi.org/10.1056/ NEJMoa042982 8.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Clin Gastroenterol Hepatol 2008; 6:1370-7; PMID:18829392;  http://dx.doi.org/10.1016/j.cgh.2008.06.007 9.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
J Pharmacol Exp Ther 2009; 330:864- 75; PMID:19509315; http://dx.doi.org/10.1124/jpet.109.153973 10.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Gastroenterology 1996; 111:1373-80;  PMID:8898653; http://dx.doi.org/10.1053/gast.1996.v111.pm8898653 11.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Inflamm Bowel Dis 2012; 18:2107-19; PMID:22419649; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Nature 2009; 461:160-3; PMID:19741679;  http://dx.doi.org/10.1038/461160a 2.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Nat Genet 2001; 29:365-71; PMID:11726920; http://dx.doi.org/10.1038/ng1201-365 3.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Protein Eng Des Sel  2009; 22:221-4; PMID:19224941; http://dx.doi.org/10.1093/protein/gzp003 4.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
BMC Med Inform Decis Mak 2008; 8(Suppl 1):S6; PMID:19007443;  http://dx.doi.org/10.1186/1472-6947-8-S1-S6 5.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
"Nat Biotechnol 2007; 25:887- 93; PMID:17687369; http://dx.doi.org/10.1038/nbt1329 December 6, 2012:   Antibody Engineering/Therapeutics   Development Status of Early Stage   Therapeutic Antibodies Kirstin A. Zettlitz The morning session of the final day of the meeting, chaired  by Rathin Das (Synergys Biotherapeutics, Inc.), was dedicated  to discussion of early stage therapeutic antibodies.",Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
N Engl J Med 2010;  362:197-205; PMID:20089970; http://dx.doi.org/10.1056/NEJMoa0907635 2.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
N Engl J Med 2011; 365:1693-703; PMID:22047560; http://dx.doi.org/10.1056/NEJMoa1012413 3.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
J Infect Dis 2012; 206:706-13; PMID:22732923; http://dx.doi.org/10.1093/infdis/jis416 4.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
"Mol Cancer Ther 2012; 11:2451-61; PMID:22869555;  http://dx.doi.org/10.1158/1535-7163.MCT-12-0278 December 6, 2012:   Antibody Engineering/Therapeutics   Immunomodulatory Antibodies for Cancer Therapy Sven Berger Louis M. Weiner (Georgetown University Medical Center) orga - nized and Kerry Chester  chaired the last session of the confer - ence, which was dedicated to discussion of immunomodulatory  antibodies and ADCs as treatments for cancer.",Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Clin  Cancer Res 2009; 15:1623-34; PMID:19208793; http://dx.doi.org/10.1158/1078- 0432.CCR-08-1825 2.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
J Clin Oncol  2010; 28:3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609 3.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
N Engl J Med  2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690 4.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Blood 2007; 109:4810-5;  PMID:17311995; http://dx.doi.org/10.1182/blood-2006-11-057216 5.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Biochem Biophys Res Commun  2010; 393:829-35; PMID:20171165; http://dx.doi.org/10.1016/j.bbrc.2010.02.092 6.,OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
Clin Cancer Res 2012; 18:3812-21; PMID:22589397; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ce/a0/mabs-5-178.PMC3893229.pdf
"Do not distribute.mAbs 5:2, 208–218; March/April 2013; © 2013 Landes Bioscience Brief report 208 mA bs  V olume 5 i ssue 2*Correspondence to: David W. LaFleur and Carlos F. Barbas, III; Email: dlafleur@zyngenia.com and carlos@scripps.edu Submitted: 10/23/12; Revised: 11/27/12; Accepted: 11/28/12http://dx.doi.org/10.4161/mabs.23043Introduction Exquisite target specificity, bivalent binding, innate effector  function and inherent in vitro and in vivo stability have allowed monoclonal antibodies (mAbs) to be successfully exploited for the treatment of human disease.",Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Lancet 2012; 379:633-40; PMID:22257673; http://dx.doi.org/10.1016/S0140-6736(11)61847-3 2.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
N Engl J Med 2012; 366:109-19; PMID:22149875; http://dx.doi.org/10.1056/NEJMoa1113216 3.,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
T rends Biotechnol 2003; 21:484-90; PMID:14573361; http://dx.doi.org/10.1016/j.tibtech.2003.08.007 4.,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
J Mol Biol 1998; 284:1141-51; PMID:9837732; http://dx.doi.org/10.1006/jmbi.1998.2238 5.,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Protein Eng 1995; 8:601-8; PMID:8532685; http://dx.doi.org/10.1093/protein/8.6.601 6.,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Int J Cancer 2004; 112:509-18; PMID:15382079; http://dx.doi.org/10.1002/ijc.204177.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Science 2009; 323:1610-4; PMID:19299620; http://dx.doi.org/10.1126/science.1165480 8.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345 9.,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Protein Eng Des Sel 2010; 23:289-97; PMID:20150180; http://dx.doi.org/10.1093/protein/gzq005 10.,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Bioorg Med Chem Lett 2009; 19:3716-20; PMID:19497743; http://dx.doi.org/10.1016/j.bmcl.2009.05.047 11.,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Protein Eng 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/pro - tein/9.7.61713.,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
J Biol Chem 2010; 285:19637-46; PMID:20400508; http://dx.doi.org/10.1074/jbc.M110.117382 15.,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
MAbs 2012; 4:600-13; PMID:22864384; http://dx.doi.org/10.4161/mabs.21227 16.,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Cancer Res 2009; 69:2435-42; PMID:19276378; http://dx.doi.org/10.1158/0008-5472.CAN-08-2495 17.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Nucleic Acids Res 2008; 36:e96; PMID:18617574; http://dx.doi.org/10.1093/nar/gkn423,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Clin Cancer Res  2009; 15:7479-91; PMID:20008848; http://dx.doi.org/10.1158/1078-0432.CCR-09-0636 34.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Mol Cancer Ther 2010; 9:2593-604; PMID:20716637; http://dx.doi.org/10.1158/1535-7163.MCT-09-1018 37.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Cancer Res 2010; 70:588-97; PMID:20068188; http://dx.doi.org/10.1158/0008-5472.CAN-09-1417 38.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
J Mol Biol 2012; 422:532-44; PMID:22706026; http://dx.doi.org/10.1016/j.jmb.2012.06.01425.,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Nat Rev Cancer 2010; 10:575-85; PMID:20651738; http://dx.doi.org/10.1038/nrc2894 26.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
MAbs 2012; 4:586-91; PMID:22820181; http://dx.doi.org/10.4161/mabs.21024 27.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Bioinformatics 2001; 17:1236-7; PMID:11751237; http://dx.doi.org/10.1093/bioinfor-matics/17.12.1236 28.,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Drugs R D 2008; 9:385-96; PMID:18989990; http://dx.doi.org/10.2165/0126839-200809060-00004 29.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
BioDrugs 2010; 24:1-8; PMID:20055528; http://dx.doi.org/10.2165/11318560-000000000-00000 30.,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Clin Immunol 2007; 124:26-32; PMID:17490912; http://dx.doi.org/10.1016/j.clim.2007.03.544 31.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
J Clin Oncol 2002; 20:719-26; PMID:11821453; http://dx.doi.org/10.1200/JCO.20.3.719 32.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
J Mammary Gland Biol Neoplasia 2008; 13:485-98; PMID:19034632; http://dx.doi.org/10.1007/s10911-008-9107-318.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Int J Oncol 2010; 36:757-63; PMID:20198317; http://dx.doi.org/10.3892/ijo_00000551 20.,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Cancer Res 2008; 68:1538-45; PMID:18316619; http://dx.doi.org/10.1158/0008-5472.CAN-07-5935 21.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Br J Cancer 2007; 97:453-7; PMID:17667926; http://dx.doi.org/10.1038/sj.bjc.6603910 22.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Mol Cancer Ther 2012; 11:582-93; PMID:22248472; http://dx.doi.org/10.1158/1535-7163.MCT-11-0820 23.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Cancer Cell 2011; 20:472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003 24.,Non-OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
Protein Eng Des Sel 2011; 24:385-96; PMID:21177282; http://dx.doi.org/10.1093/protein/gzq118,OADS,/arxiv_data1/oa_pdf/72/92/mabs-5-208.PMC3893231.pdf
"Do not distribute.www.landesbioscience.com  mAbs  219mA bs 5:2, 219–228; March/April 2013; © 2013 Landes Bioscience Repo Rt Repo Rt *Correspondence to: Albert J.R. Heck; Email: a.j.r.heck@uu.nl Submitted: 11/27/12; Revised: 01/07/13; Accepted: 01/07/13http://dx.doi.org/10.4161/mabs.23532Antibody engineering is increasingly being used to influence the properties of monoclonal antibodies to improve  their biotherapeutic potential.",Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Crit Rev Biochem Mol  Biol 1997; 32:1-100; PMID:9063619; http://dx.doi.org/10.3109/10409239709085144 26.,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Biochem Biophys Res Commun 2001; 286:243-9; PMID:11500028; http://dx.doi.org/10.1006/bbrc.2001.5382 27.,OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide produc-tion triggered through human Fcgamma receptor I. Eur J Biochem 2000; 267:7246-57; PMID:11106438; http://dx.doi.org/10.1046/j.1432-1327.2000.01839.x 28.,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Proteomics 2009; 9:4143-53; PMID:19688751; http://dx.doi.org/10.1002/pmic.200800931 29.,OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Methods Enzymol 2010; 478:365-88; PMID:20816490; http://dx.doi.org/10.1016/S0076-6879(10)78018-6 30.,OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Curr Opin Immunol 2008; 20:471-8; PMID:18606225; http://dx.doi.org/10.1016/j.coi.2008.06.007 31.,OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
J Clin Immunol 2010; 30(Suppl 1):S9-14; PMID:20480216; http://dx.doi.org/10.1007/s10875-010-9405-6 32.,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Biotechnol Prog 2005; 21:11-6; PMID:15903235; http://dx.doi.org/10.1021/bp040016j 33.,OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
"Nat Biotechnol 2009; 27:767-71; PMID:19620983; http://dx.doi.org/10.1038/nbt.1553 35.  v an Berkel PHC, Gerritsen J, van Voskuilen E, Perdok  G, Vink T, van de Winkel JGJ, et al.",OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
"Biotechnol Bioeng 2010; 105:350-7; PMID:19739094; http://dx.doi.org/10.1002/bit.22535 36.  v an Berkel PHC, Gerritsen J, Perdok G, Valbjørn J,  Vink T, van de Winkel JGJ, et al.",OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Biotechnol Prog 2009; 25:244-51; PMID:19224598; http://dx.doi.org/10.1002/btpr.9213.,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
MAbs 2010; 2:181-9; PMID:20150767; http://dx.doi.org/10.4161/mabs.2.2.11158 14.,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
"Structure 2011; 19:1274-82; PMID:21893287; http://dx.doi.org/10.1016/j.str.2011.06.016 15.  v an der Neut Kolfschoten M, Schuurman J, Losen  M, Bleeker WK, Martínez-Martínez P , Vermeulen E, et al.",OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Science 2007; 317:1554-7; PMID:17872445; http://dx.doi.org/10.1126/science.1144603 16.,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Biochemistry 1981; 20:2361-70; PMID:7236608; http://dx.doi.org/10.1021/bi00512a001 18.,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
J Mol Biol 2003; 325:979-89; PMID:12527303; http://dx.doi.org/10.1016/S0022-2836(02)01250-0 19.,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Nature 2000; 406:267-73; PMID:10917521; http://dx.doi.org/10.1038/35018508 20.,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Anal Chem 2009; 81:5966; PMID:19606834; http://dx.doi.org/10.1021/ac9009287 21.,OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Mol Cell Proteomics 2010; 9:1716-28; PMID:20103567; http://dx.doi.org/10.1074/mcp.M900540-MCP200 22.,OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Protein Sci 2010; 19:826-35; PMID:20162626; http://dx.doi.org/10.1002/pro.362 23.,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
J Immunol  Methods 2001; 248:7-15; PMID:11223065; http://dx.doi.org/10.1016/S0022-1759(00)00339-2 24.,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Protein Eng 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/pro - tein/9.7.617References 1.,OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Annu Rev Immunol 2007; 25:21-50; PMID:17029568; http://dx.doi.org/10.1146/annurev.immunol.25.022106.141702 2.,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
T rends Biotechnol 1991; 9:346-52; PMID:1367760; http://dx.doi.org/10.1016/0167-7799(91)90117-Z 3.,OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
MAbs 2012; 4:413-5; PMID:22531442; http://dx.doi.org/10.4161/mabs.19931 4.,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Biotechnol Prog 2005; 21:1644-52; PMID:16321047; http://dx.doi.org/10.1021/bp050228w 7.,OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200 8.,OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M210665200 9.,OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Science 2008; 320:373-6; PMID:18420934; http://dx.doi.org/10.1126/science.1154315 10.,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Science 2006; 313:670-3; PMID:16888140; http://dx.doi.org/10.1126/sci-ence.1129594 12.,OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
Mol Immunol 2007; 44:1524-34; PMID:17045339; http://dx.doi.org/10.1016/j.molimm.2006.09.005,Non-OADS,/arxiv_data1/oa_pdf/9b/a2/mabs-5-219.PMC3893232.pdf
"Do not distribute.www.landesbioscience.com  mAbs  229mA bs 5:2, 229–236; March/April 2013; © 2013 Landes Bioscience Repo Rt Repo Rt *Correspondence to: Tomoyuki Igawa; Email: igawatmy@chugai-pharm.co.jp Submitted: 12/05/12; Revised: 12/27/12; Accepted: 12/31/12http://dx.doi.org/10.4161/mabs.23452Introduction Monoclonal antibodies (mAbs) have enormous potential as anti - cancer therapeutics.",Non-OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
Blood  2012; 119:5640-9; PMID:22535666; http://dx.doi.org/10.1182/blood-2012-01-380121 2.,Non-OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
Blood 2002; 99:754-8; PMID:11806974; http://dx.doi.org/10.1182/blood.V99.3.754 4.,Non-OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
J Clin Oncol 2003; 21:3940-7; PMID:12975461; http://dx.doi.org/10.1200/JCO.2003.05.013 5.,Non-OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200 6.,OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M210665200 7.,OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
Cancer Res 2007; 67:8882-90; PMID:17875730; http://dx.doi.org/10.1158/0008-5472.CAN-07-0696 9.,Non-OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/7470410.,OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
Immunity 2006; 24:19-28; PMID:16413920; http://dx.doi.org/10.1016/j.immuni.2005.11.010 12.,OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
Clin Cancer Res 2004; 10:6248-55; PMID:15448014; http://dx.doi.org/10.1158/1078-0432.CCR-04-0850 14.,Non-OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
Mol Immunol 2008; 45:1872-82; PMID:18078997; http://dx.doi.org/10.1016/j.molimm.2007.10.042 15.,Non-OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
J Biol Chem 2001; 276:16469-77; PMID:11297532; http://dx.doi.org/10.1074/jbc.M100350200 16.,OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
"High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591-604; PMID:11096108; http://dx.doi.org/10.1074/jbc.M009483200 17.",Non-OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
Cancer Res 2010; 70:4481-9; PMID:20484044; http://dx.doi.org/10.1158/0008-5472.CAN-09-3704 18.,Non-OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
Nat Med 2012; 18:1570-4; PMID:23023498; http://dx.doi.org/10.1038/nm.2942 20.,OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
MAbs 2012; 4:653-63; PMID:22925968; http://dx.doi.org/10.4161/mabs.21379 21.,Non-OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
MAbs 2012; 4:182-97; PMID:22453100; http://dx.doi.org/10.4161/mabs.4.2.19000 22.,Non-OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
Mol Cancer Ther 2008; 7:2517-27; PMID:18723496; http://dx.doi.org/10.1158/1535-7163.MCT-08-0201 24.,Non-OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
J Immunol Methods 1999; 226:29-41; PMID:10410969; http://dx.doi.org/10.1016/S0022-1759(99)00039-3,Non-OADS,/arxiv_data1/oa_pdf/cc/1a/mabs-5-229.PMC3893233.pdf
"Do not distribute.www.landesbioscience.com  mAbs  237mA bs 5:2, 237–254; March/April 2013; © 2013 Landes Bioscience Repo Rt Repo Rt *Correspondence to: Alexey A. Lugovskoy; Email: alugovskoy@merrimackpharma.com Submitted: 11/27/12; Revised: 12/19/12; Accepted: 12/19/12http://dx.doi.org/10.4161/mabs.23363Introduction Monoclonal antibodies (mAbs) have significantly increased our  ability to treat human disease; however, many pathologies are het - erogeneous in nature and multiple points of pathway blockade are needed to obtain optimal therapeutic effect.",Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Supplemental Material Supplemental materials may be found here:http://www.landesbioscience.com/journals/mabs/article/23363/(MFI) were determined using FlowJo.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Clin Cancer Res 2010; 16:2489-95; PMID:20406834; http://dx.doi.org/10.1158/1078-0432.CCR-09-2318 2.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Clin Cancer Res 2010; 16:1973-8; PMID:20215532; http://dx.doi.org/10.1158/1078-0432.CCR-09-3182 3.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Acta Pharmacol Sin 2005; 26:649-58; PMID:15916729; http://dx.doi.org/10.1111/j.1745-7254.2005.00119.x 4.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Cancer T reat Rev 2010; 36:458-67; PMID:20347527; http://dx.doi.org/10.1016/j.ctrv.2010.03.001 5.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Protein Sci 2006; 15:14-27; PMID:16373474; http://dx.doi.org/10.1110/ps.051817606 6.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Cancer Res 2006; 66:1500-8; PMID:16452206; http://dx.doi.org/10.1158/0008-5472.CAN-05-2925 7.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Clin Cancer Res 2011; 17:871-9; PMID:21177764; http://dx.doi.org/10.1158/1078-0432.CCR-10-2621 8.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
J Natl Cancer Inst 2001; 93:1852-7; PMID:11752009; http://dx.doi.org/10.1093/jnci/93.24.18529.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Nat Biotechnol 1997; 15:159-63; PMID:9035142; http://dx.doi.org/10.1038/nbt0297-159 10.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Immunol Lett 2004; 92:199-205; PMID:15081612; http://dx.doi.org/10.1016/j.imlet.2004.01.012 11.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Nat Biotechnol 2010; 28:157-9; PMID:20081867; http://dx.doi.org/10.1038/nbt.1601 13.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Nat Protoc 2006; 1:755-68; PMID:17406305; http://dx.doi.org/10.1038/nprot.2006.94 14.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Nat Biotechnol 1997; 15:553-7; PMID:9181578; http://dx.doi.org/10.1038/nbt0697-553 15.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Protein Eng Des Sel 2007; 20:81-90; PMID:17242026; http://dx.doi.org/10.1093/protein/gzl057 16.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Curr Opin Struct Biol 2007; 17:467-73; PMID:17870469; http://dx.doi.org/10.1016/j.sbi.2007.08.012 17.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Appl Microbiol Biotechnol 2004; 64:28-40; PMID:14716465; http://dx.doi.org/10.1007/s00253-003-1492-318.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Comb Chem High Throughput Screen 2008; 11:127-34; PMID:18336206; http://dx.doi.org/10.2174/138620708783744516 19.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Nat Biotechnol 2000; 18:754-9; PMID:10888844; http://dx.doi.org/10.1038/77325 20.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
J Mol Biol 1999; 292:949-56; PMID:10512694; http://dx.doi.org/10.1006/jmbi.1999.3130 21.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Biotechnol Prog 2003; 19:631-8; PMID:12675608; http://dx.doi.org/10.1021/bp0200797 22.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Clin Cancer Res 2009; 15:5445-56; PMID:19706799; http://dx.doi.org/10.1158/1078-0432.CCR-08-2980 23.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Cancer Res 2010; 70:1204-14; PMID:20103628; http://dx.doi.org/10.1158/0008-5472.CAN-09-3321 24.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
MAbs 2009; 1:128-41; PMID:20061822; http://dx.doi.org/10.4161/mabs.1.2.7631,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Protein Sci 2003; 12:963-72; PMID:12717019; http://dx.doi.org/10.1110/ps.0242703 52.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Protein Sci 2003; 12:2001-14; PMID:12930999; http://dx.doi.org/10.1110/ps.03154503 53.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Proteins 2011; 79:261-70; PMID:21058396; http://dx.doi.org/10.1002/prot.22879 54.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Drug Discov Today 2005; 10:213-7; PMID:15708536; http://dx.doi.org/10.1016/S1359-6446(04)03363-X 55.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Nat Methods 2007; 4:466-7; PMID:17538626; http://dx.doi.org/10.1038/nmeth0607-466 56.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
J Mol Biol 2001; 305:989-1010; PMID:11162109; http://dx.doi.org/10.1006/jmbi.2000.4265 57.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
J Mol Biol 2003; 325:531-53; PMID:12498801; http://dx.doi.org/10.1016/S0022-2836(02)01237-8 58.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/nri2747 59.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Nat Biotechnol 2007; 25:107-16; PMID:17173035; http://dx.doi.org/10.1038/nbt1269 60.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Protein Eng Des Sel 2010; 23:155-9; PMID:20130105; http://dx.doi.org/10.1093/protein/gzq002 61.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
J Immunol Methods 2004; 290:69-80; PMID:15261572; http://dx.doi.org/10.1016/j.jim.2004.04.009 62.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Nat Biotechnol 2003; 21:163-70; PMID:12536217; http://dx.doi.org/10.1038/nbt785 63.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Protein Eng Des Sel 2011; 24:691-700; PMID:21680620; http://dx.doi.org/10.1093/protein/gzr023 39.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Nat Biotechnol 2007; 25:1171-6; PMID:17891135; http://dx.doi.org/10.1038/nbt1336 40.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Proteins 2009; 77:832-41; PMID:19626705; http://dx.doi.org/10.1002/prot.22502 41.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Protein Eng Des Sel 2010; 23:115-27; PMID:20022918; http://dx.doi.org/10.1093/protein/gzp073 42.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
J Biol Chem 2011; 286:44218-33; PMID:22002064; http://dx.doi.org/10.1074/jbc.M111.290783 43.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Protein Eng Des Sel 2010; 23:549-57; PMID:20457695; http://dx.doi.org/10.1093/protein/gzq028 44.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Biochim Biophys Acta 2012; 1824:542-9; PMID:22285845; http://dx.doi.org/10.1016/j.bbapap.2012.01.006 45.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Nat Biotechnol 2004; 22:1161-5; PMID:15300256; http://dx.doi.org/10.1038/nbt1000 46.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
N Engl J Med 2012; 366:109-19; PMID:22149875; http://dx.doi.org/10.1056/NEJMoa1113216 47.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
J Mol Biol 1996; 263:800-15; PMID:8947577; http://dx.doi.org/10.1006/jmbi.1996.0617 49.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Nat Protoc 2008; 3:1832-47; PMID:18989261; http://dx.doi.org/10.1038/nprot.2008.184 50.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Bioinformatics 2005; 21:2914-6; PMID:15845657; http://dx.doi.org/10.1093/bioinformatics/bti43825.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
J Mol Biol 2001; 305:1111-29; PMID:11162118; http://dx.doi.org/10.1006/jmbi.2000.4342 26.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Nat Biotechnol 2005; 23:344-8; PMID:15723048; http://dx.doi.org/10.1038/nbt1067 27.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
J Am Chem Soc 2009; 131:3794-5; PMID:19292479; http://dx.doi.org/10.1021/ja8049063 28.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Protein Sci 2011; 20:1546-57; PMID:21710487; http://dx.doi.org/10.1002/pro.680 29.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Nat Rev Immunol 2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761 30.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
MAbs 2011; 3:299-309; PMID:21393992; http://dx.doi.org/10.4161/mabs.3.3.15299 31.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Mol Cancer Ther 2012; 11:582-93; PMID:22248472; http://dx.doi.org/10.1158/1535-7163.MCT-11-0820 32.,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Sci Signal 2009; 2:ra31; PMID:19567914; http://dx.doi.org/10.1126/scisignal.2000352 33.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
J Biol Chem 2011; 286:4703-17; PMID:21123183; http://dx.doi.org/10.1074/jbc.M110.184317 34.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
J Mol Biol 2007; 371:934-47; PMID:17602702; http://dx.doi.org/10.1016/j.jmb.2007.05.011 36.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
Chem Biol 2002; 9:933-42; PMID:12204693; http://dx.doi.org/10.1016/S1074-5521(02)00187-4 37.,OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
J Mol Biol 1996; 255:28-43; PMID:8568873; http://dx.doi.org/10.1006/jmbi.1996.0004,Non-OADS,/arxiv_data1/oa_pdf/da/dc/mabs-5-237.PMC3893234.pdf
"Do not distribute.www.landesbioscience.com  mAbs  255mA bs 5:2, 255–262; March/April 2013; © 2013 Landes Bioscience Repo Rt Repo Rt *Correspondence to: Andrew Buchanan; Email: buchanana@medimmune.com Submitted: 11/26/12; Revised: 12/20/12; Accepted: 12/21/12http://dx.doi.org/10.4161/mabs.23392Introduction Recombinant monoclonal antibodies (mAbs) represent an estab - lished and growing class of therapeutics, with more than 20  mAbs approved for the treatment and prevention of disease.",Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
J Immunotoxicol  2006; 3:123-30; PMID:18958692; http://dx.doi.org/10.1080/15476910600845567 2.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
"J Clin Oncol 2012; 30:334, author reply 335; PMID:22162592; http://dx.doi.org/10.1200/JCO.2011.38.4701 3.",Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Rheumatol Int 2007; 27:269-74; PMID:17006705; http://dx.doi.org/10.1007/s00296-006-0183-7 4.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Adv Protein Chem Struct Biol 2011; 84:41-61; PMID:21846562; http://dx.doi.org/10.1016/B978-0-12-386483-3.00004-5 6.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Biotechnol Bioeng 2005; 89:599-607; PMID:15672379; http://dx.doi.org/10.1002/bit.20397 7.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Biotechnol J 2008; 3:1201-11; PMID:18702089; http://dx.doi.org/10.1002/biot.200800091 8.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
J Pharm Sci 2010; 100:1306-15; PMID:20960568; http://dx.doi.org/10.1002/jps.22371 9.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Biotechnol Bioeng 2011; 108:2634-44; PMID:21618474; http://dx.doi.org/10.1002/bit.23220 10.,OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
J Pharm Sci 2012; 101:102-15; PMID:21935950; http://dx.doi.org/10.1002/jps.22758 11.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Nat Biotechnol 2009; 27:26-34; PMID:19131992; http://dx.doi.org/10.1038/nbt0109-26 12.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Nat Biotechnol 2009; 27:767-71; PMID:19620983; http://dx.doi.org/10.1038/nbt.1553 15.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Anticancer Drugs 2010; 21:907-16; PMID:20847643; http://dx.doi.org/10.1097/CAD.0b013e32833f5d68 17.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Nat Biotechnol 2004; 22:1161-5; PMID:15300256; http://dx.doi.org/10.1038/nbt1000 19.,OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Protein Eng Des Sel 2007; 20:413-6; PMID:17720749; http://dx.doi.org/10.1093/protein/gzm037 20.,OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
J Virol 2003; 77:4546-57; PMID:12663761; http://dx.doi.org/10.1128/JVI.77.8.4546-4557.2003 22.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Curr Protein Pept Sci 2009; 10:614-25; PMID:19538140; http://dx.doi.org/10.2174/138920309789630534 23.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Anal Biochem 2008; 382:66-8; PMID:18675772; http://dx.doi.org/10.1016/j.ab.2008.07.016 24.,OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Anal Biochem 2006; 355:165-74; PMID:16828048; http://dx.doi.org/10.1016/j.ab.2006.05.03725.,OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Pharm Res 1992; 9:1386-93; PMID:1475223; http://dx.doi.org/10.1023/A:1015894409623 26.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
J Infect Dis 1997; 176:1215-24; PMID:9359721; http://dx.doi.org/10.1086/514115 27.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Curr Top Microbiol Immunol 2008; 317:103-23; PMID:17990791; http://dx.doi.org/10.1007/978-3-540-72146-8_4 28.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
J Chromatogr B Analyt Technol Biomed Life Sci 2006; 837:35-43; PMID:16644295; http://dx.doi.org/10.1016/j.jchromb.2006.03.053 29.,OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
J Biol Chem 2000; 275:30445-50; PMID:10880507; http://dx.doi.org/10.1074/jbc.M001672200 31.,OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
J Immunol Methods 2008; 332:41-52; PMID:18230399; http://dx.doi.org/10.1016/j.jim.2007.12.011 32.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Nat Biotechnol 2008; 26:925-32; PMID:18641636; http://dx.doi.org/10.1038/nbt.1480 33.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Bioconjug Chem 2010; 21:385-92; PMID:20092294; http://dx.doi.org/10.1021/bc900509s 34.,OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
J Biol Chem 2011; 286:25118-33; PMID:21454532; http://dx.doi.org/10.1074/jbc.M110.160457 36.,OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Pharm Res 2010; 27:544-75; PMID:20143256; http://dx.doi.org/10.1007/s11095-009-0045-6,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Protein Sci 2005; 14:2246-57; PMID:16131655; http://dx.doi.org/10.1110/ps.051489405 44.,OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Expert Opin Biol Ther 2007; 7:405-18; PMID:17309332; http://dx.doi.org/10.1517/14712598.7.3.40540.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Protein Sci 2010; 19:1601-15; PMID:20556807; http://dx.doi.org/10.1002/pro.434 41.,OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
J Biol Chem 2008; 283:29266-72; PMID:18713741; http://dx.doi.org/10.1074/jbc.M804787200 42.,OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Crit Rev Oncol Hematol 2007; 64:210-25; PMID:17624800; http://dx.doi.org/10.1016/j.critrevonc.2007.04.011 38.,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
Nucleic Acids Res 2010; 38(Database issue):D301-7; PMID:19900967; http://dx.doi.org/10.1093/nar/gkp946 39.,OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
J Mol Recognit 2004; 17:17-32; PMID:14872534; http://dx.doi.org/10.1002/jmr.647,Non-OADS,/arxiv_data1/oa_pdf/0b/5a/mabs-5-255.PMC3893235.pdf
"Do not distribute.www.landesbioscience.com  mAbs  263mA bs 5:2, 263–269; March/April 2013; © 2013 Landes Bioscience Repo Rt Repo Rt *Correspondence to: Larry Zeitlin; Email: larry.zeitlin@mappbio.com Submitted: 11/01/12; Revised: 12/01/12; Accepted: 12/14/12http://dx.doi.org/10.4161/mabs.23281Introduction Respiratory syncytial virus (RSV), a member of the Pneumovirus  genus of the Paramyxoviridae family, is commonly the cause of severe lower respiratory tract infection in infants and small chil - dren.",Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Lancet 1999; 354:541-5; PMID:10470697; http://dx.doi.org/10.1016/S0140-6736(98)10321-5 2.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
J Pediatr 2003; 143(Suppl):S127-32; PMID:14615711; http://dx.doi.org/10.1067/S0022-3476(03)00510-9 3.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Clin Microbiol Rev 2000; 13:371-84; PMID:10885982; http://dx.doi.org/10.1128/CMR.13.3.371-384.20004.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
"Am J Med 1997; 102(3A):27-30, discussion 42-3; PMID:10868139; http://dx.doi.org/10.1016/S0002-9343(97)00007-7 5.",Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Nat Rev  Drug Discov 2010; 9:15-6; PMID:20043025; http://dx.doi.org/10.1038/nrd3075 6.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Pediatrics 1998; 102:531-7; http://dx.doi.org/10.1542/peds.102.3.531 7.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Pediatrics 1999; 104:419-27; PMID:10469764; http://dx.doi.org/10.1542/peds.104.3.4198.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Clin Ther 2000; 22:1357-69; PMID:11117660; http://dx.doi.org/10.1016/S0149-2918(00)83032-5 9.,OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
J Paediatr Child Health 2000; 36:422-7; PMID:11036794; http://dx.doi.org/10.1046/j.1440-1754.2000.00303.x 10.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Pediatr Pulmonol 2001; 32:20-8; PMID:11416872; http://dx.doi.org/10.1002/ppul.1084 11.,OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
J Paediatr Child Health 2002; 38:352-7; PMID:12173995; http://dx.doi.org/10.1046/j.1440-1754.2002.00790.x,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Hum Vaccin 2011; 7:313-21; PMID:21346417; http://dx.doi.org/10.4161/hv.7.3.14207 30.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Nat Biotechnol 1998; 16:1361-4; PMID:9853620; http://dx.doi.org/10.1038/4344 31.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Virus Res 2005; 111:93-100; PMID:15896408; http://dx.doi.org/10.1016/j.virusres.2005.03.016 32.,OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Int Immunol 2001; 13:1551-9; PMID:11717196; http://dx.doi.org/10.1093/intimm/13.12.1551 34.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Blood 2011; 117:2755-63; PMID:21139081; http://dx.doi.org/10.1182/blood-2010-08-263400 35.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848:8-18; PMID:16899415; http://dx.doi.org/10.1016/j.jchromb.2006.07.037 36.,OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Ann Oncol 2010; 21:2420-7; PMID:20494963; http://dx.doi.org/10.1093/annonc/mdq256 37.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
J Infect Dis 1997; 176:1215-24; PMID:9359721; http://dx.doi.org/10.1086/514115 22.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Nature 1989; 342:76-8; PMID:2509938; http://dx.doi.org/10.1038/342076a0 23.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Nat Biotechnol 2005; 23:718-23; PMID:15883585; http://dx.doi.org/10.1038/nbt1094 24.,OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Plant Biotechnol J 2008; 6:392-402; PMID:18346095; http://dx.doi.org/10.1111/j.1467-7652.2008.00330.x 26.,OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Plant Biotechnol J 2010; 8:638-54; PMID:20514694; http://dx.doi.org/10.1111/j.1467-7652.2009.00495.x 27.,OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Vaccine 1993; 11:1415-23; PMID:7508665; http://dx.doi.org/10.1016/0264-410X(93)90170-3 28.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Hum Vaccin 2011; 7:349-56; PMID:21358287; http://dx.doi.org/10.4161/hv.7.3.1426612.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Arch Dis Child 2010; 95:493-8; PMID:20504841; http://dx.doi.org/10.1136/adc.2008.155556 14.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Pediatrics 1998; 102:648-51; PMID:9738192; http://dx.doi.org/10.1542/peds.102.3.648 15.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
Pediatrics 1997; 99:93-9; PMID:8989345; http://dx.doi.org/10.1542/peds.99.1.93 16.,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
J Infect Dis 1999; 180:268-77; PMID:10395839; http://dx.doi.org/10.1086/314876 18.,OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
J Infect Dis 1998; 177:1073-6; PMID:9534985; http://dx.doi.org/10.1086/517397,Non-OADS,/arxiv_data1/oa_pdf/40/a7/mabs-5-263.PMC3893236.pdf
"Do not distribute.mAbs 5:2, 270–278; March/April 2013; © 2013 Landes Bioscience Brief report 270 mA bs  V olume 5 i ssue 2*Correspondence to: Yingda Xu; Email: yingda.xu@adimab.com Submitted: 11/16/12; Revised: 11/27/12; Accepted: 11/28/12http://dx.doi.org/10.4161/mabs.23049Introduction Binding affinity and epitopic coverage are critical biophysical  characteristics for identification of therapeutically relevant anti - bodies.1 Generation of 1000–3000 unique lead antibodies per  week necessitates a high throughput methodology to measure affinity and determine epitopic diversity.",Non-OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Anal Biochem 2008; 377:209-17; PMID:18405656; http://dx.doi.org/10.1016/j.ab.2008.03.035 12.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Assay Drug Dev Technol 2004; 2:647-57; PMID:15674023; http://dx.doi.org/10.1089/adt.2004.2.647 13.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Anal Biochem 2011; 414:7-13; PMID:21371417; http://dx.doi.org/10.1016/j.ab.2011.02.034 14.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
PLoS One 2012; 7:e36261; PMID:22558410; http://dx.doi.org/10.1371/journal.pone.0036261 15.,Non-OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
J Mol Recognit 2012; 25:136-46; PMID:22407977; http://dx.doi.org/10.1002/jmr.21496.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Anal Biochem 2011; 411:139-51; PMID:21168382; http://dx.doi.org/10.1016/j.ab.2010.12.020 7.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Biophys J 1998; 75:583-94; PMID:9675161; http://dx.doi.org/10.1016/S0006-3495(98)77549-6 8.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
J Mol Recognit 2011; 24:892-914; PMID:22038797; http://dx.doi.org/10.1002/jmr.1138 9.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
J Biol Chem 2012; 287:13291-302; PMID:22351776; http://dx.doi.org/10.1074/jbc.M111.323766 10.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Anal Biochem 2006; 349:136-47; PMID:16337141; http://dx.doi.org/10.1016/j.ab.2005.09.034References 1.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
J Immunol Methods 2004; 289:65-80; PMID:15251413; http://dx.doi.org/10.1016/j.jim.2004.03.014 2.,Non-OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Anal Biochem 2008; 373:112-20; PMID:17889820; http://dx.doi.org/10.1016/j.ab.2007.08.017 3.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Cellular and Molecular Bioengineering 2008; 1:216-28; http://dx.doi.org/10.1007/s12195-008-0036-4 4.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Comb Chem High Throughput Screen 2009; 12:791-800; PMID:19758119; http://dx.doi.org/10.2174/138620709789104915 5.,Non-OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Anal Biochem 2009; 386:172-80; PMID:19111520; http://dx.doi.org/10.1016/j.ab.2008.11.038Figure 5.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
J Immunol Methods  2004; 290:107-20; PMID:15261575; http://dx.doi.org/10.1016/j.jim.2004.04.012 25.,Non-OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Clin Vaccine Immunol 2009; 16:387-96; PMID:19158284; http://dx.doi.org/10.1128/CVI.00415-08 26.,Non-OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Anal Biochem 2005; 339:182-4; PMID:15766727; http://dx.doi.org/10.1016/j.ab.2004.12.03220.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Protein Sci 2008; 17:1326-35; PMID:18505735; http://dx.doi.org/10.1110/ps.035402.108 21.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Biophys Chem 1997; 64:127-37; PMID:9127943; http://dx.doi.org/10.1016/S0301-4622(96)02230-2 22.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Biophys J 2003; 84:4062-77; PMID:12770910; http://dx.doi.org/10.1016/S0006-3495(03)75132-7 23.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
J Immunol Methods 1997; 200:155-9; PMID:9005954; http://dx.doi.org/10.1016/S0022-1759(96)00201-316.,Non-OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Anal Biochem 2012; 426:134-41; PMID:22542978; http://dx.doi.org/10.1016/j.ab.2012.04.023 17.,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
Anal Biochem 2012; 429:58-69; PMID:22766435; http://dx.doi.org/10.1016/j.ab.2012.06.024,OADS,/arxiv_data1/oa_pdf/db/0f/mabs-5-270.PMC3893237.pdf
"Do not distribute.mAbs 5:2, 306–322; March/April 2013; © 2013 Landes Bioscience Repo Rt 306 mA bs  V olume 5 Issue 2*Correspondence to: Trevor E. Swartz; Email: swartz.trevor@gene.com Submitted: 12/06/12; Revised: 01/14/13; Accepted: 01/17/13http://dx.doi.org/10.4161/mabs.23651Introduction We are interested in understanding the solution dynamics of  antibodies.",Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
"2 ) were further analyzed using an anisotropic network  model (ANM) 56,57 to calculate the normal modes of the trastu - zumab antibody (http://ignmtest.ccbb.pitt.edu/cgi-bin/anm/anm1.cgi).",OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Curr Protein Pept Sci 2010; 11:515-22; PMID:20887264; http://dx.doi.org/10.2174/138920310794109201 4.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Proteins 2008; 71:684-94; PMID:17975832; http://dx.doi.org/10.1002/prot.21750 7.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Biophys J 2010; 99:905-13; PMID:20682269; http://dx.doi.org/10.1016/j.bpj.2010.05.003 8.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Allergy Clin Immunol 2010; 125(Suppl 2):S41-52; PMID:20176268; http://dx.doi.org/10.1016/j.jaci.2009.09.046 9.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Mol Biol 1967; 27:615-7; PMID:4167449; http://dx.doi.org/10.1016/0022-2836(67)90063-0 10.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Nature 1965; 205:147-9; PMID:14276258; http://dx.doi.org/10.1038/205147a0 11.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Electron micro- scopic evidence for the axial rotation and inter-domain flexibility of the Fab regions of immunoglobulin G. J Mol Biol 1983; 169:771-4; PMID:6631952; http://dx.doi.org/10.1016/S0022-2836(83)80170-312.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Concerning the axial  rotational flexibility of the Fab regions of immunoglob-ulin G. J Mol Biol 1989; 206:349-56; PMID:2716050; http://dx.doi.org/10.1016/0022-2836(89)90484-1 13.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Phys Biol 2007; 4:172-80; PMID:17928656; http://dx.doi.org/10.1088/1478-3975/4/3/004 14.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Structure 2004; 12:409-15; PMID:15016357; http://dx.doi.org/10.1016/j.str.2004.02.011 15.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
T rends Immunol 2004; 25:700-7; PMID:15530842; http://dx.doi.org/10.1016/j.it.2004.09.009 16.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Methods Enzymol 1994; 239:440-64; PMID:7830594; http://dx.doi.org/10.1016/S0076-6879(94)39017-7,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Mol Biol 1994; 236:300-9; PMID:8107111; http://dx.doi.org/10.1006/jmbi.1994.1136 49.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Mol Biol 1987; 196:901-17; PMID:3681981; http://dx.doi.org/10.1016/0022-2836(87)90412-8 50.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Mol Biol 1997; 273:927-48; PMID:9367782; http://dx.doi.org/10.1006/jmbi.1997.1354 51.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Mol Biol 1994; 242:309-20; PMID:7932691; http://dx.doi.org/10.1016/S0022-2836(84)71582-8 52.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Am Chem Soc 2010; 132:1526-8; PMID:20070076; http://dx.doi.org/10.1021/ja9090353 54.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Chem Phys 2009; 131:124101; PMID:19791846; http://dx.doi.org/10.1063/1.3216567 55.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Methods 2010; 52:99-105; PMID:20570730; http://dx.doi.org/10.1016/j.ymeth.2010.06.002 56.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Biophys J 2001; 80:505-15; PMID:11159421; http://dx.doi.org/10.1016/S0006-3495(01)76033-X 57.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Proteins 2000; 40:512-24; PMID:10861943; http://dx.doi.org/10.1002/1097-0134(20000815)40:3<512::AID-PROT180>3.0.CO;2-M 58.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Bioinformatics 2005; 21:2978-87; PMID:15860562; http://dx.doi.org/10.1093/bioinformatics/bti469 59.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Nucleic Acids Res 2006; 34(Web Server issue):W24-31; PMID:16845002; http://dx.doi.org/10.1093/nar/gkl084 60.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Am Chem Soc 1996; 118:11225-36; http://dx.doi.org/10.1021/ja9621760 61.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Comput Chem 2007; 28:689-97; PMID:17195160; http://dx.doi.org/10.1002/jcc.20560 62.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Proteins 2005; 61:704-21; PMID:16231289; http://dx.doi.org/10.1002/prot.2066032.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Nature 2003; 421:756-60; PMID:12610629; http://dx.doi.org/10.1038/nature01392 33.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Mol Biol 2002; 319:9-18; PMID:12051932; http://dx.doi.org/10.1016/S0022-2836(02)00244-9 34.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Methods Enzymol 1972; 26(PtC):498-578; PMID:4680723; http://dx.doi.org/10.1016/S0076-6879(72)26026-8 35.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Biochemistry 1981; 20:6842-52; PMID:7317358; http://dx.doi.org/10.1021/bi00527a016 36.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Chem Theory Comput 2008; 4:435-47; http://dx.doi.org/10.1021/ct700301q 37.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Bioinformatics 2006; 22:2619-27; PMID:16928735; http://dx.doi.org/10.1093/bioinformatics/btl448 39.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Proteins 2008; 70:1294-312; PMID:17876828; http://dx.doi.org/10.1002/prot.21618 41.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Chem Theory Comput 2009; 5:2486-502; PMID:20161451; http://dx.doi.org/10.1021/ct9001812 43.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Biol Chem 2010; 285:40991-1000; PMID:20947510; http://dx.doi.org/10.1074/jbc.M110.170902 44.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Biol Chem 2010; 285:40991-1000; PMID:20947510; http://dx.doi.org/10.1074/jbc.M110.170902 45.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Biophys J 2000; 78:394-404; PMID:10620303; http://dx.doi.org/10.1016/S0006-3495(00)76602-1 46.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Mol Biol 1993; 229:969-95; PMID:8095303; http://dx.doi.org/10.1006/jmbi.1993.109917.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Science 2001; 293:1155-9; PMID:11498595; http://dx.doi.org/10.1126/sci-ence.1061692 18.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Mol Biol 1998; 275:861-72; PMID:9480774; http://dx.doi.org/10.1006/jmbi.1997.1508 19.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Biophys Chem 2005; 115:235-40; PMID:15752611; http://dx.doi.org/10.1016/j.bpc.2004.12.037 21.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Mol Model 2012; PMID:23160933; http://dx.doi.org/10.1007/s00894-012-1661-3 22.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Biochemistry 2007; 46:1534-44; PMID:17279618; http://dx.doi.org/10.1021/bi061500t 23.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Immunol Today 1995; 16:85-90; PMID:7888072; http://dx.doi.org/10.1016/0167-5699(95)80094-8 26.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Biophys J 2005; 89:3757-70; PMID:16169987; http://dx.doi.org/10.1529/bio-physj.105.069500 27.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Chem Phys 2010; 132:096101; PMID:20210414; http://dx.doi.org/10.1063/1.3330544 28.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Biophys J 1996; 70:1830-5; PMID:8785343; http://dx.doi.org/10.1016/S0006-3495(96)79748-5 29.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Curr  Opin Biotechnol 1995; 6:103-10; PMID:7534502; http://dx.doi.org/10.1016/0958-1669(95)80016-6 30.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Nat Biotechnol 2008; 26:925-32; PMID:18641636; http://dx.doi.org/10.1038/nbt.1480 31.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Biol Chem 1995; 270:13057-62; PMID:7768899; http://dx.doi.org/10.1074/jbc.270.22.13057,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Curr Opin Struct Biol 2008; 18:154-62; PMID:18378442; http://dx.doi.org/10.1016/j.sbi.2008.01.008 76.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Chem Phys 2008; 128:244103; PMID:18601313; http://dx.doi.org/10.1063/1.2916718 77.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Chem Phys 2005; 123:204909; PMID:16351319; http://dx.doi.org/10.1063/1.2116947 78.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Biophys J 1984; 46:45-56; PMID:6743756; http://dx.doi.org/10.1016/S0006-3495(84)83997-1 81.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Nature 1984; 307:136-40; PMID:6690993; http://dx.doi.org/10.1038/307136a069.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Biopolymers 1984; 23:1513-8; http://dx.doi.org/10.1002/bip.360230807 70.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Chem Phys 1993; 98:10089-92; http://dx.doi.org/10.1063/1.464397 71.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Comput Chem 1992; 13:952-62; http://dx.doi.org/10.1002/jcc.540130805 72.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Comput Chem 1997; 18:1463-72; http://dx.doi.org/10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H 73.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Chem Phys 2007; 126:014101; PMID:17212484; http://dx.doi.org/10.1063/1.2408420 74.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Chem Phys 1984; 81:3684-90; http://dx.doi.org/10.1063/1.44811863.,Non-OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
Proteins 2008; 73:765-83; PMID:18498103; http://dx.doi.org/10.1002/prot.22102 64.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Comput Chem 1997; 18:1955-70; http://dx.doi.org/10.1002/(SICI)1096-987X(199712)18:16<1955::AID-JCC1>3.0.CO;2-L 65.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Comput Chem 2002; 23:1416-29; PMID:12370944; http://dx.doi.org/10.1002/jcc.10139 66.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Comput Chem 2002; 23:1623-41; PMID:12395429; http://dx.doi.org/10.1002/jcc.10128 67.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Mol Graph Model 2006; 25:247-60; PMID:16458552; http://dx.doi.org/10.1016/j.jmgm.2005.12.005 68.,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
J Comput Chem 2004; 25:1157-74; PMID:15116359; http://dx.doi.org/10.1002/jcc.20035,OADS,/arxiv_data1/oa_pdf/98/af/mabs-5-306.PMC3893241.pdf
"Normal activities and employment Figure 2 and Supplemental Table S2, http://links.lww.- com/QAD/A407 report results for having a job at the time of the interview, difﬁculty with job performance, ability to perform normal activities during the previous 5-day workweek, and number of days unable to perform normal activities over the previous 5-day workweek, among those who reported inability.",OADS,/arxiv_data1/oa_pdf/7d/60/aids-28-417.PMC3893293.pdf
"3 and Table S3, http://links.lww.com/QAD/ A407).",Non-OADS,/arxiv_data1/oa_pdf/7d/60/aids-28-417.PMC3893293.pdf
Mid-year population estimates 2011. http://www.statssa.gov.za/publications/P0302/P03022011.pdf.,OADS,/arxiv_data1/oa_pdf/7d/60/aids-28-417.PMC3893293.pdf
"Quarterly Labour Force Survey Quarter 4, 2011. http://www.statssa.gov.za/publications/P0211/ P02113rdQuarter2011.pdf.",Non-OADS,/arxiv_data1/oa_pdf/7d/60/aids-28-417.PMC3893293.pdf
"2013;45(4):251-262 pISSN 1598-2998, eISSN 2005-9256  http://dx.doi.org/10.4143/crt.2013.45.4.251  Melissa M. Phillips, MD 1,2  Michael T. Sheaff, MD 3 Peter W. Szlosarek, MD, PhD 1,2  1Center for Molecular Oncology,  Barts Cancer Institute - a Cancer Research  UK Centre of Excellence,  Queen Mary University of London,  Barts and The London  School of Medicine and Dentistry,  2St Bartholomew’s Hospital,  3Pathology Group,  Institute of Cell and Molecular Sciences,  Queen Mary University of London,  Barts and The London School of Medicine  and Dentistry, London, UK  Correspondence: Peter W. Szlosarek, MD, PhD  Center for Molecular Oncology,  Barts Cancer Institute, Queen Mary  University of London, Barts and The London  School of Medicine and Dentistry,  London, EC1A 7BE, UK  Tel: 44-20-7882-3559  Fax: 44-20-7882-3884  E-mail: p.w.szlosarek@qmul.ac.uk  Received  October 31, 2013  Accepted  November 13, 2013 Arginine deprivation is a novel antimetabolite strategy for the treatment of arginine-  dependent cancers that exploits differential expression and regulation of key urea  cycle enzymes.",Non-OADS,/arxiv_data1/oa_pdf/d6/5a/crt-45-251.PMC3893322.pdf
"Testing for  metabolic genetic drivers such as mutations in Kreb’s cycle  genes (i.e., fumarate hydratase [FH], succinate dehydroge - │http://www.cancerresearchandtreatment.org │ │http://www.e-crt.org │251 Copyright ⓒ2013 by  the Korean Cancer Association  This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/  licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d6/5a/crt-45-251.PMC3893322.pdf
"2013;45(4):263-269 pISSN 1598-2998, eISSN 2005-9256  http://dx.doi.org/10.4143/crt.2013.45.4.263  Sung Ae Koh, MD, PhD 1 Kyung Hee Lee, MD, PhD 1 Mi Jung Kim, RN 1 Kyu Taek Lee, MD, PhD 2 Seung Woo Park, MD, PhD 3 Seung Hyun Nam, MD 4 Hun Mo Ryoo, MD, PhD 5 1Department of Hematology-Oncology,  Yeungnam University  College of Medicine, Daegu,  2Department of Hematology-Oncology,  Soonchunhyang University  Cheonan Hospital,  Soonchunhyang University  College of Medicine, Cheonan,  3Department of Gastroenterology,  Yonsei University College of Medicine,  4Department of Hematology-Oncology,  VHS Medical Center, Seoul,  5Department of Hematology-Oncology,  Daegu Catholic University Medical Center,  Daegu, Korea  Correspondence: Kyung Hee Lee, MD, PhD  Department of Hemato-Oncology,  Yeungnam University College of Medicine,  170 Hyeonchung-ro, Nam-gu,  Daegu 705-717, Korea  Tel: 82-53-620-3845  Fax: 82-53-654-8386  E-mail: lkhee@med.yu.ac.kr  Received  January 8, 2013  Accepted  April 19, 2013 Purpose End-of-dose failure (EOD) is a clinically common observation and many cancer  patients increase the frequency of opioid administration.",Non-OADS,/arxiv_data1/oa_pdf/3e/a3/crt-45-263.PMC3893323.pdf
"With regard to life expectancy of cancer patients,  │http://www.cancerresearchandtreatment.org │ │http://www.e-crt.org │Copyright ⓒ2013 by  the Korean Cancer Association  This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/  licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3e/a3/crt-45-263.PMC3893323.pdf
"2013;45(4):270-275 pISSN 1598-2998, eISSN 2005-9256  http://dx.doi.org/10.4143/crt.2013.45.4.270  Ji Hyung Hong, MD  Sang-Young Rho, MD, PhD  Young Seon Hong, MD, PhD  Division of Medical Oncology,  Department of Internal Medicine,  Seoul St. Mary's Hospital,  The Catholic University of Korea  College of Medicine, Seoul, Korea  Correspondence: Young Seon Hong, MD, PhD  Division of Medical Oncology,  Department of Internal Medicine,  Seoul St. Mary's Hospital, The Catholic  University of Korea College of Medicine, 222  Banpo-daero, Seocho-gu, Seoul 137-701, Korea  Tel: 82-2-2258-6042  Fax: 82-2-2258-6273  E-mail: y331@catholic.ac.kr  Received  January 31, 2013  Accepted  May 1, 2013 Purpose It is important to balance the appropriateness of active cancer treatments and end-  of-life care to improve the quality of life for terminally ill cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/83/58/crt-45-270.PMC3893324.pdf
"It is important to distinguish between terminally ill cancer  │http://www.cancerresearchandtreatment.org │ │http://www.e-crt.org │270 Copyright ⓒ2013 by  the Korean Cancer Association  This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/  licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/83/58/crt-45-270.PMC3893324.pdf
"2013;45(4):276-284 pISSN 1598-2998, eISSN 2005-9256  http://dx.doi.org/10.4143/crt.2013.45.4.276  Dae-Eun Kim, MD 1 Uh-Jin Kim, MD 1 Won-Young Choi, MD 1 Mi-Young Kim, MD 1 Seung-Hun Kim, MD 1 Min-Jee Kim, MD 1 Hyun-Jeong Shim, MD 1 Jun-Eul Hwang, MD 1 Woo-Kyun Bae, MD 1 Ik-Joo Chung, MD 1 Taek-Keun Nam, MD 2 Kook-Joo Na, MD 3 Sang-Hee Cho, MD, PhD 1 Departments of 1Internal Medicine,  2Radiation Oncology, and 3Chest Surgery,  Chonnam National University  Medical School, Gwangju, Korea  Correspondence: Sang-Hee Cho, MD, PhD  Division of Hemato-Oncology, Department of  Internal Medicine, Chonnam National University  Hwasun Hospital, Chonnam National University  Medical School, 322 Seoyang-ro,  Hwasun 519-763, Korea  Tel: 82-61-379-7633  Fax: 82-61-379-8090  E-mail: shcho@jnu.ac.kr  Received  January 17, 2013  Accepted  May 6, 2013 Purpose Locally advanced esophageal cancers are generally treated with neoadjuvant  chemoradiotherapy, followed by surgery in operable candidates.",Non-OADS,/arxiv_data1/oa_pdf/30/56/crt-45-276.PMC3893325.pdf
"In addition, the outcome of  surgery is not satisfactory: the 2-year survival rate is only  15-24%, and 30-40% of these patients suffer from postopera - │http://www.cancerresearchandtreatment.org │ │http://www.e-crt.org │276 Copyright ⓒ2013 by  the Korean Cancer Association  This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/  licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/30/56/crt-45-276.PMC3893325.pdf
"Approximately 50% of patients have distant metastasis at the  time of diagnosis, and of the remaining patients who initially  │http://www.cancerresearchandtreatment.org │ │http://www.e-crt.org │285 Copyright ⓒ2013 by  the Korean Cancer Association  This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/  licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/13/8d/crt-45-285.PMC3893326.pdf
"2013;45(4):285-294 pISSN 1598-2998, eISSN 2005-9256  http://dx.doi.org/10.4143/crt.2013.45.4.285  Correspondence: Jeeyun Lee, MD, PhD  Division of Hematology-Oncology,  Department of Medicine,  Samsung MedicalCenter,  Sungkyunkwan University School of Medicine,  81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea  Tel: 82-2-3410-3459  Fax: 82-2-3410-1754   E-mail: jyunlee@skku.edu  Received  March 15, 2013  Accepted  May 1, 2013 Original Article Open Access  Nomogram to Predict Treatment Outcome of Fluoropyrimidine/  Platinum-Based Chemotherapy in Metastatic Esophageal Squamous  Cell Carcinoma  Hyun Ae Jung, MD 1 Antoine Adenis, MD, PhD 2 Jeeyun Lee, MD, PhD 1 Se Hoon Park, MD, PhD 1 Chi Hoon Maeng, MD 1 Silvia Park, MD 1 Hee Kyung Ahn, MD 1 Young Mog Shim, MD, PhD 3 Nicolas Penel, MD, PhD 2 Young-Hyuck Im, MD, PhD 1 1Division of Hematology-Oncology,  Department of Medicine,  Samsung Medical Center,  Sungkyunkwan University  School of Medicine, Seoul, Korea,  2Medical Oncology Department,  Centre Oscar Lambret, Lille, France,  3Department of  Thoracic and Cardiovascular Surgery,  Samsung Medical Center,  Sungkyunkwan University  School of Medicine, Seoul, Korea Purpose The degree of benefit from palliative chemotherapy differs widely among patients with  metastatic esophageal squamous cell carcinoma (MESCC).",Non-OADS,/arxiv_data1/oa_pdf/13/8d/crt-45-285.PMC3893326.pdf
"2013;45(4):295-302 pISSN 1598-2998, eISSN 2005-9256  http://dx.doi.org/10.4143/crt.2013.45.4.295  Youngkyong Kim, MD  Seong Eon Hong, MD  Moonkyoo Kong, MD  Jinhyun Choi, MD  Department of Radiation Oncology,  Kyung Hee University Medical Center,  Kyung Hee University School of Medicine,  Seoul, Korea  Correspondence: Moonkyoo Kong, MD  Department of Radiation Oncology,  Kyung Hee University Medical Center,  Kyung Hee University School of Medicine,  26 Kyungheedae-ro, Dongdaemun-gu,  Seoul 130-701, Korea  Tel: 82-2-958-8661  Fax: 82-2-958-9469  E-mail: kongmoonkyoo@khu.ac.kr  Received  February 19, 2013  Accepted  May 1, 2013 Purpose Predictive factors for radiation pneumonitis (RP) after helical tomotherapy (HT) may  differ from those after linac-based radiotherapy.",Non-OADS,/arxiv_data1/oa_pdf/82/cc/crt-45-295.PMC3893327.pdf
"Helical tomotherapy (HT), one of the newest conformal RT  modalities, employs helical IMRT in which a gantry 6-MV  linear accelerator rotates continuously through 360° around  the patient using tens of thousands of narrow beamlets, and  provides an integrated megavoltage computed tomography  (CT) unit that permits real-time verification of patient set-up  │http://www.cancerresearchandtreatment.org │ │http://www.e-crt.org │295 Copyright ⓒ2013 by  the Korean Cancer Association  This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/  licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/82/cc/crt-45-295.PMC3893327.pdf
"2013;45(4):303-312 pISSN 1598-2998, eISSN 2005-9256  http://dx.doi.org/10.4143/crt.2013.45.4.303  Dong Ho Kim, MD 1 Yun Yong Lee, MD 2 Ui Sup Shin, MD 3 Sun Mi Moon, MD 3 Departments of 1Pediatrics,  2Internal Medicine, and 3Surgery,  Korea Cancer Center Hospital, Seoul, Korea  Correspondence: Sun Mi Moon, MD  Department of Surgery,  Korea Cancer Center Hospital, 75 Nowon-ro,  Nowon-gu, Seoul 139-706, Korea  Tel: 82-2-970-1237  Fax: 82-2-970-2419  E-mail: msm@kirams.re.kr  Received  December 28, 2012  Accepted  April 8, 2013 Purpose Although influenza is regarded as a major cause of morbidity and mortality in immuno - compromised patients, vaccine coverage remains poor.",Non-OADS,/arxiv_data1/oa_pdf/76/7d/crt-45-303.PMC3893328.pdf
"│http://www.cancerresearchandtreatment.org │ │http://www.e-crt.org │303 Copyright ⓒ2013 by  the Korean Cancer Association  This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/  licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/76/7d/crt-45-303.PMC3893328.pdf
"2013;45(4):313-324 pISSN 1598-2998, eISSN 2005-9256  http://dx.doi.org/10.4143/crt.2013.45.4.313  Jeongseon Kim, PhD 1 Young Ae Cho, PhD, MPH 1 Il Ju Choi, MD, PhD 2 Yeon-Su Lee, PhD 3 Sook-Young Kim, MS 3 Jung-Ah Hwang, MS 3 Soo-Jeong Cho, MD, PhD 2 Myeong-Cherl Kook, MD, PhD 2 Chan Gyoo Kim, MD, PhD 2 Young-Woo Kim, MD, PhD 2 1Molecular Epidemiology Branch,  2Center for Gastric Cancer,  3Cancer Genomics Branch,  National Cancer Center, Goyang, Korea Purpose Increasing evidence suggests that polymorphisms in innate immunity genes are  associated with Helicobacter pylori -induced inflammation and may influence suscep - tibility in developing noncardia gastric cancer.",Non-OADS,/arxiv_data1/oa_pdf/e6/70/crt-45-313.PMC3893329.pdf
"Key words Noncardia gastric cancer, Innate immunity,  Genetic polymorphisms, Smoking, Drinking water Original Article Open Access  Effects of Polymorphisms of Innate Immunity Genes and  Environmental Factors on the Risk of Noncardia Gastric Cancer  │http://www.cancerresearchandtreatment.org │ │http://www.e-crt.org │313 Copyright ⓒ2013 by  the Korean Cancer Association  This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/  licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e6/70/crt-45-313.PMC3893329.pdf
"2013;45(4):325-333 pISSN 1598-2998, eISSN 2005-9256  http://dx.doi.org/10.4143/crt.2013.45.4.325  Ji-Won Kim, MD 1,2  Youngil Koh, MD, MS 1,2  Dong-Wan Kim, MD, PhD 1,2  Yong-Oon Ahn, PhD 2 Tae Min Kim, MD, PhD 1,2  Sae-Won Han, MD, PhD 1,2  Do-Youn Oh, MD, PhD 1,2  Se-Hoon Lee, MD, PhD 1,2  Seock-Ah Im, MD, PhD 1,2  Tae-You Kim, MD, PhD 1,2  Dae Seog Heo, MD, PhD 1,2  Yung-Jue Bang, MD, PhD 1,2  1Department of Internal Medicine,  2Cancer Research Institute,  Seoul National University  College of Medicine, Seoul, Korea Purpose Vascular endothelial growth factor (VEGF)-A, VEGF 165 b, interleukin (IL)-1 β, and trans - forming growth factor (TGF)- β1 are known to influence tumor angiogenesis.",Non-OADS,/arxiv_data1/oa_pdf/d6/1d/crt-45-325.PMC3893330.pdf
"Key words Vascular endothelial growth factor, Interleukin-1beta,  Transforming growth factor beta1, Leukocytes,  Blood platelets, Non-small cell lung carcinoma Original Article Open Access  Clinical Implications of VEGF, TGF- β1, and IL-1 βin Patients with  Advanced Non-small Cell Lung Cancer  │http://www.cancerresearchandtreatment.org │ │http://www.e-crt.org │325 Copyright ⓒ2013 by  the Korean Cancer Association  This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/  licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d6/1d/crt-45-325.PMC3893330.pdf
"2013;45(4):334-342 pISSN 1598-2998, eISSN 2005-9256  http://dx.doi.org/10.4143/crt.2013.45.4.334  Jin Ho Kim, MD, PhD 1 Il Han Kim, MD, PhD 1,2,3  Jin Hee Shin, MS 1 Hak Jae Kim, MD, PhD 1 In Ah Kim, MD, PhD 1,2,4  1Department of Radiation Oncology,  2Cancer Research Institute,  Seoul National University  College of Medicine,  3Institute of Radiation Medicine,  Medical Research Center,  Seoul National University, Seoul,  4Department of Radiation Oncology,  Seoul National University  Bundang Hospital,  Seoul National University  College of Medicine, Seongnam, Korea Purpose This preclinical study is to determine whether the capacity of histone deacetylase  (HDAC) inhibitors to enhance radiation response depends on temporal sequences of  HDAC inhibition and irradiation.",Non-OADS,/arxiv_data1/oa_pdf/09/ec/crt-45-334.PMC3893331.pdf
"HDAC inhibition may  enhance radiation response by affecting cell functions such  │http://www.cancerresearchandtreatment.org │ │http://www.e-crt.org │334 Copyright ⓒ2013 by  the Korean Cancer Association  This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/  licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/09/ec/crt-45-334.PMC3893331.pdf
"2013;45(4):343-348 pISSN 1598-2998, eISSN 2005-9256  http://dx.doi.org/10.4143/crt.2013.45.4.343  Ji Yun Lee, MD  Sung Hee Lim, MD  Ji Young Lee, MD  Ji Hoon Kim, MD  Ki Hong Choi, MD  Keunchil Park, MD, PhD  Jong-Mu Sun, MD, PhD  Jin Seok Ahn, MD, PhD  Myung-Ju Ahn, MD, PhD  Division of Hematology-Oncology,  Department of Medicine,  Samsung Medical Center,  Sungkyunkwan University  School of Medicine, Seoul, Korea  Correspondence: Myung-Ju Ahn, MD, PhD  Division of Hematology-Oncology,  Samsung Medical Center, Sungkyunkwan  University School of Medicine, 81 Irwon-ro,  Gangnam-gu, Seoul 135-710, Korea  Tel: 82-2-3410-3438  Fax: 82-2-3410-1754  E-mail: silkahn@skku.edu  Received  November 24, 2012  Accepted  December 6, 2012 Tumor lysis syndrome (TLS) has rarely been observed in solid tumors.",Non-OADS,/arxiv_data1/oa_pdf/fd/7e/crt-45-343.PMC3893332.pdf
"│http://www.cancerresearchandtreatment.org │ │http://www.e-crt.org │343 Copyright ⓒ2013 by  the Korean Cancer Association  This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/  licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/fd/7e/crt-45-343.PMC3893332.pdf
"2013;45(4):349-353 pISSN 1598-2998, eISSN 2005-9256  http://dx.doi.org/10.4143/crt.2013.45.4.349  Ho Cheol Kim, MD  Jung Su Lee, MD  Sang Hyung Kim, MD  Hoon Sub So, MD  Chang Yoon Woo, MD  Jae Lyun Lee, MD  Department of Internal Medicine,  Asan Medical Center,  University of Ulsan College of Medicine,  Seoul, Korea  Correspondence: Jae Lyun Lee, MD, PhD  Department of Oncology, Asan Medical Center,  University of Ulsan College of Medicine,  88 Olympic-ro 43-gil, Songpa-gu,  Seoul 138-736, Korea  Tel: 82-2-3010-3210  Fax: 82-2-3010-6961  E-mail: jaelyun@amc.seoul.kr  Received  November 27, 2012  Accepted  January 3, 2013 Von Hippel-Lindau (VHL) disease is an autosomal dominant disease that produces a  variety of tumors and cysts in the central nervous system and visceral organs, includ - ing renal cell carcinoma (RCC).",Non-OADS,/arxiv_data1/oa_pdf/5e/41/crt-45-349.PMC3893333.pdf
"Approximately 40% to  │http://www.cancerresearchandtreatment.org │ │http://www.e-crt.org │349 Copyright ⓒ2013 by  the Korean Cancer Association  This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/  licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/5e/41/crt-45-349.PMC3893333.pdf
"2013;45(4):354-358 pISSN 1598-2998, eISSN 2005-9256  http://dx.doi.org/10.4143/crt.2013.45.4.354  Mi Hyun Kim, MD 1,2  Kwangha Lee, MD 1,2  Ki Uk Kim, MD 1 Hye-Kyung Park, MD 1 Min Ki Lee, MD 1 Dong Soo Suh, MD 3 1Department of Internal Medicine,  Pusan National University  School of Medicine,  2Biomedical Research Institute,  Pusan National University Hospital,  3Department of Obstetrics and Gynecology,  Pusan National University  School of Medicine, Busan, Korea  Correspondence: Kwangha Lee, MD  Department of Internal Medicine,  Pusan National University Hospital,  179 Gudeok-ro, Seo-gu, Busan 602-739, Korea  Tel: 82-51-240-7743       Fax: 82-51-245-3127  E-mail: jubilate@pusan.ac.kr  Received  October 5, 2012  Accepted  November 12, 2012 We report on a rare case of sarcoidosis that developed after chemotherapy for ovarian  cancer, and mimicked a cancer metastasis.",Non-OADS,/arxiv_data1/oa_pdf/7e/86/crt-45-354.PMC3893334.pdf
"│http://www.cancerresearchandtreatment.org │ │http://www.e-crt.org │354 Copyright ⓒ2013 by  the Korean Cancer Association  This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/  licenses/by-nc/3.0/)which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7e/86/crt-45-354.PMC3893334.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Breast cancer is the leading cancer in Asian females [1], and  the incidence of breast cancer has been increasing in Asia  [2,3].",Non-OADS,/arxiv_data1/oa_pdf/d7/80/jbc-16-357.PMC3893336.pdf
"We re - viewed the literature regarding BRCA1/2  mutations in Asian Distribution of BRCA1  and BRCA2  Mutations in Asian Patients with Breast  Cancer Haeyoung Kim, Doo Ho Choi1 Department of Radiation Oncology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, 1Department of Radiation Oncology, Samsung Medical  Center, Sungkyunkwan University School of Medicine, Seoul, KoreaREVIEW ARTICLEJ Breast Cancer 2013 December; 16(4): 357-365  http://dx.doi.org/10.4048/jbc.2013.16.4.357 Breast cancer is the most prevalent cancer in Asian females, and  the incidence of breast cancer has been increasing in Asia.",Non-OADS,/arxiv_data1/oa_pdf/d7/80/jbc-16-357.PMC3893336.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.357breast cancer patients to identify the epidemiologic character - istics of BRCA1/2  mutations in Asian populations.,Non-OADS,/arxiv_data1/oa_pdf/d7/80/jbc-16-357.PMC3893336.pdf
BRCA  Mutation in Asian Patients with Breast Cancer 359 http://dx.doi.org/10.4048/jbc.2013.16.4.357  http://ejbc.krtwo studies examined large genomic rearrangements (LGRs)  of BRCA1/2  genes using multiplex ligation-dependent probe  amplification.,Non-OADS,/arxiv_data1/oa_pdf/d7/80/jbc-16-357.PMC3893336.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.357cer patients.,Non-OADS,/arxiv_data1/oa_pdf/d7/80/jbc-16-357.PMC3893336.pdf
"BRCA  Mutation in Asian Patients with Breast Cancer 361 http://dx.doi.org/10.4048/jbc.2013.16.4.357  http://ejbc.krIn Malaysia, 13.5% of familial breast cancer patients had  mutations in the BRCA1/2  genes [41].",Non-OADS,/arxiv_data1/oa_pdf/d7/80/jbc-16-357.PMC3893336.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.357ethnicities, LGRs in BRCA  genes were detected in 1.3% of  Asian high-risk patients, comprising 5.3% of all BRCA  muta - tions in their Asian cohorts.",OADS,/arxiv_data1/oa_pdf/d7/80/jbc-16-357.PMC3893336.pdf
BRCA  Mutation in Asian Patients with Breast Cancer 363 http://dx.doi.org/10.4048/jbc.2013.16.4.357  http://ejbc.krrate data on BRCA1/2  gene mutations for Asian populations.,Non-OADS,/arxiv_data1/oa_pdf/d7/80/jbc-16-357.PMC3893336.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.357BRCA2 germline mutations in Malaysian women with early-onset  breast cancer without a family history.,Non-OADS,/arxiv_data1/oa_pdf/d7/80/jbc-16-357.PMC3893336.pdf
BRCA  Mutation in Asian Patients with Breast Cancer 365 http://dx.doi.org/10.4048/jbc.2013.16.4.357  http://ejbc.kr1084-91.,Non-OADS,/arxiv_data1/oa_pdf/d7/80/jbc-16-357.PMC3893336.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Breast cancer is the most commonly occurring cancer and  the leading cause of cancer death among women worldwide,  accounting for 23% of all cancers and 400,000 deaths annually  [1].",Non-OADS,/arxiv_data1/oa_pdf/ee/ae/jbc-16-366.PMC3893337.pdf
"The association of FGFR2  polymor -Case-Control Study on the Fibroblast Growth Factor Receptor 2 Gene  Polymorphisms Associated with Breast Cancer in Chinese Han Women Chun-Lian Liu1,2, Xiao-Ping Hu3, Wei-Dong Guo4, Li Y ang5, Jie Dang2,6, Hai-Y an Jiao2,6 1Department of Center for Reproductive Medicine, General Hospital, Ningxia Medical University, Ningxia;  2Key Laboratory of Fertility Preservation and  Maintenance, Ningxia Medical University, Ministry of Education, Ningxia;  3Department of Clinical Laboratory, Ningxiang Hospital, Hunan; Departments of   4Surgical Oncology and  5Clinical Laboratory, General Hospital, Ningxia Medical University, Ningxia;  6Department of Medical Genetics and Cell Biology,  Ningxia Medical University, Ningxia, ChinaORIGINAL ARTICLEJ Breast Cancer 2013 December; 16(4): 366-371  http://dx.doi.org/10.4048/jbc.2013.16.4.366 Purpose:  Genetic variation in fibroblast growth factor receptor 2  (FGFR2 ) is a newly described risk factor for breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/ee/ae/jbc-16-366.PMC3893337.pdf
"Fibroblast Growth Factor Receptor 2 Gene Polymorphisms Associated with Breast Cancer 367 http://dx.doi.org/10.4048/jbc.2013.16.4.366  http://ejbc.krphisms with breast cancer has also been reported in Jewish  and Arab Israeli [5], Taiwanese [6], European-American, and  African-American populations [7,8].",Non-OADS,/arxiv_data1/oa_pdf/ee/ae/jbc-16-366.PMC3893337.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.3660.1 µM of each primer, 0.5 units Taq DNA polymerase, and 25  µL 2X SuperMix.",OADS,/arxiv_data1/oa_pdf/ee/ae/jbc-16-366.PMC3893337.pdf
SHEsis online software (http://analysis.bio-x.cn/myAnalysis.,OADS,/arxiv_data1/oa_pdf/ee/ae/jbc-16-366.PMC3893337.pdf
Fibroblast Growth Factor Receptor 2 Gene Polymorphisms Associated with Breast Cancer 369 http://dx.doi.org/10.4048/jbc.2013.16.4.366  http://ejbc.krTable 2.,Non-OADS,/arxiv_data1/oa_pdf/ee/ae/jbc-16-366.PMC3893337.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.366Table 4.,Non-OADS,/arxiv_data1/oa_pdf/ee/ae/jbc-16-366.PMC3893337.pdf
Fibroblast Growth Factor Receptor 2 Gene Polymorphisms Associated with Breast Cancer 371 http://dx.doi.org/10.4048/jbc.2013.16.4.366  http://ejbc.krtypes of four SNPs within the LD block in intron 2 of FGFR2   are associated with breast cancer risk in Han Chinese women.,Non-OADS,/arxiv_data1/oa_pdf/ee/ae/jbc-16-366.PMC3893337.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION The universal goal of policy makers, to eliminate disparities  in gender, social class, race/ethnicity, and place, with regard to  health can be achieved by understanding its current state and  causes.",Non-OADS,/arxiv_data1/oa_pdf/64/82/jbc-16-372.PMC3893338.pdf
"My study attempted to fill the gap and examined the distri - bution of BC and OC incidence rates in Iran using data from Social Disparity in Breast and Ovarian Cancer Incidence in Iran, 2003-2009:   A Time Trend Province-Level Study Aliasghar A. Kiadaliri Division of Health Economics, Department of Clinical Sciences-Malmö, Lund University, Malmö, Sweden; Department of Health Management and  Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, IranORIGINAL ARTICLEJ Breast Cancer 2013 December; 16(4): 372-377  http://dx.doi.org/10.4048/jbc.2013.16.4.372 Purpose:  This pioneering study aimed to investigate social dispari - ties in breast cancer (BC) and ovarian cancer (OC) incidence  rates among women across Iran’s provinces from 2003 to 2009.",Non-OADS,/arxiv_data1/oa_pdf/64/82/jbc-16-372.PMC3893338.pdf
"Social Disparity in Breast and Ovarian Cancer Incidence in Iran373 http://dx.doi.org/10.4048/jbc.2013.16.4.372  http://ejbc.krthe cancer registry at province level, across years 2003 to 2009.",Non-OADS,/arxiv_data1/oa_pdf/64/82/jbc-16-372.PMC3893338.pdf
"374  Aliasghar A. Kiadaliri http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.372On the other hand, the highest and the lowest OC incidence  rates were observed in Tehran and South Khorasan, respec - tively (6.6-fold difference).",Non-OADS,/arxiv_data1/oa_pdf/64/82/jbc-16-372.PMC3893338.pdf
Social Disparity in Breast and Ovarian Cancer Incidence in Iran375 http://dx.doi.org/10.4048/jbc.2013.16.4.372  http://ejbc.krlast years of the study.,Non-OADS,/arxiv_data1/oa_pdf/64/82/jbc-16-372.PMC3893338.pdf
376  Aliasghar A. Kiadaliri http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.372mained stable over time.,Non-OADS,/arxiv_data1/oa_pdf/64/82/jbc-16-372.PMC3893338.pdf
Social Disparity in Breast and Ovarian Cancer Incidence in Iran377 http://dx.doi.org/10.4048/jbc.2013.16.4.372  http://ejbc.kr1995-2004.,Non-OADS,/arxiv_data1/oa_pdf/64/82/jbc-16-372.PMC3893338.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Axillary lymph node (ALN) status is an important prognos - tic factor in breast cancer [1].",Non-OADS,/arxiv_data1/oa_pdf/e2/7d/jbc-16-378.PMC3893339.pdf
"Among these patients, 281 underwent SLNB for axillary stag -Reliability of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy  in Breast Cancer Patients Ahram Han1,*, Hyeong-Gon Moon1,*, Jisun Kim1, Soo Kyung Ahn1, In Ae Park2, Wonshik Han1,3, Dong-Y oung Noh1,3 Departments of 1Surgery and 2Pathology, Seoul National University Hospital, Seoul; 3Cancer Research Institute, Seoul National University College of  Medicine, Seoul, KoreaORIGINAL ARTICLEJ Breast Cancer 2013 December; 16(4): 378-385  http://dx.doi.org/10.4048/jbc.2013.16.4.378 Purpose:  Sentinel lymph node biopsy (SLNB) is an accurate and  effective means of axillary nodal staging in early breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/e2/7d/jbc-16-378.PMC3893339.pdf
Reliability of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy379 http://dx.doi.org/10.4048/jbc.2013.16.4.378  http://ejbc.kring during surgery and were included in the final analysis.,Non-OADS,/arxiv_data1/oa_pdf/e2/7d/jbc-16-378.PMC3893339.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.378RESULTS Patient demographic and tumor characteristics  Clinicopathologic characteristics at the time of initial diag - nosis are illustrated in Table 1.,Non-OADS,/arxiv_data1/oa_pdf/e2/7d/jbc-16-378.PMC3893339.pdf
Reliability of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy381 http://dx.doi.org/10.4048/jbc.2013.16.4.378  http://ejbc.krpatients who underwent intraoperative lymphatic mapping  with blue dye alone.,Non-OADS,/arxiv_data1/oa_pdf/e2/7d/jbc-16-378.PMC3893339.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.378 SLN attempted Total (n= 281)SLN not identified (n= 18)ALN (+) (n= 9) SLN (+) (n= 18) SLN (+) (n= 71) SLN (+) (n= 20)*ALN (-) (n= 9) SLN (-), NSLN (-) (n= 19) SLN (-), NSLN (-) (n= 121) SLN (-), NSLN (+) (n= 14 )†SLN (-), NSLN (+) (n= 0)SLN identified (n= 263)SLN identified?SLN Frozen Bx.",OADS,/arxiv_data1/oa_pdf/e2/7d/jbc-16-378.PMC3893339.pdf
Reliability of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy383 http://dx.doi.org/10.4048/jbc.2013.16.4.378  http://ejbc.krDiscordance between intraoperative frozen section results  and final permanent section results of SLNB  The final pathologic results of SLN status were not always in  accordance with intraoperative frozen section findings.,Non-OADS,/arxiv_data1/oa_pdf/e2/7d/jbc-16-378.PMC3893339.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.378proportion of initially node-negative patients was only 10.3%  (29/281).,OADS,/arxiv_data1/oa_pdf/e2/7d/jbc-16-378.PMC3893339.pdf
Reliability of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy385 http://dx.doi.org/10.4048/jbc.2013.16.4.378  http://ejbc.krreview.,Non-OADS,/arxiv_data1/oa_pdf/e2/7d/jbc-16-378.PMC3893339.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Most studies examining the clinical significance of p53 al - terations have demonstrated that accumulation of mutant p53  in breast tumors generally correlates with aggressive clinico - pathological factors: estrogen receptor (ER) and progesterone  receptor (PR) negativity, high proliferation rate, high histolog - ical grade, aneuploidy, and poor survival outcome [1-5].",Non-OADS,/arxiv_data1/oa_pdf/eb/82/jbc-16-386.PMC3893340.pdf
"There - fore, these contradictory results need to be addressed by fo - cusing separately on the prognostic and predictive effects of Effect Modification of Hormonal Therapy by p53 Status in Invasive Breast  Cancer Sei Hyun Ahn*, Hwa Jung Kim1,*, Wonshik Han2, Jihyoung Cho3, Gyungyub Gong4, Kyung Hae Jung5, Sung-Bae Kim5,  Byung Ho Son, Jong Won Lee Departments of Surgery and 1Biostatistics and Clinical Epidemiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul; 2Department of  Surgery, Seoul National University College of Medicine, Seoul; 3Department of Surgery, Keimyung University School of Medicine, Daegu; Departments of  4Pathology and 5Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaORIGINAL ARTICLEJ Breast Cancer 2013 December; 16(4): 386-394  http://dx.doi.org/10.4048/jbc.2013.16.4.386 Purpose:  We aimed to confirm the prognostic and predictive val - ue of p53 expression, particularly in invasive breast cancer pa - tients, according to immunohistochemical hormone receptor (HR)  and human epidermal growth factor receptor 2 (HER2) status.",Non-OADS,/arxiv_data1/oa_pdf/eb/82/jbc-16-386.PMC3893340.pdf
Effect Modification of Hormonal Therapy by p53 Status387 http://dx.doi.org/10.4048/jbc.2013.16.4.386  http://ejbc.krp53 for each distinct subtype.,Non-OADS,/arxiv_data1/oa_pdf/eb/82/jbc-16-386.PMC3893340.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.3860.25 for BCSS and OS, respectively).",Non-OADS,/arxiv_data1/oa_pdf/eb/82/jbc-16-386.PMC3893340.pdf
Effect Modification of Hormonal Therapy by p53 Status389 http://dx.doi.org/10.4048/jbc.2013.16.4.386  http://ejbc.krFigure 1.,Non-OADS,/arxiv_data1/oa_pdf/eb/82/jbc-16-386.PMC3893340.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.386 FFigure 1.,Non-OADS,/arxiv_data1/oa_pdf/eb/82/jbc-16-386.PMC3893340.pdf
Effect Modification of Hormonal Therapy by p53 Status391 http://dx.doi.org/10.4048/jbc.2013.16.4.386  http://ejbc.krTable 3.,Non-OADS,/arxiv_data1/oa_pdf/eb/82/jbc-16-386.PMC3893340.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.386CI, 0.96-1.65).",Non-OADS,/arxiv_data1/oa_pdf/eb/82/jbc-16-386.PMC3893340.pdf
"Effect Modification of Hormonal Therapy by p53 Status393 http://dx.doi.org/10.4048/jbc.2013.16.4.386  http://ejbc.krthe predictive value of p53 for adjuvant endocrine therapy in  this study (Table 3) showed a significant association, and the  treatment benefit in patients without mutant p53 overexpres - sion was much greater than that in patients with mutant p53  overexpression.",Non-OADS,/arxiv_data1/oa_pdf/eb/82/jbc-16-386.PMC3893340.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.386ing breast carcinomas: evidence of a link between bcl-2 protein over- expression and a lower risk of metastasis and death in operable patients.,Non-OADS,/arxiv_data1/oa_pdf/eb/82/jbc-16-386.PMC3893340.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION In breast carcinoma, not only should classical pathologic  markers such as stage and grade be evaluated, but also molec - ular markers such as hormone receptors (HRs) and human  epidermal growth factor receptor 2 (HER2) to assist both the  prediction of prognosis and the therapeutic plan [1].",Non-OADS,/arxiv_data1/oa_pdf/f7/76/jbc-16-395.PMC3893341.pdf
"It is recommended that an as -Expression of Immunohistochemical Markers before and after Neoadjuvant  Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response Ho-chang Lee, Hyoungsuk Ko1, Hyesil Seol2, Dong-Y oung Noh3, Wonshik Han3, Tae-Y ou Kim4, Seock-Ah Im4, In Ae Park5 Department of Pathology, Chungbuk National University College of Medicine, Cheongju; 1Department of Pathology, Konyang University College of  Medicine, Daejeon; 2Department of Pathology, Korea Cancer Center, Seoul; Departments of 3Surgery, 4Internal Medicine, and 5Pathology, Seoul National  University College of Medicine, Seoul, KoreaORIGINAL ARTICLEJ Breast Cancer 2013 December; 16(4): 395-403  http://dx.doi.org/10.4048/jbc.2013.16.4.395 Purpose:  For patients with breast carcinoma, immunohistochem - ical markers are important factors in determining the breast can - cer subtype and for establishing a therapeutic plan, including the  use of neoadjuvant chemotherapy (NACT).",Non-OADS,/arxiv_data1/oa_pdf/f7/76/jbc-16-395.PMC3893341.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.395say for HRs and HER2 should be performed in a resection  specimen after NACT if they were not expressed in the pre- NACT biopsy specimen [9].,Non-OADS,/arxiv_data1/oa_pdf/f7/76/jbc-16-395.PMC3893341.pdf
"Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy397 http://dx.doi.org/10.4048/jbc.2013.16.4.395  http://ejbc.krRESULTS Associations between the response to NACT and  clinicopathological markers In total, 46 of the 345 cases (13.3%) displayed pCRs: 24 cases  had no residual invasive carcinoma or ductal carcinoma in situ   (DCIS), seven cases had residual DCIS only, and 15 cases had  minimal residual invasive carcinoma.",Non-OADS,/arxiv_data1/oa_pdf/f7/76/jbc-16-395.PMC3893341.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.39519 of 45 cases (42.2%) with PR positivity in their biopsy speci - mens exhibited negativity after NACT (Figure 1A, B), whereas  only three of 75 PR-negative cases in the biopsy specimens  displayed positivity after NACT.",Non-OADS,/arxiv_data1/oa_pdf/f7/76/jbc-16-395.PMC3893341.pdf
Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy399 http://dx.doi.org/10.4048/jbc.2013.16.4.395  http://ejbc.krthe changes after dividing the cases based on the subtype of  their pre-NACT specimens.,Non-OADS,/arxiv_data1/oa_pdf/f7/76/jbc-16-395.PMC3893341.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.395DISCUSSION This study revealed that breast cancer subtypes are associat - ed with the response to NACT.,Non-OADS,/arxiv_data1/oa_pdf/f7/76/jbc-16-395.PMC3893341.pdf
"Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy401 http://dx.doi.org/10.4048/jbc.2013.16.4.395  http://ejbc.krcell proliferation, including Ki-67 ( MKI67 ), were overex - pressed in the LB subtype, whereas HER2 was overexpressed  in a small proportion of the cases of this subtype [6,15,16].",Non-OADS,/arxiv_data1/oa_pdf/f7/76/jbc-16-395.PMC3893341.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.395is mediated through the downregulation of intratumoral aro - matase expression, which results in the suppression of intra- tumoral PR expression.",Non-OADS,/arxiv_data1/oa_pdf/f7/76/jbc-16-395.PMC3893341.pdf
Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy403 http://dx.doi.org/10.4048/jbc.2013.16.4.395  http://ejbc.kr16.,Non-OADS,/arxiv_data1/oa_pdf/f7/76/jbc-16-395.PMC3893341.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Tubular carcinoma (TC) of the breast is an uncommon his - tological subtype of invasive breast cancer that accounts for  approximately 1% to 5% of invasive breast carcinomas [1-3].",Non-OADS,/arxiv_data1/oa_pdf/75/a3/jbc-16-404.PMC3893342.pdf
"Moreover, recent  studies have documented an association between TC and mi - cropapillary and cribriform ductal carcinoma in situ  (DCIS)  and suggested a possible precursor role of low grade DCIS in Tubular Carcinoma of the Breast: Clinicopathologic Features and Survival  Outcome Compared with Ductal Carcinoma In Situ Y ejin Min*, Soo Y oun Bae*, Hyun-Chul Lee, Jun Ho Lee, Minkuk Kim, Jiyoung Kim, Se Kyung Lee, Won Ho Kil,   Seok Won Kim, Jeong Eon Lee, Seok Jin Nam Division of Breast & Endocrine Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaORIGINAL ARTICLEJ Breast Cancer 2013 December; 16(4): 404-409  http://dx.doi.org/10.4048/jbc.2013.16.4.404 Purpose:  Tubular carcinoma (TC) of the breast is an uncommon  histological subtype of invasive breast cancer with an excellent  prognosis compared with standard invasive ductal carcinoma.",Non-OADS,/arxiv_data1/oa_pdf/75/a3/jbc-16-404.PMC3893342.pdf
Tubular Carcinoma of the Breast405 http://dx.doi.org/10.4048/jbc.2013.16.4.404  http://ejbc.krthe development of tubular breast cancer [12-16].,Non-OADS,/arxiv_data1/oa_pdf/75/a3/jbc-16-404.PMC3893342.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.404rence.,Non-OADS,/arxiv_data1/oa_pdf/75/a3/jbc-16-404.PMC3893342.pdf
"Tubular Carcinoma of the Breast407 http://dx.doi.org/10.4048/jbc.2013.16.4.404  http://ejbc.kr1.5 cm, p< 0.001) and associated factors (operation and radio - therapy).",Non-OADS,/arxiv_data1/oa_pdf/75/a3/jbc-16-404.PMC3893342.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.404that of the general population [2,3,5,7,15].",Non-OADS,/arxiv_data1/oa_pdf/75/a3/jbc-16-404.PMC3893342.pdf
Tubular Carcinoma of the Breast409 http://dx.doi.org/10.4048/jbc.2013.16.4.404  http://ejbc.kr2010;17 Suppl 3:338-42.,Non-OADS,/arxiv_data1/oa_pdf/75/a3/jbc-16-404.PMC3893342.pdf
http://www.nccn.org/professionals/physi - cian_gls/pdf/breast.pdf.,Non-OADS,/arxiv_data1/oa_pdf/75/a3/jbc-16-404.PMC3893342.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Occult breast cancer (OBC) is generally defined as a tumor  that has been clinically diagnosed as having palpable axillary  lymphadenopathy with no detection of primary tumor(s) in  the breast by either palpation or mammography [1-3].",Non-OADS,/arxiv_data1/oa_pdf/54/d7/jbc-16-410.PMC3893343.pdf
"Furthermore, studies currently reported in the  literature that examined factors relating to survival rates are in -Survival Outcomes of Different Treatment Methods for the Ipsilateral Breast  of Occult Breast Cancer Patients with Axillary Lymph Node Metastasis:   A Single Center Experience Sang Min Woo, Byung Ho Son, Jong Won Lee, Hee Jeong Kim, Jong Han Yu, Beom Seok Ko, Guiyun Sohn, Yu Ra Lee,  Hanna Kim, Sei Hyun Ahn, Seung Hee Baek1 Division of Breast and Endocrine Surgery, Department of Surgery, and 1Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan  College of Medicine, Seoul, KoreaORIGINAL ARTICLEJ Breast Cancer 2013 December; 16(4): 410-416  http://dx.doi.org/10.4048/jbc.2013.16.4.410 Purpose:  This study compared the survival outcomes of different  treatment methods for the ipsilateral breast of occult breast can - cer (OBC) patients with axillary lymph node metastasis.",Non-OADS,/arxiv_data1/oa_pdf/54/d7/jbc-16-410.PMC3893343.pdf
Occult Breast Cancer: A Single Center Experience411 http://dx.doi.org/10.4048/jbc.2013.16.4.410  http://ejbc.kradequate.,Non-OADS,/arxiv_data1/oa_pdf/54/d7/jbc-16-410.PMC3893343.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.410Table 1.,Non-OADS,/arxiv_data1/oa_pdf/54/d7/jbc-16-410.PMC3893343.pdf
"Occult Breast Cancer: A Single Center Experience413 http://dx.doi.org/10.4048/jbc.2013.16.4.410  http://ejbc.krdefined as no detectable breast cancer lesion(s) on mammog - raphy, accounted for 0.27% of all breast cancer diagnoses.",Non-OADS,/arxiv_data1/oa_pdf/54/d7/jbc-16-410.PMC3893343.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.410DISCUSSION The relatively low incidence of OBC presents a major chal - lenge in conducting an independent study at a single institu - tion.,Non-OADS,/arxiv_data1/oa_pdf/54/d7/jbc-16-410.PMC3893343.pdf
"Occult Breast Cancer: A Single Center Experience415 http://dx.doi.org/10.4048/jbc.2013.16.4.410  http://ejbc.krfered significantly between mastectomy-treated patients and  observation-only patients, with respective median survival  times of 76 months and 23 months.",Non-OADS,/arxiv_data1/oa_pdf/54/d7/jbc-16-410.PMC3893343.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.410multicenter studies.,Non-OADS,/arxiv_data1/oa_pdf/54/d7/jbc-16-410.PMC3893343.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Breast cancer is the second most common cancer among  women in Korea.",Non-OADS,/arxiv_data1/oa_pdf/74/57/jbc-16-417.PMC3893344.pdf
"Comparison of the Characteristics of Medullary Breast Carcinoma and  Invasive Ductal Carcinoma Inhye Park*, Jiyoung Kim*, Minkuk Kim, Soo Y oun Bae, Se Kyung Lee, Won Ho Kil, Jeong Eon Lee, Seok Jin Nam Division of Breast and Endocrine Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaORIGINAL ARTICLEJ Breast Cancer 2013 December; 16(4): 417-425  http://dx.doi.org/10.4048/jbc.2013.16.4.417 Purpose:  Medullary breast carcinomas (MBC) have been known  to represent a rare breast cancer subtype associated with a more  favorable prognosis than invasive ductal carcinomas (IDC).",Non-OADS,/arxiv_data1/oa_pdf/74/57/jbc-16-417.PMC3893344.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.417Many previous studies have indicated that this histological  type is associated with a favorable prognosis despite the pres - ence of aggressive features such as large tumor size, a high nu - clear grade, and hormone receptor (HR) negativity, which are  usually accepted as poor prognostic factors [3,9,10].",Non-OADS,/arxiv_data1/oa_pdf/74/57/jbc-16-417.PMC3893344.pdf
Clinicopathologic Features and Prognosis of Medullary Breast Carcinoma419 http://dx.doi.org/10.4048/jbc.2013.16.4.417  http://ejbc.krTable 1.,Non-OADS,/arxiv_data1/oa_pdf/74/57/jbc-16-417.PMC3893344.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.417p< 0.001) and PR (IDC 38.8% vs. MBC 91.3%, p< 0.001) sta - tuses which are generally regarded as poor prognostic factors  of invasive breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/74/57/jbc-16-417.PMC3893344.pdf
"Clinicopathologic Features and Prognosis of Medullary Breast Carcinoma421 http://dx.doi.org/10.4048/jbc.2013.16.4.417  http://ejbc.krthe pathologic stage categorized according to the 7th AJCC  staging system, and found that survival did not differ accord - ing to histological subtype (DFS: stage I, p= 0.193, stage II, p= 0.853; OS: stage I, p= 0.684, stage II, p= 0.815).",Non-OADS,/arxiv_data1/oa_pdf/74/57/jbc-16-417.PMC3893344.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.417disease were observed in subgroup analysis of nodal status, HR  status, HER2 status, and adjuvant treatment although this dif - fered on subgroup analysis for node-positive disease and use of  hormone therapy.",OADS,/arxiv_data1/oa_pdf/74/57/jbc-16-417.PMC3893344.pdf
Clinicopathologic Features and Prognosis of Medullary Breast Carcinoma423 http://dx.doi.org/10.4048/jbc.2013.16.4.417  http://ejbc.krDISCUSSION This retrospective review of invasive breast cancer at a sin - gle institution in Korea helped elucidate the clinicopathologic  characteristics of MBC.,Non-OADS,/arxiv_data1/oa_pdf/74/57/jbc-16-417.PMC3893344.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.417motherapy, although the difference was not statistically signifi - cant.",OADS,/arxiv_data1/oa_pdf/74/57/jbc-16-417.PMC3893344.pdf
Clinicopathologic Features and Prognosis of Medullary Breast Carcinoma425 http://dx.doi.org/10.4048/jbc.2013.16.4.417  http://ejbc.krBreast Cancer Study Group (IBCSG) trials.,Non-OADS,/arxiv_data1/oa_pdf/74/57/jbc-16-417.PMC3893344.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Immediate prosthetic-based breast reconstruction contin - ues to gain popularity among mastectomy patients [1].",Non-OADS,/arxiv_data1/oa_pdf/97/1c/jbc-16-426.PMC3893345.pdf
"Fine, John Kim Northwestern University Feinberg School of Medicine, Chicago, USA ORIGINAL ARTICLEJ Breast Cancer 2013 December; 16(4): 426-431  http://dx.doi.org/10.4048/jbc.2013.16.4.426 Purpose:  Prosthetic-based breast reconstruction is performed  with increasing frequency in the United States.",Non-OADS,/arxiv_data1/oa_pdf/97/1c/jbc-16-426.PMC3893345.pdf
"High Intraoperative Fill Volumes Synergistically Increase Risk of Mastectomy Flap Necrosis 427 http://dx.doi.org/10.4048/jbc.2013.16.4.426  http://ejbc.krknown risk factors has, to our knowledge, yet to be explored.",Non-OADS,/arxiv_data1/oa_pdf/97/1c/jbc-16-426.PMC3893345.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.426four exposure categories were created from each pair of di - chotomous risk factors, including the three possible combina - tions of exposure and a fourth reference category [17].",OADS,/arxiv_data1/oa_pdf/97/1c/jbc-16-426.PMC3893345.pdf
High Intraoperative Fill Volumes Synergistically Increase Risk of Mastectomy Flap Necrosis 429 http://dx.doi.org/10.4048/jbc.2013.16.4.426  http://ejbc.krvidual effects were not significantly associated with an in - creased risk (Table 4).,Non-OADS,/arxiv_data1/oa_pdf/97/1c/jbc-16-426.PMC3893345.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.426dent risk factor for flap necrosis in either our study or in a  previous study by Crosby et al.,Non-OADS,/arxiv_data1/oa_pdf/97/1c/jbc-16-426.PMC3893345.pdf
High Intraoperative Fill Volumes Synergistically Increase Risk of Mastectomy Flap Necrosis 431 http://dx.doi.org/10.4048/jbc.2013.16.4.426  http://ejbc.krREFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/97/1c/jbc-16-426.PMC3893345.pdf
http://www.plasticsurgery.org/news-and-resources/2011- statistics-.html.,Non-OADS,/arxiv_data1/oa_pdf/97/1c/jbc-16-426.PMC3893345.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Microglandular adenosis (MGA) is a rare benign disease  that causes proliferative glandular lesions in the breast.",Non-OADS,/arxiv_data1/oa_pdf/fc/87/jbc-16-432.PMC3893346.pdf
"A  cord-like arrangement and irregular aggregates of highly Invasive Breast Carcinoma Arising in Microglandular Adenosis:  Two Case  Reports Jung Eun Choi, Y oung Kyung Bae1 Departments of Surgery and 1Pathology, Y eungnam University College of Medicine, Daegu, KoreaCASE REPORTJ Breast Cancer 2013 December; 16(4): 432-437  http://dx.doi.org/10.4048/jbc.2013.16.4.432 Microglandular adenosis (MGA) is a rare benign disease that  shows an infiltrative growth pattern of small glands, and it may  progress to include atypia and carcinoma.",Non-OADS,/arxiv_data1/oa_pdf/fc/87/jbc-16-432.PMC3893346.pdf
Carcinoma Arising in Microglandular Adenosis433 http://dx.doi.org/10.4048/jbc.2013.16.4.432  http://ejbc.kratypical cells were scattered in the stroma and extended into  the adipose tissue (Figure 3).,Non-OADS,/arxiv_data1/oa_pdf/fc/87/jbc-16-432.PMC3893346.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.432 C B  A D Figure 3.,Non-OADS,/arxiv_data1/oa_pdf/fc/87/jbc-16-432.PMC3893346.pdf
Carcinoma Arising in Microglandular Adenosis435 http://dx.doi.org/10.4048/jbc.2013.16.4.432  http://ejbc.krFigure 6.,Non-OADS,/arxiv_data1/oa_pdf/fc/87/jbc-16-432.PMC3893346.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.432follow-up at 19 months.,Non-OADS,/arxiv_data1/oa_pdf/fc/87/jbc-16-432.PMC3893346.pdf
Carcinoma Arising in Microglandular Adenosis437 http://dx.doi.org/10.4048/jbc.2013.16.4.432  http://ejbc.krsive carcinoma.,Non-OADS,/arxiv_data1/oa_pdf/fc/87/jbc-16-432.PMC3893346.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Many different surgical options are available for the recon - struction of extensive tissue defects in the thoracic wall, in - cluding the use of cutaneous, fasciocutaneous, and muscular  flaps.",Non-OADS,/arxiv_data1/oa_pdf/1a/ed/jbc-16-438.PMC3893347.pdf
"Four months after expansion, the second stage of the proce - dure was performed using a Natrelle 410 FF 740-cc anatomi - cal permanent silicone cohesive gel implant (Allergan Inc.); a  circumferential basal capsulotomy was performed and the in -Expander/Implant Breast Reconstruction after Reconstruction Using an  Extended Cutaneous Thoracoabdominal Flap: A Case Report Annalisa Cogliandro, Barbara Cagli, Angela Filoni, Gabriella Cassotta, Stefania Tenna, Paolo Persichetti Division of Plastic, Reconstructive and Aesthetic Surgery, Campus Bio-Medico University of Rome, Rome, ItalyCASE REPORTJ Breast Cancer 2013 December; 16(4): 438-441  http://dx.doi.org/10.4048/jbc.2013.16.4.438 Many flaps have been described and are being used in the re - construction of extensive tissue defects in the thoracic wall.",Non-OADS,/arxiv_data1/oa_pdf/1a/ed/jbc-16-438.PMC3893347.pdf
"Expander/Implant Breast Reconstruction, Thoracoabdominal Flap 439 http://dx.doi.org/10.4048/jbc.2013.16.4.438  http://ejbc.kr Figure 1.",Non-OADS,/arxiv_data1/oa_pdf/1a/ed/jbc-16-438.PMC3893347.pdf
"http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.438tions included total body computed tomography, ultrasonog - raphy of the reconstructed breast, and contralateral mam - mography of the healthy breast, which did not indicate recur - rence.",Non-OADS,/arxiv_data1/oa_pdf/1a/ed/jbc-16-438.PMC3893347.pdf
"Expander/Implant Breast Reconstruction, Thoracoabdominal Flap 441 http://dx.doi.org/10.4048/jbc.2013.16.4.438  http://ejbc.krfor local or systemic reasons, cannot undergo immediate re - construction.",Non-OADS,/arxiv_data1/oa_pdf/1a/ed/jbc-16-438.PMC3893347.pdf
"http://ejbc.kr  |  pISSN 1738-6756    eISSN 2092-9900 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/   licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.INTRODUCTION Association of different cancers is classified depending on  the timing of their detection.",Non-OADS,/arxiv_data1/oa_pdf/72/ea/jbc-16-442.PMC3893348.pdf
"Standardized uptake value (SUVmax) of the  lesions were calculated for body weight and expressed in gram Random Synchronous Malignancy in Male Breast: A Case Report Manjit Sarma, Chaitanya Borde, Padma Subramanyam, Palaniswamy Shanmuga Sundaram Department of Nuclear Medicine & PET CT, Amrita Institute of Medical Sciences (Amrita Vishwa Vidyapeetham), Cochin, Kerala, IndiaCASE REPORTJ Breast Cancer 2013 December; 16(4): 442-446  http://dx.doi.org/10.4048/jbc.2013.16.4.442 We report here a case of a random synchronous male breast  malignancy in a patient with a known base of tongue malignancy  that was incidentally detected on a whole body 18-fluorine de- oxyglucose positron emission tomography and computed tomo- graphy (18F-FDG PET/CT).",Non-OADS,/arxiv_data1/oa_pdf/72/ea/jbc-16-442.PMC3893348.pdf
Random Synchronous Malignancy in Male Breast 443 http://dx.doi.org/10.4048/jbc.2013.16.4.442  http://ejbc.krper milliliter (g/mL).,Non-OADS,/arxiv_data1/oa_pdf/72/ea/jbc-16-442.PMC3893348.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.442 Figure 3.,Non-OADS,/arxiv_data1/oa_pdf/72/ea/jbc-16-442.PMC3893348.pdf
Random Synchronous Malignancy in Male Breast 445 http://dx.doi.org/10.4048/jbc.2013.16.4.442  http://ejbc.kror on palpapation.,Non-OADS,/arxiv_data1/oa_pdf/72/ea/jbc-16-442.PMC3893348.pdf
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2013.16.4.44211.,Non-OADS,/arxiv_data1/oa_pdf/72/ea/jbc-16-442.PMC3893348.pdf
"Isolation and Cloning of BvpAPX cDNA In order to isolate fragments of the APX coding sequence from beet leaf cDNA, several pairs of degenerated primers (Table S 1) were designed on the basis of conserved regions of APX sequences from different plant species available in theGenBank database ( http://www.ncbi.nlm.nih.gov/genbank/ ).",OADS,/arxiv_data1/oa_pdf/e1/bb/11105_2013_Article_636.PMC3893476.pdf
Bioinformatic Tools and Phylogenetic AnalysesMultiple sequence alignments were performed using a CLC Sequence Viewer and ClustalW2 software ( http://www.ebi.ac.,OADS,/arxiv_data1/oa_pdf/e1/bb/11105_2013_Article_636.PMC3893476.pdf
The transmembrane domain was predicted using TopPred 0.01 online software ( http://mobyle.pasteur.fr/cgi- bin/portal.py?#forms::toppred ) (Claros and von Heijne 1994 ).,OADS,/arxiv_data1/oa_pdf/e1/bb/11105_2013_Article_636.PMC3893476.pdf
"Cloning and Sequence Analysis of PtSOS2 To identify the PtSOS2 genes, the cDNA sequence of Arabidopsis AtSOS2 was used to search against the Populus genome database ( http://genome.jgi-psf.org/cgi-bin/ runAlignment?Db =Poptr1) using the BLAST program.",OADS,/arxiv_data1/oa_pdf/42/81/11105_2013_Article_640.PMC3893482.pdf
The sequences were submitted to GENESCAN@ Prediction ( http://genes.mit.edu/GENSCAN.,OADS,/arxiv_data1/oa_pdf/42/81/11105_2013_Article_640.PMC3893482.pdf
The chromosomal locations ofthese three genes were determined using GENESCAN pre- diction ( http://genes.mit.edu/GENSCAN.html )( T a b l e 1).,OADS,/arxiv_data1/oa_pdf/42/81/11105_2013_Article_640.PMC3893482.pdf
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.brs.2013.09.005Brain Stimulation 7 (2014) 66 e73 Open access under CC BY-NC-ND license.Open access under CC BY-NC-ND license.,OADS,/arxiv_data1/oa_pdf/43/d6/main.PMC3893483.pdf
The primer sequences of these cassava SSR markers are available from CIAT's Cassava MolecularDiversity Network ( http://newapp.ciat.cgiar.org/molcas/ ).,OADS,/arxiv_data1/oa_pdf/fc/9c/709_2013_Article_543.PMC3893484.pdf
http://www.pukhtoonistangazette.com/news.php?news_ id=10708&cat_id=0 .,Non-OADS,/arxiv_data1/oa_pdf/fc/9c/709_2013_Article_543.PMC3893484.pdf
http://www.danforthcenter.org/iltab/cassavanet/ cbnv/abstracts/Session7/S7-21.htm .,Non-OADS,/arxiv_data1/oa_pdf/fc/9c/709_2013_Article_543.PMC3893484.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreportsCompeting financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/ee/61/srep03715.PMC3893641.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3715 | DOI: 10.1038/srep03715 7",Non-OADS,/arxiv_data1/oa_pdf/ee/61/srep03715.PMC3893641.pdf
"Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.How to cite this article: Zhou, J. et al.",Non-OADS,/arxiv_data1/oa_pdf/5c/28/srep03733.PMC3893643.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3733 | DOI: 10.1038/srep03733 11",Non-OADS,/arxiv_data1/oa_pdf/5c/28/srep03733.PMC3893643.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/ff/ed/srep03732.PMC3893645.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3732 | DOI: 10.1038/srep03732 7",Non-OADS,/arxiv_data1/oa_pdf/ff/ed/srep03732.PMC3893645.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/8e/04/srep03729.PMC3893646.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3729 | DOI: 10.1038/srep03729 7",Non-OADS,/arxiv_data1/oa_pdf/8e/04/srep03729.PMC3893646.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/7a/ba/srep03712.PMC3893647.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3712 | DOI: 10.1038/srep03712 9",Non-OADS,/arxiv_data1/oa_pdf/7a/ba/srep03712.PMC3893647.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3730 | DOI: 10.1038/srep03730 5",Non-OADS,/arxiv_data1/oa_pdf/57/ee/srep03730.PMC3893648.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3720 | DOI: 10.1038/srep03720 6",Non-OADS,/arxiv_data1/oa_pdf/76/79/srep03720.PMC3893649.pdf
EPA-822-R-08-016 http://water.epa.,Non-OADS,/arxiv_data1/oa_pdf/b2/37/srep03731.PMC3893653.pdf
EPA-822-R-07-006 http://water.epa.gov/scitech/wastetech/biosolids/ upload/sludgesurvey9-2007.pdf (2007).,OADS,/arxiv_data1/oa_pdf/b2/37/srep03731.PMC3893653.pdf
http://apps.who.int/ medicinedocs/en/d/Js6160e/6.html (2004).,OADS,/arxiv_data1/oa_pdf/b2/37/srep03731.PMC3893653.pdf
http://www.cdc.gov/ exposurereport/pdf/FourthReport_UpdatedTables_Sep2012.pdf (2009).,OADS,/arxiv_data1/oa_pdf/b2/37/srep03731.PMC3893653.pdf
http://water.epa.gov/drink/contaminants/index.cfm#Organic(2012).,OADS,/arxiv_data1/oa_pdf/b2/37/srep03731.PMC3893653.pdf
http://www.nebiosolids.org/uploads/pdf/ NtlBiosolidsReport-20July07.pdf (2007).,OADS,/arxiv_data1/oa_pdf/b2/37/srep03731.PMC3893653.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/b2/37/srep03731.PMC3893653.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3731 | DOI: 10.1038/srep03731 7",Non-OADS,/arxiv_data1/oa_pdf/b2/37/srep03731.PMC3893653.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3724 | DOI: 10.1038/srep03724 8",Non-OADS,/arxiv_data1/oa_pdf/be/32/srep03724.PMC3893654.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/89/97/srep03722.PMC3893655.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3722 | DOI: 10.1038/srep03722 6",Non-OADS,/arxiv_data1/oa_pdf/89/97/srep03722.PMC3893655.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/4f/40/srep03716.PMC3893656.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3716 | DOI: 10.1038/srep03716 7",Non-OADS,/arxiv_data1/oa_pdf/4f/40/srep03716.PMC3893656.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/87/21/srep03727.PMC3893657.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3727 | DOI: 10.1038/srep03727 7",Non-OADS,/arxiv_data1/oa_pdf/87/21/srep03727.PMC3893657.pdf
"Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.www.ejgo.orgJ Gynecol Oncol Vol.",Non-OADS,/arxiv_data1/oa_pdf/fe/16/jgo-25-1.PMC3893668.pdf
1:1-2 http://dx.doi.org/10.3802/jgo.2014.25.1.1 pISSN 2005-0380 ·eISSN 2005-0399,OADS,/arxiv_data1/oa_pdf/fe/16/jgo-25-1.PMC3893668.pdf
Yoon Soon Lee http://dx.doi.org/10.3802/jgo.2014.25.1.1 2 www.ejgo.org CONFLICT OF INTEREST No potential conflict of interest relevant to this article was  reported.,OADS,/arxiv_data1/oa_pdf/fe/16/jgo-25-1.PMC3893668.pdf
"Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.www.ejgo.orgObjective:  To assess the toxicity of delivering extended field intensity-modulated radiotherapy (EF-IMRT) and concurrent  cisplatin chemotherapy for locally advanced cervical carcinoma.",Non-OADS,/arxiv_data1/oa_pdf/03/41/jgo-25-14.PMC3893669.pdf
1:14-21 http://dx.doi.org/10.3802/jgo.2014.25.1.14 pISSN 2005-0380 ·eISSN 2005-0399,Non-OADS,/arxiv_data1/oa_pdf/03/41/jgo-25-14.PMC3893669.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.14 16  www.ejgo.org ovarian transposition underwent separate ovarian contouring  based on clips left by the surgeon.,Non-OADS,/arxiv_data1/oa_pdf/03/41/jgo-25-14.PMC3893669.pdf
"http://dx.doi.org/10.3802/jgo.2014.25.1.14 18  www.ejgo.org Late toxicities, experienced more than 90 days after comple - tion of therapy, were graded according RTOG late toxicity  scale.",OADS,/arxiv_data1/oa_pdf/03/41/jgo-25-14.PMC3893669.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.14 20  www.ejgo.org result reported by Kodaira et al.,OADS,/arxiv_data1/oa_pdf/03/41/jgo-25-14.PMC3893669.pdf
"Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.www.ejgo.orgObjective:  The therapeutic outcomes of patients with advanced vulvar cancer are poor.",Non-OADS,/arxiv_data1/oa_pdf/e5/60/jgo-25-22.PMC3893670.pdf
1:22-29 http://dx.doi.org/10.3802/jgo.2014.25.1.22 pISSN 2005-0380 ·eISSN 2005-0399,Non-OADS,/arxiv_data1/oa_pdf/e5/60/jgo-25-22.PMC3893670.pdf
"http://dx.doi.org/10.3802/jgo.2014.25.1.22 24  www.ejgo.org response criteria in solid tumors (RECIST, ver.",Non-OADS,/arxiv_data1/oa_pdf/e5/60/jgo-25-22.PMC3893670.pdf
"http://dx.doi.org/10.3802/jgo.2014.25.1.22 26  www.ejgo.org All long-term toxicities were of mild intensity (grade 1),  inclu  ding1 lymphocyst in the patient who underwent pelvic  lympha  denectomy, and 2 cases of lymphedema in the lower  extremities.",Non-OADS,/arxiv_data1/oa_pdf/e5/60/jgo-25-22.PMC3893670.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.22 28  www.ejgo.org 9.,OADS,/arxiv_data1/oa_pdf/e5/60/jgo-25-22.PMC3893670.pdf
Available from: http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/docs/ctcv20_4-30-992.pdf.,Non-OADS,/arxiv_data1/oa_pdf/e5/60/jgo-25-22.PMC3893670.pdf
NOW AVAILABLE ONLINE  at http://www.ejgo.org,Non-OADS,/arxiv_data1/oa_pdf/e5/60/jgo-25-22.PMC3893670.pdf
"Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.www.ejgo.orgThe integration of high-risk (HR) human papillomavirus (HPV) in the cell genome is an essential step in the oncogenic pathway  of lower ano-genital HPV-related squamous preinvasive and invasive lesions.",Non-OADS,/arxiv_data1/oa_pdf/89/6b/jgo-25-3.PMC3893671.pdf
1:3-5 http://dx.doi.org/10.3802/jgo.2014.25.1.3 pISSN 2005-0380 ·eISSN 2005-0399,Non-OADS,/arxiv_data1/oa_pdf/89/6b/jgo-25-3.PMC3893671.pdf
Louis-Jacques van Bogaert http://dx.doi.org/10.3802/jgo.2014.25.1.3 4 www.ejgo.org shown to be specific for dysplastic and neoplastic cervical epi - thelial cells [5].,Non-OADS,/arxiv_data1/oa_pdf/89/6b/jgo-25-3.PMC3893671.pdf
"Rijeka, Croatia: InTech;  2013. http://dx.doi.org/10.5772/55897.",Non-OADS,/arxiv_data1/oa_pdf/89/6b/jgo-25-3.PMC3893671.pdf
"Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.www.ejgo.orgObjective:  The surgical staging system for endometrial carcinoma developed by International Federation of Gynecology and  Obstetrics (FIGO) in 1988 was revised in 2009.",Non-OADS,/arxiv_data1/oa_pdf/d3/bf/jgo-25-30.PMC3893672.pdf
1:30-35 http://dx.doi.org/10.3802/jgo.2014.25.1.30 pISSN 2005-0380 ·eISSN 2005-0399,Non-OADS,/arxiv_data1/oa_pdf/d3/bf/jgo-25-30.PMC3893672.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.30 32  www.ejgo.org and II ( Fig.,Non-OADS,/arxiv_data1/oa_pdf/d3/bf/jgo-25-30.PMC3893672.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.30 34  www.ejgo.org as additional covariates.,OADS,/arxiv_data1/oa_pdf/d3/bf/jgo-25-30.PMC3893672.pdf
Avail - able from: http://www.cancerregistry.fi.,Non-OADS,/arxiv_data1/oa_pdf/d3/bf/jgo-25-30.PMC3893672.pdf
"Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.www.ejgo.orgObjective:  The objective of this study was to evaluate the effect of overexpression of epidermal growth factor receptor (EGFR)  on the expression of epithelial cell markers (E-cadherin and α-catenin) and mesenchymal cell markers (N-cadherin and vimentin)  in endometrial carcinoma.",Non-OADS,/arxiv_data1/oa_pdf/a8/18/jgo-25-36.PMC3893673.pdf
1:36-42 http://dx.doi.org/10.3802/jgo.2014.25.1.36 pISSN 2005-0380 ·eISSN 2005-0399,Non-OADS,/arxiv_data1/oa_pdf/a8/18/jgo-25-36.PMC3893673.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.36 38  www.ejgo.org (sense) and 5’- ATGGTGGTGAAGACGCCAGT -3’ (antisense).,OADS,/arxiv_data1/oa_pdf/a8/18/jgo-25-36.PMC3893673.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.36 40  www.ejgo.org 4.,Non-OADS,/arxiv_data1/oa_pdf/a8/18/jgo-25-36.PMC3893673.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.36 42  www.ejgo.org CONFLICT OF INTEREST No potential conflict of interest relevant to this article was  reported.,Non-OADS,/arxiv_data1/oa_pdf/a8/18/jgo-25-36.PMC3893673.pdf
"Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.www.ejgo.orgObjective:  This study was conducted to examine the effects of front-line chemotherapy on overall survival (OS) and  postrecurrence survival (PRS) of patients with recurrent ovarian c ancer, when stratifying the histologic type.",Non-OADS,/arxiv_data1/oa_pdf/72/29/jgo-25-43.PMC3893674.pdf
1:43-50 http://dx.doi.org/10.3802/jgo.2014.25.1.43 pISSN 2005-0380 ·eISSN 2005-0399,Non-OADS,/arxiv_data1/oa_pdf/72/29/jgo-25-43.PMC3893674.pdf
"http://dx.doi.org/10.3802/jgo.2014.25.1.43 44  www.ejgo.org progression-free survival even in patients with platinum- resistant disease [4], patients with recurrent ovarian cancer are  essentially incurable.",Non-OADS,/arxiv_data1/oa_pdf/72/29/jgo-25-43.PMC3893674.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.43 46  www.ejgo.org 2.,Non-OADS,/arxiv_data1/oa_pdf/72/29/jgo-25-43.PMC3893674.pdf
"http://dx.doi.org/10.3802/jgo.2014.25.1.43 48  www.ejgo.org serous/endometrioid/others), the four aforementioned  clinicopathological factors were individually entered into the  Cox proportional hazard analysis.",OADS,/arxiv_data1/oa_pdf/72/29/jgo-25-43.PMC3893674.pdf
"http://dx.doi.org/10.3802/jgo.2014.25.1.43 50  www.ejgo.org M, Rice LW, et al.",OADS,/arxiv_data1/oa_pdf/72/29/jgo-25-43.PMC3893674.pdf
"Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.www.ejgo.orgObjective:  The objective of this study was to explore the association of longitudinal CA-125 measurements with overall survival (OS)  time by developing a flexible model for patient-specific CA-125 profiles, and to provide a simple and reliable prediction of OS.",Non-OADS,/arxiv_data1/oa_pdf/85/a6/jgo-25-51.PMC3893675.pdf
1:51-57 http://dx.doi.org/10.3802/jgo.2014.25.1.51 pISSN 2005-0380 ·eISSN 2005-0399,Non-OADS,/arxiv_data1/oa_pdf/85/a6/jgo-25-51.PMC3893675.pdf
"http://dx.doi.org/10.3802/jgo.2014.25.1.51 52  www.ejgo.org parameters, including CA-125 half-life [4].",OADS,/arxiv_data1/oa_pdf/85/a6/jgo-25-51.PMC3893675.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.51 54  www.ejgo.org or advanced (FIGO III and IV) stage.,Non-OADS,/arxiv_data1/oa_pdf/85/a6/jgo-25-51.PMC3893675.pdf
Our model provides a simple alternative to inves - tigating how OS is related to those longitudinally measured  markers and is accessible online (http://www.math.nsysu.edu.,OADS,/arxiv_data1/oa_pdf/85/a6/jgo-25-51.PMC3893675.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.51 56  www.ejgo.org any time point with patient-specific CA-125 observations.,OADS,/arxiv_data1/oa_pdf/85/a6/jgo-25-51.PMC3893675.pdf
"Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.www.ejgo.orgObjective:  Loss of ARID1A is related to oncogenic transformation of ovarian clear cell adenocarcinoma.",Non-OADS,/arxiv_data1/oa_pdf/e5/20/jgo-25-58.PMC3893676.pdf
1:58-63 http://dx.doi.org/10.3802/jgo.2014.25.1.58 pISSN 2005-0380 ·eISSN 2005-0399,OADS,/arxiv_data1/oa_pdf/e5/20/jgo-25-58.PMC3893676.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.58 60  www.ejgo.org calculated by multiplying the staining intensity of the nuclei  by the stain-positive area within the tumor.,OADS,/arxiv_data1/oa_pdf/e5/20/jgo-25-58.PMC3893676.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.58 62  www.ejgo.org involved in tumor progression and metastasis.,OADS,/arxiv_data1/oa_pdf/e5/20/jgo-25-58.PMC3893676.pdf
"Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.www.ejgo.orgTable 1.",Non-OADS,/arxiv_data1/oa_pdf/02/cc/jgo-25-6.PMC3893677.pdf
1:6-8 http://dx.doi.org/10.3802/jgo.2014.25.1.6 pISSN 2005-0380 ·eISSN 2005-0399,Non-OADS,/arxiv_data1/oa_pdf/02/cc/jgo-25-6.PMC3893677.pdf
"Kimio Ushijima http://dx.doi.org/10.3802/jgo.2014.25.1.6 8 www.ejgo.org President of ASGO, delivered the presidential address, featur - ing the past, present, and future of ASGO.",Non-OADS,/arxiv_data1/oa_pdf/02/cc/jgo-25-6.PMC3893677.pdf
"Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.www.ejgo.orgObjective:  Compression of the left common iliac vein between the right common iliac artery and the vertebrae is known to  be associated with the occurrence of left iliofemoral deep vein thrombosis (DVT).",Non-OADS,/arxiv_data1/oa_pdf/31/eb/jgo-25-64.PMC3893678.pdf
1:64-69 http://dx.doi.org/10.3802/jgo.2014.25.1.64 pISSN 2005-0380 ·eISSN 2005-0399,OADS,/arxiv_data1/oa_pdf/31/eb/jgo-25-64.PMC3893678.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.64 66  www.ejgo.org and veins using videos and photographs in most cases.,Non-OADS,/arxiv_data1/oa_pdf/31/eb/jgo-25-64.PMC3893678.pdf
"http://dx.doi.org/10.3802/jgo.2014.25.1.64 68  www.ejgo.org DISCUSSION Iliac vein compression syndrome, also termed May-Thurner  syndrome or Cockett syndrome, is the symptomatic compres - sion of the left common iliac vein between the right common  iliac artery and the fifth lumbar vertebra.",Non-OADS,/arxiv_data1/oa_pdf/31/eb/jgo-25-64.PMC3893678.pdf
"Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.www.ejgo.orgCervical cancer is the most common female genital tract malignancy in Korean women.",Non-OADS,/arxiv_data1/oa_pdf/24/12/jgo-25-70.PMC3893679.pdf
1:70-74 http://dx.doi.org/10.3802/jgo.2014.25.1.70 pISSN 2005-0380 ·eISSN 2005-0399,Non-OADS,/arxiv_data1/oa_pdf/24/12/jgo-25-70.PMC3893679.pdf
"http://dx.doi.org/10.3802/jgo.2014.25.1.70 72  www.ejgo.org 12.3 per 100,000 women in 2010 ( Fig.",Non-OADS,/arxiv_data1/oa_pdf/24/12/jgo-25-70.PMC3893679.pdf
http://dx.doi.org/10.3802/jgo.2014.25.1.70 74  www.ejgo.org ACKNOWLEDGMENTS This paper was based on data from the Statistics Korea and  National Cancer Center website.,OADS,/arxiv_data1/oa_pdf/24/12/jgo-25-70.PMC3893679.pdf
Available from:  http://kosis.kr.,Non-OADS,/arxiv_data1/oa_pdf/24/12/jgo-25-70.PMC3893679.pdf
Available from: http://www.cancer.go.kr.,Non-OADS,/arxiv_data1/oa_pdf/24/12/jgo-25-70.PMC3893679.pdf
Available from: http://progressreport.cancer.,Non-OADS,/arxiv_data1/oa_pdf/24/12/jgo-25-70.PMC3893679.pdf
"Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology  This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License  (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and  reproduction in any medium, provided the original work is properly cited.www.ejgo.orgObjective:  The objective of this study was to estimate the reproductive outcome of young women with early-stage cervical  cancer who underwent fertility-sparing laparoscopic radical trachelectomy (LRT).",Non-OADS,/arxiv_data1/oa_pdf/a0/29/jgo-25-9.PMC3893680.pdf
1:9-13 http://dx.doi.org/10.3802/jgo.2014.25.1.9 pISSN 2005-0380 ·eISSN 2005-0399,Non-OADS,/arxiv_data1/oa_pdf/a0/29/jgo-25-9.PMC3893680.pdf
"http://dx.doi.org/10.3802/jgo.2014.25.1.9 10  www.ejgo.org a treatment of choice because it is minimally invasive [8,9].",Non-OADS,/arxiv_data1/oa_pdf/a0/29/jgo-25-9.PMC3893680.pdf
"http://dx.doi.org/10.3802/jgo.2014.25.1.9 12  www.ejgo.org trachelectomy was 24% [21] and 24% [7], respectively, com - parable with 28.6% after LRT.",Non-OADS,/arxiv_data1/oa_pdf/a0/29/jgo-25-9.PMC3893680.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/60/18/TONURSJ-7-165.PMC3893719.pdf
Available from: http://www.cdc.gov/hiv/surveillance/resources/reports/2005report/#3 [4] United Nations Programme on HIV/AIDS (UNAIDS).,OADS,/arxiv_data1/oa_pdf/f2/25/TOAIDJ-7-51.PMC3893720.pdf
"Retrieved online: December 4, 2013 at: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/20131101_JC2563_hiv-and-aging_en.pdf [5] Centers for Disease Control.",Non-OADS,/arxiv_data1/oa_pdf/f2/25/TOAIDJ-7-51.PMC3893720.pdf
"Retrieved online: December 4, 2013 at: http://www.cdc.gov/hiv/top ics/over50/ [6] Emlet C. Experiences of Stigma in Older Adults Living with HIV/AIDS: a mixed-methods analysis.",Non-OADS,/arxiv_data1/oa_pdf/f2/25/TOAIDJ-7-51.PMC3893720.pdf
"Retrieved online: December 6, 2013 at: http://data.unaids.org/publications/Fact -Sheets02/fs_older_en.pdf [13] Kirk JB, Goetz MB.",Non-OADS,/arxiv_data1/oa_pdf/f2/25/TOAIDJ-7-51.PMC3893720.pdf
"HIV/AIDS and Asian Americans; Office of Minority Health: Retrieved online: December 4, 2013 at:: http://minorityhealth.hhs.go v/templates/content.aspx?ID=3062 [24] UNAIDS.",Non-OADS,/arxiv_data1/oa_pdf/f2/25/TOAIDJ-7-51.PMC3893720.pdf
"Retrieved online: November 29, 2013 at: http://data.unaids.org/pub/Report/20 10/china_2010_country_progress_report_en.pdf [25] Wang L, Wang N, Wang L, et al.",Non-OADS,/arxiv_data1/oa_pdf/f2/25/TOAIDJ-7-51.PMC3893720.pdf
"Available from: http://www.infekt.ch/updown/documents/kongresse/ WAC2008_Daneel_THPE0482.pdf [39] Dowse R, Ramela T, Barford K-L, Browne SH.",Non-OADS,/arxiv_data1/oa_pdf/f2/25/TOAIDJ-7-51.PMC3893720.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/ 3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/f2/25/TOAIDJ-7-51.PMC3893720.pdf
"This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/ 3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d0/43/TORJ-7-119.PMC3893721.pdf
"Correspondence to: Christoph Romanin; Email: christoph.romanin@jku.at Submitted: 10/19/2013; Accepted: 10/19/2013 http://dx.doi.org/10.4161/chan.27137In this issue of Channels Special issue on STIM and Orai Christoph r omanin Institute of Biophysics; Johannes Kepler University Linz; Linz, austria Christoph Romanin  Guest Editor, Channels",Non-OADS,/arxiv_data1/oa_pdf/b6/25/chan-7-329.PMC3893731.pdf
"However, conven - tional methods of screening for the interaction of CRYAA  with proteins are cumbersome and time consuming.Molecular Vision  2014; 20:117-124 <http://www.molvis.org/molvis/v 20/117> Received 1 November 2013 | Accepted 11 January 2014 | Published 14 January 2014© 2014 Molecular Vision 117Identification of proteins that interact with alpha A-crystallin  using a human proteome microarray Qi Fan,1 Lv-Zhen Huang,2 Xiang-Jia Zhu,1 Ke-Ke Zhang,1 Hong-Fei Ye,1 Yi Luo,1 Xing-Huai Sun,1 Peng  Zhou,3 Yi Lu1 (The first three authors contributed equally to this work) 1Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai, People’ s Republic of China; 2Department  of Ophthalmology, Peking University People’ s Hospital, Beijing, People’ s Republic of China; 3Department of Ophthalmology,  Parkway Health Hong Qiao Medical Center, Shanghai, People’ s Republic of China Purpose:  To identify proteins interacting with alpha A-crystallin (CRYAA) and to investigate the potential role that  these protein interactions play in the function of CRYAA using a human proteome (HuProt) microarray.",Non-OADS,/arxiv_data1/oa_pdf/dd/85/mv-v20-117.PMC3893783.pdf
Molecular Vision  2014; 20:117-124 <http://www.molvis.org/molvis/v 20/117> © 2014 Molecular Vision  118Functional proteome microarrays were designed to  screen interactions between proteins in a single experiment  [13].,OADS,/arxiv_data1/oa_pdf/dd/85/mv-v20-117.PMC3893783.pdf
Molecular Vision  2014; 20:117-124 <http://www.molvis.org/molvis/v 20/117> © 2014 Molecular Vision  119 Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/dd/85/mv-v20-117.PMC3893783.pdf
Molecular Vision  2014; 20:117-124 <http://www.molvis.org/molvis/v 20/117> © 2014 Molecular Vision  120DISCUSSION Alpha crystallins are small HSPs that play central roles in  maintaining lens transparency and preventing cataract forma - tion [ 18].,Non-OADS,/arxiv_data1/oa_pdf/dd/85/mv-v20-117.PMC3893783.pdf
Molecular Vision  2014; 20:117-124 <http://www.molvis.org/molvis/v 20/117> © 2014 Molecular Vision  121filaments [ 24].,Non-OADS,/arxiv_data1/oa_pdf/dd/85/mv-v20-117.PMC3893783.pdf
"Molecular Vision  2014; 20:117-124 <http://www.molvis.org/molvis/v 20/117> © 2014 Molecular Vision  122identified in the functional clustering analysis is involved  in DNA metabolism and repair, which are essential for cell  proliferation and responses to DNA damage stimulus.",Non-OADS,/arxiv_data1/oa_pdf/dd/85/mv-v20-117.PMC3893783.pdf
"Molecular Vision  2014; 20:117-124 <http://www.molvis.org/molvis/v 20/117> © 2014 Molecular Vision  12381270989, and No.",Non-OADS,/arxiv_data1/oa_pdf/dd/85/mv-v20-117.PMC3893783.pdf
Molecular Vision  2014; 20:117-124 <http://www.molvis.org/molvis/v 20/117> © 2014 Molecular Vision  12425.,Non-OADS,/arxiv_data1/oa_pdf/dd/85/mv-v20-117.PMC3893783.pdf
"This is an Open Access article distributed under the terms of the Creative C ommons Attribution Non-Commercial L icense (http://creativecommons.or g/ licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c6/18/gzt061.PMC3893934.pdf
Available from: http://www.diabetesmoz.com/prevention- and-control-of-diabetes-cardio-vascular-diseases-stroke/ [Last accessed on 2010 Feb 04].,Non-OADS,/arxiv_data1/oa_pdf/58/98/JFMPC-1-79.PMC3893940.pdf
Available from  http://www.who.int/classifications/icf/en/.,OADS,/arxiv_data1/oa_pdf/e3/c0/JFMPC-1-69.PMC3893941.pdf
Available  from http://www.who.int/healthinfo/survey/whspaper37.,Non-OADS,/arxiv_data1/oa_pdf/e3/c0/JFMPC-1-69.PMC3893941.pdf
Available from http://pib.nic.in/release/release.,Non-OADS,/arxiv_data1/oa_pdf/e3/c0/JFMPC-1-69.PMC3893941.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/e3/c0/JFMPC-1-69.PMC3893941.pdf
Available from: http://www.iofbonehealth.org/health- professionals/about-osteoporosis.html.,Non-OADS,/arxiv_data1/oa_pdf/66/b5/JFMPC-1-66.PMC3893942.pdf
Available from: http://www.iofbonehealth.,Non-OADS,/arxiv_data1/oa_pdf/66/b5/JFMPC-1-66.PMC3893942.pdf
Available from: http://www.iofbonehealth.org/ download/osteofound/filemanager/publications/pdf/ Asian-audit-09/4-2009-Asian_Audit-India.pdf.,Non-OADS,/arxiv_data1/oa_pdf/66/b5/JFMPC-1-66.PMC3893942.pdf
Available from: http://www.iofbonehealth.,Non-OADS,/arxiv_data1/oa_pdf/66/b5/JFMPC-1-66.PMC3893942.pdf
Available from: http://www.who.int/hpr/NPH/docs/ declaration_almaata.pdf [Last cited on 2012 Jan 15].,OADS,/arxiv_data1/oa_pdf/5b/c1/JFMPC-1-1.PMC3893943.pdf
Available from: http://www.pppinindia.com/pdf/health- education-delivery-india-ppp_adb_dea.pdf [Last cited on  2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/5b/c1/JFMPC-1-1.PMC3893943.pdf
Available  from: http://www.thehindu.com/news/resources/ article2551581.ece [Last cited on 2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/5b/c1/JFMPC-1-1.PMC3893943.pdf
Available from: http://www.aafp.org/online/en/ home/policy/policies/f/fammeddef.html.,Non-OADS,/arxiv_data1/oa_pdf/77/5d/JFMPC-1-59.PMC3893944.pdf
Available from: http://www.npspindia.org.,OADS,/arxiv_data1/oa_pdf/77/5d/JFMPC-1-59.PMC3893944.pdf
Available from: http://news.bbc.co.uk/2/hi/south_asia/7445570.stm.,Non-OADS,/arxiv_data1/oa_pdf/77/5d/JFMPC-1-59.PMC3893944.pdf
Available from: http://pib.nic.in/archieve/ others/2009/dec/r2009121101.pdf.,Non-OADS,/arxiv_data1/oa_pdf/77/5d/JFMPC-1-59.PMC3893944.pdf
Available from: http://www.cmch-vellore.edu/.,Non-OADS,/arxiv_data1/oa_pdf/77/5d/JFMPC-1-59.PMC3893944.pdf
The application can be downloaded  from http://itunes.apple.com/us/app/medknow-journals/id458064375?ls=1&mt=8.,Non-OADS,/arxiv_data1/oa_pdf/77/5d/JFMPC-1-59.PMC3893944.pdf
Available from:  http://www.expresshealthcare.in/200810/knowledge02.,Non-OADS,/arxiv_data1/oa_pdf/14/d7/JFMPC-1-48.PMC3893947.pdf
Available from: http://www.nfhsindia.org [Last cited   on 2007].,OADS,/arxiv_data1/oa_pdf/ba/60/JFMPC-1-43.PMC3893950.pdf
Available from: http://www.nfhsindia.org/factsheet.html [Last cited on 2007].,OADS,/arxiv_data1/oa_pdf/ba/60/JFMPC-1-43.PMC3893950.pdf
Start a QR-code reading  software (see list of free applications from http://tinyurl.com/yzlh2tc) and point the camera to the QR-code printed in the  journal.,Non-OADS,/arxiv_data1/oa_pdf/ba/60/JFMPC-1-43.PMC3893950.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free applications.Announcement,Non-OADS,/arxiv_data1/oa_pdf/ba/60/JFMPC-1-43.PMC3893950.pdf
Available from: http://www.unicef.org/nutrition/ index_24850.html [Last accessed on 2008 Apr 29].,Non-OADS,/arxiv_data1/oa_pdf/6b/36/JFMPC-1-27.PMC3893951.pdf
Available  from: http://www.home2.nyc.gov/html/doh/html/vs/ vs.shtml008.,Non-OADS,/arxiv_data1/oa_pdf/6b/36/JFMPC-1-27.PMC3893951.pdf
The application can be downloaded  from https://market.android.com/details?id=comm.app.medknow.,Non-OADS,/arxiv_data1/oa_pdf/58/7c/JFMPC-1-52.PMC3893953.pdf
Available from: http://www.who.int/gho/publications/ world_health_statistics/EN_WHS2011_Full.pdf [Last cited  on 2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from: http://nrhm-mis.nic.in/UI/RHS/RHS%20 2010/RHS%202010/Key%20Highlights%20from%20 Rural%20Health%20Statistics%20in%20India.pdf [Last cited  on 2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from:  http://www.articles.timesofindia.indiatimes.com/2010-11- 11/india/28253232_1_trips-medical-tourism-rural-areas  [Last cited on 2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from  http://www.business-standard.com/india/news/primary- healthcare-catches-on/460842/ [Last cited on 2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from: http://www.unicef.org/india/ssd04_2005_ final.pdf [Last cited on 2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from: http://www.mohfw.nic.in/WriteReadData/ l892s/9457038092AnnualReporthealth.pdf [Last cited on  2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from: http://www.thehindu.com/news/ resources/article2551581.ece#.Tqi8zkY8N5w.mailto [Last  cited on 2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from:  http://www.planningcommission.nic.in/reports/genrep/ rep_uhc0812.pdf [Last cited on 2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available  from: http://www.planningcommission.nic.in/aboutus/ committee/wrkgrp12/health/WG_2tertiary.pdf [Last cited  on 2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from: http://www.jcdr.,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from: http://www.hrhindia.org/assets/images/ Paper-III.pdf [Last cited on 2012 Jan 15].,OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from: http://www.planningcommission.nic.in/ aboutus/committee/wrkgrp12/health/WG_1NRHM.pdf  [Last cited on 2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from:  http://www.articles.timesofindia.indiatimes.com/2010-05- 15/india/28317112_1_mci-president-medical-education- indian-medical-council-act [Last cited on 2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from: http://www.nrhm-mis.nic.in/ui/who/GOI- who-link.htm [Last cited on 2012 Jan 15].,OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available  from: http://www.mohfw.nic.in/NRHM/Documents/ National_Health_policy_2002.pdf [Last cited on 2012   Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from: http://www.knowledgecommission.gov.in/ recommendations/medical2.asp [Last cited on 2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from: http://www.mohfw.,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from:  http://www.mciindia.org/tools/announcement/MCI_ booklet.pdf [Last cited on 2012 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from: http://www.afpionline.,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from: http://www.thehindu.,Non-OADS,/arxiv_data1/oa_pdf/b2/ee/JFMPC-1-10.PMC3893954.pdf
Available from: http://www.mmcmumbai.,Non-OADS,/arxiv_data1/oa_pdf/a9/a9/JFMPC-1-7.PMC3893955.pdf
Available  from: http://www.iom.edu/~/media/Files/Report%20 Files/2009/Redesigning-Continuing-Education-in-the- Health-Professions/RedesigningCEreportbrief.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a9/a9/JFMPC-1-7.PMC3893955.pdf
Available from:  http://www.whoindia.org/LinkFiles/Human_Resources_ Health_Workforce_in_India_-_Apr07.pdf [Last accessed on  2011 Nov 11].,Non-OADS,/arxiv_data1/oa_pdf/5c/79/JFMPC-1-3.PMC3893956.pdf
"Regulation of Medical Practitioners in India, Ashok Kumar,  Central Bureau of Health Intelligence (CBHI) Available  from: http://www.hum.au.dk/hsre/Docs/Presentations/4_ Regulation-scope%20and%20limitations/1_Ashok_Kumar_ Regulation.pdf [Last accessed on 2011 Nov 11].",Non-OADS,/arxiv_data1/oa_pdf/5c/79/JFMPC-1-3.PMC3893956.pdf
RHS – Bulletin 2010 http://www.mohfw.nic.in/BULLETIN%20 ON.htm [Last accessed on 2011 Nov 11].,Non-OADS,/arxiv_data1/oa_pdf/5c/79/JFMPC-1-3.PMC3893956.pdf
Available from: http://www.infochangeindia.org/ health/backgrounder/health-background-perspective.html  [Last accessed on Nov 2011].,OADS,/arxiv_data1/oa_pdf/5c/79/JFMPC-1-3.PMC3893956.pdf
"Das A. Info Change News and Features., Available from:  http://www.infochangeindia.org/agenda/access-denied/ nrhm-new-hope-for-the-rural-poor.html [Last accessed on  June 2005].",Non-OADS,/arxiv_data1/oa_pdf/5c/79/JFMPC-1-3.PMC3893956.pdf
"Germany: Bamberg  University, Available from: http://www.andragogy.net.",Non-OADS,/arxiv_data1/oa_pdf/5c/79/JFMPC-1-3.PMC3893956.pdf
Available from: http://www.thehindu.com/opinion/op-ed/ article2609599.ece [Last accessed on Nov 2011].,Non-OADS,/arxiv_data1/oa_pdf/5c/79/JFMPC-1-3.PMC3893956.pdf
The application can be downloaded from http://itunes.apple.com/us/app/medknow-journals/id458064375?ls=1&mt=8.,Non-OADS,/arxiv_data1/oa_pdf/de/35/JFMPC-1-137.PMC3893959.pdf
Available from: http://www.Diabeteseducator.org/professional resources/products/fundamentals.,Non-OADS,/arxiv_data1/oa_pdf/b1/be/JFMPC-1-97.PMC3893961.pdf
Available from: http://www.hpsafind.hrsa.gov/[Last accessed on 2012 Apr 09].,OADS,/arxiv_data1/oa_pdf/b1/be/JFMPC-1-97.PMC3893961.pdf
Available from: http://www.diabeteseducator.org/policyadvocacy/state-licensure-FAQs.html.,Non-OADS,/arxiv_data1/oa_pdf/b1/be/JFMPC-1-97.PMC3893961.pdf
Available: http://www.future.org/ downloads/Health_Equity_in_Nepal.pdf.,Non-OADS,/arxiv_data1/oa_pdf/8e/aa/JFMPC-1-86.PMC3893962.pdf
Available  from: http://www.censusindia.gov.in.,OADS,/arxiv_data1/oa_pdf/c5/2e/JFMPC-1-164.PMC3893964.pdf
"Available  from: http://censusindia.gov.in/2011-prov-results/data_files/jharkhand/Jharkhand%20Provisional%20Result%20Data%20sheet%20for%20release.pdf., [Last cited on 2012 Apr 9].",OADS,/arxiv_data1/oa_pdf/c5/2e/JFMPC-1-164.PMC3893964.pdf
Available from: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx.,Non-OADS,/arxiv_data1/oa_pdf/7b/96/JFMPC-1-84.PMC3893965.pdf
Available from: http://www.pakobserver.net/detailnews.asp?id=149089.,Non-OADS,/arxiv_data1/oa_pdf/7b/96/JFMPC-1-84.PMC3893965.pdf
"Available from, http://www.thelancet.com/journals/lancet/article/PIIS0140-6736 (06)68654-6/fulltext.",Non-OADS,/arxiv_data1/oa_pdf/74/0b/JFMPC-1-144.PMC3893966.pdf
Available  from: http://www.thehindu.com/opinion/editorial/ article2042983.ece.,Non-OADS,/arxiv_data1/oa_pdf/74/0b/JFMPC-1-144.PMC3893966.pdf
Available from: http://www.ncrb.nic.in/ADSI2010/ADSI2010-full-report.pdf.,Non-OADS,/arxiv_data1/oa_pdf/74/0b/JFMPC-1-144.PMC3893966.pdf
"Available from, http://www.timesofindia.indiatimes.com//home/opinion/edit-page/Accidental-Damage/articleshow/3630126.cms.",Non-OADS,/arxiv_data1/oa_pdf/74/0b/JFMPC-1-144.PMC3893966.pdf
"Available from, http://www.thehindu.com/news/states/tamil-nadu/ article2787268.ece.",Non-OADS,/arxiv_data1/oa_pdf/74/0b/JFMPC-1-144.PMC3893966.pdf
"Available from, http://www.indiandrivingschools.com/ drunken-driving.html.",Non-OADS,/arxiv_data1/oa_pdf/74/0b/JFMPC-1-144.PMC3893966.pdf
Available  from: http://www.who.int/roadsafety/en/.,Non-OADS,/arxiv_data1/oa_pdf/74/0b/JFMPC-1-144.PMC3893966.pdf
Available from: http://www.morth.nic.in/ writereaddata/sublinkimages/RoadSafetyWeek8241614630.pdf.,Non-OADS,/arxiv_data1/oa_pdf/74/0b/JFMPC-1-144.PMC3893966.pdf
Available from: http://www.indiandrives.com/motor-vehicle-amendment-bill-2007-cleared-by-cabinet.html.,Non-OADS,/arxiv_data1/oa_pdf/74/0b/JFMPC-1-144.PMC3893966.pdf
"Available from, http://lawcommissionofindia.nic.in/reports/rep201.",Non-OADS,/arxiv_data1/oa_pdf/74/0b/JFMPC-1-144.PMC3893966.pdf
Available from: http://www.nimhans.kar.nic.in/epidemiology/epidem_who3.htm.,Non-OADS,/arxiv_data1/oa_pdf/74/0b/JFMPC-1-144.PMC3893966.pdf
"68, Bengaluru 2008; Available from: http://www.nimhans.kar.nic.in/epidemiology/bisp/sr1.pdf.",Non-OADS,/arxiv_data1/oa_pdf/74/0b/JFMPC-1-144.PMC3893966.pdf
Available from: http://www.nvbdcpchd.gov.in/reporting%20 formats/MoUManual.pdf.,Non-OADS,/arxiv_data1/oa_pdf/74/0b/JFMPC-1-144.PMC3893966.pdf
The application can be downloaded from https://market.android.com/details?id=comm.app.medknow.,Non-OADS,/arxiv_data1/oa_pdf/74/0b/JFMPC-1-144.PMC3893966.pdf
Available from: http://www.hsbc.,Non-OADS,/arxiv_data1/oa_pdf/6d/a8/JFMPC-1-127.PMC3893968.pdf
Available from: http://www.mohfw.,Non-OADS,/arxiv_data1/oa_pdf/6d/a8/JFMPC-1-127.PMC3893968.pdf
Available from: http://www.biomedcentral.com/1741-7015/2/29.,Non-OADS,/arxiv_data1/oa_pdf/66/ac/JFMPC-1-109.PMC3893969.pdf
Available from: http://www.palgrave.,Non-OADS,/arxiv_data1/oa_pdf/66/ac/JFMPC-1-109.PMC3893969.pdf
Available from: http://www.ama-assn.org/resources/doc/physician-health/icph 2010-smith-paice.pdf.,Non-OADS,/arxiv_data1/oa_pdf/66/ac/JFMPC-1-109.PMC3893969.pdf
Indian Pediatrics Available on URL: http://www.indianpediatrics.net/RB%2010.06.2012/RB-60.pdf 8.,Non-OADS,/arxiv_data1/oa_pdf/a2/8c/JFMPC-1-153.PMC3893970.pdf
Prospectus MD/MS Courses 2011.Available from:  http://www.jipmer.edu/JIPMDMS11.pdf.,Non-OADS,/arxiv_data1/oa_pdf/e0/16/JFMPC-1-141.PMC3893972.pdf
Url: http://business.gov in/legal_aspects/factories_act.php.,OADS,/arxiv_data1/oa_pdf/e0/16/JFMPC-1-141.PMC3893972.pdf
Available from: http://www.aiims.edu/aiims/aboutaiims/ aboutaiimsintro.htm [Last cited on 2012 Sept 15].,OADS,/arxiv_data1/oa_pdf/93/42/JFMPC-1-81.PMC3893973.pdf
Available from: http://www.mohfw.,Non-OADS,/arxiv_data1/oa_pdf/93/42/JFMPC-1-81.PMC3893973.pdf
Available from:  http://www.aiimsbhopal.edu.in/academics_and_research.,Non-OADS,/arxiv_data1/oa_pdf/93/42/JFMPC-1-81.PMC3893973.pdf
Available from:  http://www.mciindia.org/RulesandRegulations/ IndianMedicalCouncilRules1957.aspx [Last cited on  2012 Sept 15].6.,Non-OADS,/arxiv_data1/oa_pdf/93/42/JFMPC-1-81.PMC3893973.pdf
Available from:  http://www.mciindia.org/rules‑and‑regulation/ Postgraduate‑Medical‑Education‑Regulations‑2000.pdf  [Last cited on 2012 Sept 15].,Non-OADS,/arxiv_data1/oa_pdf/93/42/JFMPC-1-81.PMC3893973.pdf
Available from: http://www.mohfw.nic.in/NRHM/ Documents/National_Health_policy_2002.pdf [Last cited  on 2012 Sept 15].,Non-OADS,/arxiv_data1/oa_pdf/93/42/JFMPC-1-81.PMC3893973.pdf
Available  from: http://www.mohfw.nic.in/NRHM/Documents/Task_ Group_Medical_Education.pdf [Last cited on 2012 Sept 15].,Non-OADS,/arxiv_data1/oa_pdf/93/42/JFMPC-1-81.PMC3893973.pdf
Available from:  http://www.cet.natboard.edu.in/pdoofs/Seatsfordnbcet.,Non-OADS,/arxiv_data1/oa_pdf/93/42/JFMPC-1-81.PMC3893973.pdf
Available from: http://www.mohfw.nic.in/WriteReadData/ l892s/9457038092AnnualReporthealth.pdf [Last cited on  2012 Sept 15].,Non-OADS,/arxiv_data1/oa_pdf/93/42/JFMPC-1-81.PMC3893973.pdf
Available  from: http://www.afpionline.com/Documents/MOHFM.pdf  [Last cited on 2012 Sept 15].,Non-OADS,/arxiv_data1/oa_pdf/93/42/JFMPC-1-81.PMC3893973.pdf
Available  from: http://www.mciindia.org/RulesandRegulations/ TeachersEligibilityQualifications1998.aspx [Last cited on  2012 Sept 15].,Non-OADS,/arxiv_data1/oa_pdf/93/42/JFMPC-1-81.PMC3893973.pdf
Available  from: http://www.searo.who.int/LinkFiles/Reports_ SEA‑HSD‑327.pdf [Last cited on 2012 Sept 15].,OADS,/arxiv_data1/oa_pdf/93/42/JFMPC-1-81.PMC3893973.pdf
Available from: http://www.vision2020.org/main.cfm?type=PUBLICATIONS.,Non-OADS,/arxiv_data1/oa_pdf/14/26/JFMPC-1-114.PMC3893980.pdf
Available  from: http://www.who.int/mediacentre/factsheets/fs300/ en/index.html.,Non-OADS,/arxiv_data1/oa_pdf/14/26/JFMPC-1-114.PMC3893980.pdf
Available from:  http://www.hum.au.dk/hsre/index.html.,Non-OADS,/arxiv_data1/oa_pdf/14/26/JFMPC-1-114.PMC3893980.pdf
Available from: http://data.worldbank.org/ country/indonesia.,OADS,/arxiv_data1/oa_pdf/14/26/JFMPC-1-114.PMC3893980.pdf
Available from: http://www.sst.dk/publ/Publ2011/BOFO/ Sundhedsydelser/VejlBU_sundhedsyd2udg.pdf.,Non-OADS,/arxiv_data1/oa_pdf/14/26/JFMPC-1-114.PMC3893980.pdf
Available from: http://www.who.int/pbd/blindness/vision_2020/v2020_therighttosight.pdf.,Non-OADS,/arxiv_data1/oa_pdf/14/26/JFMPC-1-114.PMC3893980.pdf
Available from: http://www.interacoustics.co.uk/_ downloads/OM_OtoReadStandardClinical.pdf.,OADS,/arxiv_data1/oa_pdf/14/26/JFMPC-1-114.PMC3893980.pdf
Available from: http://www.who.int/pbd/deafness/activities/en/capetown_final_ report.pdf.,Non-OADS,/arxiv_data1/oa_pdf/14/26/JFMPC-1-114.PMC3893980.pdf
Available from: http://www.biomedcentral.com/1471-2407/9/39.,Non-OADS,/arxiv_data1/oa_pdf/5a/65/JFMPC-1-103.PMC3893981.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/5a/65/JFMPC-1-103.PMC3893981.pdf
Available from: http://bapio.co.uk/campaign‑resource [Last  cited on 2013 Jan 15].,Non-OADS,/arxiv_data1/oa_pdf/c8/c7/JFMPC-2-1.PMC3894006.pdf
Available from:  http://www.dailymail.co.uk/news/article‑2252359/ Scandal‑failing‑foreign‑doctors‑demand‑right‑sit‑GP‑exams   ‑staggering‑SIX‑times.html [Last cited on 2013 Jan 15].3.,Non-OADS,/arxiv_data1/oa_pdf/c8/c7/JFMPC-2-1.PMC3894006.pdf
Available  from: http://www.nrmp.org/data/resultsanddata2012.,OADS,/arxiv_data1/oa_pdf/c8/c7/JFMPC-2-1.PMC3894006.pdf
"MBBS seat at Rs 35 lakh, MD at Rs 1.5 cr in state, Times of India  Apr 26, 2012 Available from: http://articles.timesofindia.",Non-OADS,/arxiv_data1/oa_pdf/c8/c7/JFMPC-2-1.PMC3894006.pdf
"Canada Jan 17,  2013 Available from: http://gov.sk.ca/news?",Non-OADS,/arxiv_data1/oa_pdf/c8/c7/JFMPC-2-1.PMC3894006.pdf
Start a QR-code reading  software (see list of free applications from http://tinyurl.com/yzlh2tc) and point the camera to the QR-code printed in the  journal.,Non-OADS,/arxiv_data1/oa_pdf/1c/b3/JFMPC-2-95.PMC3894009.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free applications.Announcement,Non-OADS,/arxiv_data1/oa_pdf/1c/b3/JFMPC-2-95.PMC3894009.pdf
Available from: http://www.populationcommission.nic.in/ npp.htm.,Non-OADS,/arxiv_data1/oa_pdf/c3/c5/JFMPC-2-60.PMC3894011.pdf
Available from: http://www.censusindia.gov.in/ vital_statistics/SRS_Bulletins/MMR_release_070711.pdf.,OADS,/arxiv_data1/oa_pdf/c3/c5/JFMPC-2-60.PMC3894011.pdf
Available from: http://www.censusindia.gov.in/.Bulletins/ SRS%20Bulletin%20-%20January%20.pdf.,OADS,/arxiv_data1/oa_pdf/c3/c5/JFMPC-2-60.PMC3894011.pdf
Available from: http://www.mohfw.nic.in/ NRHM/Documents/Mission_Document.pdf.,Non-OADS,/arxiv_data1/oa_pdf/c3/c5/JFMPC-2-60.PMC3894011.pdf
The application can be downloaded  from http://itunes.apple.com/us/app/medknow-journals/id458064375?ls=1&mt=8.,Non-OADS,/arxiv_data1/oa_pdf/c3/c5/JFMPC-2-60.PMC3894011.pdf
Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2036886/pdf/brmedj03586-0038.pdf.,Non-OADS,/arxiv_data1/oa_pdf/ed/ba/JFMPC-2-4.PMC3894012.pdf
Available from: http://www.who.int/countryfocus/ cooperation_strategy/ccs_ind_en.pdf.,Non-OADS,/arxiv_data1/oa_pdf/ed/ba/JFMPC-2-4.PMC3894012.pdf
Available  from: http://www.unhcr.org/refworld/docid/48625a742.,Non-OADS,/arxiv_data1/oa_pdf/ed/ba/JFMPC-2-4.PMC3894012.pdf
The application can be downloaded  from https://market.android.com/details?id=comm.app.medknow.,Non-OADS,/arxiv_data1/oa_pdf/ca/80/JFMPC-2-79.PMC3894013.pdf
Available from: http://www.who.,Non-OADS,/arxiv_data1/oa_pdf/dc/8c/JFMPC-2-37.PMC3894015.pdf
Available  from: http://www.cochraneprimarycare.org/welcome.,Non-OADS,/arxiv_data1/oa_pdf/31/55/JFMPC-2-9.PMC3894019.pdf
Available from: http://www.cochrane‑net.,OADS,/arxiv_data1/oa_pdf/31/55/JFMPC-2-9.PMC3894019.pdf
Available  from: http://www.cochrane‑net.org/openlearning/html/ mod15‑2.htm.,OADS,/arxiv_data1/oa_pdf/31/55/JFMPC-2-9.PMC3894019.pdf
Available from: http://www.globalfamilydoctor.,Non-OADS,/arxiv_data1/oa_pdf/93/27/JFMPC-2-15.PMC3894020.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/93/27/JFMPC-2-15.PMC3894020.pdf
Available from: http://www.prcs‑mohfw.,Non-OADS,/arxiv_data1/oa_pdf/e1/81/JFMPC-2-55.PMC3894022.pdf
Available from: http://archive.org/stream/ GuerillaOpenAccessManifesto/Goamjuly2008_djvu.txt  [Last accessed on 2013 Jan 14].,Non-OADS,/arxiv_data1/oa_pdf/8c/f2/JFMPC-2-128.PMC3894027.pdf
Available from: http://www.opensocietyfoundations.org/ openaccess/read [Last accessed on 2013 Jan 14].,OADS,/arxiv_data1/oa_pdf/8c/f2/JFMPC-2-128.PMC3894027.pdf
June 2003.  http://www.earlham.edu/~peters/fos/bethesda.htm [Last  accessed 2013 Jan 14].,Non-OADS,/arxiv_data1/oa_pdf/8c/f2/JFMPC-2-128.PMC3894027.pdf
Available  from: http://oa.mpg.de/lang/en‑uk/berlin‑prozess/ berliner‑erklarung/[Last accessed on 2013 Jan 14].,Non-OADS,/arxiv_data1/oa_pdf/8c/f2/JFMPC-2-128.PMC3894027.pdf
August 2008. http://www.earlham.,Non-OADS,/arxiv_data1/oa_pdf/8c/f2/JFMPC-2-128.PMC3894027.pdf
Available from: http://news.bis.gov.uk/Press‑Releases/ Government‑to‑open‑up‑publicly‑funded‑research‑67d1d.,Non-OADS,/arxiv_data1/oa_pdf/8c/f2/JFMPC-2-128.PMC3894027.pdf
http://www.tcd.ie/Library/assets/pdf/National%20 Principles%20on%20Open%20Access%20Policy%20 Statement%20 (FINAL%2023%20Oct%202012%20v1%203).,Non-OADS,/arxiv_data1/oa_pdf/8c/f2/JFMPC-2-128.PMC3894027.pdf
Available from: http://www.wellcome.,Non-OADS,/arxiv_data1/oa_pdf/8c/f2/JFMPC-2-128.PMC3894027.pdf
Available from: http://ia600504.us.archive.,Non-OADS,/arxiv_data1/oa_pdf/8c/f2/JFMPC-2-128.PMC3894027.pdf
Available from: http://www.earlham.edu/~peters/fos/ overview.htm [Last accessed on 2013 Jan 16].,Non-OADS,/arxiv_data1/oa_pdf/8c/f2/JFMPC-2-128.PMC3894027.pdf
December  2012. http://scholarlyoa.com/2012/11/30/criteria‑for‑  determining‑predatory‑open‑access‑publishers‑2nd‑edition/ [Last accessed on 2013 Jan 16].,Non-OADS,/arxiv_data1/oa_pdf/8c/f2/JFMPC-2-128.PMC3894027.pdf
"History, Planning commission of India, Available  from,http://planningcommission.nic.in/ [Last cited on 2013  June 15].",Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
Available from http://planningcommission.gov.in/plans/ planrel/12appdrft/appraoch_12plan.pdf [Last cited on  2013 June 15].,Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
Available from http://mohfw.nic.in/NRHM/ Documents/5_Years_NRHM_Final.pdf [Last cited on 2013  June 15].,OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
"Abantika Ghosh, Unified National Health Mission for all,  says PM The Indian Express, Thu Aug 16 2012, Available  from http://www.indianexpress.com/news/unified ‑ national‑health‑mission‑for‑all‑sayspm/988836/0 [Last  cited on 2013 June 15].",Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
About NABH Available from http://www.nabh.co/main/ introduction.asp [Last cited on 2013 June 15] 7.,Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
Clinical establishments brought under Act The Hindu 2012  March 23Available from http://www.thehindu.com/todays‑ paper/tp‑national/article3156793.ece [Last cited on 2013  June 15].,Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
"Docs protest Clinical Establishment Act, Hindustan Times  June 19, 2012, Available at http://www.hindustantimes.",Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
Available from http://mohfw.nic.in/NRHM/iphs.htm [Last  cited on 2013 June 15].,OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
Available from http://articles.timesofindia.,Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
"Chetan Chauhan, A medical college in each district of the  country: Govt Hindustan Times New Delhi, August 02, 2012, Available from http://www.hindustantimes.com/Indianews/ NewDelhi/A‑medical‑college ‑in‑each‑district ‑of‑thecountry‑ Govt/Article1‑907202.aspx [Last cited on 2013 June 15].",Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
"1 62‑71 Available  from HYPERLINK ""http://www.paeaonline.org/index.",Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
"Code of Marketing Practice for Indian Pharmaceutical  Industry Department of Pharmaceuticals, Government  of India, Available from http://pharmaceuticals.gov.in/ uniformcode.pdf [Last cited on 2013 June 15].",Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
"Code of Ethics Regulations, 2002 (Amended up to  December 2010)(Published in Part III, Section 4 of  the Gazette of India, dated 6th April,2002)  Medical  Council of India Notification.Available from  http://www.mciindia.org/RulesandRegulations/ CodeofMedicalEthicsRegulations2002.aspx [Last cited on  2013 June 15].",Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
Available from http://www.narasappa.com/ resources/Uniform%20Code%20of%20Marketing%20 Practices%20for%20the%20Indian%20Pharmaceutical%20 Industry.pdf [Last cited on 2013 June 15].,Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
"NCHRC Bill 2011, MOHFW May 042012,Press Information,   Bureau Government of India Available from http://pib.nic.",Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
Available from http://www.aafpfoundation.org/online/etc/ medialib/found/documents/programs/chfm/millisreport.,Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
Available  from http://www.afmc.ca/fmec/pdf/collective_vision.pdf  [Last cited on 2013 June 15].,Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
Available from http://www.hrsa.,Non-OADS,/arxiv_data1/oa_pdf/3c/dd/JFMPC-2-123.PMC3894029.pdf
Available  from: http://www.iom.int/./workshops/mhrh23240306/ abstract_samarage.pdf.,Non-OADS,/arxiv_data1/oa_pdf/1c/00/JFMPC-2-131.PMC3894032.pdf
Available from: http://som.adzu.edu.ph/ research/pdf/2010‑05‑26‑094611Smoking_among_ Physicians_in_ZC_‑_Elham_A._Asid.pdf.,Non-OADS,/arxiv_data1/oa_pdf/0c/6d/JFMPC-2-159.PMC3894034.pdf
Available from: http://www.rsby.gov.,Non-OADS,/arxiv_data1/oa_pdf/af/87/JFMPC-2-169.PMC3894038.pdf
16 February  2012 Available from: http://www.rsby.gov.in/statewise.,Non-OADS,/arxiv_data1/oa_pdf/af/87/JFMPC-2-169.PMC3894038.pdf
Joint United Nations  Programme on HIV/AIDS.WHO.2007:Available from:  http://www.data‑unaids.Org/pub/EPISLIDES/2007/2007_ epiupdate_en.pdf.,Non-OADS,/arxiv_data1/oa_pdf/d4/c7/JFMPC-2-149.PMC3894039.pdf
Available from:http://www.nfhsindia.org/nfhs3.,Non-OADS,/arxiv_data1/oa_pdf/d4/c7/JFMPC-2-149.PMC3894039.pdf
Available from: http://www.moh.gov.sg/content/ dam/moh_web/Legislations/e‑Consultation/Past%20 Consultations/public_consultation_fp_registerfinalprint.,Non-OADS,/arxiv_data1/oa_pdf/6e/05/JFMPC-2-135.PMC3894041.pdf
Available from: http://www.sgh.com.sg/Clinical‑ Departments‑ Centers/Family ‑Medicine‑ Continuing‑Care/ Pages/overview.aspx [Last accessed on 15th June 2013].,Non-OADS,/arxiv_data1/oa_pdf/6e/05/JFMPC-2-135.PMC3894041.pdf
Available from:  http://mospi.nic.in/mospi_new/upload/elderly_in_india.,Non-OADS,/arxiv_data1/oa_pdf/1d/90/JFMPC-2-188.PMC3894043.pdf
Available from: http://www.hsph.harvard.,Non-OADS,/arxiv_data1/oa_pdf/1d/90/JFMPC-2-188.PMC3894043.pdf
Available from: http://www.who.int/ csr/don/2009_05_04a/en/index.html.,OADS,/arxiv_data1/oa_pdf/e3/da/JFMPC-2-182.PMC3894046.pdf
Available  from: http://www.expressindia.com/latest‑news/ saurashtras‑ first‑confirmed‑ swine‑flu‑case‑ detected‑in‑  bhavnagar/503678/.,Non-OADS,/arxiv_data1/oa_pdf/e3/da/JFMPC-2-182.PMC3894046.pdf
Available from: http://www.mohfw‑h1n1.nic.,Non-OADS,/arxiv_data1/oa_pdf/e3/da/JFMPC-2-182.PMC3894046.pdf
Available  from: http://www.who.int/csr/resources/publications/ swineflu/CDCrealtimeRTPCRprotocol_20090428.pdf.,OADS,/arxiv_data1/oa_pdf/e3/da/JFMPC-2-182.PMC3894046.pdf
Available from:  http://www.eurosurveillance.org/ViewArticle.,Non-OADS,/arxiv_data1/oa_pdf/e3/da/JFMPC-2-182.PMC3894046.pdf
Available  from: http://www.eurosurveillance.org/ViewArticle.,Non-OADS,/arxiv_data1/oa_pdf/e3/da/JFMPC-2-182.PMC3894046.pdf
"†Wicking Dementia and Research Education Centre, Menzies Research Institute, Hobart, Tasmania, Australia.Ageing & Society , , –.fCambridge University Press  The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence <http://creativecommons.org/licenses/by-nc-sa/ ./>.",Non-OADS,/arxiv_data1/oa_pdf/87/68/S0144686X12000827a.PMC3894066.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/e9/60/JISPCD-1-52.PMC3894069.pdf
Available from: http://ijahsp.nova.edu/ articles/vol5num4/pdf/cooper.pdf [Last Accessed on 2011  Sep 16].,Non-OADS,/arxiv_data1/oa_pdf/ce/e7/JISPCD-1-37.PMC3894070.pdf
Available from: http://www2.telemedtoday.com/articles/ whatifreimbursement.shtml  [Last Accessed on 2012   Feb 08].,Non-OADS,/arxiv_data1/oa_pdf/ce/e7/JISPCD-1-37.PMC3894070.pdf
Available from:  http://crihb.org/files/Telemedicine-Reimbursement- Handbook.pdf  [Last Accessed on 2012 Feb 08].,Non-OADS,/arxiv_data1/oa_pdf/ce/e7/JISPCD-1-37.PMC3894070.pdf
Available from: http://www.google.com/search/wikepidia/ html [Last accessed on 2007 Sep 08].2.,OADS,/arxiv_data1/oa_pdf/40/66/JISPCD-1-71.PMC3894071.pdf
Start a QR-code reading  software (see list of free applications from http://tinyurl.com/yzlh2tc) and point the camera to the QR-code printed in the  journal.,Non-OADS,/arxiv_data1/oa_pdf/d2/c0/JISPCD-1-45.PMC3894073.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free applications.Announcement,Non-OADS,/arxiv_data1/oa_pdf/d2/c0/JISPCD-1-45.PMC3894073.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/c4/d6/JISPCD-1-9.PMC3894075.pdf
Available from: http://www.autism-india.org.,Non-OADS,/arxiv_data1/oa_pdf/93/a9/JISPCD-2-58.PMC3894080.pdf
Available from: http://www.cda-adc.ca/jcda/ vol-67/issue-10/587.html.,Non-OADS,/arxiv_data1/oa_pdf/64/43/JISPCD-2-69.PMC3894081.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/7a/76/JISPCD-2-53.PMC3894085.pdf
"Retrieved June 2, 2008, from http://www.cogme.",Non-OADS,/arxiv_data1/oa_pdf/66/64/JISPCD-2-8.PMC3894088.pdf
"Retrieved June 2, 2008, from  http://www.cogme.gov/18thReport/default.htm How to cite this article:  Girish Babu KL, Doddamani GM.",Non-OADS,/arxiv_data1/oa_pdf/66/64/JISPCD-2-8.PMC3894088.pdf
Available from: http://www.who.int/tobacco/mpower  [cited on 2009 Jun 2; ] 2.,Non-OADS,/arxiv_data1/oa_pdf/55/7b/JISPCD-2-13.PMC3894090.pdf
Available at: http://www.rrh.org.au [cited 2009 Jan 17].,Non-OADS,/arxiv_data1/oa_pdf/55/7b/JISPCD-2-13.PMC3894090.pdf
Available at http://www.expressindia.com/latest-news/Many- Indians-want-pictorial-warnings-on tobacco-products/420750/ [cited 2012 Feb 20] 7.,Non-OADS,/arxiv_data1/oa_pdf/55/7b/JISPCD-2-13.PMC3894090.pdf
Available from: http://www.cancer.org/Cancer/ CancerCauses/TobaccoCancer/ChildandTeenTobaccoUse/ child‑and‑teen‑tobacco‑use‑facts‑and‑stats [According to the  2002 data].,Non-OADS,/arxiv_data1/oa_pdf/be/b6/JISPCD-3-7.PMC3894095.pdf
Available from: http://hmpsd.com/FactSheet/CSouth/ Dakota/Teens/Tobacco [May‑2011].,Non-OADS,/arxiv_data1/oa_pdf/be/b6/JISPCD-3-7.PMC3894095.pdf
Available from: http://www.health.gov.on.ca/english/ providers/program/pubhealth/oph_standards/ophs/ progstds/workshops/foundational_7a_shes_tobacco_ feedback_report_manske_leatherdale.,Non-OADS,/arxiv_data1/oa_pdf/be/b6/JISPCD-3-7.PMC3894095.pdf
Start a QR-code reading  software (see list of free applications from http://tinyurl.com/yzlh2tc) and point the camera to the QR-code printed in the  journal.,Non-OADS,/arxiv_data1/oa_pdf/b0/ec/JISPCD-3-12.PMC3894096.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free applications.Announcement,Non-OADS,/arxiv_data1/oa_pdf/b0/ec/JISPCD-3-12.PMC3894096.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/b1/c9/JISPCD-3-19.PMC3894097.pdf
Start a QR-code reading  software (see list of free applications from http://tinyurl.com/yzlh2tc) and point the camera to the QR-code printed in the  journal.,Non-OADS,/arxiv_data1/oa_pdf/4f/17/JISPCD-3-1.PMC3894098.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free applications.Announcement,Non-OADS,/arxiv_data1/oa_pdf/4f/17/JISPCD-3-1.PMC3894098.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/7f/0f/ceor-6-021.PMC3894102.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinicoEconomics and Outcomes Research 2014:6 21–27ClinicoEconomics and Outcomes Research Dove press submit your manuscript | www.dovepress.co m Dove press  21ORiginal REsEaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/CEOR.S5589 9Estimation of utility values from visual analog   scale measures of health in patients   undergoing cardiac surgery lars Oddershede1,2 Jan Jesper andreasen1 lars Ehlers2 1Department of Cardiothoracic  surgery, Center for Cardiovascular  Research, aalborg University hospital,   aalborg, Denmark; 2Danish Center for  healthcare improvements, Faculty of  social sciences and Faculty of health  sciences, aalborg University, aalborg  East, Denmark Correspondence: lars Oddershede   Danish Center for healthcare  improvements, aalborg University,  Fibigerstræde 11, DK-9220 aalborg East,  Denmark   Tel +45 4060 9448   Email lars.oddershede@gmail.co mIntroduction:  In health economic evaluations, mapping can be used to estimate utility values  from other health outcomes in order to calculate quality adjusted life-years.",Non-OADS,/arxiv_data1/oa_pdf/7f/0f/ceor-6-021.PMC3894102.pdf
"London, UK: NICE; 2013; A vailable  from: http://www.nice.org.uk/media/D45/1E/GuideTo MethodsTechnol o- gyAppraisal2013.pdf .",Non-OADS,/arxiv_data1/oa_pdf/7f/0f/ceor-6-021.PMC3894102.pdf
"ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinicoeconomics-and-outcomes-research-journa lClinicoEconomics & Outcomes Research is an international, peer- reviewed open-access journal focusing on Health Technology Assess - ment, Pharmacoeconomics and Outcomes Research in the areas of  diagnosis, medical devices, and clinical, surgical and pharmacological  intervention.",Non-OADS,/arxiv_data1/oa_pdf/7f/0f/ceor-6-021.PMC3894102.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/7f/0f/ceor-6-021.PMC3894102.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/20/01/ppa-8-053.PMC3894135.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpPatient Preference and Adherence 2014:8 53–62Patient Preference and Adherence Dove press submit your manuscript | www.dovepress.co m Dove press  53OriginAl reseArchopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/PPA.S5674 0Patient perspectives on the impact   of acromegaly: results from individual   and group interviews Michelle h gurel1 Paul r Bruening2 christine rhodes2 Kathleen g lomax3 1neuroendocrine clinical center,   Massachusetts general hospital,   Boston, MA, UsA; 2nicholas research  Associates international, n ew Y ork,   nY, UsA; 3Medical Affairs, ipsen  Biopharmaceuticals, inc., Basking   ridge, nJ, UsA correspondence: Michelle h gurel   neuroendocrine clinical center,   Massachusetts general hospital, Zero  emerson Place, Boston, MA 02114, UsA   Tel +1 617 724 0145   Fax +1 617 726 1241   email mgurel@partners.or gPurpose:  Acromegaly is a chronic condition resulting from a growth hormone-secreting pitu - itary tumor that can substantially impact patients’ physical and emotional well-being.",Non-OADS,/arxiv_data1/oa_pdf/20/01/ppa-8-053.PMC3894135.pdf
"Patient Preference and Adherence Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/patient-preference-and-adherence-journa lPatient Preference and Adherence is an international, peer-reviewed,  open access journal focusing on the growing importance of patient  preference and adherence throughout the therapeutic continuum.",Non-OADS,/arxiv_data1/oa_pdf/20/01/ppa-8-053.PMC3894135.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/20/01/ppa-8-053.PMC3894135.pdf
"Available from:  http://www.acromegalycommunity.co m. Accessed December 24,  2013.18.",Non-OADS,/arxiv_data1/oa_pdf/20/01/ppa-8-053.PMC3894135.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/d9/ff/ijn-9-461.PMC3894136.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 461–465International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  461OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S5550 5short communication: selective cytotoxicity   of curcumin on osteosarcoma cells   compared to healthy osteoblasts run chang1 linlin sun1 Thomas J Webster1,2 1Department of chemical   engineering, Northeastern  University, Boston, M a, Usa;    2center of excellence for advanced   Materials research, King abdulaziz   University, Jeddah, saudi arabia correspondence: Thomas J Webster   Department of chemical engineering,   Northeastern University, 360 huntington   ave, Boston, Ma 02115, Usa   email th.webster@neu.ed uAbstract:  Curcumin is a natural phenolic compound extracted from the plant Curcuma  longa  L. In previous studies, curcumin has been shown to have anticancer, antioxidant, and anti- inflammatory effects.",Non-OADS,/arxiv_data1/oa_pdf/d9/ff/ijn-9-461.PMC3894136.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology  in diagnostics, therapeutics, and drug delivery systems throughout  the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/d9/ff/ijn-9-461.PMC3894136.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d9/ff/ijn-9-461.PMC3894136.pdf
"Available from:  http://www.cancernetwork.com/cancer-management/bone-sarcoma s.  Accessed November 20, 2013.",Non-OADS,/arxiv_data1/oa_pdf/d9/ff/ijn-9-461.PMC3894136.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/e2/fc/cia-9-141.PMC3894137.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 141–145Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  141OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/ 10.2147/CIA.S5686 3Visual outcome of intravitreal ranibizumab   for exudative age-related macular degeneration:  timing and prognosis handan Canan1 Selçuk Sızmaz2 Rana Altan-Yaycıog ˘lu1 Çag ˘la Sarıtürk3 Gürsel Yılmaz4 1Department of Ophthalmology,   Adana Teaching and Medical research  Center, Başkent University School  of Medicine, 2Department of  Ophthalmology, Çukurova University  school of Medicine, 3Department  of Biostatistics, Adana Teaching and  Medical Research Center, Başkent  University School of Medicine,   4Department of Ophthalmology,   Başkent University School of  Medicine, Ankara, T urkey Correspondence: handan Canan   Department of Ophthalmology,   Adana Teaching and Medical research  Center, Başkent University School of  Medicine, Dadaloglu mah,   Serinevler 2591 sok, 01250 Yüreg ˘ir,  Adana, Turkey   Tel +90 322 327 2727 ext 2104   Fax +90 322 327 1274   email handanakkaya@yahoo.co mPurpose:  To describe 1-year clinical results of intravitreal ranibizumab treatment in patients with  choroidal neovascularization secondary to exudative age-related macular degeneration (AMD)  and to evaluate whether early treatment is a predictive value for prognosis of the disease.",Non-OADS,/arxiv_data1/oa_pdf/e2/fc/cia-9-141.PMC3894137.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treat - ments intended to prevent or delay the onset of maladaptive correlates  of aging in human beings.",Non-OADS,/arxiv_data1/oa_pdf/e2/fc/cia-9-141.PMC3894137.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e2/fc/cia-9-141.PMC3894137.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/bd/4e/jpr-7-047.PMC3894138.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Pain Research 2014:7 47–55Journal of Pain Research Dove press submit your manuscript | www.dovepress.co m Dove press  47ORiginal ReseaRchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/JPR.S5574 9Pulsed radiofrequency treatment of the lumbar   dorsal root ganglion in patients with chronic   lumbar radicular pain: a randomized,   placebo-controlled pilot study harsha shanthanna1 Philip chan1 James Mcchesney1 lehana Thabane2 James Paul1 1Department of anesthesia,   2Department of clinical   epidemiology and Biostatistics,    st Joseph’s hospital, McMaster   University, hamilton, On , canada correspondence: harsha shanthanna   Department of anesthesia, st Joseph’s  hospital, McMaster University,   50 charlton avenue east, hamilton,   On, canada l8n 4a6   T el +1 905 522 1155 ext 33853   Fax +1 905 521 6019   email harshamd@gmail.co mBackground:  No proof of efficacy, in the form of a randomized controlled trial (RCT), exists  to support pulsed radiofrequency (PRF) treatment of the dorsal root ganglion (DRG) for chronic  lumbar radicular (CLR) pain.",Non-OADS,/arxiv_data1/oa_pdf/bd/4e/jpr-7-047.PMC3894138.pdf
"Journal of Pain Research Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/journal-of-pain-research-journa lThe Journal of Pain Research is an international, peer-reviewed, open  access, online journal that welcomes laboratory and clinical findings  in the fields of pain research and the prevention and management  of pain.",Non-OADS,/arxiv_data1/oa_pdf/bd/4e/jpr-7-047.PMC3894138.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/bd/4e/jpr-7-047.PMC3894138.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/74/c3/ndt-10-083.PMC3894139.pdf
"Information on how to request permission may be found at: http://www.dovepress.com/permissions.phpNeuropsychiatric Disease and Treatment 2014:10 83–84Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  83LeTTeropen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NDT .S5885 9Incorporating and integrating cognitive event- related potentials in the management of  psychiatric disorders Nicola Luigi Bragazzi1,2 Giovanni Del Puente2 1School of Public Health, Department  of Health Sciences (DISSAL),   University of Genoa, Genoa,   Italy; 2DINOGMI, Department  of Neuroscience, rehabilitation,   Ophtalmology, Genetics, Maternal and  Child Health, Section of Psychiatry,   University of Genoa, Genoa, Italy Correspondence: Nicola Luigi Bragazzi   School of Public Health, Department  of Health Sciences (DISSAL),   University of Genoa, Via Antonio  Pastore 1, Genoa, Italy   T el +39 010 353 7664   Fax +39 010 353 7669   email robertobragazzi@gmail.co mDear editor Dr Salvatore Campanella has recently advocated the urgent need to incorporate cogni - tive event-related potentials (ERPs) for a proper diagnosis, treatment, and prognosis of  psychiatric disorders, on the basis of four working hypotheses, which are theoretically  solid and experimentally supported.1 Psycho-pathological diseases are characterized by a cognitive impairment (first      argument ) and the task of ERP methodology is to investigate these very cognitive  alterations (second argument), in a more effective, fast, reliable and comprehensive  way than the traditional administration of neuropsychological tests and questionnaires,  which are rather time-consuming and difficult to implement in everyday clinical  practice.",Non-OADS,/arxiv_data1/oa_pdf/74/c3/ndt-10-083.PMC3894139.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing  on concise rapid reporting of clinical or pre-clinical studies on a  range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/74/c3/ndt-10-083.PMC3894139.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/74/c3/ndt-10-083.PMC3894139.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/7c/ff/opth-8-199.PMC3894140.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 199–214Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  199Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OPTH.S5483 8electrophysiological examination   in uveitis: a review of the literature Marilita M Moschos1 Nikolaos S Gouliopoulos1 Christos Kalogeropoulos2 1Laboratory of electrophysiology,   First Department of Ophthalmology,   University of Athens, Athens, Greece;   2Department of Ophthalmology,   University of ioannina, ioannina,   Greece Correspondence: Marilita M Moschos   Laboratory of electrophysiology,  First Department of Ophthalmology,  University of Athens, 6 ikarias,   ekali, Athens 14578, Greece   Tel +30 694 488 7319   Fax +30 210 776 8321   email moschosmarilita@yahoo.f rPurpose:  Uveitis is the inflammation of the uveal tract, which usually also affects the retina and  vitreous humor.",Non-OADS,/arxiv_data1/oa_pdf/7c/ff/opth-8-199.PMC3894140.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/7c/ff/opth-8-199.PMC3894140.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/7c/ff/opth-8-199.PMC3894140.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c4/00/cia-9-131.PMC3894141.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 131–140Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  131OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S5668 2The effectiveness of a combined exercise  intervention on physical fitness factors related to  falls in community-dwelling older adults Jie Zhuang1,* liang huang1,2,* Yanqiang Wu3 Yanxin Zhang2 1school of Kinesiology, shanghai  University of sport, shanghai, People’s  republic of China; 2Department  of sport and exercise science, The  University of Auckland, Auckland, new  Zealand; 3shanghai Municipal Center  for students’ Physical Fitness and  health surveillance, shanghai, People’s  republic of China *These authors contributed equally to  this work Correspondence: Jie Zhuang   school of Kinesiology, shanghai University  of sport, rm416, sports science Building,   200 hen ren road, shanghai People’s  repubulic of China   T el +86 21 5125 3316   Fax +86 21 5125 3316   email zhuangjiesh@163.co mAbstract:  This study aimed to evaluate the effectiveness of an innovative exercise program  on muscle strength, balance, and gait kinematics in elderly community-dwellers.",Non-OADS,/arxiv_data1/oa_pdf/c4/00/cia-9-131.PMC3894141.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treat - ments intended to prevent or delay the onset of maladaptive correlates  of aging in human beings.",Non-OADS,/arxiv_data1/oa_pdf/c4/00/cia-9-131.PMC3894141.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c4/00/cia-9-131.PMC3894141.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/fa/8a/idr-7-015.PMC3894142.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInfection and Drug Resistance 2014:7 15–24Infection and Drug Resistance Dove press submit your manuscript | www.dovepress.co m Dove press  15RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/IDR.S3963 7Update on otitis media – prevention   and treatment Ali Qureishi1 Yan Lee2 Katherine Belfield3 John P Birchall4 Matija Daniel2 1Otolaryngology Head and Neck  Surgery, Northampton General  Hospital, Northampton, UK; 2NIHR  Nottingham Hearing Biomedical  Research Unit, Nottingham, UK;   3Biomaterials Related Infection   Group, 4Otorhinolaryngology Head  and Neck Surgery, The University   of Nottingham, Nottingham, UK Correspondence: Ali Qureishi   C/o Matija Daniel   Otolaryngology, Nottingham   University Hospitals, Derby Rd,   Nottingham, NG7 2UH, UK   Tel +44 115 924 9924 x61224   email aliqureishi@doctors.org.u kAbstract:  Acute otitis media and otitis media with effusion are common childhood disorders,  a source of significant morbidity, and a leading cause of antibiotic prescription in primary health  care.",Non-OADS,/arxiv_data1/oa_pdf/fa/8a/idr-7-015.PMC3894142.pdf
"Available from: http://www.who.int/pbd/deafness/activities/  hearing_care/otitis_media.pd f. Accessed November 25, 2013.",Non-OADS,/arxiv_data1/oa_pdf/fa/8a/idr-7-015.PMC3894142.pdf
"Available from:  http://www.sign.ac.uk/pdf/qrg66.pd f. Accessed October 30, 2013.",Non-OADS,/arxiv_data1/oa_pdf/fa/8a/idr-7-015.PMC3894142.pdf
Available from:  http://guidance.nice.org.uk/CG6 0.,Non-OADS,/arxiv_data1/oa_pdf/fa/8a/idr-7-015.PMC3894142.pdf
"Infection and Drug Resistance Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/infection-and-drug-resistance-journa lInfection and Drug Resistance is an international, peer-reviewed open- access journal that focuses on the optimal treatment of infection (bacte - rial, fungal and viral) and the development and institution of preventive  strategies to minimize the development and spread of resistance.",Non-OADS,/arxiv_data1/oa_pdf/fa/8a/idr-7-015.PMC3894142.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/fa/8a/idr-7-015.PMC3894142.pdf
"Available  from: http://www.ecdc.europa.eu/en/publications/Publications/1011_ SUR_annual_EARS_Net_2009.pd f. Accessed November 25, 2013.",Non-OADS,/arxiv_data1/oa_pdf/fa/8a/idr-7-015.PMC3894142.pdf
"Available  from: http://www.ecdc.europa.eu/en/publications/ publications/antimi - crobial-resistance-surveillance-europe-2011.pd f. Accessed November  25, 2013.",Non-OADS,/arxiv_data1/oa_pdf/fa/8a/idr-7-015.PMC3894142.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ad/b4/cia-9-147.PMC3894143.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 147–156Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  147OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S5381 4selection of acupoints for managing upper- extremity spasticity in chronic stroke patients Bi-huei Wang1,* Chien-lin lin1,2,* T e-Mao li2,3 shih-Din lin3 Jaung-geng lin2 li-Wei Chou1,2,4 1Department of Physical Medicine  and rehabilitation, China Medical  University hospital; 2school of  Chinese Medicine, College of Chinese  Medicine; 3graduate Institute of  Acupuncture science, 4Acupuncture  research Center, China Medical  University, Taichung, Taiwan *These authors contributed equally   to this work Correspondence: li-Wei Chou   Department of Physical Medicine and  rehabilitation, China Medical University  hospital, 2 Yuh-Der road, Taichung,  Taiwan 40447   Tel +886 4 2205 2121 ext 2381   Fax +886 4 2202 6041   email chouliwe@tcts.seed.net.t wBackground:  This study investigated the clinical efficacy of electroacupuncture (EA) in  inhibiting upper-extremity spasticity in chronic stroke patients, and also in mapping a unique  preliminary acupoint-selection protocol.",Non-OADS,/arxiv_data1/oa_pdf/ad/b4/cia-9-147.PMC3894143.pdf
1997;21(6):1088–1097  Available from: http://www.koreamed.org/SearchBasic.php?RID =0 041JKARM/1997.21.6.1088&DT =1.,OADS,/arxiv_data1/oa_pdf/ad/b4/cia-9-147.PMC3894143.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treat - ments intended to prevent or delay the onset of maladaptive correlates  of aging in human beings.",Non-OADS,/arxiv_data1/oa_pdf/ad/b4/cia-9-147.PMC3894143.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/ad/b4/cia-9-147.PMC3894143.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/c1/32/tcrm-10-045.PMC3894144.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpTherapeutics and Clinical Risk Management 2014:10 45–49Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  45Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/TCRM.S3887 2Frequency of tuberculosis among diabetic   patients in the People’s Republic of China Hong-Tian wang1 Jing Zhang1 Ling-Chao Ji1 Shao-Hua Y ou1 Yin Bai1 wei Dai2 Zhong-Yuan wang3 1Department of Otorhinolaryngology,   Head, and Neck Surgery, Chinese  PLA General Hospital, 2Department  of Medical Record Administration,   Chinese PLA General Hospital,    3The 3rd TB Department, Chinese  PLA 309 Hospital, Beijing, People’s  Republic of China Correspondence: Hong-Tian wang   Department of Otorhinolaryngology   Head Neck Surgery, Chinese PLA   General Hospital, No 28, Fuxing Road,   Beijing 100853, People’s Republic of China   Tel +86 13 911681469   Fax +86 10 68156974   email wht301@263.ne t    Zhong-Yuan wang   Department of Medical Record   Administration, Chinese PLA General   Hospital, Beijing 100853,   People’s Republic of China   Tel +86 13 146508463   email wzy2004177@sina.co mAbstract:  The People’ s Republic of China has nearly the highest incidence of both diabetes mel - litus (DM) and tuberculosis (TB) worldwide.",Non-OADS,/arxiv_data1/oa_pdf/c1/32/tcrm-10-045.PMC3894144.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/c1/32/tcrm-10-045.PMC3894144.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/c1/32/tcrm-10-045.PMC3894144.pdf
"Available from: http://www.stoptb.org/assets/documents/global/plan/TB_   GlobalPlanToStopTB2011-2015.pd f. Accessed November 5, 2013.",Non-OADS,/arxiv_data1/oa_pdf/c1/32/tcrm-10-045.PMC3894144.pdf
"Available from: http://www.who.int/entity/tb/publications/ global_report/2011/gtbr11_full.pd f. Accessed November 5, 2013.",OADS,/arxiv_data1/oa_pdf/c1/32/tcrm-10-045.PMC3894144.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/22/a1/opth-8-215.PMC3894145.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 215–217Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  215Case seriesopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S5576 3anterior segment optical coherence tomography  for demonstrating posterior capsular rent   in posterior polar cataract George D Kymionis1,2 Vasilios F Diakonis1 Dimitrios a Liakopoulos1 Konstantinos i Tsoulnaras1 Nektarios e Klados1 ioannis G Pallikaris1 1institute of Vision and Optics,   Department of Medicine, University  of Crete, Heraklion, Crete, Greece;   2Bascom Palmer eye institute,   University of Miami, Miller school of  Medicine, Miami, Florida, Usa Correspondence: Vasilios F Diakonis   institute of Vision and Optics,  Department of Medicine, University of  Crete, 71110 Heraklion, Crete, Greece   Tel +30 2810 327316   Fax +30 2810 394653   email diakonis@gmail.co mAims/purpose:  To report the preoperative use of anterior segment optical coherence tomography  (AS-OCT) for the determination of pre-existing posterior capsule defect in patients with pos - terior polar cataract.",Non-OADS,/arxiv_data1/oa_pdf/22/a1/opth-8-215.PMC3894145.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/22/a1/opth-8-215.PMC3894145.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/22/a1/opth-8-215.PMC3894145.pdf
"In addition, they have the potential to develop into all three embryonic germ ©2013 The Authors *Correspondence: llaurent@ucsd.edu http://dx.doi.org/10.1016/j.celrep.2013.08.009 .5These authors contributed equally to this work6Present address: Sanford-Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA Accession Numbers : The GEO accession number for the SNP genotyping data reported in this paper is GSE49452.",Non-OADS,/arxiv_data1/oa_pdf/d7/b5/nihms522562.PMC3894204.pdf
"Supplemental Information: Supplemental Information includes Extended Experimental Procedures, five figures, and seven tables and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2013.08.009 .",OADS,/arxiv_data1/oa_pdf/d7/b5/nihms522562.PMC3894204.pdf
JAK-STAT 2013; 2:e24931; http://dx.doi.org/10.4161/jkst.24931Osteoblast differentiation is a critical step in the maintenance  of bone homeostasis.,Non-OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
PLoS One 2012; 7:e47477;  PMID:23071812; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
Adv Dent Res 1999; 13:93-8; PMID:11276754; http://dx.doi.org/10.1177/ 08959374990130012201 5.,Non-OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
J Bone Miner  Res 2001; 16:1583-5; PMID:11547827; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
J Biol Chem 1995; 270:25028-36; PMID:7559633;  http://dx.doi.org/10.1074/jbc.270.42.25028 10.,OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
J Exp Med 1995; 181:1425- 31; PMID:7535338; http://dx.doi.org/10.1084/ jem.181.4.1425 14.,Non-OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
J Biol Chem 1996; 271:13976-80; PMID:8662778;  http://dx.doi.org/10.1074/jbc.271.24.13976 15.,OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
J Biol Chem  1997; 272:1032-7; PMID:8995399; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
J Exp Med 1995; 182:1801- 6; PMID:7500025; http://dx.doi.org/10.1084/jem.182.6.1801 17.,Non-OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
Science 1993; 261:1744- 6; PMID:7690989; http://dx.doi.org/10.1126/sci- ence.7690989 20.,OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
Nat Rev Mol Cell Biol  2002; 3:651-62; PMID:12209125; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
Ann N Y Acad Sci 2006; 1091:151- 69; PMID:17341611; http://dx.doi.org/10.1196/annals.1378.063,OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
Stem Cells 2013;  In press; PMID:23533197; http://dx.doi.org/10.1002/ stem.1380 36.,Non-OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
J Cell Biochem 2009; 106:482-90; PMID:19115250;  http://dx.doi.org/10.1002/jcb.22035 38.,Non-OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
Mol Cell Biochem 2007; 296:129-36;  PMID:16955224; http://dx.doi.org/10.1007/s11010-006-9306-428.,Non-OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
Curr Pharm Des 2007;  13:663-9; PMID:17346182; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
Mol Endocrinol 2010; 24:644-56; PMID:20133448;  http://dx.doi.org/10.1210/me.2009-0357 32.,Non-OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
Bone 2009; 45:27-41; PMID:19306956;  http://dx.doi.org/10.1016/j.bone.2009.03.656 33.,OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
J  Cell Biochem 2011; 112:3491-501; PMID:21793042;  http://dx.doi.org/10.1002/jcb.23287 34.,Non-OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
Oncogene 2004; 23:4232-7; PMID:15156178; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
Oncogene 2000; 19:2466-7; PMID:10851044; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
Genes Dev 2008; 22:711- 21; PMID:18347089; http://dx.doi.org/10.1101/ gad.1643908 24.,OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
J Bone Miner Res  2004; 19:1892-904; PMID:15476590; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
J Biol Chem 2002;  277:34879-84; PMID:12107179; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
Rejuvenation Res 2007;  10:397-405; PMID:17822355; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/17/96/jkst-2-e24931.PMC3894232.pdf
"OncoImmunology 2013; 2:e26889; http://dx.doi.org/10.4161/onci.26889Murine leukemia virus envelope gp70   is a shared biomarker for the high-sensitivity  quantification of murine tumor burden Francesca Scrimieri1, David a skew1, David J Corn2, Saada e id1, Iuliana D Bobanga3, Jaclyn a Bjelac1, Matthew L Tsao1,   Frederick a llen1, youmna S Othman4, Shih-Chung G Wang5, and a lex y Huang1,* 1Department of Pediatrics; Case Western r eserve University School of Medicine; Cleveland, OH US a; 2Department of Biomedical e ngineering; Case Western r eserve University  School of Medicine; Cleveland, OH US a; 3Department of Surgery; Case Western r eserve University School of Medicine; Cleveland, OH US a; 4Pediatric Hematology   and Oncology; Stormont Vail Hospital; Cotton-O’Neil Cancer Center; Topeka, KS US a; 5Department of Pediatrics; Changhua Christian Hospital; Changhua, Taiwan Keywords:  AH1, gp70, minimal residual disease, MuLV, retrovirus, tumor-associated antigen Abbreviations: ALL, acute lymphoblastic leukemia; BLI, bioluminescent imaging; gp70, glycoprotein 70;   HCV, hepatitis C virus; HERV, human endogenous retrovirus; HPV, human papillomavirus; ICN1, intracellular portion of Notch1;  IHC, immunohistochemistry; MuLV, murine leukemia virus; ROI, region of interest The preclinical development of anticancer drugs including immunotherapeutics and targeted agents relies on the  ability to detect minimal residual tumor burden as a measure of therapeutic efficacy.",Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
"Designed primers were aligned against the corresponding genome sequence using BLAT (http://genome.ucsc.edu/cgi-bin/hgBlat, assembly Dec.2011 (GRCm38/mm10) to confirm specificity.",OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Supplemental Material Supplemental materials may be found here: http://www.landesbioscience.com/journals/oncoimmunology/ article/26889/ References 1.,Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Annu Rev Genet 1983;  17:85-121 ; PMID:6320713 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Virology  1981; 112:548-63 ; PMID:6266139 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Virology 1977; 81:363-70 ; PMID:197696 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Nucleic Acids Res 1991; 19:7215-8 ; PMID:1662812 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Clin Exp Metastasis  2000; 18:261-71 ; PMID :11315100 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Br J Cancer 1950; 4:372- 9; PMID:14801344 ; http://dx.doi.org/10.1038/ bjc.1950.36 15.,Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
J Exp Med 2008; 205:2851-61 ;  PMID:18981238 ; http://dx.doi.org/10.1084/ jem.20081561 16.,Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Cancer Invest 2012; 30:343-63 ;  PMID:22571338 ; http://dx.doi.org/10.3109/073579 07.2012.664670 17.,Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Pediatr  Blood Cancer 2011; 57:921-9 ; PMID:21462302 ;  http://dx.doi.org/10.1002/pbc.23048 19.,Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
J Cell Biol  1963; 17:299-313 ; PMID:13985244 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Virus Genes  2003 ; 26 :291-315;  PMID:12876457 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Oncogene 2003; 22:1528-35; PMID:12629516 ;  http://dx.doi.org/10.1038/sj.onc.1206241 24.,Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Carcinogenesis 2013; 34:2531-8;  PMID:23872666 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Int J Cancer 2007; 120:81- 90; PMID:17013901 ; http://dx.doi.org/10.1002/ ijc.22256 27.,Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Cancer Res 2005; 65:4172-80; PMID :15899808 ;  http://dx.doi.org/10.1158/0008-5472.CAN-04-2983 28.,Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Exp Cell Res  2009; 315:849-62 ;  PMID:19167380 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Nat Protoc 2006; 1:2831-8;  PMID:17406542 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Cancer Res 2008; 68:5869-77;  PMID:18632641 ; http://dx.doi.org/10.1158/0008- 5472.CAN-07-6838 32.,Non-OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
Methods  2001; 25:402-8;  PMID:11846609 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/1b/be/onci-2-e26889.PMC3894233.pdf
"OncoImmunology 2013; 2:e27089; http://dx.doi.org/10.4161/onci.27089How to exploit stress-related immunity   against Hodgkin’s lymphoma Targeting ERp5 and ADAM sheddases alessandro Poggi1 and Maria r affaella Zocchi2,* 1Unit of Molecular Oncology and a ngiogenesis; I rCCS- aOU San Martino-IST; Genoa, Italy;   2Division of Immunology, Transplants and Infectious Diseases; I rCCS San r affaele; Milan, Italy Keywords:  ADAM, ERp5, MICA, MICB, MSC, NKG2D, regulatory T cells, review, sheddases, ULBP Abbreviations: ADAM, a disintegrin and metalloproteinase; ATRA, all- trans  retinoic acid; ERp5, endoplasmic reticulum  protein 5; HDAC, histone deacetylase; IFN, interferon; IL, interleukin; LN, lymph node; LNMSC, LN mesenchymal stromal  cell; mAb, monoclonal antibody; MIC, MHC Class I polypeptide-related sequence; MMP, matrix metalloproteinase; MSC,  mesenchymal stromal cell; N-BPs, aminobisphosphonates; P-Ag, phosphoantigen; PDI, protein disulfide isomerase; RIP, regulated  intramembrane proteolysis; RS, Reed-Stemberg; TGF β1, transforming growth factor β 1; TNF α, tumor necrosis factor α ; ULBP,  UL16-binding protein; VPA, valproic acid Stress-related immunity can be activated in the course  of lymphoproliferative disorders, including Hodgkin’s  lymphoma, upon the interaction between killer cell lectin- like receptor subfamily K, member 1 (KLr K1, best known  as NKG2D) on effector lymphocytes and NKG2D ligands  (NKG2DL), such as MHC class I polypeptide-related sequence a (MIC a), MICB and various UL16-binding proteins (ULBPs),  on lymphoma cells.",Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
J Clin Oncol 2011; 29:1812-26; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Br J Haematol  2009 ; 145:468-80; http://dx.doi.org/10.1111/j.1365- 2141.2009.07651.x ; PMID:19344401 4.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Blood  2007 ; 109:2078 - 85; PMID:16973957 ; http://dx.doi.org/10.1182/ blood-2006-06-028985 6.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Blood  2012 ; 119:1479 -89;  http://dx.doi.org/10.1182/blood-2011-07-370841 ;  PMID:22167753 7.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Immunity   2009 ; 31:184-96; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Nat  Rev Immunol  2010 ; 10:467-78; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Nat Rev Immunol 2008 ; 8:279-89;  http://dx.doi.org/10.1038/nri2215 ; PMID:18340345 10.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Trends Immunol   2008 ; 29:397-403; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Trends Immunol  2002 ; 23:14-8; PMID:11801449 ;  http://dx.doi.org/10.1016/S1471-4906(01)02110-X 14.,OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Blood  2003 ;  102:1389 -96; PMID:12714493 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Leukemia  2009 ;  23:641-8; http://dx.doi.org/10.1038/leu.2008.354 ;  PMID :19151770 17.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Nature  2002 ; 419:734-8;  PMID:12384702 ; http://dx.doi.org/10.1038/ nature01112 18.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Blood  2003 ; 102:200- 6; PMID:12623838 ; http://dx.doi.org/10.1182/ blood-2002-12-3665 20.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
J Exp Med 2004 ; 199:879- 84; PMID :15007091 ; http://dx.doi.org/10.1084/ jem.20031981 21.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Cancer  Res 2007 ; 67:5-8; PMID:17210676 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Science  1994 ; 264:267-70; PMID:8146660 ;  http://dx.doi.org/10.1126/science.8146660,OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
J Exp Med 2003 ; 197:163-8;  PMID:12538656 ; http://dx.doi.org/10.1084/ jem.20021500 24.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Immunol Rev  2007 ;  215:59-76; PMID:17291279 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
N Engl J Med  1999 ; 340:737-8; PMID:10068336 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Biochemistry   2004 ; 43:7227 -35; PMID :15182168 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Nat Rev Mol Cell Biol  2005 ; 6:32-43; PMID :15688065 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
J Cell Mol Med 2005 ; 9:255-66; PMID:15963248 ;  http://dx.doi.org/10.1111/j.1582-4934.2005.tb00354.x 29.,OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Cancer Sci 2004 ;  95:930-5; PMID:15596040 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Biochim Biophys Acta  2004 ; 1699 :35- 44; http://dx.doi.org/10.1016/j.bbapap.2004.02.017 ;  PMID :15158710 31.,OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
FEBS J 2007 ;  274:5223 -34; http://dx.doi.org/10.1111/j.1742- 4658.2007.06058.x ; PMID:17892489 33.,OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Antioxid Redox Signal 2009 ; 11:2807 - 50; http://dx.doi.org/10.1089/ars.2009.2466 ;  PMID:19476414 34.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Biochim Biophys Acta   2008 ; 1780 :905-13; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Oncogene   2012 ; 31:3621 -34; http://dx.doi.org/10.1038/ onc.2011.522 ; PMID:22105359 36.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Nature  2007 ; 447:482- 6; PMID:17495932 ; http://dx.doi.org/10.1038/ nature0576837.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Cancer Immunol Immunother  2012 ; 61:1201 -10;  http://dx.doi.org/10.1007/s00262-011-1195-z ;  PMID:22215138 38.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Proc Natl  Acad Sci U S A 2008 ; 105:1285 -90; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Blood   2009 ; 113:1681 -8; http://dx.doi.org/10.1182/blood- 2007-09-114157 ; PMID:19008459 40.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Leukemia  2010 ; 24:1152 -9; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Cancer Res 2008 ;  68:6368 -76; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
J Biol Chem 2010 ; 285:8543 - 51; http://dx.doi.org/10.1074/jbc.M109.045906 ;  PMID:20080967 43.,OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Cancer Res 2009 ;  69:8050 -7; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Biochem Biophys  Res Commun  2009 ; 387:476-81; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
J Med Chem 2009 ;  52:6347 -61; http://dx.doi.org/10.1021/jm900335a ;  PMID:19775099 49.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
J Med  Chem  2010 ; 53:2622 -35; http://dx.doi.org/10.1021/ jm901868z ; PMID:20180536 50.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Blood  2002 ; 99:4283 - 97; PMID:12036854 ; http://dx.doi.org/10.1182/ blood-2002-01-0099 52.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Int J Cancer  2011 ; 129:387-96; http://dx.doi.org/10.1002/ ijc.25682 ; PMID:20853320 53.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Cancer Res 2005 ; 65:6321 -9;  PMID:16024634 ; http://dx.doi.org/10.1158/0008- 5472.CAN-04-4252 55.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Blood  2008 ;  111:1428 -36; PMID:17993609 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
J Immunol  2009 ; 182:6600 - 9; http://dx.doi.org/10.4049/jimmunol.0801214 ;  PMID :19414815 57.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
PLoS One   2012 ; 7:e40597 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Cancer Res 2004 ;  64:7596 -603; PMID:15492287 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Blood  2003 ; 102:2310 - 1; PMID:12959943 ; http://dx.doi.org/10.1182/ blood-2003-05-165561.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
J Immunol  2010 ; 184:6680 - 7; http://dx.doi.org/10.4049/jimmunol.1000681 ;  PMID:2048374263.,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
Immunotherapy   2009 ; 1:663-78; http://dx.doi.org/10.2217/ imt.09.27 ; PMID:20635991,Non-OADS,/arxiv_data1/oa_pdf/eb/1e/onci-2-e27089.PMC3894235.pdf
"JAK-STAT 2013; 2:e24935; http://dx.doi.org/10.4161/jkst.24935reprogramming somatic cells to pluripotency, especially  by the induced pluripotent stem cell (iPSC) technology, has  become widely used today to generate various types of stem  cells for research and for regenerative medicine.",Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nature 2009; 460:118-22; PMID:19571885; http://dx.doi.org/10.1038/ nature08113 34.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
T rends Cell  Biol 2002; 12:432-8; PMID:12220864; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
J Biol Chem  2000; 275:12848-56; PMID:10777583; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell Signal  2009; 21:394-404; PMID:19056487; http://dx.doi.org/10.1016/j.cellsig.2008.11.002 38.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Immunity  2012; 36:239-50; PMID:22342841; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Oncogene 2006; 25:2697- 707; PMID:16407845; http://dx.doi.org/10.1038/ sj.onc.1209307 41.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Development 2007; 134:2889-94; PMID:17660197;  http://dx.doi.org/10.1242/dev.02858 42.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Development 2007; 134:2895-902; PMID:17660198; http://dx.doi.org/10.1242/ dev.02880 43.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nature 1988; 336:688-90; PMID:3143917;  http://dx.doi.org/10.1038/336688a0 17.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nature 1988; 336:684-7;  PMID:3143916; http://dx.doi.org/10.1038/336684a0 18.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Science 1992; 255:1434- 7; PMID:1542794; http://dx.doi.org/10.1126/sci-ence.1542794 20.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Annu Rev Immunol 1997; 15:797-819; PMID:9143707; http://dx.doi.org/10.1146/ annurev.immunol.15.1.797 22.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
J Biol Chem 1996; 271:30136- 43; PMID:8939963; http://dx.doi.org/10.1074/ jbc.271.47.30136 25.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell  1998; 93:397-409; PMID:9590174; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell 1996; 84:443-50; PMID:8608598; http://dx.doi.org/10.1016/S0092-8674(00)81289-1 27.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
EMBO J 1999; 18:4261-9; PMID:10428964;  http://dx.doi.org/10.1093/emboj/18.15.4261 28.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
J Biol Chem 1997; 272:4855- 63; PMID:9030543; http://dx.doi.org/10.1074/ jbc.272.8.4855 30.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nature  1981; 292:154-6; PMID:7242681; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Genes Dev 1998; 12:2048- 60; PMID:9649508; http://dx.doi.org/10.1101/ gad.12.13.2048 3.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell 2006; 126:663- 76; PMID:16904174; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nat Biotechnol 2008; 26:101-6;  PMID:18059259; http://dx.doi.org/10.1038/nbt1374 5.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nat Biotechnol 2008; 26:1276-84;  PMID:18931654; http://dx.doi.org/10.1038/nbt.1503 8.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell 2008; 134:877-86;  PMID:18691744; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell Stem  Cell 2010; 7:319-28; PMID:20804969; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nat Commun 2012; 3:817; PMID:22569365;  http://dx.doi.org/10.1038/ncomms1822 11.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Stem Cells 2012; 30:2645- 56; PMID:22968989; http://dx.doi.org/10.1002/ stem.1225 12.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Biochem J 2011; 438:11- 23; PMID:21793804; http://dx.doi.org/10.1042/BJ20102152 13.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Biochem J 2003; 374:1-20; PMID:12773095; http://dx.doi.org/10.1042/BJ20030407 14.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nature 1988; 336:690-2;  PMID:3143918; http://dx.doi.org/10.1038/336690a0 15.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Stem Cells  2010; 28:2141-50; PMID:20945330; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nat Genet 2002; 32:594- 605; PMID:12426568; http://dx.doi.org/10.1038/ ng1045 76.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nat Med 2004; 10:55-63; PMID:14702635; http://dx.doi.org/10.1038/nm979 77.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Biochem Biophys Res Commun 2007; 353:699-705; PMID:17196549; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Biochem Biophys Res Commun 2006; 343:159- 66; PMID:16530170; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Dev Biol 2006; 290:81-91; PMID:16330017;  http://dx.doi.org/10.1016/j.ydbio.2005.11.011 80.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Stem Cells 2010; 28:1794-804; PMID:20734354;  http://dx.doi.org/10.1002/stem.502 81.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Development 2010;  137:3185-92; PMID:20823062; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nature 2008; 453:519- 23; PMID:18497825; http://dx.doi.org/10.1038/nature06968 83.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nat Cell Biol  2011; 13:753-61; PMID:21685890; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nat Cell Biol 2011; 13:838-45;  PMID:21685889; http://dx.doi.org/10.1038/ncb2267 85.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell Stem Cell 2011; 8:214- 27; PMID:21295277; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell Stem Cell 2012; 11:491-504; PMID:23040478; http://dx.doi.org/10.1016/j.stem.2012.06.008 87.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
J Biol Chem 2008; 283:9713-23; PMID:18201968;  http://dx.doi.org/10.1074/jbc.M70727520060.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Development 2005; 132:885-96; PMID:15673569;  http://dx.doi.org/10.1242/dev.01670 62.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Genes Dev 1993;  7:671-82; PMID:8458579; http://dx.doi.org/10.1101/ gad.7.4.671 63.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Differentiation 2010; 80:9-19; PMID:20537458;  http://dx.doi.org/10.1016/j.diff.2010.05.001 65.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell 2003; 113:631-42;  PMID:12787504; http://dx.doi.org/10.1016/S0092- 8674(03)00393-3 66.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Stem Cells Dev 2008; 17:269-78;  PMID:18447642; http://dx.doi.org/10.1089/ scd.2007.0098 68.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
J Cell Sci  2009; 122:2311-21; PMID:19509054; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
J Biol Chem 2007; 282:6265-73; PMID:17204467; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Arch Pharm Res 2010; 33:1117-25;  PMID:20661723; http://dx.doi.org/10.1007/s12272- 010-0719-y 71.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Stem Cells 2009; 27:764- 75; PMID:19350676; http://dx.doi.org/10.1002/ stem.3 72.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nature  2010; 464:858-63; PMID:20336070; http://dx.doi.org/10.1038/nature08882 73.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Mol Cell Biol 2009; 29:2092-104; PMID:19223464; http://dx.doi.org/10.1128/ MCB.01405-0845.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Reproduction  2006; 132:511-8; PMID:16940292; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Genome Biol 2009; 10:R42;  PMID:19393038; http://dx.doi.org/10.1186/gb-2009- 10-4-r42 48.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell  2008; 133:1106-17; PMID:18555785; http://dx.doi.org/10.1016/j.cell.2008.04.043 49.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
PLoS One 2008; 3:e3932; PMID:19079543; http://dx.doi.org/10.1371/journal.pone.0003932 50.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Proc Natl Acad Sci U S  A 1996; 93:3963-6; PMID:8632998; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
J Cell Biol  1997; 138:1207-17; PMID:9298977; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell 2003; 115:281-92;  PMID:14636556; http://dx.doi.org/10.1016/S0092- 8674(03)00847-X 56.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
J Biol Chem 2008; 283:3791- 8; PMID:18065416; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Stem Cells 2005; 23:1634-42; PMID:16099994;  http://dx.doi.org/10.1634/stemcells.2005-0182 58.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell 2003; 113:643-55; PMID:12787505; http://dx.doi.org/10.1016/S0092-8674(03)00392-1,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Stem Cells 2010; 28:713-20; PMID:20201064;  http://dx.doi.org/10.1002/stem.402 111.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nature  2009; 462:595-601; PMID:19898493; http://dx.doi.org/10.1038/nature08592 113.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell 2010; 143:508-25; PMID:21074044; http://dx.doi.org/10.1016/j.cell.2010.10.008 114.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Proc Natl Acad Sci U S A  2010; 107:9222-7; PMID:20442331; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell Stem Cell 2010; 6:535- 46; PMID:20569691; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell Stem Cell 2009; 4:487-92; PMID:19497275;  http://dx.doi.org/10.1016/j.stem.2009.05.015 101.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Development  2009; 136:1063-9; PMID:19224983; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell 2009; 138:722- 37; PMID:19703398; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell Stem Cell  2009; 4:513-24; PMID:19427283; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell  1999; 98:295-303; PMID:10458605; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Cell Stem Cell 2009; 5:491-503; PMID:19818703;  http://dx.doi.org/10.1016/j.stem.2009.09.012 107.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nature  2008; 454:49-55; PMID:18509334; http://dx.doi.org/10.1038/nature07056 108.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nat Biotechnol 2008; 26:795-7;  PMID:18568017; http://dx.doi.org/10.1038/nbt141888.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Proc Natl Acad Sci U S  A 2009; 106:5181-6; PMID:19279220; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nat Cell Biol 2011; 13:903-13;  PMID:21785422; http://dx.doi.org/10.1038/ncb2285 90.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Oncogene  2004; 23:7391-8; PMID:15286705; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Science  1998; 282:1145-7; PMID:9804556; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Dev Biol  2006; 295:743-55; PMID:16678814; http://dx.doi.org/10.1016/j.ydbio.2006.03.047 95.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Development 2005; 132:1273-82;  PMID:15703277; http://dx.doi.org/10.1242/ dev.01706 96.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Dev Biol  2004; 275:403-21; PMID:15501227; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nature 2007; 448:191-5; PMID:17597762;  http://dx.doi.org/10.1038/nature05950 98.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
Nature 2007; 448:196-9; PMID:17597760;  http://dx.doi.org/10.1038/nature05972,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/jkst-2-e24935.PMC3894236.pdf
"Mobile Genetic Elements 2013; 3:e27525; http://dx.doi.org/10.4161/mge.27525 *Correspondence to: Martin D Ryan;   Email: martin.ryan@st-andrews.ac.uk Commentary to: Odon V, Luke GA, Roulston C, de Felipe P , Ruan L, Escuin-Ordinas H, Brown JD, Ryan MD, Sukhodub A. APE-type non-LTR retrotransposons of multicellular organisms encode virus-like 2A oligopeptide sequences, which mediate translational recoding during protein synthesis.",Non-OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Mol Biol Evol 2013; 30:1955–65; PMID:23728794 ; http://dx.doi.org/10.1093/ molbev/mst102,Non-OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Cell  Mol Life Sci 2006; 63:1449-60; PMID:16767356 ;  http://dx.doi.org/10.1007/s00018-006-6038-2 2.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Mol Biol Evol 2013; 30:1955-65; PMID:23728794 ; http://dx.doi.org/10.1093/ molbev/mst102 3.,Non-OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
RNA  2007; 13:803-10;  PMID:17456564 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Mol Cell Biol  2008; 28:4227-39;  PMID:18458056 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Plant J 1999;  17:453-9;  PMID:10205902 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Trends Biotechnol  2006; 24:68-75;  PMID:16380176 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Future Virology  2013; 8:983-981; http://dx.doi.org/10.2217/ fvl.13.82 9. http://www.st-andrews.ac.uk/ryanlab/page10.htm10.,Non-OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
J Gen Virol 2008; 89:1036- 42; PMID:18343847 ; http://dx.doi.org/10.1099/ vir.0.83428-0 11.,Non-OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Nature 2004; 429:314-8; PMID :15152256 ; http://dx.doi.org/10.1038/ nature02535 17.,Non-OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Mol Cell Biol 2004; 24:105-22; PMID:14673147 ; http://dx.doi.org/10.1128/ MCB.24.1.105-122.2004 18.,Non-OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Mol Cell Biol 2006; 26:5168-79; PMID:16782900 ; http://dx.doi.org/10.1128/ MCB.00096-06 19.,Non-OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
J Biomed Biotechnol 2006; 2006:45621;   PMID:16877816 ; http://dx.doi.org/10.1155/ JBB/2006/45621 20.,Non-OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Nucleic Acids  Res 2013; In press; PMID :24101588 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Mol Biol Evol 2011; 28:17-20;  PMID:20716533 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Gene 2008; 419:1-6;  PMID:18534786 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Mob DNA 2010 ; 1:15;  PMID:20462415 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Curr Biol 2012; 22:R432-7;  PMID:22677280 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
J Gen Virol 2012; 93:1385-409;  PMID:22535777 ; http://dx.doi.org/10.1099/ vir.0.042499-0 27.,Non-OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Adv Protein Chem Struct Biol 2012; 86:45- 93; PMID:22243581 ; http://dx.doi.org/10.1016/ B978-0-12-386497-0.00002-5 29.,Non-OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
J Biol Chem 2005; 280:23425-8; PMID :15749702 ;  http://dx.doi.org/10.1074/jbc.R400041200 30.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
J Biol Chem 2010;  285:29033-8;  PMID:20576611 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Cell Cycle 2011; 10:229-40; PMID:21220943 ;  http://dx.doi.org/10.4161/cc.10.2.14472 32.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
RNA 2010; 16:1182-95; PMID:20423979 ;  http://dx.doi.org/10.1261/rna.2044610 33.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Science 2002; 297:1016- 8; PMID:12114528 ; http://dx.doi.org/10.1126/ science.1072266,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Curr Opin Genet Dev 2012; 22:191-203; PMID:22406018 ;  http://dx.doi.org/10.1016/j.gde.2012.02.00636.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
Mob  Genet Elements 2013; 3:e25674; PMID:24195012 ;  http://dx.doi.org/10.4161/mge.25674 37.,OADS,/arxiv_data1/oa_pdf/f7/12/mge-3-e27525.PMC3894237.pdf
"Mobile Genetic Elements 2013; 3:e27515; http://dx.doi.org/10.4161/mge.27515 *Correspondence to: Santiago Ramón-Maiques;  Email: sramon@cnio.es Commentary to: Mizuno N, Dramićanin M, Mizuuchi M, Adam J, Wang Y, Han YW, Yang W, Steven AC, Mizuuchi K, Ramón-Maiques S. MuB is an AAA+ ATPase that forms helical filaments to control target selection for DNA transposition.",OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
Annu Rev Biochem 1997; 66:437-74;  PMID:9242914 ; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
Proc Natl Acad Sci U S A 2013;  110:E2441-50;  PMID:23776210 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
Annu Rev Biochem 1992; 61:1011-51;  PMID:1323232 ; http://dx.doi.org/10.1146/annurev.,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
Cell 1988; 53:257-66; PMID:2965985 ;  http://dx.doi.org/10.1016/0092-8674(88)90387-X 7.,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
Mol Cell 2010; 39:48-58; PMID:20603074 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
Mol Microbiol 1999;  32:595-606;  PMID:10320581 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
EMBO J 2000; 19:5625- 34; PMID:11060014 ; http://dx.doi.org/10.1093/ emboj/19.21.5625 12.,Non-OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
EMBO J 2002a; 21:1477-86;  PMID:11889053 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
Mol Cell 2002b; 9:1079- 89; PMID:12049743 ; http://dx.doi.org/10.1016/ S1097-2765(02)00514-214.,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
J Biol Chem 2004; 279:16736-43;  PMID:14871890 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
Annu Rev Biophys Biomol Struct 2006; 35:93-114; PMID:16689629 ; http://dx.doi.org/10.1146/ annurev.biophys.35.040405.101933 16.,Non-OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
J  Biol Chem 2003; 278:31210-7; PMID:12791691 ;  http://dx.doi.org/10.1074/jbc.M303693200 17.,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
J Mol Biol 2006; 357:481-92;  PMID:16430918 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
Mob DNA 2010; 1:8; PMID:20226074 ;  http://dx.doi.org/10.1186/1759-8753-1-820.,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
Proc Natl Acad Sci U S A 1998; 95:1528-33; PMID:9465049 ; http://dx.doi.org/10.1073/ pnas.95.4.1528 21.,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
Nat Struct Mol Biol 2005; 12:935-6;  PMID:16155580 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
Proc Natl Acad Sci U S A 2009; 106:16610-5;  PMID:19805345 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
Proc Natl Acad Sci U S A 2000; 97:8997-9002;  PMID:10908652 ; http://dx.doi.org/10.1073/ pnas.150240197,OADS,/arxiv_data1/oa_pdf/d2/14/mge-3-e27515.PMC3894238.pdf
"OncoImmunology 2013; 2:e26491; http://dx.doi.org/10.4161/onci.26491Role of non-classical MHC class I molecules   in cancer immunosuppression Grazyna Kochan1,*, David e scors1,2, Karine Breckpot3, and David Guerrero-Setas1 1Navarrabiomed-Fundacion Miguel Servet; Navarra, Spain; 2rayne Institute; University College London; London, UK; 3Vrije Universiteit Brussels; Brussels, Belgium Keywords:  antigen presentation, cancer, immunomodulation, NK cells, non-classical MHC class I molecules, T cells Abbreviations: APC, antigen-presenting cell; ARG, arginase CTL, cytotoxic T lymphocyte; DC, dendritic cell; ER, endoplasmic  reticulum; IFN γ, interferon γ ; IL, interleukin; ILT, immunoglobulin-like transcript; iNOS, inducible nitric oxide synthase;  MDSC, myeloid-derived suppressor cell; NK, natural killer; sHLA, soluble human leukocyte antigen; STAT3, signal transducer  and activator of transcription 3; TAA, tumor-associated antigen; TAP, transporter associated with antigen presentation; TNF,  tumor necrosis factor; Treg, regulatory T cell Growing neoplasms employ various mechanisms to evade  immunosurveillance.",Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Science  2001 ; 294:605- 9; PMID :11567106 ; http://dx.doi.org/10.1126/ science.1063916 3.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
J Exp Med  2000 ; 191:661-8; PMID:10684858 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Proc Natl Acad Sci U S A 1987 ; 84:9145 - 9; PMID:3480534 ; http://dx.doi.org/10.1073/ pnas.84.24.9145 5.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
J Exp Med  1990 ; 171:1-18; PMID:1688605 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Mol  Biol Evol  2011 ; 28:3069 -86; PMID:21622995 ;  http://dx.doi.org/10.1093/molbev/msr138 8.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Adv Immunol  2003 ; 81:199-252; PMID:14711057 ;  http://dx.doi.org/10.1016/S0065-2776(03)81006-4 9.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Mol  Cell Biochem  2013 ; 381:243- 55; PMID:23737137 ;  http://dx.doi.org/10.1007/s11010-013-1708-5 10.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Blood   2008 ; 111:4862 -70; PMID:18334671 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
J  Biol Chem  2006 ; 281:10439 -47; PMID:16455647 ;  http://dx.doi.org/10.1074/jbc.M512305200 12.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Tissue Antigens  2002 ;  60:206-12; PMID:12445303 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Curr Biol   1996 ; 6:305-14; PMID:8805247 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Autoimmun Rev   2005 ; 4:503-9; PMID:16214086 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Requirement of the proteasome for the  trimming of signal peptide-derived epitopes presented  by the nonclassical major histocompatibility complex  class I molecule HLA-E. J Biol Chem 2003 ;  278:33747 -52; PMID:12821659 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Eur J Immunol  1997 ; 27:1164 -9; PMID:9174606 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Curr Biol  1998 ; 8:1-10; PMID:9427624 ;  http://dx.doi.org/10.1016/S0960-9822(98)70014-4 18.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Eur J Immunol 2005 ; 35:3240 - 7; PMID:16224817 ; http://dx.doi.org/10.1002/ eji.200535343 19.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
J Infect Dis  2009 ; 200:820-6; PMID:19619059 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Hum Immunol  2007 ; 68:244-50;  PMID:17400059 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Transplantation  2010 ;  90:1000 -5; PMID:20814356 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Hum Immunol  2006 ; 67:561- 7; PMID:16916651 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Tissue Antigens   2003 ; 62:273-84; PMID:12974794 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
J Virol  2005 ; 79:15226 -37; PMID:16306594 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Hum Immunol  2000 ; 61:1177 - 95; PMID:11137224 ; http://dx.doi.org/10.1016/ S0198-8859(00)00154-3 27.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Cancer Res 2005 ;  65:10139 -44; PMID:16287995 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Blood   2011 ; 117:7021 -31; PMID:21482709 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
EMBO J  2007 ; 26:1423 -33; PMID:17318190 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Cancer  2001 ;  92:369-76; PMID:11466692 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Int J Cancer  2002 ; 100:580-5; PMID:12124808 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Semin Cancer Biol 2003 ; 13:371-7; PMID:14708717;  http://dx.doi.org/10.1016/S1044-579X(03)00028-2 36.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Proc Natl Acad Sci U S A 2001 ;  98:12150 -5; PMID:11572934 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Curr Mol Med  2013 ;  13:602-25; PMID:22973872 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Int Immunol   1999 ; 11:803-11; PMID:10330285 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Am J Pathol 2001 ; 159:817-24;  PMID :11549573 ; http://dx.doi.org/10.1016/ S0002-9440(10)61756-7 41.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Crit  Rev Clin Lab Sci 2012 ; 49:63-84; PMID:22537084 ;  http://dx.doi.org/10.3109/10408363.2012.677947 42.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Eur J Immunol 2003 ; 33:125-34;  PMID:12594841 ; http://dx.doi.org/10.1002/ immu.200390015 43.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
J Reprod Immunol  2007 ; 76:17-22; PMID:17467060 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Hum Immunol   2003 ; 64:1081 -92; PMID:14602239 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Proc Natl Acad Sci U S A 1998 ; 95:4510 -5;  PMID:9539768 ; http://dx.doi.org/10.1073/ pnas.95.8.4510 48.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
"Ristich  V, Liang  S, Zhang  W,  Wu J, Horuzsko  A.  Tolerization of dendritic cells by HLA-G. Eur J  Immunol  2005 ; 35:1133 -42; PMID:15770701 ;  http://dx.doi.org/10.1002/eji.200425741 49.",OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Arch Immunol Ther Exp (Warsz) 2011 ; 59:353- 67; PMID:21800130 ; http://dx.doi.org/10.1007/ s00005-011-0137-y 51.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Hum Immunol  2003 ; 64:802-10; PMID:12878359 ;  http://dx.doi.org/10.1016/S0198-8859(03)00093-4 53.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Hum Immunol   2012 ; 73:898-905; PMID:22732094 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Eur J Immunol 1999 ; 29:537-47;  PMID:10064069 ; http://dx.doi.org/10.1002/ (SICI)1521-4141(199902)29:02<537::AID- IMMU537>3.0.CO;2-6 56.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
J Exp Med 1992 ;  176:1083 -90; PMID:1402654 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Eur J Immunol 2004 ; 34:81-90; PMID:14971033 ;  http://dx.doi.org/10.1002/eji.20032443258.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
J Exp Med 2002 ; 196:1403 - 14; PMID:12461076 ; http://dx.doi.org/10.1084/ jem.20020797 59.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Chem Immunol Allergy   2005 ; 89:72-83; PMID:16129954 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Proc Natl Acad Sci U S A 2011 ; 108:10656 -61;  PMID:21670276 ; http://dx.doi.org/10.1073/ pnas.1100354108 66.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Hum Immunol  1990 ; 29:131-42; PMID:2249951 ;  http://dx.doi.org/10.1016/0198-8859(90)90076-2 67.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Eur J Immunol  1997 ; 27:1691 -5; PMID:9247579 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Eur J Immunol  2010 ; 40:2308 -18; PMID:20865824 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Eur J Immunol 2000 ;  30:3552 -61; PMID:11169396 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
"Transcriptional  regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum Immunol  2000 ; 61:1102 - 7; PMID:11137213 ; http://dx.doi.org/10.1016/ S0198-8859(00)00198-1 75.",Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Int J Cancer 2013 ; 132:82-9; PMID:22544725 ;  http://dx.doi.org/10.1002/ijc.27621 77.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Hum  Immunol  2000 ; 61:1347 -51; PMID:11163092 ;  http://dx.doi.org/10.1016/S0198-8859(00)00212-3 79.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Int J Cancer  2012 ; 131:855-63; PMID:21953582 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
J  Neuroimmunol  2012 ; 250:27-34; PMID:22688424 ;  http://dx.doi.org/10.1016/j.jneuroim.2012.05.010 81.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
PLoS One  2011 ; 6:e21118 ; PMID:21712991 ;  http://dx.doi.org/10.1371/journal.pone.002111882.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
Pathol Res Pract 2012 ; 208:45- 9; PMID:22177730 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
J Transl Med  2011 ; 9:184; PMID:22032294 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/36/2e/onci-2-e26491.PMC3894240.pdf
"OncoImmunology 2013; 2:e26840; http://dx.doi.org/10.4161/onci.26840Examining the presentation of tumor-associated  antigens on peptide-pulsed T2 cells Giovanna Bossi1, andrew B Gerry2, Samantha J Paston1, Deborah H Sutton1, Namir J Hassan1, and Bent K Jakobsen1,2,* 1Immunocore Ltd.; Oxon, UK; 2adaptimmune Ltd.; Oxon, UK Keywords:  antigen presentation, fluorescence microscopy, monoclonal TCR, T2 cells, T-cell activation,  T-cell receptor, tumor-associated antigens Abbreviations: APC, antigen-presenting cell; CTL, cytotoxic T lymphocyte; mTCR, monoclonal TCR;  TAA, tumor-associated antigen; TCR, T-cell receptor Peptide-pulsed T2 cells are routinely used to study T-cell activation by MHC-restricted peptides derived from tumor- associated antigens (T aas).",Non-OADS,/arxiv_data1/oa_pdf/f1/55/onci-2-11-26840.PMC3894244.pdf
Science 1990; 248:367-70;  PMID:2326647 ; http://dx.doi.org/10.1126/ science.2326647 2.,Non-OADS,/arxiv_data1/oa_pdf/f1/55/onci-2-11-26840.PMC3894244.pdf
Nat Med 2012; 18:980-7; PMID:22561687 ;  http://dx.doi.org/10.1038/nm.2764 4.,OADS,/arxiv_data1/oa_pdf/f1/55/onci-2-11-26840.PMC3894244.pdf
J Immunol 2009; 182:6328- 41; PMID:19414786 ; http://dx.doi.org/10.4049/ jimmunol.0801898 6.,Non-OADS,/arxiv_data1/oa_pdf/f1/55/onci-2-11-26840.PMC3894244.pdf
Protein Eng 2003; 16:707-11; PMID:14560057 ;  http://dx.doi.org/10.1093/protein/gzg087 7.,OADS,/arxiv_data1/oa_pdf/f1/55/onci-2-11-26840.PMC3894244.pdf
Nat Biotechnol  2005; 23:349-54;  PMID:15723046 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/f1/55/onci-2-11-26840.PMC3894244.pdf
Mol Cancer Ther 2007; 6:2081-91;  PMID:17620437 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/55/onci-2-11-26840.PMC3894244.pdf
J Immunol 2012; 189:2625- 34; PMID:22844111 ; http://dx.doi.org/10.4049/ jimmunol.1102965 10.,Non-OADS,/arxiv_data1/oa_pdf/f1/55/onci-2-11-26840.PMC3894244.pdf
Oncoimmunology 2012; 1:467-530; PMID:22754765 ; http://dx.doi.org/10.4161/ onci.19856 11.,Non-OADS,/arxiv_data1/oa_pdf/f1/55/onci-2-11-26840.PMC3894244.pdf
Oncoimmunology 2013; 2:e25961;   PMID:24083084 ; http://dx.doi.org/10.4161/ onci.25961 12.,Non-OADS,/arxiv_data1/oa_pdf/f1/55/onci-2-11-26840.PMC3894244.pdf
Oncoimmunology  2013; 2:e22891;  PMID:23525668 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/f1/55/onci-2-11-26840.PMC3894244.pdf
JAK-STAT 2013; 2:e24860; http://dx.doi.org/10.4161/jkst.24860STAT protein species are well-known as transcription  factors that regulate nuclear gene expression.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Sci T ransl Med 2011; 3:88ra55;  PMID:21697531; http://dx.doi.org/10.1126/scitrans- lmed.3002194 33.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Cardiovasc Res  2004; 63:747-55; PMID:15306231; http://dx.doi.org/10.1016/j.cardiores.2004.05.018 37.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Circulation 2006; 114:912- 20; PMID:16940204; http://dx.doi.org/10.1161/ CIRCULATIONAHA.106.634709 38.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
JAK-STAT 2012;  1:223-33; http://dx.doi.org/10.4161/jkst.22366 39.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
J Interferon  Cytokine Res 2002; 22:555-63; PMID:12060494;  http://dx.doi.org/10.1089/10799900252982034 40.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
J Biol Chem 2002; 277:12067-74; PMID:11815625;  http://dx.doi.org/10.1074/jbc.M200018200 41.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Science  2009; 324:1713-6; PMID:19556508; http://dx.doi.org/10.1126/science.1171721 43.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Exp Mol Med  2009; 41:226-35; PMID:19299911; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Basic Res Cardiol 2010; 105:771-85;  PMID:20960209; http://dx.doi.org/10.1007/s00395- 010-0124-1 45.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
PLoS One  2011; 6:e20188; PMID:21625522; http://dx.doi.org/10.1371/journal.pone.002018816.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Genes Dev 2008; 22:711- 21; PMID:18347089; http://dx.doi.org/10.1101/ gad.1643908 17.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Science 2009; 323:793-7;  PMID:19131594; http://dx.doi.org/10.1126/sci- ence.1164551 18.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
PLoS One 2013; 8:e55426;  PMID:23383189; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
"Prescott DM, Myerson D, Wallace J. Enucleation of mammalian cells with cytochalasin B. Exp Cell  Res 1972; 71:480-5; PMID:5065231; http://dx.doi.",OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Nat Rev Mol Cell  Biol 2007; 8:519-29; PMID:17565364; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
J Cell Sci 2012; 125:1727- 37; PMID:22328510; http://dx.doi.org/10.1242/jcs.096396 23.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Circulation  2004; 110:1499-506; PMID:15353500; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Am J Physiol Cell Physiol  2005; 288:C850-62; PMID:15561761; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Am  J Physiol Lung Cell Mol Physiol 2007; 292:L1526- 42; PMID:17337506; http://dx.doi.org/10.1152/ ajplung.00463.2006 28.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Am J Physiol Lung Cell Mol Physiol 2009; 297:L729- 37; PMID:19648286; http://dx.doi.org/10.1152/ ajplung.00087.2009 29.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Am J Physiol Heart  Circ Physiol 2011; 300:H1141-58; PMID:21217069;  http://dx.doi.org/10.1152/ajpheart.00767.2010 30.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
J Pathol 1977; 121:93- 100; PMID:874635; http://dx.doi.org/10.1002/ path.1711210205 31.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Thorax 1979; 34:177-86; PMID:573509;  http://dx.doi.org/10.1136/thx.34.2.177References 1.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Immunity 2012; 36:503-14; PMID:22520844;  http://dx.doi.org/10.1016/j.immuni.2012.03.013 2.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Semin Cell Dev Biol 2008; 19:329-40; PMID:18691663; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
J Biol Chem 1999; 274:25499- 509; PMID:10464281; http://dx.doi.org/10.1074/ jbc.274.36.25499 5.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Am J Physiol Lung Cell Mol Physiol 2008; 294:L449- 68; PMID:18083767; http://dx.doi.org/10.1152/ ajplung.00377.2007 8.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
J Cell Biol  2006; 172:245-57; PMID:16401721; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Cancer Res  2004; 64:3550-8; PMID:15150111; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
J Biol Chem 2006;  281:7302-8; PMID:16407171; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Am J Physiol Cell Physiol 2007; 293:C1374-82; PMID:17670892; http://dx.doi.org/10.1152/ajp- cell.00220.2007 12.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Exp Cell Res 2011; 317:1955-69; PMID:21619877; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Am J Physiol Cell Physiol  2012; 302:C804-20; PMID:22159083; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Am J Physiol  Cell Physiol 2013; 304:C312-23; PMID:23151802;  http://dx.doi.org/10.1152/ajpcell.00311.2012 15.,Non-OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Biochem Biophys Res Commun 2010; 402:778- 83; PMID:21036145; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
Cell 2011; 147:436- 46; PMID:22000020; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
J Biol Chem 2010; 285:23532- 6; PMID:20558729; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/27/c2/jkst-2-e24860.PMC3894245.pdf
"OncoImmunology 2013; 2:e27156; http://dx.doi.org/10.4161/onci.27156An allogeneic NK cell line engineered to express  chimeric antigen receptors A novel strategy of cellular immunotherapy against cancer Cécile Badoual1,2, Pierre-Louis Bastier1, Hélène r oussel1,2, Marion Mandavit1, and e ric Tartour,3 1INSerM U970, Universite Paris Descartes, Sorbonne Paris-Cité; Paris, France; 2Hôpital e uropéen Georges Pompidou; a P-HP; Service d’ anatomie Pathologique; Paris, France;  3Hôpital e uropéen Georges Pompidou; a P-HP; Service d’Immunologie Biologique; Paris, France",Non-OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
Oncoimmunology 2012; 1:306- 15; PMID:22737606 ; http://dx.doi.org/10.4161/ onci.19549 2.,Non-OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
Oncoimmunology 2013; 2:e24238;   PMID:23762803 ; http://dx.doi.org/10.4161/ onci.24238 3.,Non-OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
Gene Ther 2013; 20:1029-32;  PMID:23804078 ; http://dx.doi.org/10.1038/ gt.2013.34 4.,OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
N Engl J Med 2013 ; 368:1509-18 ;  PMID:23527958 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
Sci Transl Med 2013; 5:177ra38; PMID :23515080 ;  http://dx.doi.org/10.1126/scitranslmed.3005930 6.,OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
Eur J Immunol 2013; 43:331-4; PMID:23322344 ;  http://dx.doi.org/10.1002/eji.2012432648.,Non-OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
Science 2011; 331:44-9; PMID:21212348 ;  http://dx.doi.org/10.1126/science.1198687 9.,Non-OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
Biomed  Pharmacother 1992; 46:473-84; PMID:1306361 ;  http://dx.doi.org/10.1016/0753-3322(92)90005-R 10.,OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
J Immunother  2007; 30:684-93;  PMID:17893561 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
Cancer Gene Ther  2012; 19:84-100;  PMID:21979579 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
N Engl J Med 2011; 365:725- 33; PMID:21830940 ; http://dx.doi.org/10.1056/ NEJMoa1103849 13.,OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
Sci Transl Med 2013; 5:172ra20; PMID:23408053 ; http://dx.doi.org/10.1126/ scitranslmed.300488815.,Non-OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
Cancer Res 2013; 73:3499-510; PMID:23592754 ;  http://dx.doi.org/10.1158/0008-5472.CAN-13-0371 16.,Non-OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
PLoS One 2013; 8:e56820;  PMID:23441216 ; http://dx.doi.org/10.1371/jour - nal.pone.0056820 17.,Non-OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
Mol Ther 2009; 17:1453-64; PMID:19384291 ; http://dx.doi.org/10.1038/ mt.2009.83 18.,Non-OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
Curr Opin Immunol 2009; 21:525-30; PMID:19717293 ;  http://dx.doi.org/10.1016/j.coi.2009.07.015 19.,OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
Blood 2013;Forthcoming;  PMID:24055823 ; http://dx.doi.org/10.1182/ blood-2013-08-519413 20.,Non-OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
Cytotherapy  2008; 10:625-32;  PMID:18836917 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/ae/31/onci-2-e27156.PMC3894246.pdf
"OncoImmunology 2013; 2:e26403;   http://dx.doi.org/10.4161/onci.26403Antitumor immune responses mediated   by dendritic cells How signals derived from dying cancer cells  drive antigen cross-presentation Lotte Spel, Jaap-Jan Boelens, Stefan Nierkens, and Marianne Boes* U-D aNCe and Laboratory of Translational Immunology; University Medical Center Utrecht; Utrecht, The Netherlands Keywords:  apoptotic, necrotic, dendritic cells, cross-presentation, type 1 interferon, DAMPs, storage compartments Dendritic cells (DCs) are essential for the induction of  adaptive immune responses against malignant cells by virtue  of their capacity to effectively cross-present exogenous  antigens to T lymphocytes.",Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Cell 2011; 144:646-74;  PMID:21376230 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Intern Med 2001 ; 250:462-75; PMID :11902815 ;  http://dx.doi.org/10.1046/j.1365-2796.2001.00911.x 3.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Ann N Y Acad Sci 2013 ; 1284 :1- 5; PMID:23651186 ; http://dx.doi.org/10.1111/ nyas.12105 4.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Nat  Rev Immunol  2011 ; 11:575-83; PMID:21852794 ;  http://dx.doi.org/10.1038/nri3046 5.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Nat Immunol  2012 ; 13:888- 99; PMID:22797772 ; http://dx.doi.org/10.1038/ ni.2370 6.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Nat Rev Immunol  2012 ; 12:557-69; PMID:22790179 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Immunity  2002 ; 17:211- 20; PMID:12196292 ; http://dx.doi.org/10.1016/ S1074-7613(02)00365-5 9.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Annu Rev Immunol 2000 ; 18:767- 811; PMID:10837075 ; http://dx.doi.org/10.1146/ annurev.immunol.18.1.767 10.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Exp Med 2010 ; 207:1131-4; PMID:20513744 ;  http://dx.doi.org/10.1084/jem.20100985 11.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Trends Immunol  2013 ; 34:361- 70; PMID:23540650 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Exp Med 2013 ; 210:1035 -47;  PMID:23569327 ; http://dx.doi.org/10.1084/ jem.20121103 13.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Trends Immunol  2012 ; 33:381- 8; PMID:22677187 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Semin Immunol   1998 ; 10:443-8; PMID:9826577 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Immunol  2009 ; 183:1083 - 90; PMID:19553546 ; http://dx.doi.org/10.4049/ jimmunol.0900861,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Proc Natl Acad Sci U S A 2007 ;  104:1289 -94; PMID:17229838 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Blood  2012 ; 120:5163 - 72; PMID:23093620 ; http://dx.doi.org/10.1182/ blood-2012-06-434498 19.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Nature   2009 ; 458 :899-903; PMID:19219027 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Blood   2005 ; 106:1278 -85; PMID :15878980 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Br J Cancer 1972 ; 26:239- 57; PMID:4561027 ; http://dx.doi.org/10.1038/ bjc.1972.33 24.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Int Rev Cytol  1980 ; 68:251- 306; PMID:7014501 ; http://dx.doi.org/10.1016/ S0074-7696(08)62312-8 25.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Nat Rev Mol Cell Biol  2010 ; 11:700-14; PMID:20823910 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Curr Opin Cell Biol  2004 ; 16:663-9; PMID :15530778 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
FEBS Lett   2010 ; 584:4491 -9; PMID:20974143 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Biol Chem 2001 ; 276:1071 -7;  PMID:10986279 ; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Cytotherapy  2008 ; 10:642-9; PMID:18836919 ;  http://dx.doi.org/10.1080/14653240802317647 33.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Int Immunol  2000 ; 12:1741-7; PMID:11099314 ;  http://dx.doi.org/10.1093/intimm/12.12.1741 35.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Nature  1998 ; 392:86-9;  PMID:9510252 ; http://dx.doi.org/10.1038/32183 37.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Anticancer Drugs   2003 ; 14:833-43; PMID:14597879 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Vaccine  2008 ; 26:6422 -32; PMID:18848858 ;  http://dx.doi.org/10.1016/j.vaccine.2008.08.063 39.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Int J Cancer 2003 ; 106:516- 20; PMID:12845646 ; http://dx.doi.org/10.1002/ ijc.11243 40.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Oncoimmunology  2012 ; 1:1017- 26; PMID:23170250 ; http://dx.doi.org/10.4161/ onci.21098 42.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Immunity  2006 ; 24:787- 99; PMID:16782034 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Int J Cancer 2003 ; 103:205- 11; PMID:12455034 ; http://dx.doi.org/10.1002/ ijc.10777 45.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Increased immuno - genicity of colon cancer cells by selective depletion of cytochrome C. Cancer Res 2004 ; 64:2705 -11;  PMID:15087383 ; http://dx.doi.org/10.1158/0008- 5472.CAN-03-2475 50.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Immunother   2006 ; 29:545-57; PMID:16971810 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Cancer Immunol  Immunother  2006 ; 55:819-29; PMID:16187085 ;  http://dx.doi.org/10.1007/s00262-005-0078-6 53.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Immunology  2002 ; 107:183-9; PMID:12383197 ;  http://dx.doi.org/10.1046/j.1365-2567.2002.01513.x 54.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Exp Med 2002 ;  195:1289 -302; PMID:12021309 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Exp Med 2011 ;  208:1789 -97; PMID:21859845 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Exp Med  2010 ; 207:1247 -60; PMID:20479116 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Biol Chem 2008 ; 283:16693 - 701; PMID:18408006 ; http://dx.doi.org/10.1074/ jbc.M709923200 58.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Immunity  2012 ; 36:646- 57; PMID:22483802 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Clin Invest 2012 ; 122:1615 -27; PMID:22505458 ;  http://dx.doi.org/10.1172/JCI60644 61.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Nat Cell Biol 2007 ; 9:367- 78; PMID:17351642 ; http://dx.doi.org/10.1038/ ncb1552 64.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Blood  2008 ; 112:4712 -22; PMID:18682599 ;  http://dx.doi.org/10.1182/blood-2008-01-134791 65.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Cell 2006 ; 126:205- 18; PMID:16839887 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Immunity  2009 ; 30:544- 55; PMID:19328020 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Science   2007 ; 316:612-6; PMID:17463291 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Proc Natl Acad Sci U S A 2009 ; 106:6730 - 5; PMID:19346487 ; http://dx.doi.org/10.1073/ pnas.090096910669.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Immunol  2010 ; 185:3337 -47; PMID:20720209 ;  http://dx.doi.org/10.4049/jimmunol.1001619 70.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Autoimmunity   2007 ; 40:331-2; PMID:17516221 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Immunol   2012 ; 189:1747-56; PMID:22786771 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Exp Med 2011 ; 208:1989 - 2003 ; PMID:21930769 ; http://dx.doi.org/10.1084/ jem.20101158 74.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Cancer Res 2011 ; 71:6428 -37;  PMID:21788345 ; http://dx.doi.org/10.1158/0008- 5472.CAN-11-2154 75.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Immunol  2011 ; 186:5142 -50; PMID:21441457 ;  http://dx.doi.org/10.4049/jimmunol.1004163 76.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Blood  2012 ; 119:1407- 17; PMID:22184405 ; http://dx.doi.org/10.1182/ blood-2011-06-363564 77.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Immunity  2012 ; 37:986-97;  PMID:23219390 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Immunol   2013 ; 190:5609 -19; PMID:23630347 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Immunol   2011 ; 187:1166 -75; PMID :21709155 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Annu Rev Immunol 2013 ; 31:51-72;  PMID :23157435 ; http://dx.doi.org/10.1146/ annurev-immunol-032712-100008 84.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Nat Rev Cancer  2012 ; 12:860-75; PMID :23151605 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Int Immunol  2000 ; 12:1539 - 46; PMID:11058573 ; http://dx.doi.org/10.1093/ intimm/12.11.1539 86.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Nature  2002 ; 418:191-5; PMID:12110890 ;  http://dx.doi.org/10.1038/nature00858 87.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Exp Med  2000 ; 191:423-34; PMID:10662788 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
EMBO Rep 2004 ; 5:825-30; PMID:15272298 ;  http://dx.doi.org/10.1038/sj.embor.7400205 89.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Immunol Rev   2007 ; 220:47-59; PMID:17979839 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Immunol Lett  2002 ; 84:81- 7; PMID:12270543 ; http://dx.doi.org/10.1016/ S0165-2478(02)00042-1 91.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Br J Cancer 2004 ; 90:926-31;  PMID:14970875 ; http://dx.doi.org/10.1038/ sj.bjc.6601583 93.,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Biol Chem 2007 ;  282:31688 -702; PMID:17684010 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
Nat Med   2009 ; 15:1170 -8; PMID:19767732 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
J Immunol  2013 ; 190:334-9; PMID:23225887 ;  http://dx.doi.org/10.4049/jimmunol.1202737,Non-OADS,/arxiv_data1/oa_pdf/9d/fe/onci-2-e26403.PMC3894247.pdf
"Vortices that form during left ventricular (LV) filling  have specific geometry and anatomical location that are criti -pISSN 1975-4612/ eISSN 2005-9655  Copyright © 2013 Korean Society of Echocardiography  www.kse-jcu.org http://dx.doi.org/10.4250/jcu.2013.21.4.155 REVIEW J Cardiovasc Ultrasound  2013;21(4):155-162 Current Clinical Application   of Intracardiac Flow Analysis Using  Echocardiography Geu-Ru Hong, MD, PhD1, Minji Kim2, Gianni Pedrizzetti, PhD3 and Mani A Vannan, MBBS4 1Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea 2School of Medicine, University of Queensland, Herston, QLD, Australia 3University of Trieste, Trieste, Italy 4Department of Cardiovascular Medicine, Piedmont Heart Institute, Atlanta, GA, USA In evaluating the cardiac function, it is important to have a comprehensive assessment of structural factors, such as the myocardial  or valvular function and intracardiac flow dynamics that pass the heart.",Non-OADS,/arxiv_data1/oa_pdf/33/38/jcu-21-155.PMC3894365.pdf
"•	Received: December 23, 2013  •	Revised: December 23, 2013  •	Accepted: December 23, 2013    •	Address for Correspondence: Geu-Ru Hong, Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 50 Yonsei-ro,    Seodaemun-gu, Seoul 120-752, Korea     T el: +82-2-2228-8443, Fax: +82-2-393-2041, E-mail: grhong@yuhs.ac •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/33/38/jcu-21-155.PMC3894365.pdf
Measurement of ventricular torsion can provide infor - mation for detecting and follow-up of cardiac abnormality as  authors insisted; however the time and cost for measurement pISSN 1975-4612/ eISSN 2005-9655  Copyright © 2013 Korean Society of Echocardiography  www.kse-jcu.org http://dx.doi.org/10.4250/jcu.2013.21.4.163 EDITORIAL COMMENT J Cardiovasc Ultrasound  2013;21(4):163-164 Ventricular Torsion: Research Tool   or Novel Clinical Indicator?,Non-OADS,/arxiv_data1/oa_pdf/8c/11/jcu-21-163.PMC3894366.pdf
"• Received: November 22, 2013  • Revised: December 4, 2013  • Accepted: December 5, 2013    • Address for Correspondence: Sung-A Chang, Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of    Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea     T el: +82-2-3410-1485, Fax: +82-2-3410-3849, E-mail: sunga.chang@samsung.com • This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.REFER TO THE PAGE 171-176",Non-OADS,/arxiv_data1/oa_pdf/8c/11/jcu-21-163.PMC3894366.pdf
"A mitral in - flow pattern with an A-wave dominance virtually excludes se - vere MR”.3) In addition, the European Association of Echocar - diography suggests that “In the absence of mitral stenosis, a  peak E wave velocity > 1.5 m/sec suggests severe MR. Con - versely, a dominant A wave virtually excludes severe MR”.4) However, the studies evaluating the utility of E wave veloc -pISSN 1975-4612/ eISSN 2005-9655  Copyright © 2013 Korean Society of Echocardiography  www.kse-jcu.org http://dx.doi.org/10.4250/jcu.2013.21.4.165 ORIGINAL ARTICLE J Cardiovasc Ultrasound  2013;21(4):165-170 Effect of Mitral Inflow Pattern   on Diagnosis of Severe Mitral  Regurgitation in Patients with Chronic  Organic Mitral Regurgitation Nishath Quader, MD, Prasanth Katta, MD, Mohammad Q. Najib, MD and Hari P. Chaliki, MD Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, AZ, USA Background:  To determine sensitivity and specificity of E wave velocity in patients with severe chronic organic mitral  regurgitation (MR) and normal left ventricular ejection fraction (EF) and to evaluate prevalence of A wave dominance in patients  with severe MR. Methods:  We compared 35 patients with quantified severe, chronic, quantified, organic MR due to flail/prolapsed leaflets who  had reparative surgery with 35 age-matched control subjects.",Non-OADS,/arxiv_data1/oa_pdf/09/24/jcu-21-165.PMC3894367.pdf
"Chaliki, Division of Cardiovascular Diseases, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA        T el: +1-480-301-8000, Fax: +1-480-301-8018, E-mail: chaliki.hari@mayo.edu •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/09/24/jcu-21-165.PMC3894367.pdf
"Prior studies have reported anatomic and functional abnor - malities in kidney transplant recipients,10)11) but the effects of  kidney transplant on LV rotation, twist and torsion has never pISSN 1975-4612/ eISSN 2005-9655  Copyright © 2013 Korean Society of Echocardiography  www.kse-jcu.org http://dx.doi.org/10.4250/jcu.2013.21.4.171 ORIGINAL ARTICLE J Cardiovasc Ultrasound  2013;21(4):171-176 Left Ventricular Torsion Changes Post  Kidney Transplantation Yan Deng, MD1, Anil Pandit, MD2, Raymond L. Heilman, MD2, Harini A. Chakkera, MD2,  Marek J. Mazur, MD2 and Farouk Mookadam, MD2 1Department of Cardiovascular Ultrasound and Non-invasive Cardiology, Sichuan Academy of Medical Science &  Sichuan Provincial People’s Hospital, Sichuan, China 2Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA Background:  To quantify changes of left ventricular (LV) torsion in patients’ pre and post kidney transplantation.",Non-OADS,/arxiv_data1/oa_pdf/6b/19/jcu-21-171.PMC3894368.pdf
"•	Received: August 10, 2013  •	Revised: October 4, 2013  •	Accepted: November 12, 2013    •	Address for Correspondence: Farouk Mookadam, Department of Internal Medicine, Mayo Clinic College of Medicine, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA       T el: +1-480-301-6801, Fax: +1-480-301-8018, E-mail: mookadam.farouk@mayo.edu •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6b/19/jcu-21-171.PMC3894368.pdf
"It presents an objective, semi-automatic,  and angle-independent analysis of longitudinal peak systolic  strain (LS) based on speckle tracking and provides a single  bull’s-eye summary of the LV segmental wall strain.4)5) Many  published data supported the use of STE longitudinal strain to  identify and risk-stratify CAD with good accuracy and repro - ducibility.6)7) The aim of this study was to assess the accuracy  of global and segmental LS using STE to detect resting myo -pISSN 1975-4612/ eISSN 2005-9655  Copyright © 2013 Korean Society of Echocardiography  www.kse-jcu.org http://dx.doi.org/10.4250/jcu.2013.21.4.177 ORIGINAL ARTICLE J Cardiovasc Ultrasound  2013;21(4):177-182 Accuracy of Two-Dimensional Speckle  Tracking Echocardiography   for the Detection of Significant   Coronary Stenosis  Ashraf M. Anwar, MD, PhD1,2  1Department of Cardiology, King Fahd Armed Forces Hospital, Jeddah, Saudi-Arabia 2Department of Cardiology, Al-Azhar University, Cairo, Egypt Background:  Visual assessment of wall motion abnormalities (WMA) by 2-dimensional echocardiography (2DE) is the most  semi-quantitative method used to detect coronary artery disease (CAD), but it carries many limitations.",Non-OADS,/arxiv_data1/oa_pdf/6b/a1/jcu-21-177.PMC3894369.pdf
"Box: 9862, Jeddah 21159, Kingdom of Saudi     Arabia    T el: +966-566584970, Fax: +966-2-6651868, E-mail: ashrafanwar2000@hotmail.com •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/6b/a1/jcu-21-177.PMC3894369.pdf
"At this time the patient was transferred to our university pISSN 1975-4612/ eISSN 2005-9655  Copyright © 2013 Korean Society of Echocardiography  www.kse-jcu.org http://dx.doi.org/10.4250/jcu.2013.21.4.183 CASE REPORT J Cardiovasc Ultrasound  2013;21(4):183-185 Brucella Endocarditis of Pseudoaneurysm  of an Aortic Composite Graft Mohammad Bagher Sharifkazemi, MD1, Ali Reza Moarref, MD1,  Shahed Rezaian, MD2 and Gholam Reza Rezaian, MD1 Departments of 1Medicine (Cardiology), 2Radiology, Shiraz University of Medical Sciences, Shiraz, Iran The occurrence of Brucella endocarditis following Bentall operation is a rare and life threatening condition, particularly when it is  complicated by development of a pseudoaneurysm.",Non-OADS,/arxiv_data1/oa_pdf/d9/9c/jcu-21-183.PMC3894370.pdf
"•	Received: April 15, 2013  •	Revised: October 7, 2013  •	Accepted: November 12, 2013    •	Address for Correspondence: Gholam Reza Rezaian, Department of Medicine (Cardiology), Namazee Hospital, Shiraz University of Medical Sciences,    Shiraz 71937-11351, Iran    T el: +98-711-648-6508, Fax: +98-711-648-6509, E-mail: grezaian@gmail.com •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/d9/9c/jcu-21-183.PMC3894370.pdf
"Microscopic examination showed stellate and globular pISSN 1975-4612/ eISSN 2005-9655  Copyright © 2013 Korean Society of Echocardiography  www.kse-jcu.org http://dx.doi.org/10.4250/jcu.2013.21.4.186 CASE REPORT J Cardiovasc Ultrasound  2013;21(4):186-188 Asymptomatic Myxoma Originating   from the Right Ventricular Outflow Tract Dong-Hwi Kim, MD, Jeong-Eun Yi, MD, Hyun Ji In, MD, Minyeong Jeong, MD,   Moon Sung Kim, MD, Joune Seup Lee, MD, Jong Hoon Lee, MD, Borami Kang, MD,   Hae-Ok Jung, PhD and Ho-Joong Youn, PhD Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea,  Seoul, Korea Asymptomatic right ventricular outflow tract (RVOT) myxoma is quite rare.",Non-OADS,/arxiv_data1/oa_pdf/31/56/jcu-21-186.PMC3894371.pdf
"•	Received: July 23, 2013  •	Revised: October 1, 2013  •	Accepted: November 12, 2013    •	Address for Correspondence: Jeong-Eun Yi, Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic    University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 137-701, Korea    T el: +82-2-2258-1301, Fax: +82-2-2258-1303, E-mail: jung30134@naver.com •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/31/56/jcu-21-186.PMC3894371.pdf
"After 2 years with meticulous anticoagula - tion therapy, the patient was stable and follow-up echocardio - gram showed normal aortic prosthetic valve function with a  mean transprosthetic gradient of 10 mmHg.pISSN 1975-4612/ eISSN 2005-9655  Copyright © 2013 Korean Society of Echocardiography  www.kse-jcu.org http://dx.doi.org/10.4250/jcu.2013.21.4.189 CASE REPORT J Cardiovasc Ultrasound  2013;21(4):189-191 Intermittent, Non Cyclic Severe  Mechanical Aortic Valve Regurgitation Jong Hyun Choi, MD1, Jung Hyun Choi, MD1, Seunghwan Song, MD2 and  Myung-Yong Lee, MD3 Divisions of 1Cardiology, 2Cardiac Surgery, Pusan National University Hospital, Busan, Korea 3Division of Cardiology, Dankook University College of Medicine, Cheonan, Korea Mechanical aortic prosthesis dysfunction can result from thrombosis or pannus formation.",Non-OADS,/arxiv_data1/oa_pdf/e2/be/jcu-21-189.PMC3894372.pdf
"•	Received: July 23, 2013  •	Revised: August 23, 2013  •	Accepted: November 12, 2013    •	Address for Correspondence: Jung Hyun Choi, Division of Cardiology, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 602-739, Korea       Tel: +82-51-240-7514, Fax: +82-51-240-7765, E-mail: mariahyeon@hotmail.com •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/e2/be/jcu-21-189.PMC3894372.pdf
"Therefore, under impression of iron deficiency ane -pISSN 1975-4612/ eISSN 2005-9655  Copyright © 2013 Korean Society of Echocardiography  www.kse-jcu.org http://dx.doi.org/10.4250/jcu.2013.21.4.192 CASE REPORT J Cardiovasc Ultrasound  2013;21(4):192-196 Organized Prosthetic Tricuspid Valve  Thrombosis Treated Successfully   with Medical Treatment Hyo-Sun Shin, MD1, Kyung-Hee Kim, MD1, Hee-Sun Lee, MD1, Hong-Mi Choi, MD1,  Seung-Ah Lee, MD1, Eun-Ah Park, MD2 and Hyung-Kwan Kim, MD1 1Division of Cardiology, Department of Internal Medicine, 2Department of Radiology, Seoul National University  College of Medicine, Seoul National University Hospital, Seoul, Korea Prosthetic valve thrombosis (PVT) can be a life-threatening complication that requires immediate treatment.",Non-OADS,/arxiv_data1/oa_pdf/69/d0/jcu-21-192.PMC3894373.pdf
"•	Received: August 16, 2013  •	Revised: September 26, 2013  •	Accepted: November 12, 2013    •	Address for Correspondence: Kyung-Hee Kim, Division of Cardiology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul    National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea   T el: +82-2-2072-2228, Fax: +82-2-2072-2577, E-mail: learnbyliving9@gmail.com •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/69/d0/jcu-21-192.PMC3894373.pdf
"pISSN 1975-4612/ eISSN 2005-9655  Copyright © 2013 Korean Society of Echocardiography  www.kse-jcu.org http://dx.doi.org/10.4250/jcu.2013.21.4.197 CASE REPORT J Cardiovasc Ultrasound  2013;21(4):197-199 The Case of Isolated Double Atrial Septum  with Persistent Interatrial Space In-Soo Kim, MD, Moo-Nyun Jin, MD, Changho Song, MD, Young Ju Kim, MD,   Ah-Young Ji, MD, Jung-Woo Son, MD, Hyuk-Jae Chang, MD, PhD, Geu-Ru Hong, MD, PhD,  Jong-Won Ha, MD, PhD and Namsik Chung, MD, PhD Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea Double atrial septum is very rare atrial septal malformation which has double layered atrial septum with persistent interatrial  space between the two atria.",Non-OADS,/arxiv_data1/oa_pdf/3c/99/jcu-21-197.PMC3894374.pdf
"•	Received: August 23, 2013  •	Revised: October 11, 2013  •	Accepted: November 12, 2013    •	Address for Correspondence: Geu-Ru Hong, Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro,     Seodaemun-gu, Seoul 120-752, Korea   Tel: +82-2-2228-8443, Fax: +82-2-2227-7732, E-mail: grhong@yuhs.ac •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/3c/99/jcu-21-197.PMC3894374.pdf
"Transthoracic echocardiogram apical 4-chamber  view showing dilated systemic ventricle with mild systolic  dysfunction and normal sub-pulmonary ventricular size and pISSN 1975-4612/ eISSN 2005-9655  Copyright © 2013 Korean Society of Echocardiography  www.kse-jcu.org http://dx.doi.org/10.4250/jcu.2013.21.4.200 IMAGES IN CARDIOVASCULAR ULTRASOUND J Cardiovasc Ultrasound  2013;21(4):200-201 Early Complication of Mustard Procedure  after Late Repair Sherif Moustafa, MBBCh1, Mansour Al Shanawani, MSc2,  David J. Patton, MD3, Nanette Alvarez, MD4, Hamed Zuhairy, MD1,  Abdulrahman AlMoukirish, MD5 and Farouk Mookadam, MD6 1Department of Cardiovascular Diseases, Prince Salman Heart Center, King Fahad Medical City, Riyadh, Kingdom of  Saudi Arabia 2Department of Radiology, Prince Salman Heart Center, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia 3Section of Pediatric Cardiology, University of Calgary, Calgary, AB, Canada 4Adult Congenital Heart Disease Clinic, University of Calgary, Calgary, AB, Canada 5Department of Pediatric Cardiology, Prince Salman Heart Center, King Fahad Medical City, Riyadh, Kingdom of  Saudi Arabia 6Division of Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, AZ, USA KEY WORDS:  Transposition of great arteries  · Mustard procedure  · Baffle stenosis  · Echocardiogram  · Magnetic resonance.",Non-OADS,/arxiv_data1/oa_pdf/91/10/jcu-21-200.PMC3894375.pdf
"11463), Fax: +966-1-461-4006, E-mail: simustafa@kfmc.med.sa •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/91/10/jcu-21-200.PMC3894375.pdf
"Medical treatment under TEE monitoring, with spatial pISSN 1975-4612/ eISSN 2005-9655  Copyright © 2013 Korean Society of Echocardiography  www.kse-jcu.org http://dx.doi.org/10.4250/jcu.2013.21.4.202 IMAGES IN CARDIOVASCULAR ULTRASOUND J Cardiovasc Ultrasound  2013;21(4):202-203 A Successful Dissolution   of an Obstructive Prosthetic Mitral Valve  Thrombus: Sequential Two and   Three Dimensional Transesophageal  Echocardiography Examination Khalifa Selmi, MD, PhD, Iskander Slama, MD, Rami Tlili, MD, Sami Milouchi, MD,   Aida Mokaddem, MD and Mohamed Rachid Boujnah, MD Department of Cardiology, Clinical Echocardiography Laboratory, Mongi Slim University Hospital - La Marsa,   Sidi Daoud,Tunisia KEY WORDS:  Thrombosis  · Mitral valve prosthesis  · 2D and 3D transesophageal echocardiography.",Non-OADS,/arxiv_data1/oa_pdf/c9/fb/jcu-21-202.PMC3894376.pdf
"•	Received: July 24, 2013  •	Revised: August 29, 2013  •	Accepted: November 12, 2013    •	Address for Correspondence: Khalifa Selmi, Department of Cardiology, Mongi Slim University Hospital - La Marsa, PO Box 29, Sidi Daoud 2046, Tunisia      Tel: +216-98-485-726, Fax: +216-71-379-040, E-mail: khalifa.selmi@gmail.com •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c9/fb/jcu-21-202.PMC3894376.pdf
"235 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/licenses/by-nc/3.0 ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is prop erly cited.BLOOD RESEARCH Volume 48 ㆍNumber 4 ㆍDecember 2013 http://dx.doi.org/10.5045/br.2013.48.4.235 Editorial Attempts to treat patients with hemophilia, the „royal disease‰ Rojin Park, M.D.",Non-OADS,/arxiv_data1/oa_pdf/07/93/br-48-235.PMC3894377.pdf
"Survey results of hereditary hemolytic anemia incidence in Korea  showing the increasing proportions of hemoglobinopathy and enzy-mopathy.BLOOD RESEARCH Volume 48 ㆍNumber 4 ㆍDecember 2013 http://dx.doi.org/10.5045/br.2013.48.4.237 Perspective A new paradigm in the diagnosis  of hereditary hemolytic anemia Hye Lim Jung, M.D., Ph.D.",Non-OADS,/arxiv_data1/oa_pdf/a4/b5/br-48-237.PMC3894378.pdf
"240 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial us e, distribution, and reproduction in any medium, provided the original work is prop erly cited.Blood Research Educational Material BLOOD RESEARCH Volume 48 ㆍNumber 4 ㆍDecember 2013 http://dx.doi.org/10.5045/br.2013.48.4.240 Relapsed intravascular large B-cell lymphoma Kyoung Il Jo1, Rojin Park1, Jong Ho Won2 Departments of  1Laboratory Medicine, 2Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea Correspondence to Rojin Park, M.D.",Non-OADS,/arxiv_data1/oa_pdf/48/0d/br-48-240.PMC3894379.pdf
"241 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial us e, distribution, and reproduction in any medium, provided the original work is prop erly cited.Blood Research Educational Material BLOOD RESEARCH Volume 48 ㆍNumber 4 ㆍDecember 2013 http://dx.doi.org/10.5045/br.2013.48.4.241 Chronic myeloid leukemia with marked splenomegaly and  pseudo-Gaucher cells Hyung-Seok Yang1, Kyung Sam Cho2, Tae Sung Park1 Departments of  1Laboratory Medicine, 2Hematology-Oncology, School of Medici ne, Kyung Hee University, Seoul, Korea Correspondence to Tae Sung Park, M.D., Ph.D., Department of Laboratory Medicine, School of Medicine, Kyung Hee University, 23, Kyungheedae-ro,  Dongdaemun-gu, Seoul 130-872, Korea, E-mail: 153jesus@hanmail.net A 17-year-old boy with no specific medical history presen ted with abdominal distension.",Non-OADS,/arxiv_data1/oa_pdf/73/c5/br-48-241.PMC3894380.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/licenses/by-nc/3.0 ) which permits unrestricted non-commercial use, distribution, and re production in any medium, provided the original work is prop erly cited.BLOOD RESEARCHVOLUME 48 ㆍNUMBER 4 December 2013REVIEW  ARTICLE Next generation sequencing: new tools in immunology and  hematology Antonio Mori1, Sara Deola2, Luciano Xumerle1, Vladan Mijatovic1, Giovanni Malerba1, Vladia Monsurrò3 1Department of Life and Re production Science, Univer sity of Verona, Verona, 2Hematology Unit, Bolzano Central Hospital, Bolzano,  3Department of Pathology and Diagnostics,  University of Verona, Verona, Italy p-ISSN 2287-979X / e-ISSN 2288-0011 http://dx.doi.org/10.5045/br.2013.48.4.242Blood Res 2013;48:242-9.",Non-OADS,/arxiv_data1/oa_pdf/4b/d2/br-48-242.PMC3894381.pdf
"When a nucleo-tide is incorporated into a neosynthetized DNA strand, a  hydrogen ion is released and detected by a hypersensitive ion sensor (http://www.iontorrent.com/).",OADS,/arxiv_data1/oa_pdf/4b/d2/br-48-242.PMC3894381.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/licenses/by-nc/3.0 ) which permits unrestricted non-commercial use, distribution, and re production in any medium, provided the original work is prop erly cited.BLOOD RESEARCHVOLUME 48 ㆍNUMBER 4 December 2013ORIGINAL  ARTICLE Comparison of laboratory characteristics between acute  promyelocytic leukemia and other subtypes of acute myeloid leukemia with disseminated intravascular coagulation Hee-Jeong Lee, Hyung-Jin Park, Hyun-Wook Kim, Sang-Gon Park  Department of Internal Medicine, Hematology-Oncol ogy, Chosun University Hospital, Gwangju, Korea p-ISSN 2287-979X / e-ISSN 2288-0011 http://dx.doi.org/10.5045/br.2013.48.4.250Blood Res 2013;48:250-3.",Non-OADS,/arxiv_data1/oa_pdf/21/f5/br-48-250.PMC3894382.pdf
"(Accessed September 23, 2013, at http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf) 6.",Non-OADS,/arxiv_data1/oa_pdf/21/f5/br-48-250.PMC3894382.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/licenses/by-nc/3.0 ) which permits unrestricted non-commercial use, distribution, and re production in any medium, provided the original work is prop erly cited.BLOOD RESEARCHVOLUME 48 ㆍNUMBER 4 December 2013ORIGINAL  ARTICLE Clinical characteristics of hemophagocytic lymphohistiocytosis  following Kawasaki disease: differentiation from recurrent Kawasaki disease Hae-Ryong Kang1, Yong-hoon Kwon1, Eun-Sun Yoo2, Kyung-Ha Ryu2, Ji Yoon Kim3, Heung-Sik Kim3,  Hwang Min Kim4, Young-Ho Lee1 Department of Pediatrics, 1Hanyang University College of Medicine, 2Ewha Womans University Sc hool of Medicine, Seoul,  3Keimyung University, Dongsan Medical Center, Daegu, 4Yonsei University Wonju College  of Medicine, Wonju, Korea p-ISSN 2287-979X / e-ISSN 2288-0011 http://dx.doi.org/10.5045/br.2013.48.4.254Blood Res 2013;48:254-7.",Non-OADS,/arxiv_data1/oa_pdf/f5/b2/br-48-254.PMC3894383.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/licenses/by-nc/3.0 ) which permits unrestricted non-commercial use, distribution, and re production in any medium, provided the original work is prop erly cited.BLOOD RESEARCHVOLUME 48 ㆍNUMBER 4 December 2013ORIGINAL  ARTICLE Posterior reversible encephalopathy syndrome in pediatric patients  undergoing treatment for hemophagocytic lymphohistiocytosis: clinical outcomes and putative risk factors Goni Lee, Seung Eun Lee, Kyung-Ha Ryu, Eun Sun Yoo Department of Pediatrics, Ewha Womans Univ ersity School of Me dicine, Seoul, Korea p-ISSN 2287-979X / e-ISSN 2288-0011 http://dx.doi.org/10.5045/br.2013.48.4.258Blood Res 2013;48:258-65.",Non-OADS,/arxiv_data1/oa_pdf/f9/d2/br-48-258.PMC3894384.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/licenses/by-nc/3.0 ) which permits unrestricted non-commercial use, distribution, and re production in any medium, provided the original work is prop erly cited.BLOOD RESEARCHVOLUME 48 ㆍNUMBER 4 December 2013ORIGINAL  ARTICLE Prognostic value of immunohistochemical algorithms in  gastrointestinal diffuse large B-cell lymphoma Hee Sang Hwang1, Dok Hyun Yoon2, Cheolwon Suh2, Chan-Sik Park1, Jooryung Huh1 Departments of  1Pathology, 2Oncology, University of Ulsan College of Me dicine, Asan Medical Center, Seoul, Korea p-ISSN 2287-979X / e-ISSN 2288-0011 http://dx.doi.org/10.5045/br.2013.48.4.266Blood Res 2013;48:266-73.",Non-OADS,/arxiv_data1/oa_pdf/4a/4f/br-48-266.PMC3894385.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/licenses/by-nc/3.0 ) which permits unrestricted non-commercial use, distribution, and re production in any medium, provided the original work is prop erly cited.BLOOD RESEARCHVOLUME 48 ㆍNUMBER 4 December 2013ORIGINAL  ARTICLE Sequential chemotherapy followed by radiotherapy versus  concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T -cell lymphoma, nasal type Jieun Lee, Chul Yong Kim, Young Je Park, Nam Kwon Lee Department of Radiation Oncolo gy, Korea University Medical Ce nter, Korea University College of Medicine, Seoul, Korea p-ISSN 2287-979X / e-ISSN 2288-0011 http://dx.doi.org/10.5045/br.2013.48.4.274Blood Res 2013;48:274-81.",Non-OADS,/arxiv_data1/oa_pdf/40/0d/br-48-274.PMC3894386.pdf
"(Accessed August 22, 2013, at http://download.mw.go.kr/front_new/modules/download.jsp?BOARD_ID=1003&CONT_SEQ=283331&FILE_SEQ=131977) 3.",Non-OADS,/arxiv_data1/oa_pdf/40/0d/br-48-274.PMC3894386.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/licenses/by-nc/3.0 ) which permits unrestricted non-commercial use, distribution, and re production in any medium, provided the original work is prop erly cited.BLOOD RESEARCHVOLUME 48 ㆍNUMBER 4 December 2013ORIGINAL  ARTICLE Sequential therapy with activated prothrombin complex  concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience Myung Hee Han, Young Shil Park Department of Pediatrics, Kyung Hee University Hospital at Ga ngdong, School of Me dicine, Kyung Hee University, Seoul, Korea p-ISSN 2287-979X / e-ISSN 2288-0011 http://dx.doi.org/10.5045/br.2013.48.4.282Blood Res 2013;48:282-6.",Non-OADS,/arxiv_data1/oa_pdf/1b/da/br-48-282.PMC3894387.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://c reativecommons.org/licenses/by-nc/3.0 ) which permits unrestricted non-commercial use, distribution, and re production in any medium, provided the original work is prop erly cited.BLOOD RESEARCHVOLUME 48 ㆍNUMBER 4 December 2013CASE  REPORT Nodular lymphoid hyperplasia of the stomach in a patient with  multiple submucosal tumors Ja Young Jeon1, Sun Gyo Lim2, Jang Hee Kim3, Kee Myung Lee2, Sung Ran Cho4, Jae Ho Han3 Departments of  1Internal Medicine, 2Gastroenterology, 3Pathology, 4Laboratory Medicine, Ajou University Hospital, Ajou Universit y  School of Medicine, Suwon, Korea p-ISSN 2287-979X / e-ISSN 2288-0011 http://dx.doi.org/10.5045/br.2013.48.4.287Blood Res 2013;48:287-91.",Non-OADS,/arxiv_data1/oa_pdf/f9/f3/br-48-287.PMC3894388.pdf
"26, 2013; Revised on Sep. 9, 2013; Accepted on Nov. 21, 2013 http://dx.doi.org/10.5045/br.2013.48.4.292 AuthorsÊ Disclosures of Pote ntial Conflicts of Interest No potential conflicts of intere st relevant to this article  were reported.",Non-OADS,/arxiv_data1/oa_pdf/05/8e/br-48-292.PMC3894389.pdf
"26, 2013; Revised on Sep. 9, 2013; Accepted on Nov. 21, 2013 http://dx.doi.org/10.5045/br.2013.48.4.292 AuthorsÊ Disclosures of Pote ntial Conflicts of Interest No potential conflicts of intere st relevant to this article  were reported.",Non-OADS,/arxiv_data1/oa_pdf/50/7e/br-48-293.PMC3894390.pdf
"23, 2013; Revised on Nov. 1, 2013; Accepted on Nov. 21, 2013 http://dx.doi.org/10.5045/br.2013.48.4.293 AuthorsÊ Disclosures of Potential Conflicts of Interest No potential conflicts of intere st relevant to this article  were reported.",Non-OADS,/arxiv_data1/oa_pdf/50/7e/br-48-293.PMC3894390.pdf
"27, 2013; Revised on Aug. 1, 2013; Accepted on Nov. 21, 2013 http://dx.doi.org/10.5045/br.2013.48.4.296 AuthorsÊ Disclosures of Pote ntial Conflicts of Interest No potential conflicts of intere st relevant to this article  were reported.",Non-OADS,/arxiv_data1/oa_pdf/c3/cf/br-48-296.PMC3894391.pdf
"27, 2013; Revised on Aug. 1, 2013; Accepted on Nov. 21, 2013 http://dx.doi.org/10.5045/br.2013.48.4.296 AuthorsÊ Disclosures of Pote ntial Conflicts of Interest No potential conflicts of intere st relevant to this article  were reported.",Non-OADS,/arxiv_data1/oa_pdf/db/0d/br-48-297.PMC3894392.pdf
"28, 2013; Revised on Aug. 15, 2013; Accepted on Nov. 21, 2013 http://dx.doi.org/10.5045/br.2013.48.4.297 AuthorsÊ Disclosures of Potential Conflicts of Interest No potential conflicts of intere st relevant to this article  were reported.",Non-OADS,/arxiv_data1/oa_pdf/db/0d/br-48-297.PMC3894392.pdf
"13, 2013; Revised on Aug. 25, 2013; Accepted on Nov. 18, 2013 http://dx.doi.org/10.5045/br.2013.48.4.299 AuthorsÊ Disclosures of Pote ntial Conflicts of Interest No potential conflicts of intere st relevant to this article  were reported.",Non-OADS,/arxiv_data1/oa_pdf/6f/c6/br-48-299.PMC3894393.pdf
"13, 2013; Revised on Aug. 25, 2013; Accepted on Nov. 18, 2013 http://dx.doi.org/10.5045/br.2013.48.4.299 AuthorsÊ Disclosures of Pote ntial Conflicts of Interest No potential conflicts of intere st relevant to this article  were reported.",Non-OADS,/arxiv_data1/oa_pdf/99/4d/br-48-300.PMC3894394.pdf
"Antonio Abate” di Gallarate,  Via Pastori 4, Varese, Italy E-mail: guido.dangelo@aogallarate.it   Received on Oct. 14, 2013; Revised on Nov. 22, 2013; Accepted on Nov. 28, 2013 http://dx.doi.org/10.5045/br.2013.48.4.300 ACKNOWLEDGMENTS We are grateful to Mr. Giorgio Donelli for his technical  contribution in flow cytometry.",Non-OADS,/arxiv_data1/oa_pdf/99/4d/br-48-300.PMC3894394.pdf
"11       http://www.medsci.org  116  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2014;  11(2): 116-126. doi: 10.7150/ ijms.7073   Research Paper   Effects of a Pre -workout Supplement on Lean Mass,  Muscular Performance, Subjective Workout Experience  and Biomarkers of Safety   A. William  Kedia1, Jennifer E. Hofheins1, Scott M. Habowski1, Arny A. Ferrando2, M. David Gothard3, and  Hector L. Lopez1   1.",Non-OADS,/arxiv_data1/oa_pdf/ed/17/ijmsv11p0116.PMC3894395.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/ed/17/ijmsv11p0116.PMC3894395.pdf
"11       http://www.medsci.org  117  Introduction  Supplementation with various over -the-counter  dietary supplements and “nutrient timing” are two  popular approaches used by athletes to aid in pe r- formance and recovery [1, 2].",Non-OADS,/arxiv_data1/oa_pdf/ed/17/ijmsv11p0116.PMC3894395.pdf
"11     http://www.medsci.org  118  aware, this is the first in vivo  trial in humans of a  pre-workout product containing Dendrobex™ or any  product containing components of dendrobium.",Non-OADS,/arxiv_data1/oa_pdf/ed/17/ijmsv11p0116.PMC3894395.pdf
11     http://www.medsci.org  119  supplement after observing a modified fast of 8 -10  hours.,Non-OADS,/arxiv_data1/oa_pdf/ed/17/ijmsv11p0116.PMC3894395.pdf
11     http://www.medsci.org  120  (BMI) ≤30 kg/m2 who had been undergoing r e- sistance training regularly (defined as completing an  average of three workouts/week) for ≥2 years w ere  eligible for inclusion.,Non-OADS,/arxiv_data1/oa_pdf/ed/17/ijmsv11p0116.PMC3894395.pdf
"11     http://www.medsci.org  121   Lean mass, fat mass, and %fat were determined  by dual- energy x -ray absorptiometry (DEXA; Ge neral  Electric Lunar DPX Pro) at baseline and weeks 3 and  6.",Non-OADS,/arxiv_data1/oa_pdf/ed/17/ijmsv11p0116.PMC3894395.pdf
"11     http://www.medsci.org  122  ingestion of comparator, no significant changes of SBP  were noted at 30, 60, 90, and 120 minutes post -ingestion whereas DBP was significantly i n- creased at 30, 60, 90, and 120 minutes post -ingestion  (3.0-3.6 mm Hg, p<0.01).",Non-OADS,/arxiv_data1/oa_pdf/ed/17/ijmsv11p0116.PMC3894395.pdf
"11     http://www.medsci.org  123  in the MPP versus comparator gr oup consistently  during all sets at weeks 3 and 6, although the differ- ences did not reach statistical significance.",Non-OADS,/arxiv_data1/oa_pdf/ed/17/ijmsv11p0116.PMC3894395.pdf
11     http://www.medsci.org  124  Vital Signs and Adverse Events   Six weeks of daily supplementation with MPP  exerted no overall effect on change of vital signs such  as blood pressure and heart rate (Tab le 4).,Non-OADS,/arxiv_data1/oa_pdf/ed/17/ijmsv11p0116.PMC3894395.pdf
"11     http://www.medsci.org  125  tissue, fat, lean mass and L:F ratio as revealed by  DEXA, trends were observed for a reduction of fat mass accompanied by an increase of lean mass over the 6 -week efficacy study period.",Non-OADS,/arxiv_data1/oa_pdf/ed/17/ijmsv11p0116.PMC3894395.pdf
"11     http://www.medsci.org  126  tute endorsement by the any of the investigators, The  Center for Applied Health Sciences, or the journal in which it is published.",Non-OADS,/arxiv_data1/oa_pdf/ed/17/ijmsv11p0116.PMC3894395.pdf
"11       http://www.medsci.org  127  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2014;  11(2): 127-133. doi: 10.7150/ ijms.7516   Research Paper   Comparison  of Laparoscopic Versus Open Left  Hemi hepatectomy for Left -Sided Hepatolithiasis   Jung- Man Namgoong, Ki -Hun Kim, Gil- Chun Park, Dong -Hwan Jung, Gi -Won Song, Tae- Yong Ha,  Duk- Bok Moon, Chul -Soo Ahn, Shin Hwang, Sung -Gyu Lee   Department  of Surgery , University of  Ulsan College of Medicine, Asan Medical Center, Seoul, Korea     Corresponding author : Ki-H un Kim, M.D., Ph.D., Department of Surgery , University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro  43-gil, Songpa -gu, Seoul 13 8-736, Korea.",Non-OADS,/arxiv_data1/oa_pdf/1b/0c/ijmsv11p0127.PMC3894396.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/1b/0c/ijmsv11p0127.PMC3894396.pdf
"11     http://www.medsci.org  128  strictures is considered to be the best treatment option  [1, 2].",Non-OADS,/arxiv_data1/oa_pdf/1b/0c/ijmsv11p0127.PMC3894396.pdf
11       http://www.medsci.org  129    Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/1b/0c/ijmsv11p0127.PMC3894396.pdf
11     http://www.medsci.org  130  The operator used two  trocars on the right side  of the patient and the assistant performed traction of  the liver and suction via the two  trocars on the mi d- line and left side of the patient.,Non-OADS,/arxiv_data1/oa_pdf/1b/0c/ijmsv11p0127.PMC3894396.pdf
11       http://www.medsci.org  131  Table 1 .,Non-OADS,/arxiv_data1/oa_pdf/1b/0c/ijmsv11p0127.PMC3894396.pdf
"11     http://www.medsci.org  132  latation  should be considered  in the treatment plan,  and hepatic parenchyma  resection is regarded as the  best treatment option  [1, 2, 4, 9] .",Non-OADS,/arxiv_data1/oa_pdf/1b/0c/ijmsv11p0127.PMC3894396.pdf
11     http://www.medsci.org  133  likely  to occur  [21].,Non-OADS,/arxiv_data1/oa_pdf/1b/0c/ijmsv11p0127.PMC3894396.pdf
"1 1      http://www.medsci.org  134  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2014;  11(2): 134-141. doi: 10.7150/ ijms.7137   Research Paper   Anatomical Analysis on the Lateral Bone Window of the  Sella Turcica: A Study  on 530 Adult D ry Skull B ase  Specimens   Jianxin WANG1*, Renzhi WANG1*, Yunta o LU2*, Yong YAO 1, Songtao QI 2  1.",Non-OADS,/arxiv_data1/oa_pdf/c8/20/ijmsv11p0134.PMC3894397.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/20/ijmsv11p0134.PMC3894397.pdf
"11     http://www.medsci.org  135  and the lateral border of dorsum sella e, and etc .",Non-OADS,/arxiv_data1/oa_pdf/c8/20/ijmsv11p0134.PMC3894397.pdf
1 1      http://www.medsci.org  136    Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/c8/20/ijmsv11p0134.PMC3894397.pdf
11     http://www.medsci.org  137  mation of the STB.,Non-OADS,/arxiv_data1/oa_pdf/c8/20/ijmsv11p0134.PMC3894397.pdf
11     http://www.medsci.org  138  Table  3.,Non-OADS,/arxiv_data1/oa_pdf/c8/20/ijmsv11p0134.PMC3894397.pdf
"11     http://www.medsci.org  139  Discussion    The majority of previous  studies of the lateral  wall of the sella turcica have focused on the anterior  and posterior clinoid processes and on the CCF  [9,13 -14].",Non-OADS,/arxiv_data1/oa_pdf/c8/20/ijmsv11p0134.PMC3894397.pdf
"11     http://www.medsci.org  140  ported an incidence of 8.86%, after the examination of   the bridge between the anterior and posterior pro- cesses.",Non-OADS,/arxiv_data1/oa_pdf/c8/20/ijmsv11p0134.PMC3894397.pdf
11     http://www.medsci.org  141  Abbreviations   LBW: Lateral bone window of sella turcica; APD:  Distance between anterior clinoid process and post e- rior clinoid process; MTD: Maximum traverse dia m- eter; MLD: Maximum longitudinal diameter; STB:  Sella turcica bridge; MCP: Middle clinoid process;  LBH: Height of lateral bone of pituitary fossa; STD:  Depth of sella turcica; CCFH: Carotico -clinoid for a- men of Henle   Conclusion   The lateral bone window of sella turcica is an  important structure located between pituiary fossa and parasellar region.,Non-OADS,/arxiv_data1/oa_pdf/c8/20/ijmsv11p0134.PMC3894397.pdf
"11       http://www.medsci.org  142  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2014;  11(2): 142-150. doi: 10.7150/ ijms.7142   Research Paper   Single Nucleotide Polymorphism s in the Metastasis-   associated i n Colon C ancer -1 Gene Predict t he  Recurrence of Hepatocellular  Carcinoma after  Transplantation  Zhiyun Zheng1*, Sheng Gao1*, Zhe Yang1,2, Haiyang Xie1, Cheng Zhang1, Bingyi Lin1, Liming Wu1,2, Shusen   Zheng1,2, Lin Zhou1,2  1.",Non-OADS,/arxiv_data1/oa_pdf/20/e9/ijmsv11p0142.PMC3894398.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/20/e9/ijmsv11p0142.PMC3894398.pdf
11     http://www.medsci.org  143  timated to occur in China [1].,Non-OADS,/arxiv_data1/oa_pdf/20/e9/ijmsv11p0142.PMC3894398.pdf
"11     http://www.medsci.org  144  tissue  and adjacent normal tissue  using DNeasy Ti s- sue Kit (Qiagen,  Valencia, CA) according to the ma n- ufacturer’s  instructions.",Non-OADS,/arxiv_data1/oa_pdf/20/e9/ijmsv11p0142.PMC3894398.pdf
"2) by analysis of HapMap  geno typing data  in Chinese (http://www.hapmap.org),  with high  frequencies [minor allelic frequency (MAF) >0.1] ac- cording to the  method used by Carlson et al [20].",Non-OADS,/arxiv_data1/oa_pdf/20/e9/ijmsv11p0142.PMC3894398.pdf
11       http://www.medsci.org  145  Analysis of SNP frequencies and HCC  development  as well as tumor recurrence and  overall survival   Five SNPs in the MACC1  gene were genotyped  in tumorous tissue samples and  adjacent normal ti s- sue sample s of HCC patients with LT .,Non-OADS,/arxiv_data1/oa_pdf/20/e9/ijmsv11p0142.PMC3894398.pdf
"11       http://www.medsci.org  146  Then, further assessment was performed by  univariate and multivariate Cox regression analysis   for the impact of SNP rs1990172 or SNP rs975263  on  recurrence and overall survival in HCC patients  treated with LT on the basis of an additive, dominant,  recessive and overdominant model of inheritance,  respectively.",Non-OADS,/arxiv_data1/oa_pdf/20/e9/ijmsv11p0142.PMC3894398.pdf
11     http://www.medsci.org  147  Table 4.,Non-OADS,/arxiv_data1/oa_pdf/20/e9/ijmsv11p0142.PMC3894398.pdf
"11     http://www.medsci.org  148    Figure 2 Kaplan -Meier curve of MACC1 SNP rs975263 on recurrence -free survival for HCC patients undergoing LT in an additive( A), dominant( B),  recessive( C), and overdominant model( D) of inheritance, respectively.",Non-OADS,/arxiv_data1/oa_pdf/20/e9/ijmsv11p0142.PMC3894398.pdf
11     http://www.medsci.org  149  the prognosis  of HCC.,Non-OADS,/arxiv_data1/oa_pdf/20/e9/ijmsv11p0142.PMC3894398.pdf
"In fact, these two SNPs are  in  strong linkage disequilibrium with  each other  (r 2=0.858; http://www.hapmap.org ).",Non-OADS,/arxiv_data1/oa_pdf/20/e9/ijmsv11p0142.PMC3894398.pdf
11     http://www.medsci.org  150  References   1.,Non-OADS,/arxiv_data1/oa_pdf/20/e9/ijmsv11p0142.PMC3894398.pdf
"1 1      http://www.medsci.org  151  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2014;  11(2): 151-157. doi: 10.7150/ ijms.7152   Research Paper   Serum Osteocalcin  Is Significantly Related to Indices o f  Obesity a nd Lipid Profile in Malaysian Men  Kok-Yong Chin1, Soelaiman Ima -Nirwana1, Isa Naina Mohamed1, Fairus Ahmad2, Elvy Suhana Mohd  Ramli2, Amilia Aminuddin3, Wan Zurinah Wan Ngah4   1.",Non-OADS,/arxiv_data1/oa_pdf/13/04/ijmsv11p0151.PMC3894399.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-n c-nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/13/04/ijmsv11p0151.PMC3894399.pdf
"11     http://www.medsci.org  152  intracerebroventricular infusion exerted negative e f- fects on bone mass of rats (6, 7).",Non-OADS,/arxiv_data1/oa_pdf/13/04/ijmsv11p0151.PMC3894399.pdf
"11     http://www.medsci.org  153  Diagnostics, Illinois, USA).",Non-OADS,/arxiv_data1/oa_pdf/13/04/ijmsv11p0151.PMC3894399.pdf
11     http://www.medsci.org  154  Table 1: Characteristics of the subjects.,Non-OADS,/arxiv_data1/oa_pdf/13/04/ijmsv11p0151.PMC3894399.pdf
11     http://www.medsci.org  155  Table 5.,Non-OADS,/arxiv_data1/oa_pdf/13/04/ijmsv11p0151.PMC3894399.pdf
11     http://www.medsci.org  156  (254 men) and Bao et al.,OADS,/arxiv_data1/oa_pdf/13/04/ijmsv11p0151.PMC3894399.pdf
11     http://www.medsci.org  157  obesity and lipid profile in men.,Non-OADS,/arxiv_data1/oa_pdf/13/04/ijmsv11p0151.PMC3894399.pdf
"1 1      http://www.medsci.org  158  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2014;  11(2): 158-163. doi: 10.7150/ ijms.7567   Research Paper   A Nonsense Mutation of γD-crystallin  Associated with  Congenital Nuclear and Posterior Polar Cataract  in a  Chinese Family   Yi Zhai1,2, Jinyu  Li1,2,Yanan Zhu1,2, Yan Xia3,Wei Wang1,2,Yinhui Yu1,2, Ke Yao1,2  1.",Non-OADS,/arxiv_data1/oa_pdf/04/aa/ijmsv11p0158.PMC3894400.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/04/aa/ijmsv11p0158.PMC3894400.pdf
"11     http://www.medsci.org  159  Methods   The research protocols of this study adhered to  the guidelines of the Declaration of Helsinki and were  approved by the Medical Ethics Committees of the  Second Affiliated Hospital, College of Medicine,  Zhejiang University (Hangzhou, China).",Non-OADS,/arxiv_data1/oa_pdf/04/aa/ijmsv11p0158.PMC3894400.pdf
Bioinformatics Analysis   The γD -crystallin amino acid sequence s were  obtained from the NCBI Gene Database  (http://www.ncbi.nlm.nih.gov/gene/).,OADS,/arxiv_data1/oa_pdf/04/aa/ijmsv11p0158.PMC3894400.pdf
We also used the BEST/COREX web server  (http://best.bio.jhu.edu/BEST/index.php ) to predict  the stability of the native and mutant proteins.,OADS,/arxiv_data1/oa_pdf/04/aa/ijmsv11p0158.PMC3894400.pdf
"11     http://www.medsci.org  160  member II:2 was 0.1/0.1 due to amblyopia, and he still  exhibited severe horizontal nystagmus.",Non-OADS,/arxiv_data1/oa_pdf/04/aa/ijmsv11p0158.PMC3894400.pdf
"Moreover, this mutation  was not present in either the 1000 Genomes Project   database ( http://browser.1000genomes.org/index.",Non-OADS,/arxiv_data1/oa_pdf/04/aa/ijmsv11p0158.PMC3894400.pdf
"html ) or the NHLBI Exome Variant Server (EVS,  http://evs.gs.washington.edu/EVS/ ).",OADS,/arxiv_data1/oa_pdf/04/aa/ijmsv11p0158.PMC3894400.pdf
11     http://www.medsci.org  161    Figure 3.,Non-OADS,/arxiv_data1/oa_pdf/04/aa/ijmsv11p0158.PMC3894400.pdf
11     http://www.medsci.org  162  gene that cause childhood cataracts have been ident i- fied in more than 23 families thus far (Table 3) [16 -37].,Non-OADS,/arxiv_data1/oa_pdf/04/aa/ijmsv11p0158.PMC3894400.pdf
"11     http://www.medsci.org  163  a tail, lose transparency.",Non-OADS,/arxiv_data1/oa_pdf/04/aa/ijmsv11p0158.PMC3894400.pdf
"11       http://www.medsci.org  164  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2014;  11(2): 164-171. doi: 10.7150/ ijms.6745   Research Paper   Aberrant DNA Methylation of G -protein -coupled Bile  Acid Receptor Gpbar1 (TGR5 ) is a Potential Biomarker  for Hepatitis B Virus Associated Hepatocellular  Carcinoma   Li-Yan Han1, 2, Yu-Chen Fan1, 2, Nan -Nan Mu3, Shuai Gao1, Feng Li1, Xiang -Fen Ji1, Cheng -Yun Dou1, Kai  Wang1, 2  1.",Non-OADS,/arxiv_data1/oa_pdf/c4/2f/ijmsv11p0164.PMC3894401.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/c4/2f/ijmsv11p0164.PMC3894401.pdf
11     http://www.medsci.org  165  5-years survival of HCC was as low as about 0%- 10%  [3].,Non-OADS,/arxiv_data1/oa_pdf/c4/2f/ijmsv11p0164.PMC3894401.pdf
"11     http://www.medsci.org  166  Department of Medical Imaging, Qilu Hospital who  was unaware of patients’ characteristics.",Non-OADS,/arxiv_data1/oa_pdf/c4/2f/ijmsv11p0164.PMC3894401.pdf
"11     http://www.medsci.org  167  tients (χ2=29.35, p<0.01) and HCs (χ2=28.29, p<0.01).",OADS,/arxiv_data1/oa_pdf/c4/2f/ijmsv11p0164.PMC3894401.pdf
11     http://www.medsci.org  168  was no significan t difference between AUC of serum  AFP and TGR5  promoter methylation (p=0.388) (Fi g- ure 4).,Non-OADS,/arxiv_data1/oa_pdf/c4/2f/ijmsv11p0164.PMC3894401.pdf
11     http://www.medsci.org  169  Table 4 .,Non-OADS,/arxiv_data1/oa_pdf/c4/2f/ijmsv11p0164.PMC3894401.pdf
11     http://www.medsci.org  170  nation of AFP and TGR5  methylation with AFP alone  in discriminating HCC from CHB patients and  showed that the combination of AFP and TGR5   methylation could enhance the diagnostic value of AFP at different cut -off points.,Non-OADS,/arxiv_data1/oa_pdf/c4/2f/ijmsv11p0164.PMC3894401.pdf
11     http://www.medsci.org  171  14.,Non-OADS,/arxiv_data1/oa_pdf/c4/2f/ijmsv11p0164.PMC3894401.pdf
"1 1      http://www.medsci.org  172  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2014;  11(2): 172-179. doi: 10.7150/ ijms.6875   Research Paper   Intracellular Distributing and Interferon -γ Secretion of  Human Interleukin -18 in BxPC -3 Cells  Jin Yang1*, Linlin Chen1*, Bin Xu1, Jian Xu2, Jinquan Sun2, Wen Shen2, Ting Zhang2  1.",Non-OADS,/arxiv_data1/oa_pdf/42/d9/ijmsv11p0172.PMC3894402.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/42/d9/ijmsv11p0172.PMC3894402.pdf
11     http://www.medsci.org  173  effects were reported [5].,Non-OADS,/arxiv_data1/oa_pdf/42/d9/ijmsv11p0172.PMC3894402.pdf
11     http://www.medsci.org  174    Figure 1.,Non-OADS,/arxiv_data1/oa_pdf/42/d9/ijmsv11p0172.PMC3894402.pdf
"11     http://www.medsci.org  175  version 1 8.0 (SPSS, Inc. Chicago,  IL, USA).",Non-OADS,/arxiv_data1/oa_pdf/42/d9/ijmsv11p0172.PMC3894402.pdf
1 1      http://www.medsci.org  176  3.,Non-OADS,/arxiv_data1/oa_pdf/42/d9/ijmsv11p0172.PMC3894402.pdf
11     http://www.medsci.org  177  Table 3.,Non-OADS,/arxiv_data1/oa_pdf/42/d9/ijmsv11p0172.PMC3894402.pdf
"11     http://www.medsci.org  178  Mu2), C -terminal 20 amino  acid peptide  (form of  Mu3), and middle 20  amino  acid peptide (form of  Mu4) of hIL -18 cDNA respectively, which were i n- serted into p EGFP -C1.",Non-OADS,/arxiv_data1/oa_pdf/42/d9/ijmsv11p0172.PMC3894402.pdf
"1 1      http://www.medsci.org  179  The results of RT -PCR products  and express ion  level  of hIL-18 in BxPC -3 cells revealed that five r e- combinant plasmids were transfected into BxPC -3  cells successfully , and all mutants of IL -18 were active  in IL-18 induction ( P<0.05) , although quantity of in- duced IL- 18 were decreased rapidly , autocrine e x- pression of IL -18 in BxPC -3 cells is transient.",Non-OADS,/arxiv_data1/oa_pdf/42/d9/ijmsv11p0172.PMC3894402.pdf
"11       http://www.medsci.org  180  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2014;  11(2): 180-191. doi: 10.7150/ ijms.6283   Research Paper   Sex-Steroid Regulation  of Relaxin Receptor Isoforms  (RXFP1 & RXFP2) Expression in the Patellar Tendon  and Lateral Collateral Ligament of Female WKY Rats   Firouzeh Dehghan1, Sekaran Muniandy2, Ashril Yusof3 and Naguib  Salleh1  1.",Non-OADS,/arxiv_data1/oa_pdf/91/86/ijmsv11p0180.PMC3894403.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/91/86/ijmsv11p0180.PMC3894403.pdf
11     http://www.medsci.org  181  [8] however is required to maintain pregnancy in rats  and pigs  [10].,Non-OADS,/arxiv_data1/oa_pdf/91/86/ijmsv11p0180.PMC3894403.pdf
11     http://www.medsci.org  182  logical and supra -physiological plasma levels in f e- male rats respectively (Refer Table 1 for plasma level  for the related doses of hormones administered).,Non-OADS,/arxiv_data1/oa_pdf/91/86/ijmsv11p0180.PMC3894403.pdf
11     http://www.medsci.org  183  used to determine the level of significance with p<  0.05 was considered as significant.,OADS,/arxiv_data1/oa_pdf/91/86/ijmsv11p0180.PMC3894403.pdf
"11     http://www.medsci.org  184  In figure 6, the expression of RXFP2 mRNA in  the lateral collateral ligament was increased following  progesterone treatment which was 1.58 fold higher  than the control.",Non-OADS,/arxiv_data1/oa_pdf/91/86/ijmsv11p0180.PMC3894403.pdf
"11     http://www.medsci.org  185    Figure 3:  The expression of RXFP1 protein in the total homogenate of the patellar  tendon from ovariectomised rats treated with different sex -steroids: C - control; 0.2E –   0.2µg/kg estrogen; 2E - 2µg/kg estrogen, 20E -  20µg/kg estrogen; 50E – 50µg/kg estrogen; P –  4mg progesterone; 125T –  125µg testosterone; 250T –  250µg testosterone PT -  patellar  tendon.",Non-OADS,/arxiv_data1/oa_pdf/91/86/ijmsv11p0180.PMC3894403.pdf
"11     http://www.medsci.org  186    Figure 5:  The expression of RXFP2 protein in the total homogenate of the lateral collateral ligament from ovariectomised rats treated w ith different sex -steroids: C - control;  0.2E – 0.2µg/kg estrogen; 2E - 2µg/kg estrogen, 20E - 20µg/kg estrogen; 50E –50µg/kg estrogen; P – 4mg progesterone; 125T – 125µg testosterone; 250T – 250µg testosterone,  LCL-lateral collateral ligament.",Non-OADS,/arxiv_data1/oa_pdf/91/86/ijmsv11p0180.PMC3894403.pdf
"11     http://www.medsci.org  187    Figure 7:  The expression of RXFP2 protein in the total homogenate of the patellar  tendon from ovariectomised rats treated with different sex -steroids: C - control; 0.2E –   0.2µg/kg estrogen; 2E - 2µg/kg estrogen, 20E - 20µg/kg estrogen; 50E –50µg/kg estrogen; P – 4mg progesterone; 125T – 125µg testosterone; 250T – 250µg testosterone,  PT-patella r tendon.",Non-OADS,/arxiv_data1/oa_pdf/91/86/ijmsv11p0180.PMC3894403.pdf
11     http://www.medsci.org  188  form expressed in the patellar  tendon and lateral co l- lateral ligament of the rat knee joint.,Non-OADS,/arxiv_data1/oa_pdf/91/86/ijmsv11p0180.PMC3894403.pdf
11     http://www.medsci.org  189  consumption of oral contraceptive pills (OCP) that  contains 15 to 50 µ g estrogen [51] .,Non-OADS,/arxiv_data1/oa_pdf/91/86/ijmsv11p0180.PMC3894403.pdf
11     http://www.medsci.org  190  References   1.,Non-OADS,/arxiv_data1/oa_pdf/91/86/ijmsv11p0180.PMC3894403.pdf
11     http://www.medsci.org  191  53.,Non-OADS,/arxiv_data1/oa_pdf/91/86/ijmsv11p0180.PMC3894403.pdf
"1 1      http://www.medsci.org  192  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2014;  11(2): 192-198. doi: 10.7150/ ijms.6295   Research Paper   Retrospective  Evaluation of Standard Diagnostic  Procedures in Identification of the Causes of  New-Onset Syndrome of inappropriate Antidiuresis  Chih -Yang Hsu1, Chieh -Liang Chen1,2, Wei- Chieh Huang1, Po-Tsang Lee1, 2, Hua -Chang Fang1, 2, Kang -Ju  Chou1,2  1.",Non-OADS,/arxiv_data1/oa_pdf/51/b6/ijmsv11p0192.PMC3894404.pdf
This is an open- access article dis tributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/51/b6/ijmsv11p0192.PMC3894404.pdf
1 1      http://www.medsci.org  193  Introduction  Syndrome of inappropriate antidiure sis (SIAD)  is the most common cause  of euvolemic hyp o- natremia.,Non-OADS,/arxiv_data1/oa_pdf/51/b6/ijmsv11p0192.PMC3894404.pdf
11     http://www.medsci.org  194  lignancy in terminal stage or refractory respiratory  failure) with sustained hypona tremia till the date of  mortality or loss of follow -up.,Non-OADS,/arxiv_data1/oa_pdf/51/b6/ijmsv11p0192.PMC3894404.pdf
11     http://www.medsci.org  195  completely  normal for those whose causes of SIAD  were drug related reactions and post -surgery related  reactions.,Non-OADS,/arxiv_data1/oa_pdf/51/b6/ijmsv11p0192.PMC3894404.pdf
11     http://www.medsci.org  196  lated later from sputum for two and gastric juice for  three patients.,Non-OADS,/arxiv_data1/oa_pdf/51/b6/ijmsv11p0192.PMC3894404.pdf
1 1      http://www.medsci.org  197  Table 5.,Non-OADS,/arxiv_data1/oa_pdf/51/b6/ijmsv11p0192.PMC3894404.pdf
11     http://www.medsci.org  198  cause was originated from these sites.,Non-OADS,/arxiv_data1/oa_pdf/51/b6/ijmsv11p0192.PMC3894404.pdf
"11       http://www.medsci.org  199  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2014;  11(2): 199-208. doi: 10.7150/ ijms.7178   Research Paper   Prolyl Endopeptidase  Activity Is Correlated with  Colorectal Cancer Prognosis  Gorka Larrinaga1,2,6, Itxaro Perez1,2, 6, Lorena Blanco2, 6, Begoña Sanz2, 6, Peio Errarte2, 6, Maider Beitia2,6,  María C. Etxezarraga3, 6, Alberto Loizate4, 6, Javier Gil2, 6, Jon Irazusta2, 6, José I. López5, 6  1.",Non-OADS,/arxiv_data1/oa_pdf/b3/e5/ijmsv11p0199.PMC3894405.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/b3/e5/ijmsv11p0199.PMC3894405.pdf
"11     http://www.medsci.org  200  clinical management of patients once the lesion d e- velops, and to improve survival.",Non-OADS,/arxiv_data1/oa_pdf/b3/e5/ijmsv11p0199.PMC3894405.pdf
11     http://www.medsci.org  201  Table 1.,Non-OADS,/arxiv_data1/oa_pdf/b3/e5/ijmsv11p0199.PMC3894405.pdf
"11     http://www.medsci.org  202  mation, PEP activity differences in tissue and plasma  were analyzed with parametric (Student t ) and  non- parametric (Mann -Whitney test) probes, respec- tively.",OADS,/arxiv_data1/oa_pdf/b3/e5/ijmsv11p0199.PMC3894405.pdf
11     http://www.medsci.org  203        Figure 2.,Non-OADS,/arxiv_data1/oa_pdf/b3/e5/ijmsv11p0199.PMC3894405.pdf
"11     http://www.medsci.org  204  (12 ± 0.74 UP/L vs. 9.6 ± 0.62 UP/L, Mann -Whitney  test p<0.05) (Fig.",Non-OADS,/arxiv_data1/oa_pdf/b3/e5/ijmsv11p0199.PMC3894405.pdf
11     http://www.medsci.org  205         Figure 5.,Non-OADS,/arxiv_data1/oa_pdf/b3/e5/ijmsv11p0199.PMC3894405.pdf
"11       http://www.medsci.org  206  Discussion   PEP is a serine peptidase involved in different i- ation, development and carcinogenesis of several ti s- sues [14 , 16, 17, 19, 22, 24].",Non-OADS,/arxiv_data1/oa_pdf/b3/e5/ijmsv11p0199.PMC3894405.pdf
11     http://www.medsci.org  207  this enzyme in neoplasia most probably is the result of  the sum of its different actions [17].,Non-OADS,/arxiv_data1/oa_pdf/b3/e5/ijmsv11p0199.PMC3894405.pdf
11     http://www.medsci.org  208  30.,Non-OADS,/arxiv_data1/oa_pdf/b3/e5/ijmsv11p0199.PMC3894405.pdf
"1 1      http://www.medsci.org  209  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2014;  11(2): 209-214.  doi: 10.7150/ ijms.6801   Review  Masticatory Deficiency as a Risk Factor for Cognitive  Dysfunction  Francisco Bruno Teixeira1, Luanna de Melo Pereira Fernandes1,2, Patrycy Assis Tavares Noronha3, Marcio  Antonio Raiol dos Santos1, Walace Gomes -Leal3, Cristiane do Socorro Ferraz Maia2, Rafael Rodrigues  Lima1   1.",Non-OADS,/arxiv_data1/oa_pdf/7c/9f/ijmsv11p0209.PMC3894406.pdf
This is an open -access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/7c/9f/ijmsv11p0209.PMC3894406.pdf
11     http://www.medsci.org  210  portance.,Non-OADS,/arxiv_data1/oa_pdf/7c/9f/ijmsv11p0209.PMC3894406.pdf
11     http://www.medsci.org  211  The consistency of the chewing gum may con- tribute to the discrepa ncies in effects observed in  studies using fMRI and PET.,Non-OADS,/arxiv_data1/oa_pdf/7c/9f/ijmsv11p0209.PMC3894406.pdf
"11     http://www.medsci.org  212  line[10,68]  and dopamine[44] concomitant with reduced  levels of synaptophysin have been observed in the  hippocampus following removal of molar teeth [68].",Non-OADS,/arxiv_data1/oa_pdf/7c/9f/ijmsv11p0209.PMC3894406.pdf
11     http://www.medsci.org  213  tivity during chewing may improve certain motor  functions related to this motor behavior[84].,Non-OADS,/arxiv_data1/oa_pdf/7c/9f/ijmsv11p0209.PMC3894406.pdf
Projeção da população do Brasil  por sexo e idade para o período 1980-2050: revisão 2004.  ftp://ftp.ibge.gov.br/Estimativas_Projecoes_Populacao/Revisao2004_Projec oes_1980_2050.,OADS,/arxiv_data1/oa_pdf/7c/9f/ijmsv11p0209.PMC3894406.pdf
11     http://www.medsci.org  214  46.,Non-OADS,/arxiv_data1/oa_pdf/7c/9f/ijmsv11p0209.PMC3894406.pdf
"1 1      http://www.medsci.org  215  IInntteerrnnaattiioonnaall  JJoouurrnnaall  ooff  MMeeddiiccaall  SScciieenncceess   2014;  11(2): 215-221.  doi: 10.7150/ ijms.7231   Research Paper   Gene Expression Analysis  of TREM1  and GRK2 in  Polymorphonuclear Leukocytes as the Surrogate  Biomarkers of Acute Bacterial Infections   Tsuneyuki Ubagai, Ryuichi Nakano, Hirotoshi Kikuchi, and Yasuo Ono   Department of Microbiology & Immunology, Teikyo University School of Medicine.",Non-OADS,/arxiv_data1/oa_pdf/54/94/ijmsv11p0215.PMC3894407.pdf
This is an open- access article distributed under the terms of the Creative Commons License (http://creativecommons.org/   licenses/by-nc -nd/3.0/).,Non-OADS,/arxiv_data1/oa_pdf/54/94/ijmsv11p0215.PMC3894407.pdf
"11     http://www.medsci.org  216   In acute bacterial infections such as pneumonia  and sepsis, PMNs are critical effector cells of the i n- nate immune system, which protect the host by mi- grating  to inflammatory sites and killing pathogenic  microbes.",Non-OADS,/arxiv_data1/oa_pdf/54/94/ijmsv11p0215.PMC3894407.pdf
"11     http://www.medsci.org  217  Complementary DNA synthesis   Total RNA was reverse transcribed to cDNA by  using SuperScript VILO cDNA synthesis kit (Invitr o- gen Life Technologies, CA, USA).",Non-OADS,/arxiv_data1/oa_pdf/54/94/ijmsv11p0215.PMC3894407.pdf
"PCR primer sets were des igned using  the Primer3  web site (http://bioinfo.ut.ee/primer3/),  and the primer sequences are shown in Table 2 [21].",OADS,/arxiv_data1/oa_pdf/54/94/ijmsv11p0215.PMC3894407.pdf
"11     http://www.medsci.org  218  vere pneumonia patient (patient I.D.# 16 and 16C*),  and 3 septic shock patients (patient I.D.# 22 and 22C*, 23 and 23C*, 24 and 24C*) recovered to those of  healthy subjects.",Non-OADS,/arxiv_data1/oa_pdf/54/94/ijmsv11p0215.PMC3894407.pdf
11     http://www.medsci.org  219    Figure 2. mRNA expression analys is of TREM1 .,Non-OADS,/arxiv_data1/oa_pdf/54/94/ijmsv11p0215.PMC3894407.pdf
"11     http://www.medsci.org  220  Discussion   Among phagocytes, PMNs are remarkable for  their migratory capacity.",Non-OADS,/arxiv_data1/oa_pdf/54/94/ijmsv11p0215.PMC3894407.pdf
11     http://www.medsci.org  221  8.,Non-OADS,/arxiv_data1/oa_pdf/54/94/ijmsv11p0215.PMC3894407.pdf
/C2112014 Rustgi This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/b5/a9/1.PMC3894408.pdf
[Keywords : familial pancreatic cancer; hereditary pancreatitis; BRCA2; genetic testing] 1Correspondence E-mail anil2@mail.med.upenn.edu Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.228452.113.,Non-OADS,/arxiv_data1/oa_pdf/b5/a9/1.PMC3894408.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/37/03/14.PMC3894409.pdf
4Corresponding author E-mail jtl10@cornell.edu Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.231886.113.,Non-OADS,/arxiv_data1/oa_pdf/37/03/14.PMC3894409.pdf
For example motor neurons eliminate in- dividual branches when neuromuscular junctions (NMJs) resolve states of polyinnervation to monoinnervation /C2112014 Tasdemir-Yilmaz and Freeman This article is distributed exclu- sively by Cold Spring Harbor Laboratory Press for the first six monthsafter the full-issue publication date (see http://genesdev.cshlp.org/site/ misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/df/aa/20.PMC3894410.pdf
"After six months, it is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported), as de- scribed at http://creativecommons.org/licenses/by-nc/3.0/.1Corresponding author E-mail marc.freeman@umassmed.edu Article published online ahead of print.",Non-OADS,/arxiv_data1/oa_pdf/df/aa/20.PMC3894410.pdf
Article and publication date are online at http://www.genesdev.org/cgi/doi/10.1101/gad.229518.113.,Non-OADS,/arxiv_data1/oa_pdf/df/aa/20.PMC3894410.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/8d/63/34.PMC3894411.pdf
Article and publication date are online at http://www.genesdev.or g/cgi/doi/10.1101/gad.233643.113.,Non-OADS,/arxiv_data1/oa_pdf/8d/63/34.PMC3894411.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/3e/f0/44.PMC3894412.pdf
"After six months, it is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported), as described at http:// creativecommons.org/licenses/by-nc/3.0/.3Present address: Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, Switzerland 4Corresponding authors E-mail nbonini@sas.upenn.edu E-mail agrigoriev@camden.rutgers.edu Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.226654.113.",Non-OADS,/arxiv_data1/oa_pdf/3e/f0/44.PMC3894412.pdf
"Computational analyses Mapping and histograms Adaptor sequences were removed from the 3 9ends of the reads in the Illumina fastQ-generated files using the fastx toolkit (http://hannonlab.cshl.edu/fastx_toolkit).The adapter sequences were as follows: 5 9adapter, 5 9-GUUCA-Abe et al.",OADS,/arxiv_data1/oa_pdf/3e/f0/44.PMC3894412.pdf
Change in the read number and percentage of total miRNAs and other classes of small RNAs All processed reads were first mapped to transposons annotated by FlyBase (ftp://ftp.flybase.net/genomes/Drosophila_melanogaster/current/fasta).,OADS,/arxiv_data1/oa_pdf/3e/f0/44.PMC3894412.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for t he first six months after the full- issue publication date (see http://genesdev.cshlp.org/site/misc/terms.,Non-OADS,/arxiv_data1/oa_pdf/6f/bd/58.PMC3894413.pdf
"After six months, it is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported), as described at http://creativecommons.org/licenses/by-nc/3.0/.5These authors contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/6f/bd/58.PMC3894413.pdf
7Corresponding authors E-mail strasser@wehi.edu.au E-mail gkelly@wehi.edu.au Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.232009.113.,Non-OADS,/arxiv_data1/oa_pdf/6f/bd/58.PMC3894413.pdf
"This article, published in Genes &Develop- ment , is available under a Creative Commons License (Attribution- NonCommercial 3.0 Unported), as descr ibed at http://creativecommons.org/ licenses/by-nc/3.0/.4Corresponding author E-mail stuart.austin66@gmail.com Article is online at http://www.genesde v.org/cgi/doi/10.1101/gad.231050.113.",Non-OADS,/arxiv_data1/oa_pdf/32/07/71.PMC3894414.pdf
This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issuepublication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/d5/ba/8.PMC3894415.pdf
2Corresponding authors E-mail rosbash@brandeis.edu E-mail menet@bio.tamu.edu Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.228536.113.,Non-OADS,/arxiv_data1/oa_pdf/d5/ba/8.PMC3894415.pdf
Additional information All data sets are publicly available on Gene Expression Omnibus data-base at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token =vreftaseme- sumjw &acc=GSE47145.,OADS,/arxiv_data1/oa_pdf/d5/ba/8.PMC3894415.pdf
"This article, published in Genes &Develop- ment , is available under a Creative Commons License (Attribution- NonCommercial 3.0 Unported), as described at http://creativecommons.org/ licenses/by-nc/3.0/.4Corresponding author E-mail lowes@mskcc.org Article is online at http: //www.genesdev.org/c gi/doi/10.1101/gad.232082.113.",Non-OADS,/arxiv_data1/oa_pdf/a3/0e/85.PMC3894416.pdf
"Image data were extracted with Agilent Feature Ex- traction software, and data were normalized using the MSKCC Bioinformatics Core Facility algorithm for array CGH (http://cbio.mskcc.org/CGCC) by the GCL.",OADS,/arxiv_data1/oa_pdf/a3/0e/85.PMC3894416.pdf
"Copyright © 2013 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2013.19.4.325 Clinical and Molecular Hepatology 2013;19:325-348 Review PREAMBLE Until recently, the major causes of end-stage liver disease in Ko - rea were chronic hepatitis B virus (HBV) and chronic hepatitis C vi - rus (HCV) infections and alcoholic liver disease.",Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
326 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325of ten gastroenterologists and two pediatricians specializing in  hepatology.,Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
327The Korean Association for the Study of the Liver (KASL) KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325NAFLD?,Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
Release of the guidelines and plan for updates The Korean version of the KASL Clinical Practice Guideline for  the Management of NAFLD was released and published in August  2013 on the KASL Web site ( http://www.kasl.org ).,Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"328 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325have been performed.4-7 The annual incidence of NAFLD was ap - proximately 86 cases per 1,000 persons in a study performed in  Japan.4 In contrast, the annual incidence was considerably lower,  at approximately 29 cases per 100,000 persons, in a study per - formed in the UK.6 According to a 5-year retrospective cohort  study performed domestically in health screening examinees, the  annual incidence was approximately 26 cases per 1,000 persons.7  The prevalence of NAFLD has varied according to the study sub - jects, diagnostic standards, and definition of NAFLD.",Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"329The Korean Association for the Study of the Liver (KASL) KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325to be the principal preceding disease of cryptogenic cirrhosis.39,40  Some prospective studies compared the natural history of cirrhosis  progressing from NASH and from HCV infection, and the authors  concluded that decompensation rates and overall mortality rates  were lower in patients with NASH cirrhosis.41-43 In a multinational  cohort study recently performed in 247 NAFLD patients with ad - vanced fibrosis or cirrhosis, the overall mortality rates were similar  in both groups of patients with cirrhosis induced by NASH and by  the HCV.39 The annual cumulative incidence of hepatocellular car - cinoma was estimated to be 2.6% in patients with NASH cirrhosis,  which was 2- to 3-fold lower than that in patients with cirrhosis  induced by the HCV.",Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"330 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325al, liver function tests, such as AST and ALT, and abdominal so - nography have commonly been performed.",Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"331The Korean Association for the Study of the Liver (KASL) KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325Magnetic resonance elastography The recently developed magnetic resonance elastography (MRE)  technique, which has only utilized in a few studies, was demon - strated to be useful in distinguishing between NAFL, NASH, and  fibrosis.75 Unlike TE, MRE enables the assessment of the entire liv - er; it has no observer dependency; and it can be performed in  obese patients.76 However, this technique is expensive and cannot  yet be regularly used in all medical institutions.",Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"332 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325of steatohepatitis or advanced fibrosis.54,80,98,99  [Recommendations] 4.",Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
333The Korean Association for the Study of the Liver (KASL) KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325for Korean NAFLD patients.122 [Recommendation] 7.,Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"334 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325antihyperlipidemic agent), viusid,145 and silibinin (milk thistle)146  have been investigated in the NASH population, but it is difficult  to make definitive recommendations on their use.",Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
335The Korean Association for the Study of the Liver (KASL) KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325[Recommendations] 10.,Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"336 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325have identified that pentoxifylline prevents liver injury caused by  oxidized lipid products by slowing the fat oxidation rate.183 In a pi - lot study of a small number of patients with NASH, pentoxifylline  showed improvement in AST and ALT levels and insulin resis - tance.184-186 Wagner et al administered pentoxifylline for 12 months  to 30 patients with NASH in a randomized, controlled  study.",Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"337The Korean Association for the Study of the Liver (KASL) KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325tient with a BMI greater than 40 kg/m2.200 Several studies have re - ported significant weight loss, in addition to NAFLD improvement,  due to bariatric surgery.",Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"338 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325NAFLD is characterized by macrovesicular steatosis, portal inflam - mation, and portal fibrosis, which are commonly observed in type  2 NAFLD and are distinct from adult NAFLD characteristics.",Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"339The Korean Association for the Study of the Liver (KASL) KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325atric and adolescent patients with NAFLD.228,230 In a prospective  study of NAFLD children and adolescents aged 3-19 years, lifestyle  modification including diet and exercise, improved ALT levels and  ultrasonographic findings.228 Moreover, a randomized, con - trolled  study investigated the effects of placebo and antioxidants  in 53 pediatric patients with NAFLD who made lifestyle modifica - tions.",Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"340 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325DV, et al.",OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
341The Korean Association for the Study of the Liver (KASL) KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325course of nonalcoholic fatty liver disease: a longitudinal study of  103 patients with sequential liver biopsies.,Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
342 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325biochemical markers and biopsy in patients with chronic hepatitis C.  Clin Chem 2004;50:1344-1355.,Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
343The Korean Association for the Study of the Liver (KASL) KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325fatty liver disease.,Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"WGO web site,  <http://www.worldgastroenterology.org/assets/export/user - files/2012_NASH%20and%20NAFLD_Final_long.pdf>.",OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"344 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325Y, et al.",OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"NIFDS web site, <http://rnd.mfds.go.kr/ >.",Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"Korea  Health Statistics 2009: Korea National Health and Nutrition Exami - nation Survey.KCDC web site, < http://knhanes.cdc.go.kr/knhanes/ index.do >.",OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
345The Korean Association for the Study of the Liver (KASL) KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.3251826.,Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
346 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325and meta-analysis of randomised trials.,Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"347The Korean Association for the Study of the Liver (KASL) KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325ano M, et al.",Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
348 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.325222.,Non-OADS,/arxiv_data1/oa_pdf/b6/49/cmh-19-325.PMC3894432.pdf
"Copyright © 2013 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2013.19.4.349 Clinical and Molecular Hepatology 2013;19:349-359 Review INTRODUCTION  Acute-on-chronic liver failure (ACLF) is an increasingly recog - nized distinct disease entity encompassing an acute deterioration  of liver function in patients with chronic liver disease.1  Scrutiny of the existing data indicates several important conclu - sions regarding ACLF.",Non-OADS,/arxiv_data1/oa_pdf/78/5d/cmh-19-349.PMC3894433.pdf
350 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.349sociated with cirrhosis have remained essentially unchanged over  20 years.2 This review summarizes the current understanding of  ACLF from clinical and pathophysiologic perspectives and provides  an overview for current areas of uncertainty.,Non-OADS,/arxiv_data1/oa_pdf/78/5d/cmh-19-349.PMC3894433.pdf
"Acute-on-chronic liver failure http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.349ACLF, two representative consensus definitions are commonly  used.",Non-OADS,/arxiv_data1/oa_pdf/78/5d/cmh-19-349.PMC3894433.pdf
"352 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.349patients with cirrhosis and acute decompensation (AD, defined by  development of ascites, encephalopathy, gastrointestinal hemor - rhage, bacterial infection) who were revealed to have organ failure  (defined by the chronic liver failure-sequential organ failure as - sessment [CLIF-SOFA] score) and high 28-day mortality rate (>  15%).",Non-OADS,/arxiv_data1/oa_pdf/78/5d/cmh-19-349.PMC3894433.pdf
"Acute-on-chronic liver failure http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.349Host response to injury (response, R) Host response determines the severity of injury.",Non-OADS,/arxiv_data1/oa_pdf/78/5d/cmh-19-349.PMC3894433.pdf
354 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.349Kidney dysfunction The most common organ to fail besides liver is the kidney.,Non-OADS,/arxiv_data1/oa_pdf/78/5d/cmh-19-349.PMC3894433.pdf
Acute-on-chronic liver failure http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.349derlying etiologies of acute deterioration of liver disease between  the East and the West.,Non-OADS,/arxiv_data1/oa_pdf/78/5d/cmh-19-349.PMC3894433.pdf
"356 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.349intestinal hemorrhage, or bacterial infection) and single liver fail - ure (or any other single ‘nonkidney’ organ failure) had a low risk of  death unless they also had kidney dysfunction and/or mild to  moderate hepatic encephalopathy.",Non-OADS,/arxiv_data1/oa_pdf/78/5d/cmh-19-349.PMC3894433.pdf
Acute-on-chronic liver failure http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.349tives is rarely necessary.,Non-OADS,/arxiv_data1/oa_pdf/78/5d/cmh-19-349.PMC3894433.pdf
358 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.349Acute-on-chronic liver failure: consensus recommendations of the  Asian Pacific Association for the study of the liver (APASL).,Non-OADS,/arxiv_data1/oa_pdf/78/5d/cmh-19-349.PMC3894433.pdf
Acute-on-chronic liver failure http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.349disease: a nationwide population-based case-control study.,Non-OADS,/arxiv_data1/oa_pdf/78/5d/cmh-19-349.PMC3894433.pdf
"Copyright © 2013 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2013.19.4.360 Clinical and Molecular Hepatology 2013;19:360-366 Review INTRODUCTION  Hepatic malignancies including hepatocellular carcinoma (HCC),  cholangiocarcinoma and hepatic metastasis are usually encoun - tered during practice.",Non-OADS,/arxiv_data1/oa_pdf/00/34/cmh-19-360.PMC3894434.pdf
Liver MRI using gadoxetic acid http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.360by the kidneys and a very small amount of contrast agent was  eliminated via the hepatobiliary system.,Non-OADS,/arxiv_data1/oa_pdf/00/34/cmh-19-360.PMC3894434.pdf
"362 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.360Imaging patterns on hepatobiliary phase im - ages As written above, gadolinium-based hepatocyte-specific MR  contrast agents have the dynamic phase of contrast enhancement,  which are similar to conventional extracellular contrast agents.",Non-OADS,/arxiv_data1/oa_pdf/00/34/cmh-19-360.PMC3894434.pdf
Liver MRI using gadoxetic acid http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.360function.,Non-OADS,/arxiv_data1/oa_pdf/00/34/cmh-19-360.PMC3894434.pdf
"364 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.360agents, similar imaging features are demonstrated during the dy - namic study: typical peripheral rim enhancement and central hy - pointensity due to necrosis.10 Because the metastatic lesions de - plete hepatocytes, the lesions are significantly hypointense on the  hepatobiliary phase without exception.",Non-OADS,/arxiv_data1/oa_pdf/00/34/cmh-19-360.PMC3894434.pdf
Liver MRI using gadoxetic acid http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.360“pseudo-wash-out” which is expected given the lack of hepato - cytes (Fig.,Non-OADS,/arxiv_data1/oa_pdf/00/34/cmh-19-360.PMC3894434.pdf
366 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.360functional information and are helpful to estimate hepatic func - tional reservoir.,Non-OADS,/arxiv_data1/oa_pdf/00/34/cmh-19-360.PMC3894434.pdf
"Copyright © 2013 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728        eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2013.19.4.367 Clinical and Molecular Hepatology 2013;19:367-369 Editorial Cirrhosis, the end stage of any chronic liver disease, can lead  to portal hypertension (PHT), which can lead to fatal complica - tions.",Non-OADS,/arxiv_data1/oa_pdf/02/25/cmh-19-367.PMC3894435.pdf
"368 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.367hepatitis C virus (HCV) cohorts, where the higher values in the  alcoholic group (alcoholic group, 34.9 kPa vs. HCV infected group,  20.5 kPa) suggest that LSM values must be closely interpreted  according to the causes of the liver disease.8 These differences  suggest that the extent of liver fibrosis and the degree of PHT are  more important in the alcoholic patients.",Non-OADS,/arxiv_data1/oa_pdf/02/25/cmh-19-367.PMC3894435.pdf
http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.367Future studies can be carried out to investigate the relationship  between LSM and HVPG in larger population of patients with ho - mogenous causes of liver disease applying the combined methods  to improve the weak correlation between LSM and HVPG values  over 10-12 mmHg.,Non-OADS,/arxiv_data1/oa_pdf/02/25/cmh-19-367.PMC3894435.pdf
"Copyright © 2013 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2013.19.4.370 Clinical and Molecular Hepatology 2013;19:370-375 Original Article The usefulness of non-invasive liver stiffness measure - ments in predicting clinically significant portal hyper - tension in cirrhotic patients: Korean data Won Ki Hong1, Moon Young Kim1, Soon Koo Baik1, Seung Yong Shin1, Jung Min Kim1, Yong Seok Kang1, Yoo Li Lim1,  Young Ju Kim2, Youn Zoo Cho1, Hye Won Hwang1, Jin Hyung Lee1, Myeong Hun Chae1, Hyoun A Kim1, Hye Won Kang1,  and Sang Ok Kwon1 1Departments of Internal Medicine and 2Radiology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine,  Korea Corresponding author :  Moon Young Kim Department of Internal Medicine, Wonju Serverance Christian Hospital,  Yonsei University Wonju College of Medicine, 20 Ilsan-ro, Wonju  220-701,  Korea Tel.",Non-OADS,/arxiv_data1/oa_pdf/2b/b8/cmh-19-370.PMC3894436.pdf
Transient elastography and portal hypertension http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.370INTRODUCTION  The prognosis and management of chronic liver diseases strong - ly depend on the severity of portal hypertension.1-6 Measurement  of the hepatic venous pressure gradient (HVPG) is the gold stan - dard for the assessment of the presence of portal hypertension  and correlates with the occurrence of its complications in patients  with cirrhosis.,Non-OADS,/arxiv_data1/oa_pdf/2b/b8/cmh-19-370.PMC3894436.pdf
"372 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.370Measurements of HVPG  After an overnight fast, the HVPG was measured.",OADS,/arxiv_data1/oa_pdf/2b/b8/cmh-19-370.PMC3894436.pdf
"Transient elastography and portal hypertension http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.370HVPG and LSM (r2=0.496, P< 0.05).",Non-OADS,/arxiv_data1/oa_pdf/2b/b8/cmh-19-370.PMC3894436.pdf
374 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.370ly depend on the severity of portal hypertension.,Non-OADS,/arxiv_data1/oa_pdf/2b/b8/cmh-19-370.PMC3894436.pdf
Transient elastography and portal hypertension http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.370portal hypertension.,Non-OADS,/arxiv_data1/oa_pdf/2b/b8/cmh-19-370.PMC3894436.pdf
"Copyright © 2013 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2013.19.4.376 Clinical and Molecular Hepatology 2013;19:376-381 Original Article Predicting factors of present hepatitis C virus infection  among patients positive for the hepatitis C virus anti - body Chi Hoon Lee, Hyun Phil Shin, Joung Il Lee, Kwang Ro Joo, Jae Myung Cha, Jung Won Jeon, Jun Uk Lim, Joon Ki Min,  Dong Hee Kim, Sung Wook Kang, and Hyun Jun Joung Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Korea Corresponding author :  Hyun Phil Shin Department of Internal Medicine, Kyung Hee University Hospital at  Gangdong, Kyung Hee University College of Medicine, 892 Dongnam-ro,  Gangdong-gu, Seoul 134-727, Korea Tel.",Non-OADS,/arxiv_data1/oa_pdf/fe/03/cmh-19-376.PMC3894437.pdf
Predicting factors of present HCV infection http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.376munoblot assay (RIBA) is the supplemental anti-HCV test with  high specificity.,Non-OADS,/arxiv_data1/oa_pdf/fe/03/cmh-19-376.PMC3894437.pdf
"378 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.376(DM), hemodialysis treatment, hemophilia, and HIV infection), in - dex values of anti-HCV IgG, and laboratory test results (including  platelet count, hemoglobin, total bilirubin, prothrombin time inter - national normalized ratio (PT INR), albumin, alanine transaminase  (ALT), and alkaline phosphatase (ALP) were reviewed retrospec - tively.",Non-OADS,/arxiv_data1/oa_pdf/fe/03/cmh-19-376.PMC3894437.pdf
"Predicting factors of present HCV infection http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.376values of anti-HCV, high ALT and low albumin levels were related  to the present HCV infection.",Non-OADS,/arxiv_data1/oa_pdf/fe/03/cmh-19-376.PMC3894437.pdf
380 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.376group.,Non-OADS,/arxiv_data1/oa_pdf/fe/03/cmh-19-376.PMC3894437.pdf
Predicting factors of present HCV infection http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.3767.,Non-OADS,/arxiv_data1/oa_pdf/fe/03/cmh-19-376.PMC3894437.pdf
"Copyright © 2013 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2013.19.4.382 Clinical and Molecular Hepatology 2013;19:382-388 Original Article The levels of liver enzymes and atypical lymphocytes  are higher in youth patients with infectious mononucle - osis than in preschool children Yan Wang*, Jun Li*, Yuan-yuan Ren, and Hong zhao Department of Infectious Diseases, Peking University First Hospital, Beijing, China Corresponding author :  Hong Zhao Department of Infectious Diseases, Peking University First Hospital, 8#  XiShiKu Street, XiCheng District, Beijing, 100034, China Tel.",Non-OADS,/arxiv_data1/oa_pdf/01/ed/cmh-19-382.PMC3894438.pdf
"Markedly elevated liver enzymes in youth with IM http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.382viral capsid antigen (VCA) in children aged 5-to 7-year old was  higher than 80% in early 1990s, contrasting to 59% in years  1995-1999.1 An early study published in 1994 addressed that al - most all the children younger than 10 years in Hong Kong had  been infected with EBV.2 A recent survey in year 2006 found that  the overall seropositive rate of EBV VCA IgG was 83.6% in chil - dren under 14 years old in Beijing.3 The positive rate in rural areas  was significantly higher (86.2%) than that in urban areas (80.8%).",Non-OADS,/arxiv_data1/oa_pdf/01/ed/cmh-19-382.PMC3894438.pdf
"384 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.382youth (older than 15-but younger than 24-year old, 101/287,  35.2%).",Non-OADS,/arxiv_data1/oa_pdf/01/ed/cmh-19-382.PMC3894438.pdf
Markedly elevated liver enzymes in youth with IM http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.382Table 3.,Non-OADS,/arxiv_data1/oa_pdf/01/ed/cmh-19-382.PMC3894438.pdf
"386 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.382More clinical signs in preschool children on  admission We noticed that there existed 2 age peaks of our 287 patients:  preschool ( ≤7-year old, 45.3%) and youth (from 15-to 24-year old,  35.2%), as shown in Figure 1.",Non-OADS,/arxiv_data1/oa_pdf/01/ed/cmh-19-382.PMC3894438.pdf
"Markedly elevated liver enzymes in youth with IM http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.382students.13-14 We collected patients with confirmed diagnose of IM  at all ages, hospitalized in paediatrics department and non-paedi - atrics department.",Non-OADS,/arxiv_data1/oa_pdf/01/ed/cmh-19-382.PMC3894438.pdf
388 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.382Eur J Haematol 2012;89:417-422.,Non-OADS,/arxiv_data1/oa_pdf/01/ed/cmh-19-382.PMC3894438.pdf
"Copyright © 2013 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2013.19.4.389 Clinical and Molecular Hepatology 2013;19:389-398 Original Article Ultrasonographic scoring system score versus liver stiff - ness measurement in prediction of cirrhosis Kyoung Min Moon1*, Gaeun Kim2*, Soon Koo Baik3,4,5, Eunhee Choi5, Moon Young Kim3,4,5, Hyoun A Kim3, Mee Yon Cho6,  Seung Yong Shin3, Jung Min Kim3, Hong Jun Park3, Sang Ok Kwon3, and Young Woo Eom4 1Department of Internal Medicine, Konyang University College of Medicine, Daejeon; 2Department of Nursing, Keimyung University  College of Nursing, Daegu; 3Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju; 4Cell Therapy and  Tissue Engineering Center, Yonsei University Wonju College of Medicine, Wonju; 5Institute of Lifestyle Medicine, Yonsei University Wonju  College of  Medicine, Wonju; 6Department of Pathology, Yonsei University Wonju College of Medicine, Wonju, Korea Corresponding author :  Soon Koo Baik Division of Gastoenterology and Hepatology, Department of Internal  Medicine, Yonsei University, Wonju College of Medicine, 162 Ilsan-ro,  Wonju 220-701, Korea Tel.",Non-OADS,/arxiv_data1/oa_pdf/4b/ba/cmh-19-389.PMC3894439.pdf
390 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.389liver samples.,Non-OADS,/arxiv_data1/oa_pdf/4b/ba/cmh-19-389.PMC3894439.pdf
Ultrasonographic scoring system of cirrhosis http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.389trasound examination to determine the USSS.,Non-OADS,/arxiv_data1/oa_pdf/4b/ba/cmh-19-389.PMC3894439.pdf
"392 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.389mild uneven or waveform surface and mildly blunted edge (=1),  and undulated or irregular nodular surface and blunted edge (=2).",Non-OADS,/arxiv_data1/oa_pdf/4b/ba/cmh-19-389.PMC3894439.pdf
Ultrasonographic scoring system of cirrhosis http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.389in kilopascals (kPa).,Non-OADS,/arxiv_data1/oa_pdf/4b/ba/cmh-19-389.PMC3894439.pdf
394 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.389Table 3.,Non-OADS,/arxiv_data1/oa_pdf/4b/ba/cmh-19-389.PMC3894439.pdf
Ultrasonographic scoring system of cirrhosis http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.3892 operators.,Non-OADS,/arxiv_data1/oa_pdf/4b/ba/cmh-19-389.PMC3894439.pdf
396 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.389was 0.885 (95% CI 0.826-0.945) (Fig.,Non-OADS,/arxiv_data1/oa_pdf/4b/ba/cmh-19-389.PMC3894439.pdf
"Ultrasonographic scoring system of cirrhosis http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.389DISCUSSION  LB has been regarded as the gold standard for estimating the  severity of fibrosis and diagnosing cirrhosis.1 However, noninvasive  methods to estimate the stage of fibrosis have been developed,26  because LB is an invasive procedure with risk of life-threatening  complications.3  Recently, LSM by TE has been identified as a promising nonin - vasive measurement of liver elasticity, which has a significant cor - relation to fibrosis.8 This novel method (with an average procedure  time of ~5 min) is a safe alternative to LB for the evaluation of fi - brosis in CLD.4 Additionally, several studies reported that LSM ap - peared to surpass US in the prediction of cirrhosis.27 However,  LSM has some limitations, including the confounding effects of in - flammatory activity and, to a lesser extent, steatosis on liver stiff - ness.28 In the case of patients with narrow intercostal spaces, asci - tes, or elevated liver enzymes, inspection of liver elasticity is less  accurate or unworkable.4,29-32 In addition, LSM findings should be  carefully interpreted, because food intake and the respiratory cycle  affect liver stiffness values.33,34 US is an effective form of imaging that has been used by physi - cians for more than half a century.35 Because of its low cost, ease  of performance, and high patient compliance,36 it has become the  most common and valuable diagnostic modality for detecting not  only parenchymal disease but also liver hemodynamics by Doppler  imaging.37 Hence, previous studies have evaluated several meth - ods for the diagnosis of cirrhosis using various US features.",Non-OADS,/arxiv_data1/oa_pdf/4b/ba/cmh-19-389.PMC3894439.pdf
398 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.389measurement by transient elastography in clinical practice.,Non-OADS,/arxiv_data1/oa_pdf/4b/ba/cmh-19-389.PMC3894439.pdf
"Copyright © 2013 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2013.19.4.399 Clinical and Molecular Hepatology 2013;19:399-408 Original Article Performance evaluation of the HepB Typer-Entecavir kit  for detection of entecavir resistance mutations in chron - ic hepatitis B Sang Hoon Ahn1,2,3*, Ji-Yong Chun4*, Soo-Kyung Shin4, Jun Yong Park1,2, Wangdon Yoo4, Sun Pyo Hong4, Soo-Ok Kim4,  and Kwang-Hyub Han1,2,3 1Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul; 2Liver Cirrhosis Clinical  Research Center, Seoul; 3Brain Korea 21 Project for Medical Science, Seoul; 4Research and Development Center, GeneMatrix Inc.,  Seongnam, Korea Corresponding author :  Soo-Ok Kim Research and Development Center, GeneMatrix Inc., KOREA BIO PARK,  700 Daewangpangyo-ro, Bundang-gu, Seongnam 463-400, Korea Tel.",Non-OADS,/arxiv_data1/oa_pdf/11/62/cmh-19-399.PMC3894440.pdf
"400 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.399rhosis or HCC was directly proportional to serum HBV DNA lev - els,4-6 and it appears that the sustained suppression of serum HBV  DNA replication is essential for impeding or reversing disease pro - gression.",Non-OADS,/arxiv_data1/oa_pdf/11/62/cmh-19-399.PMC3894440.pdf
Performance evaluation of the HepB typer-entecavir kit http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.399HBV DNA titer ( ≥60 IU/mL).,Non-OADS,/arxiv_data1/oa_pdf/11/62/cmh-19-399.PMC3894440.pdf
"402 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.399vision, Tarrytown, NY, USA), which has a detection limit of 2,000  copies/mL.",Non-OADS,/arxiv_data1/oa_pdf/11/62/cmh-19-399.PMC3894440.pdf
"Performance evaluation of the HepB typer-entecavir kit http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.399Effect of interfering substances To determine the effect of different interfering substances on  assay performance, serum samples containing HBV reference stan - dards at a titer of 1,500 copies/mL were spiked with a wafarin,  heparin, EDTA, sodium citrate, aspirin, ticlopidine, ACD, CPD,  CPDA, adefovir, lamivudine, entecavir or ethanol as described in  Materials and Methods.",Non-OADS,/arxiv_data1/oa_pdf/11/62/cmh-19-399.PMC3894440.pdf
"404 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.399dard (50,000 copies/mL) were spiked with HPV, HSV-1, HSV-2,  HTLV, HCV, HAV, adenovirus, VZV, or HIV as described in Materi - als and Methods.",Non-OADS,/arxiv_data1/oa_pdf/11/62/cmh-19-399.PMC3894440.pdf
"Performance evaluation of the HepB typer-entecavir kit http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.399in single codon was identified only by HepB Typer-Entecavir kit, as  a result of the inability of the direct sequencing assay to determine  the only wild type in the clinical samples.",Non-OADS,/arxiv_data1/oa_pdf/11/62/cmh-19-399.PMC3894440.pdf
"406 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.399of reference standards showed 99.9% agreement, demonstrating  that the HepB Typer-Entecavir kit provide highly precise and repro - ducible genotype results for HBV entecavir resistance mutation.",Non-OADS,/arxiv_data1/oa_pdf/11/62/cmh-19-399.PMC3894440.pdf
Supplementary material Table 1 can be found via http://e-cmh.org/ suppl/chm-19-4-399-s01 Supplementary material Figure 1 can be found via http://e-cmh.,Non-OADS,/arxiv_data1/oa_pdf/11/62/cmh-19-399.PMC3894440.pdf
Performance evaluation of the HepB typer-entecavir kit http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.3994.,Non-OADS,/arxiv_data1/oa_pdf/11/62/cmh-19-399.PMC3894440.pdf
"408 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.399ionization time of flight-based assay, restriction fragment mass  polymorphism.",Non-OADS,/arxiv_data1/oa_pdf/11/62/cmh-19-399.PMC3894440.pdf
"Copyright © 2013 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2013.19.4.409 Clinical and Molecular Hepatology 2013;19:409-416 Original Article HBsAg level and clinical course in patients with chronic  hepatitis B treated with nucleoside analogue: five years  of follow-up data Jeong Han Kim1, Yun Jung Choi1, Hee Won Moon2, Soon Young Ko1, Won Hyeok Choe1, and So Young Kwon1 1 Digestive Disease Center, Departments of Internal Medicine, 2Laboratory Medicine, Konkuk University School of Medicine,  Seoul, Korea Corresponding author :  Jeong Han Kim Digestive Disease Center, Department of Internal Medicine, Konkuk  University School of Medicine, Konkuk University Medical Center, 120-1  Neungdong-ro, Gwangjin-gu, Seoul 143-729, Korea Tel.",Non-OADS,/arxiv_data1/oa_pdf/ab/d9/cmh-19-409.PMC3894441.pdf
410 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.409between HBsAg level and clinical course in patients with CHB with  long-term nucleoside analogues treatment.,Non-OADS,/arxiv_data1/oa_pdf/ab/d9/cmh-19-409.PMC3894441.pdf
HBsAg level in CHB treatment with oral agent http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.409Table 2.,Non-OADS,/arxiv_data1/oa_pdf/ab/d9/cmh-19-409.PMC3894441.pdf
412 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.409Table 3.,Non-OADS,/arxiv_data1/oa_pdf/ab/d9/cmh-19-409.PMC3894441.pdf
"HBsAg level in CHB treatment with oral agent http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.409RESULTS Baseline characteristics Fourty-eight patients (37 [77.1%] males; median age, 49.5  years) were included in the study.",Non-OADS,/arxiv_data1/oa_pdf/ab/d9/cmh-19-409.PMC3894441.pdf
"414 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.409Korea.8  Since the 1960s, HBsAg has been the hallmark of HBV infec - tion.9 Studies that used newly available automated quantitative  assays have shown that serum HBsAg levels vary significantly dur - ing the different phases of chronic HBV infection and are inversely  correlated with the immune control of HBV; the higher the control,  the lower the HBsAg level.10 Several studies have shown that the  decline in serum HBsAg levels during treatment with peg-interfer - on mimics that of intrahepatic covalently closed circular DNA, sug - gesting that a decline in serum HBsAg level is associated with the  induction of an effective anti-HBV immune response.11-13 In con - trast, treatment with nucleoside analogues may induce pro - nounced HBV DNA declines; however, the effect on serum HBsAg  level is very limited and the HBsAg decline during treatment is  considerably slower than that observed for HBV DNA.3,14,15 There - fore, the clinical application of HBsAg level in patients treated  with nucleoside analogues is limited.10 Many patients were treated with LMV in our study.",Non-OADS,/arxiv_data1/oa_pdf/ab/d9/cmh-19-409.PMC3894441.pdf
HBsAg level in CHB treatment with oral agent http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.409served resistance is reported to be 24% if treated for >1 year and  70% if treated for >4 years.20 Fasano et al21 reported 11.7% HB - sAg clearance in HBeAg-negative patients with CHB successfully  treated with LMV monotherapy for at least 5 years.,Non-OADS,/arxiv_data1/oa_pdf/ab/d9/cmh-19-409.PMC3894441.pdf
416 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.409tion.,Non-OADS,/arxiv_data1/oa_pdf/ab/d9/cmh-19-409.PMC3894441.pdf
"Copyright © 2013 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2013.19.4.417 Clinical and Molecular Hepatology 2013;19:417-420 Case Report INTRODUCTION  Hepatorenal syndrome (HRS), a form of functional renal impair - ment, is one of the most serious complications in patients with  advanced liver cirrhosis or acute liver failure.",Non-OADS,/arxiv_data1/oa_pdf/a8/99/cmh-19-417.PMC3894442.pdf
418 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.417no evidence of cardiac dysfunction.,Non-OADS,/arxiv_data1/oa_pdf/a8/99/cmh-19-417.PMC3894442.pdf
Severe ischemic bowel necrosis caused by terlipressin http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.417no thrombus within vessel or free air in peritoneal cavity.,Non-OADS,/arxiv_data1/oa_pdf/a8/99/cmh-19-417.PMC3894442.pdf
"420 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.417ter treatment of terlipressin for variceal bleeding,10-12 but those  cases were unrelated to HRS.",Non-OADS,/arxiv_data1/oa_pdf/a8/99/cmh-19-417.PMC3894442.pdf
"Copyright © 2013 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2013.19.4.421 Clinical and Molecular Hepatology 2013;19:421-425 Case Report INTRODUCTION  Glycogenic hepatopathy (GH) was first identified at 1930 and it  is characterized by elevated liver enzyme, hepatomegaly, and gly - cogen accumulation within hepatocytes and it can be found in pa - tients with type I Diabetes Mellitus (DM) with poorly controlled  blood sugar.1,2 Clinically, GH has been known to have benign na - ture; however it is difficult to distinguish with nonalcoholic fatty  liver disease (NAFLD) which could progress into advance liver dis - ease without histological confirmation.2,3 Recently, we have diag - nosed three cases of GH presented marked serum transaminases  elevation more than 30 times of upper normal range as like acute hepatitis with poorly controlled type I DM history.",Non-OADS,/arxiv_data1/oa_pdf/50/e5/cmh-19-421.PMC3894443.pdf
422 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.421CASE REPORT Case 1  A 22-year old female was referred to a hepatologist for evalua - tion of elevated liver enzymes.,Non-OADS,/arxiv_data1/oa_pdf/50/e5/cmh-19-421.PMC3894443.pdf
Glycogen hepatopathy in Type I DM http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.421liver and mild hepatomegaly (Fig.,Non-OADS,/arxiv_data1/oa_pdf/50/e5/cmh-19-421.PMC3894443.pdf
"424 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.421UL, thyroid function test, serum ceruloplasmin level were all nor - mal.",Non-OADS,/arxiv_data1/oa_pdf/50/e5/cmh-19-421.PMC3894443.pdf
Glycogen hepatopathy in Type I DM http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.421l’insuline.,Non-OADS,/arxiv_data1/oa_pdf/50/e5/cmh-19-421.PMC3894443.pdf
"Copyright © 2013 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2013.19.4.426 Clinical and Molecular Hepatology 2013;19:426-430 Liver Pathology INTRODUCTION  Sclerosing hemangioma of the liver is an unusual tumor type.",Non-OADS,/arxiv_data1/oa_pdf/fa/30/cmh-19-426.PMC3894444.pdf
A sclerosing hemangioma of the liver http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.426tectomy.,Non-OADS,/arxiv_data1/oa_pdf/fa/30/cmh-19-426.PMC3894444.pdf
428 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.426lumen.,Non-OADS,/arxiv_data1/oa_pdf/fa/30/cmh-19-426.PMC3894444.pdf
"A sclerosing hemangioma of the liver http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.426mosiderin deposits are found in the majority of sclerosing heman - giomas and are often associated with dystrophic and psammoma - tous calcification or infarction.3 The basement membrane of a  sclerosing hemangioma can be detected by type IV collagen and  laminin immunostaining, which form rings around the vascular  components.",Non-OADS,/arxiv_data1/oa_pdf/fa/30/cmh-19-426.PMC3894444.pdf
"430 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.426able size that lack an elastic tissue.3 The terms cavernous heman - gioma, sclerosing hemangioma, and solitary fibrous nodule have  been used to describe different stages in the development and in - volution of the same lesions.11 The sclerotic area in a sclerosing  cavernous hemangioma is best explained by localized regressive  changes secondary to thrombosis, infarction, or hemorrhage.",Non-OADS,/arxiv_data1/oa_pdf/fa/30/cmh-19-426.PMC3894444.pdf
"Copyright © 2013 by The Korean Associa tion for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)  which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.pISSN 2287-2728       eISSN 2287-285X http://dx.doi.org/10.3350/cmh .2013.19.4.431 Clinical and Molecular Hepatology 2013;19:431-434 Liver Imaging INTRODUCTION  Clinical course, diagnosis and therapy of hepatic abscesses have  been changed for several decades according to development of  imaging modalities, antibiotics and treatment technique.1 Al- though, recently, the incidence of amebic hepatic abscess has  been decreasing in developed countries, pyogenic hepatic ab - scesses still often occur.",Non-OADS,/arxiv_data1/oa_pdf/dd/f4/cmh-19-431.PMC3894445.pdf
432 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.431cinoma with underlying alcoholic liver disease and intrahepatic  cholangitis.,Non-OADS,/arxiv_data1/oa_pdf/dd/f4/cmh-19-431.PMC3894445.pdf
Hepatic abscess mimicking hepatocellular carcinoma in a patient with alcoholic liver disease  http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.431tate dehydrogenase (441 IU/L) and CA19-9 (14.7 U/mL) were  markedly improved.,Non-OADS,/arxiv_data1/oa_pdf/dd/f4/cmh-19-431.PMC3894445.pdf
434 Clin Mol Hepatol Volume _19  Number _4  December 2013 http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.4.431update.,Non-OADS,/arxiv_data1/oa_pdf/dd/f4/cmh-19-431.PMC3894445.pdf
"Quantitative PCRLILR copy number was determined by quantitative PCR (qPCR), on genomic DNA extracted from 48 humancell lines from the International Histocompatibility Working Group ( http://www.ihwg.org/hla/ )u s i n gt h e QIAamp DNA Blood Midi Kit (QIAGEN) followingthe manufacturer's instruct ions.",Non-OADS,/arxiv_data1/oa_pdf/9f/f3/251_2013_Article_742.PMC3894450.pdf
LILR sequences were analysed for specificity using the primerBLAST tool from the National Centre for Biotechnology Information ( http://www.ncbi.nlm.nih.gov/ tools/primer-blast ).,OADS,/arxiv_data1/oa_pdf/9f/f3/251_2013_Article_742.PMC3894450.pdf
1997 ).bdN and dS values for previously reported LILRB1 (circles )a n d LILRB2 (squares ) sequences deposited in Genbank ( http://www.ncbi.nlm.nih.gov/genbank/ )78 Immunogenetics (2014) 66:73 –83,Non-OADS,/arxiv_data1/oa_pdf/9f/f3/251_2013_Article_742.PMC3894450.pdf
"The effects of the mutations on protein function were assessed by four online softwares, inclu- deing Polyphen2 (http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/),Pmut (http://mmb2.pcb.ub.es:8080/PMut/) and Panther (http://www.pantherdb.org/ tools/csnpScoreForm.jsp).",OADS,/arxiv_data1/oa_pdf/f4/54/srep03745.PMC3894538.pdf
"Briefly, using the Solexa QA the cutadapt (http://code.google.",Non-OADS,/arxiv_data1/oa_pdf/f4/54/srep03745.PMC3894538.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/f4/54/srep03745.PMC3894538.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3745 | DOI: 10.1038/srep03745 5",Non-OADS,/arxiv_data1/oa_pdf/f4/54/srep03745.PMC3894538.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3752 | DOI: 10.1038/srep03752 7",Non-OADS,/arxiv_data1/oa_pdf/36/72/srep03752.PMC3894547.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3744 | DOI: 10.1038/srep03744 5",Non-OADS,/arxiv_data1/oa_pdf/c9/5a/srep03744.PMC3894548.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3736 | DOI: 10.1038/srep03736 7",Non-OADS,/arxiv_data1/oa_pdf/3a/92/srep03736.PMC3894549.pdf
"TUSC3 gene expression, promoter methylation and gene copy number were analyzed using the Caleydo visualization software 47and publicly available TCGA (http://cancergenome.nih.gov/) datasets for prostate adenocarcinoma after obtaining a written permission from the TCGA Research Network.",OADS,/arxiv_data1/oa_pdf/b9/70/srep03739.PMC3894551.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/b9/70/srep03739.PMC3894551.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3739 | DOI: 10.1038/srep03739 9",Non-OADS,/arxiv_data1/oa_pdf/b9/70/srep03739.PMC3894551.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3741 | DOI: 10.1038/srep03741 5",Non-OADS,/arxiv_data1/oa_pdf/32/07/srep03741.PMC3894552.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/be/91/srep03748.PMC3894553.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3748 | DOI: 10.1038/srep03748 10",Non-OADS,/arxiv_data1/oa_pdf/be/91/srep03748.PMC3894553.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3754 | DOI: 10.1038/srep03754 8",Non-OADS,/arxiv_data1/oa_pdf/a1/1e/srep03754.PMC3894554.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3742 | DOI: 10.1038/srep03742 6",Non-OADS,/arxiv_data1/oa_pdf/9a/3c/srep03742.PMC3894555.pdf
The sequences were analysed with the BLASTn tool (http://blast.ncbi.nlm.nih.gov).,OADS,/arxiv_data1/oa_pdf/fc/88/srep03746.PMC3894556.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3746 | DOI: 10.1038/srep03746 4",Non-OADS,/arxiv_data1/oa_pdf/fc/88/srep03746.PMC3894556.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/76/dd/srep03751.PMC3894557.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3751 | DOI: 10.1038/srep03751 10",Non-OADS,/arxiv_data1/oa_pdf/76/dd/srep03751.PMC3894557.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3750 | DOI: 10.1038/srep03750 7",Non-OADS,/arxiv_data1/oa_pdf/22/fc/srep03750.PMC3894559.pdf
"Still, slip distributions vary among authors and processing methodo- logies59(see http://equake-rc.info/ for a extensive collection of fault rupture models for many earthquakes).",Non-OADS,/arxiv_data1/oa_pdf/8b/06/srep03646.PMC3894560.pdf
The PGV values obtained from the COSMOS virtual data center (http://db.cosmos-eq.org) have been interpolated using the surface function of Generic Mapping Tools on a 5-km interval grid.,OADS,/arxiv_data1/oa_pdf/8b/06/srep03646.PMC3894560.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/8b/06/srep03646.PMC3894560.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3646 | DOI: 10.1038/srep03646 9",Non-OADS,/arxiv_data1/oa_pdf/8b/06/srep03646.PMC3894560.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3753 | DOI: 10.1038/srep03753 7",Non-OADS,/arxiv_data1/oa_pdf/41/3c/srep03753.PMC3894561.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/67/8a/srep03735.PMC3894562.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3735 | DOI: 10.1038/srep03735 7",Non-OADS,/arxiv_data1/oa_pdf/67/8a/srep03735.PMC3894562.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3740 | DOI: 10.1038/srep03740 5",Non-OADS,/arxiv_data1/oa_pdf/da/d2/srep03740.PMC3894563.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3747 | DOI: 10.1038/srep03747 8",Non-OADS,/arxiv_data1/oa_pdf/d9/f2/srep03747.PMC3894564.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/66/ac/srep03692.PMC3894565.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3692 | DOI: 10.1038/srep03692 9",Non-OADS,/arxiv_data1/oa_pdf/66/ac/srep03692.PMC3894565.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3749 | DOI: 10.1038/srep03749 5",Non-OADS,/arxiv_data1/oa_pdf/aa/e6/srep03749.PMC3894566.pdf
"To view a copy of this license, visit  http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)",Non-OADS,/arxiv_data1/oa_pdf/5a/86/mtna201364a.PMC3894581.pdf
Supplementary Information accompanies this paper on the Molecular Therapy–Nucleic Acids website (http://www.nature.com/mtna)Molecular Therapy–Nucleic Acids is an open-access jour - nal published by Nature Publishing Group.,OADS,/arxiv_data1/oa_pdf/3a/2c/mtna201361a.PMC3894583.pdf
"To view a copy of this license, visit  http://creativecommons.org/licenses/by-nc-sa/3.0/",Non-OADS,/arxiv_data1/oa_pdf/3a/2c/mtna201361a.PMC3894583.pdf
"CORRIGENDUM TO: Seeing with the mind ’s eye: top-down, bottom-up, and conscious awareness Alumit Ishai Address: Institute of Neuroradiology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland ORIGINAL CITATION: F1000 Biology Reports 2010, 2:34 (doi:10.3410/B2-34) This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/26/b5/biolrep-02-34.1.PMC3894598.pdf
The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/b/2/34 The PDF of this article can be found at: http://f1000.com/prime/reports/b/2/34/pdf CORRIGENDUM: The author would like to acknowledge that this article is a modified version of their article previously published in Archives Italiennes de Biologie.,Non-OADS,/arxiv_data1/oa_pdf/26/b5/biolrep-02-34.1.PMC3894598.pdf
"CORRIGENDUM TO: Neuromodulation for treatment-resistant depression Paul E. Holtzheimer 1 and Helen S. Mayberg 2 Addresses: 1 Departments of Psychiatry and Surgery, Dartmouth-Hitchcock Medical Center, 5D, One Medical Center Drive, Lebanon NH 03756, USA; 2 Departments of Psychiatry and Neurology, Emory University School of Medicine, 1648 Pierce Drive Northeast, Atlanta, GA 30307, USA ORIGINAL CITATION: F1000 Medicine Reports 2012,4:22 (doi:10.3410/M4-22) This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/4d/3a/medrep-04-22.1.PMC3894606.pdf
"The electronic version of this article is the complete one and can be found at: http://f1000.com/reports/m/4/22 The PDF of this article can be found at: http://f1000.com/reports/m/4/22/pdf CORRIGENDUM: The authors regret that there was an omission from their Competing Interests section and wish to add the following: Dr. Mayberg consults and receives licensing fees for intellectual property related to deep brain stimulation for depression from St. Jude Medical, Inc.",Non-OADS,/arxiv_data1/oa_pdf/4d/3a/medrep-04-22.1.PMC3894606.pdf
"doi:10.1093/her/cyt103 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.or g/ licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/57/23/cyt103.PMC3894669.pdf
Available at: http://www.nascop.or.VMMC rollout in Kenya 129,Non-OADS,/arxiv_data1/oa_pdf/57/23/cyt103.PMC3894669.pdf
"The genome annotation has been updated; the latest version of TAIR, TAIR10 (The Arabidopsis Information Resource, http://www.arabidopsis.org/; Lamesch et al.",OADS,/arxiv_data1/oa_pdf/0c/ce/pct189.PMC3894704.pdf
"To date, the entire genomes of >40 plant species have been sequenced and published (NCBI Genome database, http://www.ncbi.nlm.nih.gov/genome/; NCBI Resource Coordinators 2013).",OADS,/arxiv_data1/oa_pdf/0c/ce/pct189.PMC3894704.pdf
"For example, the Gramene DB (http://www.gramene.org/; Jaiswal 2011, Youens-Clark et al.",Non-OADS,/arxiv_data1/oa_pdf/0c/ce/pct189.PMC3894704.pdf
"2011) providesdata resources for comparative analysis of grass genomes.TAIR maintains molecular biological and genetic data of the model plant A. thaliana , and provides GBrowse (the Generic Genome Browser, http://gbrowse.org/; Donlin 2009) for eightplant species, allowing comparison of gene models with A. thaliana .",OADS,/arxiv_data1/oa_pdf/0c/ce/pct189.PMC3894704.pdf
"The Sol Genomics Network (SGN) provides genomic, genetic, phenotypic and taxonomic information for membersof the Solanaceae family (http://solgenomics.net/; Bombarelyet al.",OADS,/arxiv_data1/oa_pdf/0c/ce/pct189.PMC3894704.pdf
The PlantGDB (http://www.plantgdb.org/; Duvick Plant Cell Physiol.,OADS,/arxiv_data1/oa_pdf/0c/ce/pct189.PMC3894704.pdf
Phytozome (http://www.phytozome.net/ ; Goodstein et al.,OADS,/arxiv_data1/oa_pdf/0c/ce/pct189.PMC3894704.pdf
"To solve this problem and provide a wide range ofresearchers with the beneﬁt of plant genome-related data, we have constructed the Plant Genome DataBase Japan (PGDBj, http://pgdbj.jp/?ln=en).",OADS,/arxiv_data1/oa_pdf/0c/ce/pct189.PMC3894704.pdf
Full text searches are run by Hyper Estraier (http://fallabs.com/hyperestraier/).,OADS,/arxiv_data1/oa_pdf/0c/ce/pct189.PMC3894704.pdf
"Construction of the Ortholog DB Approximately 500,000 amino acid sequences of 20 plant spe-cies classiﬁed in the Viridiplantae kingdom ( Table 1 ) were ob- tained from the NCBI RefSeq database (Release 57, NCBIReference Sequence database, http://www.ncbi.nlm.nih.gov/refseq/; NCBI Resource Coordinators 2013).",OADS,/arxiv_data1/oa_pdf/0c/ce/pct189.PMC3894704.pdf
1 The PGDBj portal website (http://pgdbj.jp/?ln=en).,Non-OADS,/arxiv_data1/oa_pdf/0c/ce/pct189.PMC3894704.pdf
"Moreover, tens of thousands of resources have been collectedand distributed for grain, legumes and grass by the NIAS Genebank at the Ministry of Agriculture, Forestry, and Fisheries (http://www.gene.affrc.go.jp/index_en.php; Takeyaet al.",Non-OADS,/arxiv_data1/oa_pdf/0c/ce/pct189.PMC3894704.pdf
"To facilitate the use of plant bioresources, we have incorpo- rated the SABRE2 (Systematic consolidation of Arabidopsis andother Botanical REsources2, http://saber.epd.brc.riken.jp/sabre2/SABRE2.cgi; Fukami-Kobayashi et al.",OADS,/arxiv_data1/oa_pdf/0c/ce/pct189.PMC3894704.pdf
"1.4.13, http://fallabs.com/hyperestraier/) was adopted to carry out full-text searchesagainst all contents of the DBs.",Non-OADS,/arxiv_data1/oa_pdf/0c/ce/pct189.PMC3894704.pdf
The MEGANTE web service is available athttps://megante.dna.affrc.go.jp/.,OADS,/arxiv_data1/oa_pdf/1c/3e/pct157.PMC3894707.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium,provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1c/3e/pct157.PMC3894707.pdf
The ﬁle contains the annotation information in bothMicrosoft Excel and GFF3 (http://www.sequenceontoloty.org/gff3.html) formats.,OADS,/arxiv_data1/oa_pdf/1c/3e/pct157.PMC3894707.pdf
"After retrievingFLcDNAs and ESTs for each species listed in Table 1 , we run a SeqClean script (http://sourceforge.net/projects/seqclean/)to remove poly(A) tails, vectors, low complexities and short sequences from the transcripts.",OADS,/arxiv_data1/oa_pdf/1c/3e/pct157.PMC3894707.pdf
The anno- tation process begins with ﬁltering out repeat elements de-tected by RepeatMasker (http://repeatmasker.org) with theMIPS Repeat Element Database (Nussbaumer et al.,OADS,/arxiv_data1/oa_pdf/1c/3e/pct157.PMC3894707.pdf
This service is avail-able for free at https://megante.dna.affrc.go.jp/.,Non-OADS,/arxiv_data1/oa_pdf/1c/3e/pct157.PMC3894707.pdf
"In agreement with this, a prediction programWoLF PSORT (http://wolfpsort.seq.cbrc.jp/) predicted the lo-calization of ONI3 in the chloroplast.",Non-OADS,/arxiv_data1/oa_pdf/9b/6a/pct154.PMC3894709.pdf
We noticed that an Arabidopsis HTH homolog (Os09g0363900) is located near this position in RAP-DB build3 (http://rapdb.dna.affrc.go.jp/).,OADS,/arxiv_data1/oa_pdf/9b/6a/pct154.PMC3894709.pdf
"http://www.thebsa.org.uk/images/stories/BSA_RP_PTA_FINAL_24Sept11_ MinorAmend06Feb12.pdf (accessed Feb 25th, 2013).",Non-OADS,/arxiv_data1/oa_pdf/cc/a4/IJA-53-60.PMC3894713.pdf
Recording of adverse events and follow-up   Adverse events were graded according to the National  Cancer Institute Common Terminology Criteria for Adverse Events  v 3.0 (http://ctep.cancer.gov) [14].,Non-OADS,/arxiv_data1/oa_pdf/77/a5/ONC-53-186.PMC3894716.pdf
"The following link provides the list of articles that are frequently accessed and downloaded, http://jbclinpharm.org/showstats.asp?a=ts Some of the most viewed and frequently downloaded articles  of JBCP (since September, 2012) are:•  S. Dwajani, V. S. Harish Kumar, D. Keerthi.",Non-OADS,/arxiv_data1/oa_pdf/1c/81/JBCP-4-1.PMC3894734.pdf
[http://www.jbclinpharm.org/article.asp?issn=0976-0105;year=2012;volume=3;issue=4;spage=332;epage=335;aulast=Dwajani].,Non-OADS,/arxiv_data1/oa_pdf/1c/81/JBCP-4-1.PMC3894734.pdf
[http://www.jbclinpharm.org/article.asp?issn=0976-0105;year=2012;volume=3;issue=4;spage=352;epage=357;aulast=Palit].,Non-OADS,/arxiv_data1/oa_pdf/1c/81/JBCP-4-1.PMC3894734.pdf
[http://www.jbclinpharm.org/temp/J Basic Clin Pharma 12115-4267481_115114.pdf].,Non-OADS,/arxiv_data1/oa_pdf/1c/81/JBCP-4-1.PMC3894734.pdf
[Total citations: 10– Source: Google Scholar].[http://www.jbclinpharm.org/temp/JBasicClinPharma14215-7105127_194411.pdf].,OADS,/arxiv_data1/oa_pdf/1c/81/JBCP-4-1.PMC3894734.pdf
For detailed information on the editorial board members of JBCP please visit http://jbclinpharm.org/editorialboard.asp.,Non-OADS,/arxiv_data1/oa_pdf/1c/81/JBCP-4-1.PMC3894734.pdf
"To facilitate faster review process, articles nowcan be submitted online (http://www.journalonweb.com/jbcp) and authors will receive a notification at every stage of the review process starting from the submission to the decision-making and finally publishing the manuscript.",Non-OADS,/arxiv_data1/oa_pdf/1c/81/JBCP-4-1.PMC3894734.pdf
Complete information about instructions for authors regarding preparation and submission of manuscripts can be obtained from http://www.jbclinpharm.org/contributors.asp.,Non-OADS,/arxiv_data1/oa_pdf/1c/81/JBCP-4-1.PMC3894734.pdf
Available from: http://www.medknow.com/ pdf/12_05_11_Wolters_Kluwer_Health_Acquires_Medknow.pdf.,Non-OADS,/arxiv_data1/oa_pdf/1c/81/JBCP-4-1.PMC3894734.pdf
Available  from: http://www.ada.org/sections/scienceAndResearch/pdfs/guide_home_bleach.pdf4- Association Dentaire Française.,Non-OADS,/arxiv_data1/oa_pdf/5f/d4/jaos-20-02-0186.PMC3894761.pdf
"Available from: <http://www.medscape.com/ viewarticle/558856>.2- Douglas LR, Douglass JB, Sieck JO, Smith PJ.",Non-OADS,/arxiv_data1/oa_pdf/b1/03/jaos-20-02-0241.PMC3894770.pdf
"Materials and methods Drosophila stocks Sixteen lines expressing RNAi corresponding to Obp tran - scripts under UAS promoters inserted in the neutral phiC31  integration site along with the co-isogenic progenitor control  line ( y,w1118;P{attP ,y+,w3’}) were obtained from the Vienna  Drosophila RNAi Center ( http://www.vdrc.at ; Dietzl et  al.",OADS,/arxiv_data1/oa_pdf/8c/fc/bjt061.PMC3894858.pdf
Supplementary material Supplementary material can be found at http://www.chemse.,Non-OADS,/arxiv_data1/oa_pdf/8c/fc/bjt061.PMC3894858.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/2c/64/cia-9-157.PMC3894951.pdf
"Information on how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 157–164Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  157OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S5624 6Personality traits influencing somatization  symptoms and social inhibition in the elderly Tinakon Wongpakaran nahathai Wongpakaran Faculty of Medicine, Chiang Mai  University, Chiang Mai, Thailand Correspondence: Tinakon Wongpakaran   Department of Psychiatry, Faculty   of Medicine, Chiang Mai University,  110 Intawarorot rd, Tambon sriphum,  Amphur Muang, Chiang Mai,   Thailand, 50200   Tel +66 53 945 422   Fax +66 53 945 426   email tinakon.w@cmu.ac.t hPurpose:  Somatization is a common symptom among the elderly, and even though personality  disorders have been found to be associated with somatization, personality traits have not yet  been explored with regard to this symptom.",Non-OADS,/arxiv_data1/oa_pdf/2c/64/cia-9-157.PMC3894951.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treat - ments intended to prevent or delay the onset of maladaptive correlates  of aging in human beings.",Non-OADS,/arxiv_data1/oa_pdf/2c/64/cia-9-157.PMC3894951.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/2c/64/cia-9-157.PMC3894951.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/42/dd/ijn-9-485.PMC3894953.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 485–494International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  485OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S5299 0analyzing the behavior of a porous nano- hydroxyapatite/polyamide 66 (n-ha/P a66)  composite for healing of bone defects Yan Xiong1 cheng ren1 Bin Zhang1 hongsheng Yang1 Yun lang1 li Min1 Wenli Zhang1 Fuxing Pei1 Y onggang Yan2 hong li2 anchun Mo3 chongqi T u1 hong Duan1 1Department of Orthopedics, West  china hospital, 2school of Physical  science and T echnology, 3Department  of Oral Implant, West china college  of stomatology, sichuan University,   chengdu, People’s republic of china correspondence: hong Duan; chongqi  Tu  Department of Orthopedics, West china   hospital, sichuan University, No 37   guo Xue lane, chengdu, sichuan  610064, People’s republic of china   Tel +86 28 8542 2570   Fax +86 28 8542 2570   email duanhong1970@126.com;  tuchongqitucq@163.comAbstract:  The aim of this study was to analyze the behavior of the porous nano-hydroxyapatite/ polyamide 66 (n-HA/PA66) composite grafted for bone defect repair through a series of biological  safety experiments, animal experiments, and a more than 5-year long clinical follow-up.",Non-OADS,/arxiv_data1/oa_pdf/42/dd/ijn-9-485.PMC3894953.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology  in diagnostics, therapeutics, and drug delivery systems throughout  the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/42/dd/ijn-9-485.PMC3894953.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/42/dd/ijn-9-485.PMC3894953.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/0a/97/ijn-9-403.PMC3894954.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 403–417International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  403OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S4813 6Dendrosomal curcumin nanoformulation  downregulates pluripotency genes via miR-145   activation in U87Mg glioblastoma cells Maryam Tahmasebi Mirgani1 Benedetta Isacchi2 Majid sadeghizadeh1,* Fabio Marra3 anna rita Bilia2,* seyed Javad Mowla1 Farhood Najafi4 esmael Babaei5 1Department of genetics, Tarbiat  Modares University, T ehran, Iran;   2Department of chemistry, University  of Florence, sesto Fiorentino, Italy;   3Department of experimental and  clinical Medicine, University of  Florence, Italy; 4Department of resin  and additives, Institute for color  science and T echnology, T ehran, Iran;   5Department of Biology, University   of Tabriz, Tabriz, Iran *These authors contributed equally to  this work correspondence: Majid sadeghizadeh   Tarbiat Modares University, Faculty of  Bioscience, Department of Molecular  genetics, Jalal ale ahmad highway,   PO Box 14115-111, Tehran, Iran   Tel +98 21 8288 4409   Fax +98 21 8800 7598   email sadeghma@modares.ac.i rAbstract:  Glioblastoma is an invasive tumor of the central nervous system.",Non-OADS,/arxiv_data1/oa_pdf/0a/97/ijn-9-403.PMC3894954.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology  in diagnostics, therapeutics, and drug delivery systems throughout  the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/0a/97/ijn-9-403.PMC3894954.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/0a/97/ijn-9-403.PMC3894954.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/18/5c/ijn-9-495.PMC3894956.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpInternational Journal of Nanomedicine 2014:9 495–504International Journal of Nanomedicine Dove press submit your manuscript | www.dovepress.co m Dove press  495OrIg INal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/IJN.S5664 8Surface-modified solid lipid nanoparticles   for oral delivery of docetaxel: enhanced   intestinal absorption and lymphatic uptake hyun-Jong cho1 Jin Woo Park2 In-soo Y oon2 Dae-Duk Kim3 1college of Pharmacy, Kangwon  National University, chuncheon,   2college of Pharmacy and Natural  Medicine research Institute, Mokpo  National University, Jeonnam, 3college  of Pharmacy and research Institute  of Pharmaceutical sciences, seoul  National University, seoul, republic  of Korea correspondence: In-soo Yoon   college of Pharmacy and Natural  Medicine research Institute, Mokpo  National University, 1666 Youngsan-ro,  Jeonnam 534-729, republic of Korea   Tel +82 61 450 2688   Fax +82 61 450 2689   email isyoon@mokpo.ac.k r    Dae-Duk Kim   college of Pharmacy and research  Institute of Pharmaceutical sciences,  seoul National University, 1 gwanak-ro,  seoul 151-742, republic of Korea   Tel +82 2 880 7870   Fax +82 2 873 9177   email ddkim@snu.ac.k rAbstract:  Docetaxel is a potent anticancer drug, but development of an oral formulation has  been hindered mainly due to its poor oral bioavailability.",Non-OADS,/arxiv_data1/oa_pdf/18/5c/ijn-9-495.PMC3894956.pdf
"International Journal of Nanomedicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/international-journal-of-nanomedicine-journa lThe International Journal of Nanomedicine is an international, peer- reviewed journal focusing on the application of nanotechnology  in diagnostics, therapeutics, and drug delivery systems throughout  the biomedical field.",Non-OADS,/arxiv_data1/oa_pdf/18/5c/ijn-9-495.PMC3894956.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/18/5c/ijn-9-495.PMC3894956.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/ae/3f/cia-9-165.PMC3894957.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Interventions in Aging 2014:9 165–177Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  165RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S4605 8Reducing inappropriate antibiotic prescribing   in the residential care setting: current perspectives Ching Jou Lim1 David CM Kong1 Rhonda L Stuart2,3 1Centre for Medicine Use and  Safety, Monash University, Parkville,   vIC, Australia; 2Monash Infectious  Diseases, Monash Health, Clayton,   vIC, Australia; 3Department of  Medicine, Monash University, Clayton,   vIC, Australia Correspondence: Rhonda L Stuart   Monash Infectious Diseases,   Monash Health, Level 3, 246 Clayton  Road, Clayton, vIC, 3168, Australia   Tel +61 395 944 564   Fax +61 395 944 533   email r honda.stuart@monashhealth.or gAbstract:  Residential aged care facilities are increasingly identified as having a high burden  of infection, resulting in subsequent antibiotic use, compounded by the complexity of patient  demographics and medical care.",Non-OADS,/arxiv_data1/oa_pdf/ae/3f/cia-9-165.PMC3894957.pdf
"Available from: http://www.cdc.gov/hicpac/pdf/guidelines/ MDROGuideline 2006.pd f. Accessed May 25, 2013.",OADS,/arxiv_data1/oa_pdf/ae/3f/cia-9-165.PMC3894957.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treat - ments intended to prevent or delay the onset of maladaptive correlates  of aging in human beings.",Non-OADS,/arxiv_data1/oa_pdf/ae/3f/cia-9-165.PMC3894957.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/ae/3f/cia-9-165.PMC3894957.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/74/02/jbm-5-001.PMC3894958.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpJournal of Blood Medicine 2014:5 1–3Journal of Blood Medicine Dove press submit your manuscript | www.dovepress.co m Dove press  1Letteropen access to scientific and medical research Open Access Full text Article http: //dx.doi.org/10.2147/JBM.S5521 6A novel supplemental approach to capturing   post-marketing safety information on  recombinant factor VIIa in acquired hemophilia:  the Acquired Hemophilia Surveillance project Steven r Lentz1 Anand tandra2 robert Z Gut3 David L Cooper3 1Division of Hematology,   Oncology and Blood and Marrow  transplantation, Department of  Internal Medicine, University of Iowa,   Iowa City, IA, USA; 2Hematology,   Indiana Hemophilia and thrombosis  Center, Indianapolis, IN, USA; 3Clinical,   Medical, and regulatory Affairs, Novo  Nordisk, Inc, Princeton, NJ, USA Correspondence: Steven r Lentz   Division of Hematology, Oncology and  Blood and Marrow transplantation,  Department of Internal Medicine, C32  GH, University of Iowa, 200 Hawkins  Drive, Iowa City, IA 52242, USA   tel +1 319 356 4048   Fax +1 319 353 8383   email steven-lentz@uiowa.ed uDear editor Acquired hemophilia (AH) is a rare (incidence is 1 per 1.5 million) but often severe  bleeding disorder characterized by autoantibodies to coagulation factor VIII (FVIII).",Non-OADS,/arxiv_data1/oa_pdf/74/02/jbm-5-001.PMC3894958.pdf
"Journal of Blood Medicine Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/Journal-of-blood-medicine-journa lThe Journal of Blood Medicine is an international, peer-reviewed, open  access, online journal publishing laboratory, experimental and clinical aspects  of all topics pertaining to blood based medicine including but not limited to:  Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases,  and Blood banking logistics; Immunohematology; Artificial and alternative blood based therapeutics; Hematology; Biotechnology/nanotechnology of  blood related medicine; Legal aspects of blood medicine; Historical perspec - tives.",Non-OADS,/arxiv_data1/oa_pdf/74/02/jbm-5-001.PMC3894958.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/74/02/jbm-5-001.PMC3894958.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/96/39/nss-6-011.PMC3894960.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpNature and Science of Sleep 2014:6 11–18Nature and Science of Sleep Dove press submit your manuscript | www.dovepress.co m Dove press  11OrigiNal reSearchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NSS.S5553 8Predictors of poor sleep quality among lebanese  university students: association between evening  typology, lifestyle behaviors, and sleep habits colette S Kabrita1 Theresa a hajjar-Muça2 Jeanne F Duffy3 1Department of Sciences,   2Department of Mathematics and  Statistics, Faculty of Natural and  applied Sciences, Notre Dame  University – louaize, Zouk Mosbeh,   lebanon; 3Division of Sleep Medicine,   Department of Medicine, Brigham and  Women’s hospital, harvard Medical  School, Boston, M a, USa correspondence: colette S Kabrita   Department of Sciences, Faculty   of Natural and applied Sciences,   Notre Dame University – louaize,   PO Box 72, Zouk Mikael,   Zouk Mosbeh, lebanon   Tel +961 9 208 728   Fax +961 9 218 771   email ckabrita@ndu.edu.l bAbstract:  Adequate, good night sleep is fundamental to well-being and is known to be  influenced  by myriad biological and environmental factors.",Non-OADS,/arxiv_data1/oa_pdf/96/39/nss-6-011.PMC3894960.pdf
"Nature and Science of Sleep Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/nature-and-science-of-sleep-journa lNature and Science of Sleep is an international, peer-reviewed, open  access journal covering all aspects of sleep science and sleep medicine,  including the neurophysiology and functions of sleep, the genetics of  sleep, sleep and society, biological rhythms, dreaming, sleep disorders and  therapy, and strategies to optimize healthy sleep.",Non-OADS,/arxiv_data1/oa_pdf/96/39/nss-6-011.PMC3894960.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/96/39/nss-6-011.PMC3894960.pdf
The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0 /.,Non-OADS,/arxiv_data1/oa_pdf/dc/d5/opth-8-219.PMC3895032.pdf
"Information on  how to request permission may be found at: http://www.dovepress.com/permissions.phpClinical Ophthalmology 2014:8 219–228Clinical Ophthalmology Dove press submit your manuscript | www.dovepress.co m Dove press  219Original researChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OPTH.S5559 0Safety and efficacy of a fixed versus unfixed  brinzolamide/timolol combination in Japanese  patients with open-angle glaucoma or ocular  hypertension Mikio nagayama1 T oru nakajima2 Junji Ono3 1nagayama eye Clinic, Okayama,   2nakajima eye Clinic, shizuoka, 3Ono  Ophthalmic Clinic, shizuoka, Japan Correspondence: Mikio nagayama   nagayama eye Clinic, 3-2 goban-cho,  Kasaoka-shi, Okayama, Japan   Tel +81 865 62 3123   Fax +81 865 62 3122   email nagayama-eye@po.harenet.ne.j pBackground:  The purpose of this study was to assess the safety and efficacy of fixed-combination  brinzolamide 1%/timolol 0.5% (BRINZ/TIM-FC) compared with concomitant brinzolamide  1% and timolol 0.5% (BRINZ + TIM) in Japanese patients with open-angle glaucoma (primary  open-angle, exfoliation, pigmentary) or ocular hypertension.",Non-OADS,/arxiv_data1/oa_pdf/dc/d5/opth-8-219.PMC3895032.pdf
"Clinical Ophthalmology Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-ophthalmology-journa lClinical Ophthalmology is an international, peer-reviewed journal  covering all subspecialties within ophthalmology.",Non-OADS,/arxiv_data1/oa_pdf/dc/d5/opth-8-219.PMC3895032.pdf
Visit http://www.dovepress.com/   testimonials.ph p to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/dc/d5/opth-8-219.PMC3895032.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by-nc/3.0/), which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/83/62/rjt122.PMC3895046.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by-nc/3.0/), which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/43/07/rjt120.PMC3895048.pdf
http://www.nice.org.uk/nicemedia/pdf/CG027quickrefguide.pdf.,Non-OADS,/arxiv_data1/oa_pdf/43/07/rjt120.PMC3895048.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by-nc/3.0/), which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/dc/c6/rjt121.PMC3895049.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by-nc/3.0/), which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/7f/ba/rjt114.PMC3895141.pdf
http://www.asas.or.,Non-OADS,/arxiv_data1/oa_pdf/26/96/535_2013_Article_802.PMC3895199.pdf
http://www.fmrib.ox.ac.uk/analysis/techrep (2007).,Non-OADS,/arxiv_data1/oa_pdf/13/24/12311_2013_Article_515.PMC3895203.pdf
[online](2011-07-20) Accessible: http://www.fao.org/countries/ 55528/en/uga/ [2011-12-29] FAO–Food and Agriculture Organization of the United Nations.,Non-OADS,/arxiv_data1/oa_pdf/9c/3f/11250_2013_Article_455.PMC3895220.pdf
"Accessible: http://www.agriculture.go.ug orwww.ubos.org [2012-11-26] Vaarst, M., Byarugaba, D. K., Nak avuma, J. and Laker, C., 2007.",Non-OADS,/arxiv_data1/oa_pdf/9c/3f/11250_2013_Article_455.PMC3895220.pdf
3Corresponding author E-mail stephana@ucsd.eduArticle is online at http://www.learnmem.org/cgi/doi/10.1101 /lm.033613.113.#2014 Carmack et al.,Non-OADS,/arxiv_data1/oa_pdf/47/63/CarmackLM033613.PMC3895222.pdf
"Watson SJ), http://www.acnp.org/g4/gn401000166/ch162.htm.",Non-OADS,/arxiv_data1/oa_pdf/47/63/CarmackLM033613.PMC3895222.pdf
"Next, we determined if synaptic 1Corresponding author E-mail eweeber@health.usf.eduArticle is online at http://www.learnmem.org/cgi/doi/10.1101 /lm.032375.113.#2014 Filonova et al.",OADS,/arxiv_data1/oa_pdf/28/9c/FilonovaLM032375.PMC3895224.pdf
4Corresponding author E-mail vanpraagh@mail.nih.govArticle is online at http://www.learnmem.org/cgi/doi/10.,Non-OADS,/arxiv_data1/oa_pdf/c1/1a/KobiloLM033332.PMC3895225.pdf
2002) and are accessible through GEOSeries accession number GSE50873 (http://www.ncbi.nlm.nih.,OADS,/arxiv_data1/oa_pdf/c1/1a/KobiloLM033332.PMC3895225.pdf
"Similarly, Holland (2007)found that projections from the CeA to the SI /nBM are necessary to increase attention enough for rats to perform a modiﬁed ﬁve- 4Corresponding author E-mail noros@uci.eduArticle is online at http://www.learnmem.org/cgi/doi/10.",OADS,/arxiv_data1/oa_pdf/63/fe/OrosLM032433.PMC3895228.pdf
enables repeated novel experiences 3Corresponding author E-mail s.wang@ed.ac.ukArticle is online at http://www.learnmem.org/cgi/doi/10.,Non-OADS,/arxiv_data1/oa_pdf/55/a3/SalvettiLM032177.PMC3895229.pdf
2012); and a single bout of post-training aerobic exercise increased recall for positive emotional images in both elderly patients with normal cognition and those with mild 1Corresponding author E-mail f.westbrook@unsw.edu.auArticle is online at http://www.learnmem.org/cgi/doi/10.,Non-OADS,/arxiv_data1/oa_pdf/51/96/SietteLM032557.PMC3895230.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/Ethanol drinking pattern and striatal synapses MV Wilcox et al 594 Neuropsychopharmacology",Non-OADS,/arxiv_data1/oa_pdf/b9/ff/npp2013230a.PMC3895236.pdf
"Data Analysis Following image preprocessing using Statistical Parametric Mapping (SPM8; http://www.fil.ion.ucl.ac.uk/spm/) and the Resting State fMRI Data Analysis Toolkit (REST; http://www.restfmri.net/forum), we performed the statistical ana-lysis of the data using multivariate RVR (Tipping, 2001) as implemented in the Pattern Recognition for Neuroimaging Toolbox (PRoNTo; http://www.mlnl.cs.ucl.ac.uk/pronto/).",OADS,/arxiv_data1/oa_pdf/87/f6/npp2013251a.PMC3895245.pdf
"For each participant, EPI images were realigned to the first image and unwarped to correct for susceptibility-by-movement interaction using SPM8software (http://www.fil.ion.ucl.ac.uk/spm/) running under Matlab (Mathworks, 2010 release).",OADS,/arxiv_data1/oa_pdf/87/f6/npp2013251a.PMC3895245.pdf
"In addition, we examined the relationship between clinical scores and the mean amplitude of spontaneous low frequency fluctuations at rest using multivariate RVR as implemented in PRoNTo (http://www.mlnl.cs.ucl.ac.uk/pronto/) running under Matlab (Mathworks, 2010 release).",OADS,/arxiv_data1/oa_pdf/87/f6/npp2013251a.PMC3895245.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ Supplementary Information accompanies the paper on the Neuropsychopharmacology website (http://www.nature.com/npp)Predicting psychopathology using resting-state fMRI Q Gong et al 687 Neuropsychopharmacology",Non-OADS,/arxiv_data1/oa_pdf/87/f6/npp2013251a.PMC3895245.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ Supplementary Information accompanies the paper on the Neuropsychopharmacology website (http://www.nature.com/npp)STAT1 mediates the memory-impairing effect of A b W-L Hsu et al 758 Neuropsychopharmacology",Non-OADS,/arxiv_data1/oa_pdf/f1/8a/npp2013263a.PMC3895253.pdf
Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.042325.113.© 2014 Durairaj et al.,OADS,/arxiv_data1/oa_pdf/3a/b0/133.PMC3895266.pdf
This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/3a/b0/133.PMC3895266.pdf
"After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial3.0 Unported), as described at http://creativecommons.org/licenses/by-nc/3.0/.REPORT RNA 20:133 –142; Published by Cold Spring Harbor Laboratory Press for the RNA Society 133",Non-OADS,/arxiv_data1/oa_pdf/3a/b0/133.PMC3895266.pdf
Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.042507.113.,OADS,/arxiv_data1/oa_pdf/30/2d/143.PMC3895267.pdf
"This article, published in RNA , is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported),as described at http://creativecommons.org/licenses/by-nc/3.0/.REPORT RNA 20:143 –149; Published by Cold Spring Harbor Laboratory Press for the RNA Society 143",Non-OADS,/arxiv_data1/oa_pdf/30/2d/143.PMC3895267.pdf
"The tissue of origin, as verified from NCBI and http://biogps.org, is marked above each bar.Circulating RNA quantification of gene modulation www.rnajournal.org 147",Non-OADS,/arxiv_data1/oa_pdf/30/2d/143.PMC3895267.pdf
Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.042069.113.© 2014 Martin-Marcos et al.,Non-OADS,/arxiv_data1/oa_pdf/c1/04/150.PMC3895268.pdf
This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publica- tion date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/c1/04/150.PMC3895268.pdf
"After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported), as described at http://creativecommons.org/licenses/by-nc/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/c1/04/150.PMC3895268.pdf
Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.041285.113.© 2014 Fu et al.,OADS,/arxiv_data1/oa_pdf/5d/87/168.PMC3895269.pdf
"After 12 months, it is avail-able under a Creative Commons License (Attribution-NonCommercial 3.0Unported), as described at http://creativecommons.org/licenses/by-nc/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/5d/87/168.PMC3895269.pdf
Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.042358.113.© 2014 Mandal et al.,OADS,/arxiv_data1/oa_pdf/a8/ea/177.PMC3895270.pdf
This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/a8/ea/177.PMC3895270.pdf
"After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial3.0 Unported), as described at http://creativecommons.org/licenses/by-nc/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/a8/ea/177.PMC3895270.pdf
Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.042168.113.,OADS,/arxiv_data1/oa_pdf/33/f3/189.PMC3895271.pdf
"This article, published in RNA , is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported), asdescribed at http://creativecommons.org/licenses/by-nc/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/33/f3/189.PMC3895271.pdf
"Indeed, immunohistochemical analysis ofovarian cancer tissues confirms the predominant expression of stromal markers in the ovarian tumor microenvironment and the expression of the epithelial marker in ovarian cancercells (http://www.proteinatlas.org; data not shown).",Non-OADS,/arxiv_data1/oa_pdf/33/f3/189.PMC3895271.pdf
"2007) was examined using endpoint PCR amplification of five RNA samples extracted from normal Fallopian tube tissue and ovarian cancer tissues (for details, see Materials and Methods; see raw data in http://palace.lgfus.ca/ pcrreactiongroup/list/226).",Non-OADS,/arxiv_data1/oa_pdf/33/f3/189.PMC3895271.pdf
"Cancer-specific splicing factors To understand how the CES and CSS are produced, we examined the expression of 328 putative splicing factors in epithelial and stromal cells isolated from normal and cancertissues using quantitative RT-PCR (raw data are accessi- ble through http://palace.lgfus.ca/pcrreactiongroup/list/227).",OADS,/arxiv_data1/oa_pdf/33/f3/189.PMC3895271.pdf
"Accordingly, we depleted 41 out of 51 cancer-associat-ed splicing factors by at least twofold using two independent siRNAs in the model ovarian cancer cell line SKOV3ip1(Supplemental Table S7; raw data are accessible through http://palace.lgfus.ca/ pcrreactiongroup/list/232) and tested theimpact on the splicing pattern of bothCES and CSS ASEs.",Non-OADS,/arxiv_data1/oa_pdf/33/f3/189.PMC3895271.pdf
Allraw PCR data are available through http://palace.lgfus.ca/data/ related/844.Brosseau et al.,OADS,/arxiv_data1/oa_pdf/33/f3/189.PMC3895271.pdf
Data clustering were performed using R statistical software (http://www.r-project.org).,OADS,/arxiv_data1/oa_pdf/33/f3/189.PMC3895271.pdf
ASEs dis-playing quantitative splicing shift ( ΔQψ) of at least 10 between the knockdowns and mock transfection were considered significant.All cancer-associated ASEs regulated by at least one splicing factorand splicing factors regulating at least one ASE are shown inFigure 3B (the raw data are accessible through http://palace.lgfus.ca/pcrreactiongroup/list/229).,Non-OADS,/arxiv_data1/oa_pdf/33/f3/189.PMC3895271.pdf
Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.041012.113.© 2014 Dolan and Müller This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http:// rnajournal.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/c7/58/202.PMC3895272.pdf
"After 12 months, it is availableunder a Creative Commons License (Attribution-NonCommercial 3.0 Un-ported), as described at http://creativecommons.org/licenses/by-nc/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/c7/58/202.PMC3895272.pdf
Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.042341.113.This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/ site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/65/66/214.PMC3895273.pdf
"After 12 months, it is available under a CreativeCommons License (Attribution-NonCommercial 3.0 Unported), as de-scribed at http://creativecommons.org/licenses/by-nc/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/65/66/214.PMC3895273.pdf
Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.042226.113.© 2014 Miller and Buskirk This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/2c/f6/228.PMC3895274.pdf
"After 12 months, it is available under a Creative Commons License (Attribution-NonCommer-cial 3.0 Unported), as described at http://creativecommons.org/licenses/by-nc/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/2c/f6/228.PMC3895274.pdf
Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.038927.113.© 2014 Nielsen et al.,OADS,/arxiv_data1/oa_pdf/a0/65/236.PMC3895275.pdf
This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/a0/65/236.PMC3895275.pdf
"After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial3.0 Unported), as described at http://creativecommons.org/licenses/by-nc/3.0/.",Non-OADS,/arxiv_data1/oa_pdf/a0/65/236.PMC3895275.pdf
A UCSCGenome Browser mirror including all transcripts is available at http://moma.ki.au.dk/genome-mirror-mmn.,OADS,/arxiv_data1/oa_pdf/a0/65/236.PMC3895275.pdf
"In addition, we provide access to all transcripts through a mirrorof the UCSC genome browser (http://mmn.moma.ki.au.dk).",OADS,/arxiv_data1/oa_pdf/a0/65/236.PMC3895275.pdf
DATA DEPOSITION Microarray and NGS data are available at NCBI ’s Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/) under acces-sion numbers GSE41947 and GSE45326.,OADS,/arxiv_data1/oa_pdf/a0/65/236.PMC3895275.pdf
"The release of 19 of the miRBase sequence database (http://www.mirbase.org/) contains 25,141 mature miRNAs in 193 species, and new molecules are constantly being dis-covered.",OADS,/arxiv_data1/oa_pdf/5e/ce/252.PMC3895276.pdf
Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.040220.113.© 2014 Li et al.,OADS,/arxiv_data1/oa_pdf/5e/ce/252.PMC3895276.pdf
"After 12 months, it is available under aCreative Commons License (Attribution-NonCommercial 3.0 Unported),as described at http://creativecommons.org/licenses/by-nc/3.0/.METHOD 252 RNA 20:252 –259; Published by Cold Spring Harbor Laboratory Press for the RNA Society",Non-OADS,/arxiv_data1/oa_pdf/5e/ce/252.PMC3895276.pdf
Article and publication date are at http://www.rnajournal.org/cgi/doi/10.1261/rna.041905.113.© 2014 Sinnamon and Czaplinski This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml).,Non-OADS,/arxiv_data1/oa_pdf/58/d0/260.PMC3895277.pdf
"After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported), as described at http://creativecommons.org/licenses/by-nc/3.0/.METHOD 260 RNA 20:260 –266; Published by Cold Spring Harbor Laboratory Press for the RNA Society",Non-OADS,/arxiv_data1/oa_pdf/58/d0/260.PMC3895277.pdf
http://dx.doi.org/10.1016/j.gynor.2013.11.001 Contents lists available at ScienceDirect Gynecologic Oncology Reports journal homepage: www.elsevier.com/locate/gynor,Non-OADS,/arxiv_data1/oa_pdf/9e/2e/main.PMC3895280.pdf
http://dx.doi.org/10.1016/j.gynor.2013.10.002 Contents lists available at ScienceDirect Gynecologic Oncology Reports journal homepage: www.elsevier.com/locate/gynor,Non-OADS,/arxiv_data1/oa_pdf/50/23/main.PMC3895281.pdf
http://dx.doi.org/10.1016/j.gynor.2013.02.006 Contents lists available at ScienceDirect Gynecologic Oncology Reports journal homepage: www.elsevier.com/locate/gynor,Non-OADS,/arxiv_data1/oa_pdf/82/18/main.PMC3895282.pdf
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.gynor.2013.09.001 Contents lists available at ScienceDirect Gynecologic Oncology Reports journal homepage: www.elsevier.com/locate/gynor,Non-OADS,/arxiv_data1/oa_pdf/76/11/main.PMC3895283.pdf
http://dx.doi.org/10.1016/j.gynor.2013.10.001 Contents lists available at ScienceDirect Gynecologic Oncology Reports journal homepage: www.elsevier.com/locate/gynor,Non-OADS,/arxiv_data1/oa_pdf/6e/ac/main.PMC3895284.pdf
http://dx.doi.org/10.1016/j.gynor.2013.10.003 Contents lists available at ScienceDirect Gynecologic Oncology Reports journal homepage: www.elsevier.com/locate/gynor,Non-OADS,/arxiv_data1/oa_pdf/17/c9/main.PMC3895285.pdf
http://www.who.int/dietphysicalactivity/  fruit/en/  29.,Non-OADS,/arxiv_data1/oa_pdf/44/aa/JRPS-8-51.PMC3895300.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permitsnon-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/9b/3e/not214.PMC3895387.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permitsnon-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/1c/99/not215.PMC3895388.pdf
"OncoImmunology 2013; 2:e26677; http://dx.doi.org/10.4161/onci.26677Longitudinal confocal microscopy imaging   of solid tumor destruction following adoptive   T cell transfer andrea Schietinger1, †, ainhoa arina1, †, rebecca B Liu1, Sam Wells2, Jianhua Huang3, Boris e ngels1, Vytas Bindokas4,   Todd Bartkowiak5, David Lee6, andreas Herrmann7, David W Piston2, Mikael J Pittet8, P Charles Lin3,9,‡, Tomasz Zal5,‡,   and Hans Schreiber1,‡,* 1Department of Pathology; The University of Chicago; Chicago, IL US a; 2Department of Physiology and Biophysics; Vanderbilt University School of Medicine; Nashville, TN US a;  3Department of r adiation Oncology and The Vanderbilt-Ingram Cancer Center; Vanderbilt University School of Medicine; Nashville, TN US a; 4Integrated Microscopy Core;   The University of Chicago; Chicago, IL US a; 5Department of Immunology; The University of Texas MD a nderson Cancer Center; Houston, TX US a; 6School of Medicine;   The University of Chicago; Chicago, IL US a; 7Departments of Cancer Immunotherapeutics & Tumor Immunology; City of Hope; Duarte, C a US a; 8Center for Systems Biology;  Massachusetts General Hospital and Harvard Medical School; Boston, M a US a; 9Center for Cancer r esearch; National Cancer Institute; NIH; Frederick, MD US a †These authors contributed equally to this work.",Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Supplemental Figures Supplemental figures may be found here: http://www.landesbio - science.com/journals/oncoimmunology/article/26677 / References 1.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Annu Rev Immunol 2007; 25:267- 96; PMID:17134371 ; http://dx.doi.org/10.1146/ annurev.immunol.25.022106.141609 2.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
J Exp Med 1995; 181:435-40; PMID:7807024 ;  http://dx.doi.org/10.1084/jem.181.1.435 3.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Cancer Res 2004; 64:7022-9;  PMID:15466195 ; http://dx.doi.org/10.1158/0008- 5472.CAN-04-1449 6.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Immunity  2002; 17:737-47;  PMID:12479820 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Clin Transl Oncol 2009; 11:75-81; PMID:19211371 ; http://dx.doi.org/10.1007/ s12094-009-0317-y 11.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Nat Med 2004; 10:294-8; PMID:14981514 ;  http://dx.doi.org/10.1038/nm999 12.,OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
J Exp Med 2007; 204:49-55; PMID:17210731 ; http://dx.doi.org/10.1084/ jem.2006205613.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Cancer Res  2008; 68:1563-71;  PMID:18316622 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Trends Cell Biol  2009; 19:43-51;  PMID:19144520 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Nat Rev Immunol 2009; 9:581-93;  PMID:19498381 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Lancet 2002; 360:295-305;  PMID:12147373 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Nature 2005; 434:83-8;  PMID:15744304 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
J Exp Med 2005; 202:1313- 8; PMID:16287713 ; http://dx.doi.org/10.1084/ jem.20051379 19.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
J Clin Invest 2008; 118:1398-404; PMID:18317595 ;  http://dx.doi.org/10.1172/JCI33522 20.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Curr Top Microbiol Immunol 2009; 334:265-87;  PMID:19521689 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
J Exp Med 2006; 203:2749- 61; PMID:17116735 ; http://dx.doi.org/10.1084/ jem.20060710 25.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Curr Opin Oncol 2009; 21:53- 9; PMID:19125019 ; http://dx.doi.org/10.1097/ CCO.0b013e32831bc38a26.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Curr Opin Genet Dev  2010; 20:72-8;  PMID:19942428 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Semin Immunopathol 2010; 32:305-17;  PMID:20652252 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Nat Rev Immunol 2006; 6:497-507;  PMID:16799470 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Nat Rev Immunol 2006; 6:173- 82; PMID:16498448 ; http://dx.doi.org/10.1038/ nri1785 31.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Nature 1988; 335:271-4; PMID:3261843 ;  http://dx.doi.org/10.1038/335271a0 33.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Nat Biotechnol 2004; 22:445-9; PMID:14990965 ; http://dx.doi.org/10.1038/nbt945 38.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Genesis 2004; 40:241- 6; PMID:15593332 ; http://dx.doi.org/10.1002/ gene.20095 39.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Cancer Cell 2013; 23:516-26;  PMID:23597565 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Microvasc Res 1979; 18:311-8; PMID:537508 ;  http://dx.doi.org/10.1016/0026-2862(79)90039-6 41.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Nat Biotechnol  1999; 17:1033-5;  PMID:10504711 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Immunol Rev  2008; 222:162-79;  PMID:18364001 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Semin Cancer Biol 2006; 16:53-65; PMID:16168663 ;  http://dx.doi.org/10.1016/j.semcancer.2005.07.005 44.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Eur J Cancer  2006; 42:717-27;  PMID:16520032 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Cell Cycle 2006 ; 5:1597-601;  PMID:16880743 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Cancer Metastasis Rev 2008; 27:31-40;  PMID:18087678 ; http://dx.doi.org/10.1007/ s10555-007-9108-5 49.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
J Immunother  2004; 27:184-90;  PMID :15076135 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Eur J Immunol  1995; 25:340-7;  PMID:7875194 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Proc Natl Acad Sci U S A 2002; 99:16168- 73; PMID:12427970 ; http://dx.doi.org/10.1073/ pnas.242600099 55.,OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Proc Natl Acad Sci U S A 2012; 109:7835-40;  PMID:22547816 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Eur J Immunol 2006; 36:468-77; PMID:16385625 ; http://dx.doi.org/10.1002/ eji.200526175 57.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
PLoS One 2012; 7:e34552;  PMID:22479645 ; http://dx.doi.org/10.1371/jour - nal.pone.0034552 58.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Int J Cancer 2011; 128:371- 8; PMID:20333679 ; http://dx.doi.org/10.1002/ ijc.2535059.,Non-OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Proc Natl Acad Sci U S A 1986; 83:5233-7; PMID:3487788 ; http://dx.doi.org/10.1073/ pnas.83.14.5233 61.,OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Proc Natl Acad Sci U S A 1993; 90:8392-6;  PMID:7690960 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
Nat Protoc  2008; 3:1703-8;  PMID:18846097 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/40/9a/onci-2-e26677.PMC3895414.pdf
"The hypothesis of targeted cholesterol efflux, if further supported by future experimental work, may have important implications for basic  *Correspondence to: Yury I Miller; Email: yumiller@ucsd.edu Submitted: 08/13/2013; Accepted: 08/06/2013http://dx.doi.org/10.4161/cc.26401Comment on: Fang L, et al.",Non-OADS,/arxiv_data1/oa_pdf/ca/5b/cc-12-3345.PMC3895418.pdf
"Nature 2013; 498:118-22; PMID:23719382; http://dx.doi.org/10.1038/nature12166Targeted cholesterol efflux longhou  Fang and y ury i Miller* department of Medicine; u niversity of California, s an d iego; l a Jolla, C a usa",Non-OADS,/arxiv_data1/oa_pdf/ca/5b/cc-12-3345.PMC3895418.pdf
Endocrinology 2008; 149:2108- 20; PMID:18202122 ; http://dx.doi.org/10.1210/ en.2007-0582 2.,Non-OADS,/arxiv_data1/oa_pdf/ca/5b/cc-12-3345.PMC3895418.pdf
Nature 2013; 498:118-22;  PMID:23719382 ; http://dx.doi.org/10.1038/ nature12166 3.,Non-OADS,/arxiv_data1/oa_pdf/ca/5b/cc-12-3345.PMC3895418.pdf
Science 2010; 328:1689-93; PMID:20488992 ; http://dx.doi.org/10.1126/ science.1189731 4.,Non-OADS,/arxiv_data1/oa_pdf/ca/5b/cc-12-3345.PMC3895418.pdf
J Immunol 2011; 187:1529- 35; PMID:21810617 ; http://dx.doi.org/10.4049/ jimmunol.1100253 5.,Non-OADS,/arxiv_data1/oa_pdf/ca/5b/cc-12-3345.PMC3895418.pdf
Genomics 2002; 79:693-702; PMID:11991719 ; http://dx.doi.org/10.1006/ geno.2002.6761 Figure 1.  aiBP-targeted cholesterol efflux from EC disrupts lipid rafts and inhibits angiogenesis.,OADS,/arxiv_data1/oa_pdf/ca/5b/cc-12-3345.PMC3895418.pdf
"In contrast, PTEN-positive models were resistant to inhibitor treat - ment, indicating that the PTEN protein expression status can be utilized to pre - dict response to PI3K inhibitor treatment  *Correspondence to: Georg Lenz; Email: georg.lenz@charite.de Submitted: 07/25/13; Accepted: 07/29/13http://dx.doi.org/10.4161/cc.26575Comment on: Pfeifer M, et al.",Non-OADS,/arxiv_data1/oa_pdf/2d/d7/cc-12-3347.PMC3895419.pdf
J Clin Oncol 2011; 29:1803-11;  PMID:21483013 ; http://dx.doi.org/10.1200/ JCO.2010.33.3252 2.,Non-OADS,/arxiv_data1/oa_pdf/2d/d7/cc-12-3347.PMC3895419.pdf
Nature 2000; 403:503- 11; PMID:10676951 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2d/d7/cc-12-3347.PMC3895419.pdf
N Engl J Med 2008; 359:2313- 23; PMID:19038878 ; http://dx.doi.org/10.1056/ NEJMoa0802885 4.,Non-OADS,/arxiv_data1/oa_pdf/2d/d7/cc-12-3347.PMC3895419.pdf
Nature 2009; 459:717-21;  PMID:19412164 ; http://dx.doi.org/10.1038/ nature079685.,Non-OADS,/arxiv_data1/oa_pdf/2d/d7/cc-12-3347.PMC3895419.pdf
Nat Genet 2010; 42:181-5; PMID:20081860 ; http://dx.doi.org/10.1038/ng.518 6.,OADS,/arxiv_data1/oa_pdf/2d/d7/cc-12-3347.PMC3895419.pdf
Proc Natl Acad Sci U S A 2013; 110:12420-5;  PMID:23840064 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2d/d7/cc-12-3347.PMC3895419.pdf
Nat Rev Mol Cell Biol 2012; 13:283- 96; PMID:22473468 ; http://dx.doi.org/10.1038/ nrm3330 8.,OADS,/arxiv_data1/oa_pdf/2d/d7/cc-12-3347.PMC3895419.pdf
Proc Natl Acad Sci U S A 2008; 105:13520-5;  PMID:18765795 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2d/d7/cc-12-3347.PMC3895419.pdf
"*Correspondence to: Gail Risbridger; Email: gail.risbridger@monash.edu Submitted: 07/24/2013; Accepted: 07/29/2013http://dx.doi.org/10.4161/cc.26576Comment on: Toivanen R, et al.",Non-OADS,/arxiv_data1/oa_pdf/fd/32/cc-12-3349.PMC3895420.pdf
"Sci Transl Med 2013; 5:87ra71; PMID:23720582; http://dx.doi.org/10.1126/scitranslmed.3005688To target or not to target the enemy   within localized prostate cancer Gail risbridger*  and r enea  taylor Monash u niversity; Clayton, V iC, australia",Non-OADS,/arxiv_data1/oa_pdf/fd/32/cc-12-3349.PMC3895420.pdf
Cancer Res 2008; 68:6407-15;  PMID:18676866 ; http://dx.doi.org/10.1158/0008- 5472.CAN-07-5997 2.,Non-OADS,/arxiv_data1/oa_pdf/fd/32/cc-12-3349.PMC3895420.pdf
Trends Endocrinol Metab  2010; 21:315-24;  PMID:20138542 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/fd/32/cc-12-3349.PMC3895420.pdf
Stem Cells 2012; 30:1076-86; PMID:22438320 ; http://dx.doi.org/10.1002/ stem.1087 5.,Non-OADS,/arxiv_data1/oa_pdf/fd/32/cc-12-3349.PMC3895420.pdf
J Steroid Biochem Mol Biol  2012; 131:122-31;  PMID:22342674 ; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/fd/32/cc-12-3349.PMC3895420.pdf
Am J Pathol 2010; 177:229-39; PMID:20472887 ; http://dx.doi.org/10.2353/ ajpath.2010.090821 7.,Non-OADS,/arxiv_data1/oa_pdf/fd/32/cc-12-3349.PMC3895420.pdf
Am J Pathol 2010; 176:1901-13; PMID:20167861 ; http://dx.doi.org/10.2353/ ajpath.2010.090873 8.,Non-OADS,/arxiv_data1/oa_pdf/fd/32/cc-12-3349.PMC3895420.pdf
Nature 2012; 487:239-43;  PMID:22722839 ; http://dx.doi.org/10.1038/ nature11125 Figure  1.,Non-OADS,/arxiv_data1/oa_pdf/fd/32/cc-12-3349.PMC3895420.pdf
"Thus, Klf4 is an essen - tial reprogramming factor functioning by binding at the Oct4 loci to set up the  *Correspondence to: Wange Lu; Email: wangelu@usc.edu Submitted: 07/29/2013; Accepted: 07/31/2013http://dx.doi.org/10.4161/cc.26577Comment on: Wei Z, et al.",OADS,/arxiv_data1/oa_pdf/f4/e1/cc-12-3351.PMC3895421.pdf
"Cell Stem Cell 2013; 13:36-47; PMID:23747203; http://dx.doi.org/10.1016/j.stem.2013.05.010Genome organization by Klf4 regulates  transcription in pluripotent stem cells david  Huang , Zong  Wei , and Wange  lu* Eli and Edythe Broad Center for r egenerative Medicine and s tem Cell r esearch and d epartment of Biochemistry and Molecular Biology;   university of s outhern California; l os a ngeles, C a usa",Non-OADS,/arxiv_data1/oa_pdf/f4/e1/cc-12-3351.PMC3895421.pdf
J Biol Chem 2013; 288:22369-77;  PMID:23779110; http://dx.doi.org/10.1074/jbc.,OADS,/arxiv_data1/oa_pdf/f4/e1/cc-12-3351.PMC3895421.pdf
Cell Stem Cell 2013; 13:36-47;  PMID:23747203 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f4/e1/cc-12-3351.PMC3895421.pdf
PLoS One 2008; 3:e1661; PMID:18286208 ; http://dx.doi.org/10.1371/jour - nal.pone.0001661 4.,Non-OADS,/arxiv_data1/oa_pdf/f4/e1/cc-12-3351.PMC3895421.pdf
Stem Cells 2009; 27:2969-78;  PMID:19816951 ; http://dx.doi.org/10.1634/ stemcells.2008-0333 5.,Non-OADS,/arxiv_data1/oa_pdf/f4/e1/cc-12-3351.PMC3895421.pdf
Cell 2012; 149:1233-44;  PMID:22682246 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f4/e1/cc-12-3351.PMC3895421.pdf
Cell Stem Cell 2013; 12:699- 712; PMID:23665121 ; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/f4/e1/cc-12-3351.PMC3895421.pdf
Science 2009; 326:289- 93; PMID :19815776 ; http://dx.doi.org/10.1126/ science.1181369 8.,Non-OADS,/arxiv_data1/oa_pdf/f4/e1/cc-12-3351.PMC3895421.pdf
Nature 2012; 485:376-80;  PMID:22495300 ; http://dx.doi.org/10.1038/ nature11082Figure 1.  specific long-range interactions initiate during reprogramming by the loading of Klf4 to  the o ct4 distal enhancer and its in trans interacting gene loci.,OADS,/arxiv_data1/oa_pdf/f4/e1/cc-12-3351.PMC3895421.pdf
"Since rapamycin-treated rats have a similar phenotype to CR rats, we  *Correspondence to: Yu-cai Fu; Email: ycfu@stu.edu.cn Submitted: 08/01/2013; Accepted: 08/04/2013http://dx.doi.org/10.4161/cc.26578Comment on: Zhang XM, et al.",Non-OADS,/arxiv_data1/oa_pdf/c9/e3/cc-12-3353.PMC3895422.pdf
"Gene 2013; 523:82-7; PMID:23566837; http://dx.doi.org/10.1016/j.gene.2013.03.039Rapamycin prolongs female reproductive lifespan li-li luo1, Jin-jie  Xu2, and  yu-cai  Fu2,* 1department of Gynecology and o bstetrics of the First a ffiliated Hospital; s hantou u niversity Medical College; s hantou, P r China;   2laboratory of Cell s enescence; s hantou u niversity Medical College; s hantou, P r China",Non-OADS,/arxiv_data1/oa_pdf/c9/e3/cc-12-3353.PMC3895422.pdf
Endocr Rev 2000; 21:200-14;  PMID:10782364 ; http://dx.doi.org/10.1210/ er.21.2.200 2.,Non-OADS,/arxiv_data1/oa_pdf/c9/e3/cc-12-3353.PMC3895422.pdf
Mol Hum Reprod 2009; 15:765- 70; PMID:19843635 ; http://dx.doi.org/10.1093/ molehr/gap092 3.,OADS,/arxiv_data1/oa_pdf/c9/e3/cc-12-3353.PMC3895422.pdf
Hum Mol Genet 2010; 19:397-410; PMID:19843540 ; http://dx.doi.org/10.1093/ hmg/ddp483 4.,OADS,/arxiv_data1/oa_pdf/c9/e3/cc-12-3353.PMC3895422.pdf
Nature 2013; 493:338-45;  PMID:23325216 ; http://dx.doi.org/10.1038/ nature11861 5.,Non-OADS,/arxiv_data1/oa_pdf/c9/e3/cc-12-3353.PMC3895422.pdf
Reprod Sci 2008; 15:128-38; PMID:18276949 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/c9/e3/cc-12-3353.PMC3895422.pdf
PLoS One 2011; 6:e21415;  PMID:21750711 ; http://dx.doi.org/10.1371/journal.,Non-OADS,/arxiv_data1/oa_pdf/c9/e3/cc-12-3353.PMC3895422.pdf
"Cell Cycle 2013; 12:3001–12;   PMID:23974110; http://dx.doi.org/10.4161/cc.26029 Indu S Ambudkar; Secretory Physiology Section; Molecular Physiology and Therapeutics Branch; National Institute of Dental and Craniofacial Research;   National Institues of Health; Bethesda, MD USA; Email: indu.ambudkar@nih.gov; http://dx.doi.org/10.4161/cc.26637 Alteration of natural gravitational forces  leads to changes in gene expression, cell  growth, and cell function.",Non-OADS,/arxiv_data1/oa_pdf/4a/a4/cc-12-3355.PMC3895423.pdf
Annu Rev Biochem 2006; 75:19-37;  PMID:16756483 ; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/4a/a4/cc-12-3355.PMC3895423.pdf
Cell Mol Life Sci 2005; 62:2405-13; PMID:16003492 ; http://dx.doi.org/10.1007/ s00018-005-5083-6 4.,OADS,/arxiv_data1/oa_pdf/4a/a4/cc-12-3355.PMC3895423.pdf
Pflugers Arch 2010; 460:571-81;  PMID:20490539 ; http://dx.doi.org/10.1007/ s00424-010-0847-8 5.,Non-OADS,/arxiv_data1/oa_pdf/4a/a4/cc-12-3355.PMC3895423.pdf
J Cell Sci 2008; 121:3951-9;  PMID:19001499 ; http://dx.doi.org/10.1242/ jcs.037218 7.,OADS,/arxiv_data1/oa_pdf/4a/a4/cc-12-3355.PMC3895423.pdf
FASEB J 2013; 27:2045- 54; PMID:23363573 ; http://dx.doi.org/10.1096/ fj.12-218693 8.,OADS,/arxiv_data1/oa_pdf/4a/a4/cc-12-3355.PMC3895423.pdf
Cell Cycle 2013; 12; PMID:23974110 ; http://dx.doi.org/10.4161/ cc.26029,OADS,/arxiv_data1/oa_pdf/4a/a4/cc-12-3355.PMC3895423.pdf
"*Correspondence to: Peiwen Fei; Email: pfei@cc.hawaii.edu Submitted: 07/13/2013; Accepted: 09/05/2013http://dx.doi.org/10.4161/cc.26387In vitro FANCD2 monoubiquitination   by HHR6 and hRad18 Anna Pickering1, Jayabal Panneerselvam1, Jun Zhang2, Junnian Zheng3, Yanbin Zhang4, and Peiwen Fei1,* 1University of h awaii Cancer Center; University of h awaii; h onolulu, hi USA; 2department of Laboratory Medicine and Pathology; Mayo Clinic; r ochester, MN USA;   3Jiangsu Key Laboratory of Biological Cancer t herapy; Xuzhou Medical College; Xuzhou, China; 4department of Biochemistry and Molecular Biology;   University of Miami Miller School of Medicine; Miami, FL USA",Non-OADS,/arxiv_data1/oa_pdf/a7/82/cc-12-3448.PMC3895433.pdf
